<SEC-DOCUMENT>0001161697-24-000139.txt : 20240313
<SEC-HEADER>0001161697-24-000139.hdr.sgml : 20240313
<ACCEPTANCE-DATETIME>20240313161817
ACCESSION NUMBER:		0001161697-24-000139
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240313
DATE AS OF CHANGE:		20240313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KORU Medical Systems, Inc.
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39086
		FILM NUMBER:		24746155

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE DRIVE
		CITY:			MAHWAH
		STATE:			NJ
		ZIP:			07430
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE DRIVE
		CITY:			MAHWAH
		STATE:			NJ
		ZIP:			07430

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REPRO MED SYSTEMS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form_10-k.htm
<DESCRIPTION>FORM 10-K ANNUAL REPORT FOR 12-31-2023
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:krmd="http://korumedical.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_krmd_korumedical.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000704440 -->
<!-- Field: Set; Name: xdx; ID: xdx_075_XDX_D%2D%2D\EDGARbiz\Clients (D)\KORU (fka Repro%2DMed)\10%2DK 2023%2D12%2D31 KORU\korumed__form.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_064_N_0_Number -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AmendmentFlag" id="ixv-6876">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:CurrentFiscalYearEndDate" id="ixv-6877">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-6878">2023</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-6879">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityCentralIndexKey" id="ixv-6880">0000704440</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl0088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredRentReceivablesNetNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0091" decimals="0" unitRef="USD">0</ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredPurchasedPowerCosts" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:FinanceLeaseROUAsset" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0466" decimals="INF" unitRef="N">1</ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2023-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember" id="xdx2ixbrl0480" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">P6Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember" id="xdx2ixbrl0482" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">P20Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0506" decimals="0" unitRef="USD">3967480</ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0508" decimals="0" sign="-" unitRef="USD">2014018</ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember_custom_FurnitureAndOfficeEquipmentMember" id="xdx2ixbrl0516" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember_custom_FurnitureAndOfficeEquipmentMember" id="xdx2ixbrl0517" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P10Y0M0D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember_custom_EquipmentAndToolingMember" id="xdx2ixbrl0518" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember_custom_EquipmentAndToolingMember" id="xdx2ixbrl0519" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P12Y</ix:nonNumeric>
  <ix:nonFraction name="krmd:AntiDilutiveStockOptions" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0531" decimals="INF" unitRef="Shares">0</ix:nonFraction>
  <ix:nonFraction name="krmd:StockOptions" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0541" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0560" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0561" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0707" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P10Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0709" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P10Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0737" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0739" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:CashReceivedFromOptionExercise" contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0781" decimals="0" unitRef="USD">0</ix:nonFraction>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" id="xdx2ixbrl0797" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">P8Y3M19D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0807" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P46M</ix:nonNumeric>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions" contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0816" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0818" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions" contextRef="AsOf2021-12-31_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0820" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0822" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions" contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0852" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0854" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0858" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P36M</ix:nonNumeric>
  <ix:nonFraction name="krmd:TaxBenefitFromRestrictedStockCompensation" contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember" id="xdx2ixbrl0862" decimals="0" unitRef="USD">0</ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0878" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0880" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0890" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0892" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0894" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0896" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_LeaseOneMember" id="xdx2ixbrl0914" name="krmd:LesseeOperatingLeaseRemainingTerm">P8Y7M6D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_LeaseTwoMember" id="xdx2ixbrl0916" name="krmd:LesseeOperatingLeaseRemainingTerm">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_LeaseOneMember" id="xdx2ixbrl0918" name="krmd:LesseeFinanceLeaseRemainingTerm">P3Y4M24D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_LeaseTwoMember" id="xdx2ixbrl0920" name="krmd:LesseeFinanceLeaseRemainingTerm">P3Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_LeaseThreeMember" id="xdx2ixbrl0922" name="krmd:LesseeFinanceLeaseRemainingTerm">P4Y9M0D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31" id="xdx2ixbrl0997" name="us-gaap:LesseeOperatingLeaseRenewalTerm">P6Y10M25D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-12-31" id="xdx2ixbrl0998" name="us-gaap:LesseeOperatingLeaseRenewalTerm">P9Y8M12D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31" id="xdx2ixbrl1000" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">P3Y8M12D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-12-31" id="xdx2ixbrl1001" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">P4Y7M6D</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2023-12-31" id="xdx2ixbrl1033" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1063" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1064" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:WriteoffOfDeferredTaxAsset" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1067" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1082" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:WriteoffOfDeferredTaxAsset" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:AllowanceForNonRealizationOfDeferredTaxAsset" contextRef="AsOf2022-12-31" id="xdx2ixbrl1112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1114" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="krmd-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MinimumMember_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MaximumMember_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MinimumMember_custom_EquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MaximumMember_custom_EquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ManufacturingEquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutivesEmployeesConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutivesEmployeesConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutivesEmployeesConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LeaseOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LeaseTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LeaseThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-262023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-26</xbrli:startDate>
        <xbrli:endDate>2023-07-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-262023-07-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-26</xbrli:startDate>
        <xbrli:endDate>2023-07-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AONPremiumFinanceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AONPremiumFinanceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-08_us-gaap_SubsequentEventMember_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_TermLoanFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">krmd:TermLoanFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-062024-03-08_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-06</xbrli:startDate>
        <xbrli:endDate>2024-03-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="N">
      <xbrli:measure>krmd:Number</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<div style="width: 7.5in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_901_edei--DocumentType_c20230101__20231231_z0snirRs9cq7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentType" id="ixv-7757">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--DocumentAnnualReport_c20230101__20231231_zj4nhPUwq1ef"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport" id="ixv-7758">&#9746;</ix:nonNumeric></span></span>&#160;&#160;ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the fiscal year ended <span id="xdx_907_edei--DocumentPeriodEndDate_c20230101__20231231_z3qVJ6elHhWa"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-7759">December 31, 2023</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">OR</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--DocumentTransitionReport_c20230101__20231231_ztbalt7ix44f"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="ixv-7760">&#9744;</ix:nonNumeric></span></span>&#160;&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from ____________ to __________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Commission file number <span id="xdx_904_edei--EntityFileNumber_c20230101__20231231_zavom1fe6bGl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityFileNumber" id="ixv-7761">0-12305</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityRegistrantName_c20230101__20231231_zofzpcr0c6vh"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityRegistrantName" id="ixv-7762">KORU MEDICAL SYSTEMS, INC</ix:nonNumeric></span>.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 7.5in; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="width: 3.5in; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20230101__20231231_zYIP0tDOQJm"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-7763">Delaware</ix:nonNumeric></span></span></b></td>
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 3.5in; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20230101__20231231_zhMaTQYNMsA"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityTaxIdentificationNumber" id="ixv-7764">13-3044880</ix:nonNumeric></span></span></b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">(State or other jurisdiction of incorporation or organization)</td>
    <td>&#160;</td>
    <td style="text-align: center">(I.R.S. Employer Identification No.)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityAddressAddressLine1_c20230101__20231231_ztHOgH3Bu1ha"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressAddressLine1" id="ixv-7765">100 Corporate Drive</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressCityOrTown_c20230101__20231231_z7gq81Qtcl63"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressCityOrTown" id="ixv-7766">Mahwah</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20230101__20231231_zBSQmbGboTqd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-7767">New Jersey</ix:nonNumeric></span></span></b></td>
    <td>&#160;</td>
    <td style="text-align: center"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityAddressPostalZipCode_c20230101__20231231_z5kpKTnQJsU9"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressPostalZipCode" id="ixv-7768">07430</ix:nonNumeric></span></span></b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">(Address of principal executive offices)</td>
    <td>&#160;</td>
    <td style="text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">(<span id="xdx_90F_edei--CityAreaCode_c20230101__20231231_zBbqGk6wGnt"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:CityAreaCode" id="ixv-7769">845</ix:nonNumeric></span>)-<span id="xdx_90E_edei--LocalPhoneNumber_c20230101__20231231_zy2dOfHrKbOa"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:LocalPhoneNumber" id="ixv-7770">469-2042</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number, including area
code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 7.5in; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="width: 2.5in"><span style="text-decoration: underline">Title of each class</span></td>
    <td style="width: 2.5in"><span style="text-decoration: underline">Trading Symbol(s)</span></td>
    <td style="width: 2.5in"><span style="text-decoration: underline">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td><b><span id="xdx_909_edei--Security12bTitle_c20230101__20231231_zTZFqgOAKPHe"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:Security12bTitle" id="ixv-7771">common stock, $0.01 par value</ix:nonNumeric></span> </b></td>
    <td><b><span id="xdx_902_edei--TradingSymbol_c20230101__20231231_zFg2uNggWgK2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:TradingSymbol" id="ixv-7772">KRMD</ix:nonNumeric></span></b></td>
    <td><b><span id="xdx_900_edei--SecurityExchangeName_c20230101__20231231_z4NSrj8uWpVc"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-7773">The Nasdaq Stock Market</ix:nonNumeric></span></b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(g) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">None</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Title of Class)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is a well-known seasoned issuer,
as defined in Rule 405 of the Securities Act. Yes&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<span id="xdx_907_edei--EntityWellKnownSeasonedIssuer_c20230101__20231231_zFdn0fQ8ZRAk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-7774">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<span id="xdx_90B_edei--EntityVoluntaryFilers_c20230101__20231231_zLdHNr1Jsg9j"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityVoluntaryFilers" id="ixv-7775">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
<span id="xdx_900_edei--EntityCurrentReportingStatus_c20230101__20231231_z2djLx6GZoqb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityCurrentReportingStatus" id="ixv-7776">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T &#160;(&#167; 232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) <span id="xdx_906_edei--EntityInteractiveDataCurrent_c20230101__20231231_zfvG1Yfeueh8"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityInteractiveDataCurrent" id="ixv-7777">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 7.5in; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="width: 3.75in">Large accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td>
    <td style="width: 3.75in">Accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span id="xdx_905_edei--EntityFilerCategory_c20230101__20231231_zfyXaAqHeQ7i"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-7778">Non-accelerated filer</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></td>
    <td>Smaller reporting company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--EntitySmallBusiness_c20230101__20231231_zkmDEUfjMyR8"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="ixv-7779">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20230101__20231231_zvtUmio2NR29"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="ixv-7780">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has filed a report on and
attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b)
of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If securities are registered pursuant to Section 12(b) of the Act, indicate
by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously
issued financial statements. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether any of those error corrections are restatements
that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during
the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--DocumentFinStmtErrorCorrectionFlag_c20230101__20231231_zhraaIhifiLj"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-7781">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Act). Yes&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<span id="xdx_909_edei--EntityShellCompany_c20230101__20231231_ziTW6OelQ3Of"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="ixv-7782">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Based on the closing sales price of June 30, 2023, the aggregate market
value of the voting and nonvoting common equity held by non-affiliates of the registrant was $<span id="xdx_90D_edei--EntityPublicFloat_iI_c20230630_zDxEXuLyoP3d"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7783">111,191,841</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 13, 2024, <span id="xdx_902_edei--EntityCommonStockSharesOutstanding_iI_pid_uShares_c20240313_zoMUpn3ivuD"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-03-13" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7784">45,710,500</ix:nonFraction></span> shares of common stock, $0.01 par value
per share, were outstanding, which excludes <span id="xdx_90F_eus-gaap--TreasuryStockCommonShares_iI_pid_uShares_c20240313_zIe03VfrFCmi"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-03-13" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7785">3,420,502</ix:nonFraction></span> shares of Treasury Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">DOCUMENTS INCORPORATED BY REFERENCE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Portions of the registrant&#8217;s proxy statement for the 2024 Annual
Meeting of Shareholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein.
Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended
December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="toc"></span><b>INDEX TO FORM 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif">
  <tr>
    <td style="vertical-align: top; width: 0.7in">&#160;</td>
    <td style="vertical-align: top; width: 6.3in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 0.5in; text-align: center">Page</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART I</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_1">Item 1.</a></td>
    <td><a href="#Item_1">Business</a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_1A">Item 1A.</a></td>
    <td><a href="#Item_1A">Risk Factors</a></td>
    <td style="text-align: center">8</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_1B">Item 1B.</a></td>
    <td><a href="#Item_1B">Unresolved Staff Comments</a></td>
    <td style="text-align: center">23</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_2">Item 2.</a></td>
    <td><a href="#Item_2">Properties</a></td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_3">Item 3.</a></td>
    <td><a href="#Item_3">Legal Proceedings</a></td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_4">Item 4.</a></td>
    <td><a href="#Item_4">Mine Safety Disclosures</a></td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART II</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_5">Item 5.</a></td>
    <td><a href="#Item_5">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a> </td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_6">Item 6.</a></td>
    <td><a href="#Item_6">Selected Financial Data</a></td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_7">Item 7.</a></td>
    <td><a href="#Item_7">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
    <td style="text-align: center">25</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_7A">Item 7A.</a></td>
    <td><a href="#Item_7A">Quantitative and Qualitative Disclosures about Market Risk</a></td>
    <td style="text-align: center">30</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_8">Item 8.</a></td>
    <td><a href="#Item_8">Financial Statements and Supplementary Data</a></td>
    <td style="text-align: center">30</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_9">Item 9.</a></td>
    <td><a href="#Item_9">Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</a></td>
    <td style="text-align: center">49</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_9A">Item 9A.</a></td>
    <td><a href="#Item_9A">Controls and Procedures</a></td>
    <td style="text-align: center">49</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_9B">Item 9B.</a></td>
    <td><a href="#Item_9B">Other Information</a></td>
    <td style="text-align: center">49</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_9C">Item 9C.</a></td>
    <td><a href="#Item_9C">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
    <td style="text-align: center">49</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART III</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_10">Item 10.</a></td>
    <td><a href="#Item_10">Directors, Executive Officers, and Corporate Governance</a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_11">Item 11.</a></td>
    <td><a href="#Item_11">Executive Compensation</a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_12">Item 12.</a></td>
    <td><a href="#Item_12">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_13">Item 13.</a></td>
    <td><a href="#Item_13">Certain Relationships and Related Transactions, and Director Independence</a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_14">Item 14.</a></td>
    <td><a href="#Item_14">Principal Accountant Fees and Services</a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART IV</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_15">Item 15.</a></td>
    <td><a href="#Item_15">Exhibits and Financial Statement Schedules</a></td>
    <td style="text-align: center">51</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_16">Item 16.</a></td>
    <td><a href="#Item_16">Form 10-K Summary</a></td>
    <td style="text-align: center">52</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Signatures">Signatures</a></td>
    <td>&#160;</td>
    <td style="text-align: center">53</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- ii -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Throughout this report, the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to KORU Medical Systems, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>FORWARD LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">This Annual Report on Form 10-K contains &#8220;forward-looking
statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. &#160;Forward-looking statements can be identified by words such as: &#8220;mission,&#8221;
&#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;expect,&#8221;
&#8220;will,&#8221; and similar references to future periods. Examples of forward-looking statements include, among others,
statements we make under &#8220;Our Strategy&#8221; in Business under Item 1 of this Form 10-K and &#8220;Liquidity and Capital
Resources&#8221; in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations under Item 7 of this
Form 10-K, and statements regarding success of our EU certification appeal, completion of a next-generation pump and consumable
system, compliance with EU MDR, 2024 expenses, needs for additional capital, capital investments, plans for expansion of our share
position and products, and increase in patient SCIg prescriptions. Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future
conditions.&#160; Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of which are outside of our control. &#160;Our actual results and
financial condition may differ materially from those indicated in the forward-looking statements. Therefore, readers should not rely
on any of these forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Important factors that could cause our actual results and financial condition
to differ materially from those indicated in the forward-looking statements include, among others, those discussed in this Annual Report
on Form 10-K, and in particular, the risks discussed under the caption &#8220;Risk Factors&#8221; in Item 1A, and those discussed in other
documents we file with the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Any forward-looking statement made by us in this Annual Report on Form
10-K is based only on information currently available to us and speaks only as of the date on which it is made. &#160;We undertake no
obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a
result of new information, future developments or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_1"></span><b>ITEM 1. BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU Medical develops, manufactures and commercializes innovative and patient-centric
large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United States Food
and Drug Administration (the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management.
Our focus is primarily concentrated on our mechanical infusion products, the FREEDOM Infusion Systems (which we refer to as the &#8220;FREEDOM
System&#8221; when used with one or more accessories), which include the FREEDOM60&#174; Syringe Driver, the FreedomEdge&#174; Syringe Driver,
HIgH-Flo Subcutaneous Safety Needle Sets&#8482; and Precision Flow Rate Tubing&#8482;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the FREEDOM System, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency Diseases
(&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies revenues consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including product innovation, testing
and registration services) received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial
use across multiple drug categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR MISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our mission is to improve the quality of life of patients around the world
by delivering innovative, effective, and easy-to-use drug delivery systems that can be used at home or alternate site settings, for patient
self-administration of drug therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 1 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR STRATEGY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our goal is to expand our position as a leading provider of large volume
subcutaneous infusion systems (&gt;10ml) self-administered in the home by the patient and/or delivered in an ambulatory infusion center
by a healthcare professional. . We intend to accomplish this objective by increasing our leadership position and penetration in our domestic
and international core subcutaneous immunoglobulin (&#8220;SCIg&#8221;) market and extending this position into novel subcutaneous drug
therapies. Both the Ig and novel therapy drugs, will use our Freedom Infusion system and new innovations that are in development for the
Freedom Infusion system platform.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the goal of increasing our leadership position in SCIg, we have identified
multiple factors that we believe are driving growth of the SCIg market. These include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Increasing diagnoses of Primary Immunodeficiency Diseases (&#8220;PIDD&#8221;), which often require immunoglobulin (&#8220;Ig&#8221;) treatment</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>New on-label indications for SCIg drugs such as Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;), Secondary Immunodeficiency Diseases (&#8220;SIDD&#8221;), and others in clinical development.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Increase in the number of available SCIg medications such as the introduction of Cutaquig&#174; and Xembify&#174; in the United States and Europe, and planned launches of Cuvitru&#174; and HyQvia&#174; in Japan</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Biopharmaceutical investment in SCIg products, such as prefilled syringe formats that make infusion easier for patients, which may make more patients eligible for SCIg therapy</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Increasing supply of donated plasma, which increases the global supply of Ig medications</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Favorable patient preference, side effect profile, and health economics for at-home SCIg compared with intravenous Ig therapy</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We intend to maintain and extend our leadership position in the SCIg market
through clinical and product innovation and commercial excellence. By improving our products, establishing thought leadership in subcutaneous
therapy, partnering with drug manufacturers, expanding geographically, and executing commercially, we intend to increase our overall global
share position and the number of patients prescribed SCIg over intravenous Ig.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In our goal to expand into novel therapies outside of SCIg, we estimate
that at least 100 large-volume drugs are in clinical development utilizing subcutaneous infusion, with approximately 30% greater than
10ml. The pipeline is driven by the need to deliver high therapeutic doses, difficulty in formulating large molecules into small volumes,
nursing shortage, pharmaceutical companies shifting development programs toward at-home subcutaneous therapy, and patient preference.
Biopharmaceutical manufacturers seek device partners during the drug development process. We intend to partner with them during clinical
development&#8212;generating non-recurring services revenues to prepare and customize our products for use during the clinical trial process
and to obtain regulatory clearance for use with their drug. Post launch, we intend to commercialize our products for use with these drugs,
working with our pharmaceutical partners, our distributors and our specialty pharmacy partners who distribute and train patients on the
use of these products both in the home and in ambulatory infusion centers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe our track record of regulatory clearance and successful patient
use, combined with our channel access, position KORU to both maximize our growth in the core SCIg market and expand into new therapeutic
areas.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR PRODUCTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU&#8217;s infusion devices work together as a system to deliver life-saving
therapies to patients with chronic illnesses, such as PIDD and CIDP. &#160;The FREEDOM System comprises the FREEDOM60 Syringe Driver (standard
60/50ml syringe compatible) and FreedomEdge Syringe Driver (standard 30ml and 20ml syringe and prefilled syringe compatible), HIgH-Flo
Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. &#160;The systems are portable, easy to operate, maintenance free and
do not require batteries or electricity. The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains
a balance between what a patient&#8217;s subcutaneous tissues can tolerate what the system delivers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our FREEDOM System is cleared for several on-label subcutaneous indications
including specific FDA clearance for: delivery of specific medications through subcutaneous and intravenous routes, including specific
clearance for leading immune globulins Cutaquig &#174;, Cuvitru&#174;, Hizentra&#174;, Xembify, Empaveli&#174; (branded Aspaveli&#174; outside
the United States), Gammagard Liquid&#174;, and selected intravenously administered antibiotics. Outside of the U.S. our indications for
use also include treatments for hydration and iron chelation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 2 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Ambulatory infusion systems such as the FREEDOM System are most prevalent
in the home care and alternate infusion site markets. The SCIg products administered with delivered by the FREEDOM System are indicated
for a variety of conditions, including Primary Immunodeficiency (PIDD ) and Chronic Inflammatory Demelinating Polyneuropathy (CIDP) in
the United States and PIDD, CIDP and Secondary Immunodeficiency Disease (&#8220;SIDD&#8221;) outside of the United States. Empaveli&#174;
is indicated for Paroxysmal Nocturnal Hemoglobinuria (&#8220;PNH&#8221;). The use of the FREEDOM System for SCIg drug delivery continues
to increase, and it remains the market leading delivery system in the U.S. for these treatments. In recent years Hizentra&#174; and HyQvia&#174;
has received an expanded indication for treatment of CIDP in the United States. Multiple SCIg drugs have received indications for SID
outside of the United States. It is expected that patient access to SCIg will expand as new drugs are developed, existing drugs are approved
and/or marketed in new countries, and existing drugs receive new indications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">HIgH-Flo Subcutaneous Safety Needle Sets are an important element of the
FREEDOM System. The needle sets are available in 26- and 24-gauge sizes and feature unique design elements specific to subcutaneous self-administration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Precision Flow Rate Tubing is designed for repeatable flow rates without
allowing unrestricted flow. &#160;The tubing regulates the flow rate and infusion time for various applications when used with the FREEDOM
System. &#160;Each tubing set provides a different level of flow restriction and consistently delivers medication with low residual volume
to minimize drug waste.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>SALES AND DISTRIBUTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The FREEDOM System is sold through both direct sales and medical device
distributors to pharmaceutical companies, specialty pharmacy customers and home infusion providers.&#160; Our products are sold principally
through a small number of distributors so our specialty pharmacy customers receive the benefit of remote inventory management and one-stop
shopping.&#160; We sell the majority of our products through three distributors in the U.S. and two distributors outside the U.S. &#160;As
of December 31, 2023, these five distributors comprised approximately 74% of our net revenues with one of our U.S. distributors contributing
approximately 41%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Specialty pharmacies, home infusion providers, and distributors are our
primary sales contacts, although we provide education and training materials to clinicians, patients, and patient advocates both in the
field and online.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>MANUFACTURING AND RAW MATERIALS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">We currently manufacture, assemble and package
all of our pump products, assemble and complete final packaging of our consumables (which consist of needle and tubing sets), and perform
calibration, pre- and post-assembly quality control inspection and testing at our Mahwah, NJ facility. &#160;Command Medical Products,
Inc. (&#8220;Command&#8221;), </span><span style="font-size: 8pt">&#160;</span><span style="font-size: 10pt">a contract manufacturing
organization with operations in Nicaragua, currently provides subassemblies, and manufactures, assembles and packages approximately 80%
of our consumables.. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ability to meet customer demand depends, in part, on our ability to
obtain timely and adequate delivery of components for our products. All of the components that go into the manufacturing of our products
and accessories are sourced from third-party suppliers on a single source basis. The Company uses single-source suppliers in part due
to governmental approval and validation requirements. A change in supplier, or the use of multiple suppliers of the same materials, often
would necessitate additional approvals and validations, which the Company seeks to avoid unless and until the need arises. The Company
does not have any contracts with suppliers that impose material binding obligations on the Company or provide the Company with any material
rights or benefits, other than the Company&#8217;s agreement with Command. Command currently stores our finished goods in their warehouse located
in Miami Florida once the products are released and shipped from Nicaragua.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESEARCH AND DEVELOPMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize the importance of innovation to our long-term success and
are committed to research and new product development activities. &#160;Our product development team along with outside engineering resources
are continuously engaged in improving existing product performance and innovating on new product opportunities to enhance our product
portfolio. &#160;We spent $5.7 million and $5.0 million on research and development for the years ended December 31, 2023 and 2022, respectively.
&#160;We intend to make additional investments in research and development over the next twelve months to support completing research
and development for a &#8220;next-generation&#8221; infusion pump and consumable system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 3 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>REGULATORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our medical devices and technologies, as well as our business activities,
are subject to a complex set of regulations and rigorous enforcement, principally by the FDA, and numerous other federal, state, and non-U.S.
governmental authorities. &#160;To varying degrees, each of these agencies requires us to comply with laws and regulations governing the
development, testing, manufacturing, labeling, marketing and distribution of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The FDA regulates, among other things, the research, development, testing,
manufacturing, approval, labeling, storage, recordkeeping, advertising, promotion, marketing, distribution, post approval monitoring and
reporting, import and export of medical devices in the U.S. to assure the safety and effectiveness of medical products for their intended
use. &#160;Thus, both before and after a product is commercially released, we have ongoing responsibilities under the FDA. For instance,
all medical devices marketed in the U.S. must be manufactured in accordance with the FDA&#8217;s quality system regulations (&#8220;QSRs&#8221;).
&#160;Accordingly, our facility and procedures and those of our applicable suppliers are also subject to periodic inspections by the FDA
to determine compliance with applicable laws and regulations. &#160;The Federal Trade Commission also regulates the advertising of our
products. &#160;Further, we are subject to laws directed at preventing fraud and abuse, which subject our sales and marketing, training
and other practices to government scrutiny.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our business is also affected by patient privacy laws and government payor
cost containment initiatives, as well as environmental health and safety laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>U.S. Device Classification and Clearance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Except where an exemption applies, each new or significantly modified medical
device we seek to commercially distribute in the U.S. will require either a premarket notification to the FDA requesting permission for
commercial distribution under Section&#160;510(k) of the Federal Food, Drug and Cosmetic Act (&#8220;FFDCA&#8221;), also known as a 510(k)
clearance, approval of a pre-market approval (&#8220;ra&#8221;) application, or as part of a drug-device combination product through a
Biologics License Application (&#8220;BLA&#8221;) or New Drug Application (&#8220;NDA&#8221;). &#160;For example, the use of our FREEDOM
System with therapies not covered by the existing FDA clearance will require additional 510(k) clearance , BLA, NDA or PMA approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the 510(k) process, applicants must demonstrate to the FDA that a
device is as safe and effective as, or substantially equivalent to, a legally marketed device, known as the &#8220;predicate&#8221; device.
&#160;Applicants must submit performance data to establish substantial equivalence. &#160;In some instances, data from human clinical
trials must also be submitted in support of a 510(k), and this data must be collected in a manner that conforms to the applicable Investigational
Device Exemption (&#8220;IDE&#8221;) regulations. &#160;The FDA must issue a substantial equivalence determination before commercial distribution
can occur. &#160;Changes to cleared devices that will not significantly affect the safety or effectiveness of the device can generally
be made without additional 510(k) submissions. &#160;Changes that will significantly affect the safety or effectiveness of the device
will require a new 510(k) prior to marketing of the modified device. &#160;We cannot predict with any certainty how future reforms to
Federal regulations may impact our business. &#160;See &#8220;ITEM 1A. RISK FACTORS.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the PMA application process, the applicant must demonstrate that
the device is safe and effective for its intended use. &#160;This approval process applies to most Class III devices, and generally requires
clinical data to support the safety and effectiveness of the device, obtained in conformance with IDE regulations. &#160;The FDA will
approve a PMA application if it finds that there is a reasonable assurance that the device is safe and effective for its intended purpose,
and that the proposed manufacturing is in compliance with the QSRs. &#160;For novel technologies, the FDA will seek input from an advisory
panel of medical experts regarding the safety and effectiveness of, and their benefit-risk analysis for the device. &#160;The PMA process
is generally more detailed, lengthier and more expensive than the 510(k) process, though both processes can be expensive and lengthy,
and requires payment of significant user fees, unless an exemption is available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are also required to comply with the regulations of every other country
where we commercialize products before we can launch or maintain new products on the market. &#160;Many countries that previously did
not have medical device regulations, or had minimal regulations, are now introducing them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">International sales of medical devices manufactured in the U.S. that are
not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance standards, are subject to FDA export
requirements. &#160;Additionally, exported devices are subject to the regulatory requirements of each country to which the device is exported.
&#160;Some countries do not have medical device regulations, but in most foreign countries, medical devices are regulated. &#160;Frequently,
regulatory approval may first be obtained in a foreign country prior to application in the U.S. due to differing regulatory requirements;
however, other countries require approval in the country of origin first. &#160;Most countries outside of the U.S. require that product
approvals be recertified on a regular basis, generally every five years. &#160;The recertification process requires that we evaluate any
device changes and any new regulations or standards relevant to the device and, where needed, conduct appropriate testing to document
continued compliance. &#160;Where recertification applications are required, they must be approved in order to continue selling our products
in those countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 4 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Post-Approval Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Even after a device is cleared or approved by FDA for marketing, numerous
regulatory requirements continue to apply. &#160;The FDA and other worldwide regulatory agencies and competent authorities actively monitor
compliance to local laws and regulations through review and inspection of design and manufacturing practices, record-keeping, reporting
of adverse events, labeling and promotional practices. &#160;The FDA can ban certain medical devices, detain or seize adulterated or misbranded
medical devices, order repair, replacement or refund of these devices and require notification of health professionals and others with
regard to medical devices that present unreasonable risks of substantial harm to the public health. &#160;The FDA may also enjoin and
restrain a company for certain violations of the FFDCA and the Safe Medical Devices Act pertaining to medical devices or initiate action
for criminal prosecution of such violations. &#160;In addition, FDA and other governmental agencies such as the Department of Justice
can take action against a company that promotes &#8220;off-label&#8221; uses. &#160;Regulatory agencies and authorities in the countries
where we do business can halt production in or distribution within their respective country or otherwise take action in accordance with
local laws and regulations. &#160;Any adverse regulatory action, depending on its magnitude, may restrict a company from effectively marketing
and selling its products, may limit a company&#8217;s ability to obtain future premarket clearances or approvals, and could result in
a substantial modification to a company&#8217;s business practices and operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Manufacturing Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We must also comply with FDA and foreign agency regulations governing medical
device manufacturing practices.&#160; The FDA and foreign agencies require manufacturers to register their establishments, and they monitor
compliance with device manufacturing requirements through inspections of manufacturing facilities.&#160; If an investigator observes conditions
that might be violative, the manufacturer must correct those conditions or explain them satisfactorily or face potential regulatory action
that might include physical removal of the product from the marketplace. &#160;We are an FDA-registered medical device manufacturer and
must demonstrate that we comply with the FDA&#8217;s QSR and Current Good Manufacturing Practices (&#8220;cGMPs&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe that our products and procedures are in compliance with all
applicable FDA and international regulations.&#160; There is no assurance, however, that other products we are developing or products
that we may develop in the future will be cleared by the FDA and classified as Class II products, or that additional regulations restricting
the sale of our present or proposed products will not be promulgated by the FDA or other foreign agencies.&#160; In addition, changes
in FDA, or other federal or state health, environmental or safety regulations or their applications could adversely affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Other Healthcare Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are subject to additional healthcare regulation and enforcement by the
federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. &#160;These laws include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs. &#160;A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other federal third-party payors that are false or fraudulent. &#160;In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>federal criminal laws that prohibit executing a scheme to defraud any federal healthcare benefit program or making false statements relating to healthcare matters;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 5 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">the federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain health care professionals beginning in 2022, and teaching hospitals and ownership and investment interests held by the physicians described above and their immediate family members, and payments or other &#8220;transfers of value&#8221; to such physician owners; and</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical and device companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to track and report information related to payments and other &#8220;transfers of value&#8221; to physicians and other healthcare providers or pricing, marketing expenditures and information; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Violations of any of the laws described above include civil and criminal
penalties, damages, fines, the curtailment or restructuring of an entity&#8217;s operations, the debarment, suspension or exclusion from
federal and state healthcare programs and/or imprisonment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Coverage and Reimbursement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our profitability and operations are subject to changes in legislative,
regulatory and reimbursement policies and decisions as well as changes in private payer reimbursement coverage and payment decisions and
policies. &#160;Our products are purchased by specialty pharmacies and ambulatory service providers or hospitals that typically bill various
third-party payors, such as governmental programs (e.g., Medicare, Medicaid, and comparable non-U.S. programs), private insurance plans
and managed care plans, for the healthcare services and products provided to their patients. &#160;The ability of our customers to obtain
appropriate coverage and reimbursement for our products and the drugs they administer is critical because it affects which products customers
purchase and the price they are willing to pay. &#160;Third-party payors are increasingly reducing coverage and reimbursement for certain
healthcare services and products and challenging prices charged for healthcare services and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Environmental Health and Safety Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are required to comply with federal, state, and local environmental
laws; however, there is no significant effect of compliance on capital expenditures, earnings, or competitive position. &#160;We do not
use significant amounts of hazardous materials in the assembly of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>COMPETITION AND THE MARKET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Competition for the FREEDOM System includes electronic (volumetric) pumps,
elastomeric (infuser) pumps, and fully mechanical pumps as well as other types of pumps. &#160;Safety, ease of use, familiarity, cost
effectiveness, accuracy, and sustainability are the principal driving influencers of pump selection. &#160;Electronic pumps deliver drugs
at a programmed flow rate. &#160;They are more costly and require electricity or batteries, extensive training and maintenance and must
be programmed by a qualified pharmacist or clinician. Elastomeric pumps are one-time-use balloon type devices used for infusion of drugs
in intravenous and surgical wound site applications. &#160;Pharmacies are required to fill them with drugs and deliver them to the patient.
&#160;They are easy to use from the patient point of view but can be more costly and time consuming to fill, are temperature sensitive
and have larger residual volumes than other delivery systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Competition for infusion devices for new drugs includes a variety of technologies
and companies. No single technological approach&#8212;autoinjectors, electronic (volumetric pumps), mechanical pumps, needle-free injectors,
on-body wearable devices, pen injectors, and pre-filled syringes&#8212;will meet the needs of all or even a majority of drugs. For drugs
requiring infusion volumes over 3 ml, the segment most similar to the SCIg drugs currently delivered by the FREEDOM System, the most relevant
approaches include mechanical pumps, on-body wearable devices, and simple electronic pumps. Challenges to their successful commercialization
include high costs per infusion, increased environmental impact, complexity for users, and complex mechanisms with multiple failure modes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 6 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>HUMAN CAPITAL RESOURCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2023, we had 82 full time employees, including 3 international
employees. &#160;As of December 31, 2023, approximately 51% of the Company&#8217;s workforce was female and approximately 37% of the Company&#8217;s
employees in managerial roles were female. &#160;Approximately 39% were minorities (non-White) in the Company workforce as of December
31, 2023. &#160;None of our employees are represented by a collective bargaining agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To help drive consistent execution of our business strategy, including
our customer focused philosophy, and support their development, we provide training opportunities to our employees that align with their
responsibilities over their career with us. &#160;We maintain a dedicated Internet-based learning platform with a broad portfolio of written,
audio-visual and interactive enterprise-wide and discipline-specific policy and training materials. &#160;This platform includes a library
of self-directed courses and virtual, instructor-led programs for employees at all levels of our organization. &#160;Managers and supervisors
are provided training to help their employees progress in their professional development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe our employees are key to achieving our business objectives.
&#160;Our key human capital measures include employee safety, turnover, absenteeism and production. &#160;We frequently benchmark our
compensation practices and benefits programs against those of comparable industries and in the geographic areas where our facilities are
located. &#160;We believe that our compensation and employee benefits are competitive and allow us to attract and retain skilled and unskilled
labor throughout our organization. &#160;Our notable health, welfare and retirement benefits include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Company subsidized health insurance</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>401(k) Plan with Company matching contributions</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td style="text-align: justify">Paid time off</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Life and disability insurance</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We strive to maintain an inclusive environment free from discrimination
of any kind, including sexual or other discriminatory harassment. &#160;Our employees have multiple avenues available through which inappropriate
behavior can be reported, including a confidential hotline. &#160;All reports of inappropriate behavior are promptly investigated with
appropriate action taken to stop such behavior.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>PATENTS AND INTELLECTUAL PROPERTY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have patents and other intellectual property that we believe protect
the FREEDOM System, and we continue to file patent applications in connection with our research and development activities. As of December
31, 2023, we own 15 U.S. Patents and 60 foreign patents. In addition, we have 12 pending U.S. patent applications and 13 foreign patent
applications. The fundamental patents protecting our drug delivery systems extend until 2039 and beyond.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>EXECUTIVE OFFICERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth certain information with respect to our
executive officers as of March 13, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 1.5in"><b>Name</b></td>
    <td style="width: 0.25in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 0.5in; text-align: center"><b>Age</b></td>
    <td style="width: 0.25in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5in"><b>Position / Held Since</b></td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>Linda Tharby</td>
    <td>&#160;</td>
    <td style="text-align: center">55</td>
    <td>&#160;</td>
    <td>Chief Executive Officer and President (since April 2021)</td></tr>
  <tr style="vertical-align: top">
    <td>Tom Adams</td>
    <td>&#160;</td>
    <td style="text-align: center">51</td>
    <td>&#160;</td>
    <td>Chief Financial Officer, Secretary and Treasurer (since August 2023)</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>Brian Case</td>
    <td>&#160;</td>
    <td style="text-align: center">51</td>
    <td>&#160;</td>
    <td>Chief Technology Officer (since April 2022)</td></tr>
  <tr style="vertical-align: top">
    <td>Ken Miller</td>
    <td>&#160;</td>
    <td style="text-align: center">55</td>
    <td>&#160;</td>
    <td>Chief Commercial Officer (since November 2023)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Executive officers hold office at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 7 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Ms. Tharby was appointed as President and CEO in April 2021. Ms. Tharby
has over 25 years of executive leadership experience building and leading strong performing global organizations that develop and commercialize
products and service innovations, while delivering solutions to patients in the home setting. Prior to joining KORU, Ms. Tharby spent
24 years working in various roles of increased responsibility at Becton Dickinson (&#8220;BD&#8221;). Ms. Tharby was a member of the Executive
Leadership team of BD that transformed the company from an $8 billion medical supplies company to an $18 billion global medical technology
company. Ms. Tharby&#8217;s last role at BD was as Chief Customer Experience Officer from July 2018 through December 2020. Prior to that
she served as BD&#8217;s Chief Human Resources Officer, from October 2016 through July 2018. From 1998 to 2016, she held numerous senior
global business leadership roles at BD, including Executive Vice President and President of Life Sciences, Group President of Pre-Analytical
Systems and Biosciences, Worldwide President of Diabetes Care, and Vice President/General Manager of Pharmaceutical Systems. Ms. Tharby
has an Honors Bachelor of Business Administration from Wilfrid Laurier University in Waterloo, Ontario Canada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Adams joined KORU Medical in November 2021 as Vice President of Financial
Planning and Analysis, was appointed Interim-Chief Financial Officer in July 2022 and Chief Financial Officer in August 2023. Mr. Adams
has an extensive background in financial planning, corporate finance, commercial and supply chain finance, and mergers and acquisitions
(M&amp;A). Prior to joining KORU Medical, Mr. Adams spent 10 years at Integra Life Sciences in various leadership positions in Finance
and Accounting Controllership with his most recent position as Senior Director of Finance. In this role, Mr. Adams was the head of finance
for Integra&#8217;s Tissue Technology Business where he served a leading role in supporting a $500 million business unit to high growth
and profitability. Previous roles included Group Controller/Head of FP&amp;A Global Supply and prior to Integra Life Sciences, Mr. Adams
served as Director of Finance at Pfizer Inc serving in many domestic and international roles. Mr. Adams earned his Bachelor of Science
in Business Administration-Accounting &amp; Finance from the Ohio State University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Case joined KORU Medical in April 2022 as Chief Technology Officer.
Mr. Case has over 20 years of research and development experience working with a combination of large and small medical device companies.
For the 16 years prior to joining KORU Medical, Mr. Case was an R&amp;D leader with Fresenius Kabi, a global leader specializing in lifesaving
medicines and technologies for infusion, transfusion, and clinical nutrition. As the Vice President of R&amp;D for the Transfusion and
Cell Technologies business, Mr. Case provided global business and technical leadership to drive the long-term product vitality of the
business and promote entry into new business areas. &#160;During his time at Fresenius, Mr. Case&#8217;s many accomplishments included
bringing new products and technologies to market, leading to new business divisions, multiple international product approvals and value
creation for the company. Mr. Case also led the Project Management office for the company, responsible for the identification and implementation
of best practices and functional excellence. &#160;Prior to Fresenius, Mr. Case was the R&amp;D Manager, Advanced Research at Cook Medical
where he led a cross-functional team that developed and assessed new technologies to create a product portfolio to service the peripheral
disease market. Mr. Case&#8217;s work has been prolific with over 100 patents filed during his career. Mr. Case received his Master of
Science in Engineering Management from Rose-Hulman Institute of Technology, and his Bachelor of Science in Engineering Mechanics, from
University of Illinois.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Miller joined KORU Medical in November 2023 as Chief Commercial Officer.
Mr. Miller has over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing
strategy, international expansion, and driving sustainable growth and profitability.&#160; As Chief Commercial Officer, Mr. Miller has
oversight of the global commercial function, including U.S. and International sales and marketing organizations. He was President &amp;
CEO of NASCO HealthCare from October 2018 through January 2023. At NASCO, he transformed sales &amp; marketing, and led the consolidation
of NASCO&#8217;s manufacturing footprint which delivered year-over-year double digit revenue and EBITDA growth.&#160; Prior to NASCO,
Ken spent 7 years at BD with his last role as the Worldwide President Diabetes Care where he led the transition from a product focus to
a full-service diabetes management solution provider. Ken also held leadership roles in marketing, sales, and business development with
Novo Nordisk, Adams Respiratory Therapeutics, and Roche Laboratories.&#160; He earned his Bachelor of Arts in Business Management from
State University of New York at Albany and his Master of Business Administration from The University of Chicago, Booth School of Business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_1A"></span><b>ITEM 1A. RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>An investment in our common stock involves significant risks. &#160;Before
making an investment in our common stock, you should carefully consider all of the information contained in this Annual Report on Form
10-K and our other filings with the SEC including the material risks and uncertainties that we have identified below. &#160;The risks
and uncertainties identified below are not the only risks and uncertainties we face. &#160;If any of the material risks or uncertainties
that we face were to occur, the trading price of our common stock could decline and you could lose part or all of your investment. &#160;Please
note that additional risks not currently known to us or that we currently deem immaterial also may adversely affect our business, operations,
results of operations, financial condition and prospects.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 8 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Risks Related to Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If we are unable to successfully introduce new products or fail to
keep pace with advances in technology, our business, financial condition and results of operations could be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We need to successfully introduce new products to achieve our strategic
business objectives. &#160;A significant element of our strategy is to increase revenue growth by investing in innovation and new product
development, which will require substantial resources. &#160;Our successful product development will depend on many factors, including
our ability to attract strong talent to lead our research and development efforts, properly anticipate and satisfy customer needs, adapt
to new technologies, obtain regulatory concurrence on a timely basis, demonstrate satisfactory clinical results, manufacture products
in an economical and timely manner, obtain appropriate intellectual property protection for our products, gain and maintain market acceptance
of our products, and differentiate our products from those of our competitors. &#160;In addition, patents attained by others can preclude
or delay our commercialization of a product. There can be no assurance that any products now in development or that we may seek to develop
in the future will achieve technological</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">feasibility, obtain regulatory concurrence or gain market acceptance. &#160;If
we cannot successfully introduce new products or adapt to changing technologies, our products may become obsolete, and our revenue and
profitability could suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our business depends on an adequate supply of drugs to be administered
by our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Demand for our products depends on the availability of drugs to be administered
through our delivery system.. &#160;Currently, most of our products require immunoglobulin therapies that rely on blood plasma collection
for drugs such as Hizentra&#174; and Cuvitru&#174;. &#160;Any disruption in the supply of these drugs for any reason, including contamination,
could significantly adversely affect our business. &#160;The change of any drug indication by the FDA or comparable foreign governmental
agencies could also result in decreased demand for our products. &#160;In addition, pharmaceutical companies and other competitors have
or are developing alternative therapies for disease states that are deliverable with devices we do not offer or without a medical device.
&#160;If there is not an adequate supply of drugs requiring administration by medical devices such as those provided by us or alternative
therapies are developed, our sales may suffer and/or our products may become obsolete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our compliance with EU MDR regulations by December 2028 will require
significant investment and, if we are not in compliance by that time, we will not be able to sell our products in the EU.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the European Union (&#8220;EU&#8221;), we are required to comply with
the new Medical Device Regulation (&#8220;MDR&#8221; or &#8220;EU MDR&#8221;) effective May 2021, which supersedes the prior Medical Device
Directives. Medical devices which have a valid CE certificate to the current Medical Device Directives (issued before May 2021), as do
all of our current products, can continue to be sold until December 2028 or until the CE certificate expires, whichever comes first, providing
there are no significant changes as defined in Article 120 of EU MDR. The MDR was published in May 2017 with a 3-year transition period.
That transition period was extended to May 2021 due to the COVID-19 pandemic. In early 2023, the transition period was further extended
to December 2028 for class IIa products. The CE mark required to sell medical devices in the EU is affixed following conformity assessment
and either approval from an appointed independent notified body or through self-certification by the manufacturer. The selected pathway
to CE marking is based on product risk classification. CE marking indicates conformity to the applicable essential requirements of the
relevant Medical Device Directives and in the future to the general safety and performance requirements for the new MDR. The MDR will
change multiple aspects of the existing regulatory framework for CE marking, such as increased clinical evidence requirements and other
new requirements, including Unique Device Identification (&#8220;UDI&#8221;) as well as many other post-market obligations. MDR also significantly
modifies and increases the compliance requirements for the industry and will require significant investment by us in the near future to
implement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our products are also subject to approval and regulation by foreign regulatory
and safety agencies. For example, the EU has adopted the EU Medical Device Regulation (the &#8220;EU MDR&#8221;) and the In Vitro Diagnostic
Regulation (the &#8220;EU IVDR&#8221;), each of which impose stricter requirements for the marketing and sale of medical devices, including
in the area of clinical evaluation requirements, quality systems and post-market surveillance. Implementation of the compliance requirements
of these regulations requires us to incur significant expenditures and utilize resources. Failure to continue to meet these requirements
could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If we are unable to comply with the MDR by December 2028, we will not be
able to sell our products in the EU, which will materially impact our net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 9 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Interruption of our manufacturing or our contract manufacturing operations
could adversely affect our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Command currently provides subassemblies for all of our consumables (needle
and tubing sets), and manufactures, assembles and packages approximately substantially all of our consumables. In the event of any interruption
in Command&#8217;s operations or supply of goods, the Company may have to seek alternative sources of subassemblies, which may be not
be readily available on commercially reasonable terms or at all, and increase its capacity for manufacturing finished goods in Mahwah,
NJ, which could be time-consuming and costly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The FDA and other U. S. and non-U.S. government agencies regulate our manufacturing
and contract manufacturing operations for all of our products. Variations in our or Command&#8217;s manufacturing process may result in
production failures which could lead to launch delays, product shortage, unanticipated costs, lost revenues and damage to our reputation.
&#160;A failure to identify and address manufacturing problems prior to the release of products to our customers may also result in a
quality or safety issue that could result in a recall or other inability to sell our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our products are currently manufactured in Nicaragua and Mahwah, NJ, and
stored at our corporate headquarters in Mahwah, NJ. &#160;Loss or damage to our manufacturing or contract manufacturing and storage site
due to weather, vandalism, terrorism, a natural disaster, issues in our manufacturing process, equipment failure or other factors, could
adversely affect our ability to manufacture sufficient quantities of products or otherwise deliver products to meet customer demand or
contractual requirements which may result in a loss of revenue and other adverse business consequences, including damage to our relationship
with customers. Additionally, because Command manufactures and supplies the Company&#8217;s subassemblies and finished goods for needle
sets and tubing products in Nicaragua, there could be a delay in providing the products timely due to their climate and international
boundaries. Command currently stores our finished goods in their warehouse located in Miami Florida once the products are released from Nicaragua.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We take precautions to safeguard our facility, including acquiring insurance,
adopting health and safety protocols and utilizing off-site storage of computer data. &#160;Our insurance may not cover our losses in
any particular case. &#160;In addition, regardless of the level of insurance coverage, damage to our facility may harm our business, financial
condition and operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Public health crises, such as the COVID-19 pandemic, have had, and
could in the future have, a negative effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pandemics or disease outbreaks, such as the COVID-19 pandemic, have created
and may continue to create significant volatility, uncertainty and economic disruption in the markets we sell our products into and operate
in, primarily the U.S., Europe, and Asia-Pacific and may negatively impact business and healthcare activity globally. In response to the
COVID-19 pandemic, governments around the world have imposed measures designed to reduce the transmission of COVID-19 and individuals
continue to respond to the fear of contracting COVID-19. In particular, elective procedures and exams were delayed or cancelled, there
were significant reductions in physician office visits, and hospitals postponed or canceled capital purchases as well as limited or eliminated
services. While elective procedures and exams and capital purchases have increased from initially depressed levels, the reduction in elective
procedures, exams and capital purchases has had, and we believe may continue to have, a negative impact on the sales of our products.
Additionally, governments and other third-party payors around the world facing tightening budgets could move to further reduce the reimbursement
rates or the scope of coverage offered, which could further adversely affect sales of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The extent to which fear of exposure to or actual effects of COVID-19,
new variants, disease outbreak, epidemic or a similar widespread health concern impacts our business will depend on future developments,
which are highly uncertain and cannot be predicted with confidence, such as the speed and extent of geographic spread of the disease,
the duration of the outbreak, travel restrictions, the efficacy of vaccination and treatment; impact on the U.S. and international healthcare
systems, the U.S. economy and worldwide economy; the timing, scope and effectiveness of U.S. and international governmental response;
and the impact on the health, well-being and productivity of our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We may be unable to compete successfully in our highly competitive
industry.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We operate in a single market &#8211; ambulatory infusion &#8211; and are
dependent upon our success in that market. We face competition in our market from a wide range of international and domestic companies,
including those that deliver electronic volumetric pumps, elastomeric infuser pumps, other mechanical devices, novel drug delivery devices
and methodologies, and devices and formulation technologies that allow drugs to be delivered in volumes smaller than the FREEDOM System
is designed to deliver.&#160; These include large medical device companies with multiple product lines, some of which may have greater
financial and marketing resources than we do. &#160;We also face competition from companies that are even more specialized than ours with
respect to particular markets or product lines. &#160;Some of those companies have greater financial and sales and marketing resources
than we do or offer products at a lower price point than ours. &#160;In addition, former employees may develop products that are competitive
with ours or capitalize on customer relationships developed while employed with us, subject to their continuing obligations under confidentiality
agreements and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 10 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">other restrictive covenants that may survive their employment. &#160;We
face competition on the basis of product features, clinical or economic outcomes, product quality, availability, price, services, technological
innovation and other factors. &#160;In addition, we face changing customer preferences and requirements, changes in the ways health care
services are delivered, including the transition of high-acuity care to lower-acuity, and non-acute care settings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Competition may increase further as additional companies begin to enter
our market or modify their existing products to compete directly with ours. &#160;If we are forced to reduce our prices due to increased
competition, our business could suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The medical technology industry has also experienced a significant amount
of consolidation, resulting in larger companies with greater access to markets. &#160;Pharmaceutical manufacturers, health care systems,
other health care companies and even retail pharmacies are also consolidating, resulting in greater purchasing power for these companies.
&#160;As a result, competition among medical device suppliers to provide goods and services has increased. &#160;Group purchasing organizations
and integrated health delivery networks have also served to concentrate purchasing decisions for some customers, which has led to downward
pricing pressure for medical device suppliers. &#160;Further consolidation in the industry could intensify competition among medical device
suppliers and exert additional pressure on the prices of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Consolidation in the medical industry could have a negative impact with
payor and provider relationships and distributor relationships, as we could lose market share as consolidation occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Technological developments by others may disrupt our business and
negatively impact our revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The medical device industry is subject to rapid technological change and
discovery and frequent product introductions. &#160;The development of new or improved products, processes or technologies by other companies
that provide better features, pricing or clinical outcomes or economic value may render our products or proposed products obsolete or
less competitive. &#160;If our competitors respond more quickly to new or emerging technologies and changes in customer requirements or
we do not introduce new versions or upgrades to our product portfolio in response to those requirements, our products may not be marketable.
&#160;If competitors develop more effective or affordable products or achieve earlier patent protection or product commercialization for
new products than we do, our operations will likely be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to costly and complex laws and governmental regulations
and any adverse regulatory action may materially adversely affect our financial condition and business operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our medical devices and technologies, as well as our business activities,
are subject to a complex set of regulations and rigorous enforcement, principally by the FDA, numerous other federal, state, and non-U.S.
governmental authorities and equivalent regulatory bodies of other countries. &#160;To varying degrees, each of these agencies requires
us to comply with laws and regulations governing the design, development, and manufacturing; testing, labeling, content and language of
instructions for use and storage; clinical trials; product safety; establishment registration and device listing; marketing, promotion,
and distribution of our products; premarket clearance and approval; record keeping procedures; advertising and promotion; recalls and
field safety corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if
they were to recur, could lead to death or serious injury; post-market approval studies; and product import and export.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the U.S., our device products are subject to clearance or approval by
FDA under the FFDCA. &#160;Before we can market a new medical device, or a new use of, new claim for, or significant modification to,
an existing product, we must first receive either 510(k) clearance or approval of a PMA application from the FDA, unless an exemption
applies. &#160;Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device
is &#8220;substantially equivalent,&#8221; as defined in the statute, to a legally marketed predicate device. &#160;To be &#8220;substantially
equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological
characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or
effectiveness than the predicate device. &#160;If the manufacturer is unable to demonstrate substantial equivalence to FDA&#8217;s satisfaction,
or if there is no available predicate device, then the manufacturer may be required to seek approval through the PMA application process,
which is generally more costly and time consuming than the 510(k) process. &#160;Through the PMA application process, the applicant must
submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use. &#160;Accordingly,
a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development,
pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators
in device studies. In the future our device products may be approved as part of a drug submission under a combination product regulatory
pathway. Under the combination product approval process, our device would typically be submitted as part of a drug application, typically
a BLA or NDA in the United States. The proof required for approval as a combination product is similar to that required for a 510(k),
but may differ in material ways. In addition, the regulatory approval is held by the pharmaceutical manufacturer, not KORU.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 11 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We cannot guarantee that we will be able to obtain or maintain FDA 510(k)
clearance or premarket approval for our new products or enhancements or modifications to existing products (including the use of our FREEDOM
System with therapies not covered by the existing FDA clearance), and the failure to maintain approvals or clearances, or obtain approval
or clearance could have a material adverse effect on our business, results of operations, financial condition and cash flows. Even if
we are able to obtain approval or clearance, it may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">take a significant amount of time</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>require the expenditure of substantial resources</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>involve stringent clinical and pre-clinical testing, as well as increased post-market surveillance</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>involve modifications, repairs, or replacements of our products, and</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>limit the proposed uses of our products.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Both before and after a product is commercially released, we have ongoing
responsibilities under the FDA and other applicable non-U.S. government agency laws and regulations. &#160;The FDA and other worldwide
regulatory agencies actively monitor compliance with local laws and regulations through review and inspection of design and manufacturing
practices, recordkeeping, reporting of adverse events, labeling and promotional practices. &#160;The results of these inspections can
include inspectional observations on the FDA&#8217;s Form 483, warning letters, or other forms of enforcement. &#160;If the FDA or any
state or foreign regulatory authorities were to conclude that we are not in compliance with any applicable laws or regulations, or that
any of our medical products are ineffective or pose an unreasonable health risk, they could deem our products adulterated or misbranded,
and take enforcement action against us. &#160;FDA and state and foreign regulatory authorities have broad enforcement powers. &#160;Possible
enforcement actions include, but are not limited to:&#160; temporarily or permanently suspending the sale and/or distribution of such
medical products; detaining or seizing all adulterated or misbranded medical products; ordering recall, repair, replacement, or refund
of such products; refusing to grant pending pre-market approval or 510(k) clearance applications; and/or requiring us to notify health
professionals and others that the devices present unreasonable risks of substantial harm to the public health. &#160;In addition, the
FDA prohibits device manufacturers from promoting their products for uses and indications other than those set forth in the approved product
labeling, and failure to comply with this prohibition could subject us to significant civil or criminal exposure, administrative obligations
and costs, and/or other potential penalties from, and/or agreements with, the federal government. &#160;The FDA and other non-U.S. government
agencies may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide
basis. &#160;The FDA may also recommend prosecution to the U.S. Department of Justice. &#160;Any adverse regulatory action, depending
on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future pre-market
clearances or approvals, and could result in a substantial modification to our business practices and operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Regulations regarding the development, manufacture and sale of medical
devices are evolving and subject to future change and have tended to become more stringent over time. &#160;Regulatory changes could result
in restrictions on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. We
cannot predict what impact, if any, those changes might have on our business; however, failure to comply with applicable regulatory requirements
could have a material adverse effect on our business, financial condition, and results of operations. &#160;Later discovery of previously
unknown problems with a product or manufacturer could result in fines, delays or suspensions of regulatory clearances or approvals, seizures
or recalls of products, physician advisories or other field actions, operating restrictions and/or criminal prosecution. &#160;We may
also initiate field actions as a result of a failure to strictly comply with our internal quality policies. &#160;The failure to receive
product approval clearance on a timely basis, suspensions of regulatory clearances, seizures or recalls of products, physician advisories
or other field actions, or the withdrawal of product approval by the FDA or by comparable agencies in foreign countries could have a material
adverse effect on our business, financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Governmental regulations outside the U.S. have also, and may continue to,
become increasingly stringent and common. &#160;Penalties for regulatory non-compliance could be severe, including fines and revocation
or suspension of a company&#8217;s EU device approval, ability to distribute products and criminal sanctions. &#160;Future foreign governmental
laws and regulations may have a material adverse effect on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, exported devices are subject to the regulatory requirements
of each country to which the device is exported. &#160;Some countries do not have medical device regulations, but in most foreign countries,
medical devices are regulated. &#160;Frequently, regulatory approval may first be obtained in a foreign country prior to application in
the U.S. due to differing regulatory requirements; however, other countries, such as China for example, require approval in the country
of origin or legal manufacturer first. &#160;Most countries outside of the U.S. require that product approvals be renewed or recertified
on a regular basis, generally every four to five years. &#160;The renewal or recertification process requires that we evaluate any device
changes and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance.
&#160;Where renewal or recertification applications are required, they may need to be renewed and/or approved in order to continue selling
our products in those countries. &#160;There can be no assurance that we will receive the required approvals for new products or modifications
to existing products on a timely basis or that any approval will not be subsequently withdrawn or conditioned upon extensive post market
study requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 12 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our global regulatory environment is becoming increasingly stringent and
unpredictable, which could increase the time, cost and complexity of obtaining regulatory approvals for our products, as well as the clinical
and regulatory costs of supporting those approvals. &#160;Several countries that did not have regulatory requirements for medical devices
have established such requirements in recent years and other countries have expanded on existing regulations. &#160;Certain regulators
are exhibiting less flexibility and are requiring local preclinical and clinical data in addition to global data. &#160;While harmonization
of global regulations has been pursued, requirements continue to differ significantly among countries. &#160;In the United Kingdom, for
example, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating the UK medical device market. &#160;With
recent changes in the United Kingdom&#8217;s membership with the European Union, the MHRA has and will continue to impose new regulatory
obligations becoming effective in 2021 through 2023, for medical device manufacturers. &#160;We expect this global regulatory environment
will continue to evolve, which could impact our ability to obtain future approvals for our products or could increase the cost and time
to obtain such approvals in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If our EU device approval is suspended, it could have a material
adverse effect on our business and financial results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s products are currently certified by its notified body,
BSI, for sale in the EU.&#160; In March 2024, the Company received an assessment report from BSI stating that, following BSI&#8217;s review
of technical documentation submitted by the Company in connection with a prior audit nonconformance, a recommendation for continued certification
cannot be made. &#160;The Company has filed an appeal to this determination.&#160; If the Company&#8217;s appeal is denied, then its EU
certification may be suspended with respect to some or all of the Company&#8217;s products.&#160; Any such suspension would affect the
Company&#8217;s EU revenues, which effect could be material depending on the extent of the suspension.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Health care policy changes and industry cost-containment measures
could result in downward pricing pressure for our products and limit our sales.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Most of our customers, and those to whom our customers supply medical devices,
rely on third-party payers, including government programs and private health insurance plans, to reimburse some or all the cost of the
medical devices we manufacture. &#160;The continuing efforts of governmental authorities, insurance companies and other payers of health
care costs to contain or reduce these costs and, more generally, to reform the health care system, could limit the prices we are able
to charge for our products or the amounts of reimbursement available for our products or the drugs that they administer, which would put
pressure on us to reduce our prices for our products and/or limit our sales. &#160;The adoption of some or all of these proposals could
have a material adverse effect on our business, results of operations, financial condition and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Issues with product quality could have an adverse effect upon our
business, subject us to regulatory actions, cause a loss of customer confidence in us or our products, among other negative consequences.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Quality management plays an essential role in determining and meeting customer
requirements, preventing defects, improving our products and services, and assuring the safety and efficacy of our products. &#160;Our
future success depends on our ability to maintain and continuously improve our quality management program. &#160;While we have a quality
system that covers the lifecycle of our products, quality and safety issues may occur with respect to any of our products. &#160;A quality
or safety issue may result in adverse inspection reports, voluntary or official action indicated, warning letters, import bans, product
recalls (either voluntary or required by the FDA or similar governmental authorities in other countries) or seizures, monetary sanctions,
injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a government
to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses. &#160;An inability to address
a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or
our current or future products, which may result in the loss of sales and difficulty in successfully launching new products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Defects or quality issues associated with our products could adversely
affect the results of our operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The design, manufacture and marketing of medical devices involve certain
inherent risks. &#160;Manufacturing or design defects, component failures, unapproved or improper use of our products, or inadequate disclosure
of risks or other information relating to the use of our products can lead to injury or other serious adverse events. &#160;We are subject
to the FDA&#8217;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we
receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death
or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious
injury. &#160;The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature
of the event. &#160;If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled
letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearances or
approvals, seizure of our products, or delay in clearance or approval of future products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 13 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These adverse events could also lead to safety alerts relating to our products
or recalls (either voluntary or as required by the FDA or similar governmental authorities in other countries), and could result, in certain
cases, in the removal of a product from the market. &#160;A recall could result in significant costs and lost sales and customers, enforcement
actions and/or investigations by state and federal governments or other enforcement bodies, as well as negative publicity and damage to
our reputation that could reduce future demand for our products. &#160;Any corrective action, whether voluntary or involuntary, as well
as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business
and may harm our reputation and financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Personal injuries relating to the use of our products can also result in
significant product liability claims being brought against us. &#160;A product liability claim, regardless of its merit or outcome, could
not only result in significant legal defense costs, but also have a material adverse effect on our business and reputation and ability
to attract and retain customers for our products. &#160;In some circumstances, adverse events could also cause delays in regulatory approval
of new products or the imposition of post-market approval requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to lawsuits.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have been and may be party to lawsuits, settlement discussions, mediations,
arbitrations and other disputes, including patent and product liability claims, whether brought by companies, individuals or governmental
authorities. &#160;These matters may result in a loss of patent protection, reduced revenue, incurrence of significant liabilities and
diversion of our management&#8217;s time, attention and resources. Our insurance coverage may not provide adequate protection against
actual losses. &#160;In addition, we are subject to the risk that one or more of our insurers may become insolvent and become unable to
pay claims that may be made in the future. &#160;Even if we maintain adequate insurance, claims could have a material adverse effect on
our financial condition, liquidity and results of operations and on our ability to obtain suitable, adequate or cost-effective insurance
in the future. &#160;Litigation and other disputes, including any adverse outcomes, may have an adverse impact on our business, operations
or financial condition. &#160;Even claims without merit could subject us to adverse publicity and require us to incur significant legal
fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If we are unable to protect our patents or other proprietary rights,
or if we infringe the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Patent and other proprietary rights are essential to our business. &#160;We
own patents, trade secrets, trademarks and/or other intellectual property rights related to many of our products. &#160;Our success depends
to a significant degree on our ability to obtain and enforce patents, both in the U.S. and in other countries. &#160;We can lose the protection
afforded by these intellectual property assets through patent expirations, legal challenges or governmental action. &#160;Additionally,
our intellectual property rights may be challenged or infringed upon by third parties, particularly in countries where property rights
are not highly developed or protected, or we may be unable to enter into license agreements with third-party owners of intellectual property
on reasonable terms. &#160;Unauthorized use of our intellectual property rights or inability to preserve existing intellectual property
rights could adversely impact our competitive position and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The patent position of a medical device company is often uncertain and
involves complex legal and factual questions. &#160;Significant litigation concerning patents and products is pervasive in our industry.
&#160;Patent claims include challenges to the coverage and validity of our patents on products or processes as well as allegations that
our products infringe patents held by competitors or other third parties. &#160;A loss in any of these types of cases could result in
a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially
affect future results of operations. &#160;We also rely on trademarks, trade secrets and know-how to develop, maintain and strengthen
our competitive positions. &#160;Third parties may know, discover or independently develop equivalent proprietary information or techniques,
or they may gain access to our trade secrets or disclose our trade secrets to the public.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Although our employees, consultants, parties to collaboration agreements
and other business partners are generally subject to confidentiality or similar agreements to protect our confidential and proprietary
information, these agreements may be breached, and we may not have adequate remedies in the event of a breach of confidence. &#160;To
the extent that our employees, consultants, parties to collaboration agreements and other business partners use intellectual property
owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Furthermore, our intellectual property, other proprietary technology and
other sensitive company data is potentially vulnerable to loss, damage or misappropriation from system malfunction, computer viruses,
unauthorized access to our data or misappropriation or misuse thereof by those with permitted access and other events. &#160;While we
have invested to protect our intellectual property, confidential information and other data, and continue to work diligently in this area,
there can be no assurance that our precautionary measures will prevent breakdowns, breaches, cyber incidents or other events. Such events
could have a material adverse effect on our reputation, business, financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 14 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Misappropriation or other loss of our intellectual property from any of
the foregoing would have an adverse effect on our competitive position and may cause us to incur substantial litigation costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We need to attract and retain key employees to be competitive.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ability to compete effectively depends upon our ability to attract
and retain executives and other key employees, including people in technical, marketing, sales, research and development, quality assurance
and regulatory compliance positions. &#160;We depend on key management personnel and attracting and retaining other qualified personnel,
and our business could be harmed if we lose key management personnel or cannot attract and retain other qualified personnel. &#160;We
do not maintain any &#8220;key man&#8221; insurance policies on the lives of any of our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The failure to attract, integrate, motivate, and retain skilled and qualified
personnel could have a material adverse effect on our business. &#160;We compete for such personnel against numerous companies, including
larger, more established companies with significantly greater financial resources than we possess. &#160;Our ability to recruit such talent
will depend on a number of factors, including compensation and benefits, work location and work environment. &#160;There can be no assurance
that we will be successful in attracting or retaining such personnel and the failure to do so could have a material adverse effect on
our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We sell a majority of our products through only a few distributors
on whom we depend, and our financial results depend on their purchasing patterns.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Most of our customers prefer to purchase our products through distributors,
rather than directly from us, because of &#8220;one-stop shopping&#8221; convenience and their ability to ship directly to patients. &#160;We
sell most of our products through a small number of distributors, three in the U.S. and two outside the U.S. &#160;As of December 31,
2023, these five distributors comprised approximately 74% of our net revenues with one U.S. distributor contributing 41%. &#160;Purchasing
patterns by these distributors cannot always be predicted and fluctuate from quarter to quarter and year to year based on, among other
things, their expectations of customer demand.&#160; Any decline in business with the distributors outside the U.S. could have an adverse
impact on our business. &#160;If we were unable to sell through the distributors outside the U.S., we would have to find other distributors
or broaden our customer base and expand direct relationships with customers. &#160;Other distributors may not be available or may not
agree to arrangements that are commercially reasonable. &#160;In the U.S. we could transition to direct customer purchase; however, customers
may not want to purchase directly from us and may decide to purchase competitors&#8217; products through their distributors. &#160;Moreover,
a transition from distributors to direct customer purchase would be time consuming and costly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We and the biopharmaceutical companies with whom we do novel therapies
business (&#8220;our biopharma customers&#8221;) are subject to extensive regulation by governments around the world, and if these regulations
are not complied with, existing and future operations may be curtailed, and we could be subject to liability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our devices and our biopharma customers&#8217; products that may utilize
our device are subject to extensive regulation by governmental authorities in the United States, Europe and other countries, including
the FDA. &#160;Not only do these regulations present challenges during the regulatory approval process, but after our devices or our biopharma
customers&#8217; products that may utilize our device are approved for new indications and placed in the market, numerous regulatory requirements
will apply. &#160;These include, but are not limited to QSR, labeling regulations and FDA prohibitions against the promotion of products
for uncleared, unapproved or &#8220;off label&#8221; uses, medical device reporting regulations and post-market surveillance regulations,
and laws and regulations that govern the development, testing, manufacturing, advertising, marketing and distribution of medical devices,
including our devices and our biopharma customers&#8217; products that may utilize our device. &#160;The FDA has broad post-market and
regulatory enforcement powers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the European Union (&#8220;EU&#8221;), we are required to comply with
the new Medical Device Regulation (&#8220;MDR&#8221; or &#8220;EU MDR&#8221;) effective May 2021, which will supersedes the prior Medical
Device Directives. &#160;Class IIa medical devices which have a valid CE certificate to the current Medical Device Directives can continue
to be sold until December 2028 or until the CE certificate expires, whichever comes first, providing there are no significant changes
as defined in Article 120 of EU MDR. &#160;The MDR was published in May 2017 with a 3-year transition period. &#160;That transition period
was extended to May 2021 due to the COVID-19 pandemic. &#160;In 2023, the transition period was extended further to December 2028 for
Class IIa products. The CE mark required to sell medical devices in the EU is affixed following conformity assessment and either approval
from an appointed independent notified body or through self-certification by the manufacturer. &#160;The selected pathway to CE marking
is based on product risk classification. &#160;CE marking indicates conformity to the applicable essential requirements of the relevant
Medical Device Directives and in the future to the general safety and performance requirements for the new MDR. &#160;The MDR will change
multiple aspects of the existing regulatory framework for CE marking, such as increased clinical evidence requirements and other new requirements,
including Unique Device Identification (&#8220;UDI&#8221;) as well as many other post-market obligations. &#160;MDR also significantly
modifies and increases the compliance requirements for the industry and will require significant investment in the near future to implement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 15 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If our devices are commercialized as part of a drug-delivery combination
product we, as the manufacturer of the device component of that combination product, we are subject to unannounced and preapproval inspections
by the FDA of our manufacturing facility to determine our compliance with QSR and cGMP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin: 0">Failure to comply with applicable regulatory requirements can result in
an enforcement action by the FDA or other regulatory authority, which may include any or all of the following sanctions: fines, injunctions,
consent decrees and civil penalties, recall or seizure of our products or our biopharma customers&#8217; products, operating restrictions,
partial suspensions or total shutdown of production, refusing our biopharma customers&#8217; requests for regulatory approvals of their
drug-device combination products or new intended uses, as applicable, refusing our requests for regulatory approval of our devices, withdrawing
our biopharma customers&#8217; or our regulatory approvals that may be granted and criminal prosecution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>The therapeutic efficacy of certain of our biopharma customers&#8217;
products that may utilize our device are either unproven in humans or has only been proven in limited circumstances, and we may not be
able to successfully develop and sell our products in combination with our biopharma customers&#8217; products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">While some of our biopharma customers use our products with established,
approved drugs, in certain instances, the benefits of those drugs as injectable therapies are either unproven or have only been proven
in limited circumstances. &#160;Our ability to generate revenue from our products will depend heavily on the successful development, commercialization
and sales of our biopharma customers&#8217; products, which is subject to many potential risks. &#160;For example, data developed in clinical
trials or following the commercialization of our biopharma customers&#8217; products may show that such therapies do not prove to be effective
treatments for the targets they are being designed to act against (or as effective as other treatments available). In clinical trials
or following commercialization, it may be shown that those drugs interact with human biological systems in unforeseen, ineffective or
harmful ways. &#160;If those drugs are associated with undesirable side effects or have characteristics that are unexpected, the pharmaceutical
companies that make those drugs may need to abandon clinical development or discontinue commercial sales or limit clinical development
or sales to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe
or more acceptable from a risk-benefit perspective. &#160;As a result of these and other risks described herein that are inherent in the
development and sale of therapeutic agents, pharmaceutical companies may never successfully develop or successfully commercialize their
drugs, or the commercialization of their drugs may be abandoned or severely limited, which may limit our profitability with respect to
biopharma customers with drugs or drug-device combination products including those drugs and our device, and we may not be successful
in achieving commercial scale production and sales of our injectable drug delivery systems in combination with certain drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Certain of the injectable therapies being targeted for use with our
products are not approved but are in various phases of clinical development. These injectable therapies may be independently terminated
by their makers prior to submission of a regulatory filing or even after regulatory approval and pharmaceutical developers may cease their
efforts with us, resulting in the cessation of any revenue associated with that contract or program.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We work with pharmaceutical and biotechnology companies who are targeting
the use of our products with a variety of injectable therapies. &#160;When we collaborate with pharmaceutical developers, they may engage
us in a variety of ways, including <i>in vitro </i>feasibility testing, product customization and validation (&#8220;development&#8221;),
non-interventional user testing of our devices, animal or human clinical research using our devices, regulatory submissions, manufacturing
development, and commercialization. Certain of those injectable therapies are not FDA approved and are in various phases of clinical development.
&#160;The clinical development of these pipeline therapies can be terminated by their developers at any stage. &#160;Our biopharma customers
may choose to continue their drug program without use of our devices. Use in one stage of work does not guarantee use in a future development
stage or in commercialization. Furthermore, these pharmaceutical companies could obtain regulatory approval for their injectable therapies
and decide for business reasons not to require or encourage utilization of our device. &#160;Prior investments we have made in manufacturing
capacity or research and development will then not result in the generation of revenue that would have previously been anticipated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our commercial success depends upon the attainment of significant
market acceptance of drug product candidates to be included in our biopharma customers&#8217; products that may utilize our device, if
approved, among physicians, patients, healthcare payers or the medical community.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Even if biopharmaceutical companies obtain regulatory approval for their
drug product candidates, their product candidates may not gain sufficient levels of market acceptance among physicians, healthcare payers,
patients or the medical community to make them commercially feasible. Market acceptance of our biopharma customers&#8217; product candidates,
if they receive approval, depends on a number of factors, including the:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 16 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">efficacy and safety of the product candidates;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>clinical indications for which the product candidates are approved;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>acceptance by physicians, patients and the medical community of the product candidates as a safe and effective treatment;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>potential and perceived advantages of the product candidates over alternative treatments;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>safety of the product candidates seen in a broader patient group;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>prevalence and severity of any side effects;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>product labeling or product insert requirements of the FDA or other regulatory authorities;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>timing of market introduction of the product candidates as well as competitive products;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>cost of treatment in relation to alternative treatments;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>availability of coverage and adequate reimbursement and pricing by third party payers and government authorities;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>relative convenience and ease of administration; and</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>effectiveness of the pharmaceutical companies&#8217; sales and marketing efforts.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If pharmaceutical companies&#8217; candidates are approved but fail to
achieve market acceptance among physicians, patients or healthcare payers, we may not be able to generate anticipated revenue. &#160;This
may limit our ability to generate anticipated revenue from our prior investments. &#160;Moreover, even if we achieve commercial scale
production and sales of our injectable drug delivery systems in combination with certain injectable therapies, the makers of such therapies
may face indirect competition from companies who develop and market other brand name, biosimilar or generic injectable therapies as well
as alternative treatments and delivery methods that compete with our biopharma customers&#8217; products that may utilize our device,
which may have a material adverse effect on our results of operations, our financial condition and/or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Most brand name injectable therapies will face future competition
from generic or biosimilar therapies, which could significantly reduce their commercial viability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Brand name injectable therapies will usually become exposed to competition
from generic or biosimilar rivals at some time after their regulatory approval and commercial launch. &#160;The average selling price
and market share of brand name injectable therapies can be significantly diminished following the introduction of generic or biosimilar
competition. &#160;These factors may result in our biopharma customers using our products with their brand name injectable therapies seeking
to withdraw such injectable therapy from the market or change market tactics in a way that makes the use of our products cost prohibitive.
&#160;This may result in reduction of revenues due to lower demand, termination of supply contracts, and other factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Most of our components and raw materials, including all of our consumables
subassemblies, are sourced from single suppliers. If we are unable to obtain sufficient components or raw materials on a timely basis
or for a cost-effective price, or if we experience other supply difficulties, our business and results of operations may be adversely
affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ability to meet customer demand depends, in part, on our ability to
obtain timely and adequate delivery of raw materials and components for our products. &#160;A majority of the materials and components
that go into the manufacturing of our products, including all of our consumables subassemblies. are single-sourced from third-party suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The price and supply of materials and components for our products may be
impacted or disrupted for reasons beyond our control. A significant price increase from a single-source supplier could have a material
impact on our financial results. While we work with suppliers to ensure continuity of supply, no assurance can be given that these efforts
will be successful. &#160;Although we do carry strategic inventory and maintain insurance to help mitigate the potential risk related
to any supply disruption, there can be no assurance that such measures will be sufficient or effective. &#160;The termination, reduction
or interruption in supply of raw materials and components and an inability to quickly develop acceptable alternative sources for such
supply, could adversely impact our ability to manufacture and sell our products in a timely or cost-effective manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We do not have long-term agreements in place with any of our suppliers,
with the exception of a five- year agreement with Command which we entered in 2020. Due to regulatory requirements relating to the qualification
of suppliers, we are not likely to be able to establish additional or replacement sources on a timely basis or without excessive cost.
&#160;We are in the process of establishing alternative sources of supply for our raw materials and components, but there can be no assurance
we will be able to do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Additionally, volatility in our cost of energy, raw materials, components,
subassemblies, transportation/freight, and manufacturing and distribution could adversely affect our results of operations. &#160;Climate
change (including laws or regulations passed in response to it) could increase our costs, in particular our costs of supply, energy and
transportation/freight. &#160;Material or sustained increases in the price of oil and natural gas could have an adverse impact on the
cost of many of the plastic materials we use to make and package our products, as well as our transportation/freight costs. &#160;These
outcomes may in turn result in customers transitioning to available competitive products, loss of market share, negative publicity, reputational
damage, loss of customer confidence or other negative consequences (including a decline in stock price).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 17 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our failure to comply with laws and regulations relating to reimbursement
of health care products may subject us to penalties and adversely impact our reputation, business, results of operations, financial condition
and cash flows.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our devices are purchased principally by specialty pharmacies and ambulatory
service providers or hospitals that typically bill various third-party payers, such as governmental programs (e.g., Medicare, Medicaid
and comparable non-U.S. programs), private insurance plans and managed care plans, for the healthcare services provided to their patients.
&#160;The ability of those customers to obtain appropriate reimbursement from third-party payers for our products and the drugs they administer
is critical because it affects which products customers purchase and the prices they are willing to pay. &#160;As a result, our devices
are subject to regulation regarding quality and cost by U.S. governmental agencies, including the Centers for Medicare &amp; Medicaid
Services (&#8220;CMS&#8221;), as well as comparable state and non-U.S. agencies responsible for reimbursement and regulation of health
care goods and services, including laws and regulations related to kickbacks, false claims, self-referrals and health care fraud. &#160;Many
states have similar laws that apply to reimbursement by state Medicaid and other funded programs, and in some cases to all payers. &#160;In
certain circumstances, insurance companies can attempt to bring a private cause of action against a manufacturer for causing a false claim
to be filed under the Federal Racketeer Influenced and Corrupt Organizations Act. In addition, as a manufacturer of FDA-approved devices
reimbursable by federal healthcare programs, we are subject to the Physician Payments Sunshine Act, which requires us to annually report
certain payments and other transfers of value we make to U.S.-licensed physicians or U.S. teaching hospitals. &#160;Any failure to comply
with these laws and regulations could subject us or our officers and employees to criminal and civil financial penalties. &#160;Similar
reporting requirements applicable to medical device manufacturers have also been implemented by some states. Failure to comply with these
state requirements could result in civil monetary penalties being assessed against us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These laws and regulations, among other things, constrain our business,
marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with
hospitals, physicians or other potential purchasers of our products. Due to the breadth of these laws, the narrowness of statutory exceptions
and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current
or future practices might be challenged under one or more of these laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To enforce compliance with the healthcare regulatory laws, certain enforcement
bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to
a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be
time-and resource-consuming and can divert management&#8217;s attention from the business. Additionally, as a result of these investigations,
healthcare providers and entities may have to agree to additional compliance and reporting requirements as part of a consent decree or
corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our
business. &#160;Even an unsuccessful challenge or investigation into our practices could cause adverse publicity and be costly to respond
to. &#160;If our operations are found to be in violation of any of the healthcare laws or regulations described above or any other healthcare
regulations that apply to us, we may be subject to penalties, including administrative, civil and criminal penalties, damages, fines,
exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, contractual damages, reputational
harm, disgorgement and the curtailment or restructuring of our operations. &#160;In addition, we are subject to the U.S. Foreign Corrupt
Practices Act and similar anti-corruption laws outside the U.S. Actual or alleged violation of these laws by our employees, consultants,
sales agents or distributors could subject us to investigations by the U.S. or foreign governments, significant criminal or civil sanctions
and other liabilities, and damage our reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We may need additional funding in the future, and if we are unable
to raise capital when needed, we may be forced to delay, reduce or eliminate our product development, commercial efforts, or sales efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Producing and marketing our developed products is costly. &#160;Although
we believe we currently have adequate capital to fulfill our near-term funding needs, we may need to raise additional capital in the future
in order to execute our business plan and help us fund the development and commercialization of new products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may finance future cash needs through public or private equity offerings
and may also use debt financings or strategic collaboration and licensing arrangements. &#160;We may seek to access the public or private
equity markets whenever conditions are favorable, even if we do not have an immediate need for additional capital. &#160;To the extent
that we raise additional funds by issuing equity securities, our shareholders may experience additional dilution; any debt financing,
if available, may involve restrictive covenants and could result in high interest expense. &#160;If we raise additional funds through
collaboration and licensing arrangements, it may require us to relinquish certain enumerated rights to our product candidates, processes,
technologies, or development projects, or to enter into licenses on terms that are not favorable to us. &#160;We cannot be certain that
additional funding will be available on acceptable terms, or at all. &#160;If adequate funds are not available from the foregoing sources,
we may consider additional strategic financing options, or we may be required to delay, reduce the scope of, or eliminate our research
or development and/or some of our commercialization efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 18 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are required to comply with certain financial and operating covenants
under our credit facility. Failure to comply with these covenants would prevent us from drawing on our facility and, once drawn, could
cause amounts borrowed to become immediately due and payable.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If we want to draw on our credit facility, we must comply with specified
financial and operating covenants under our credit facility and make payments, limiting our ability to operate our business as we otherwise
might. Our failure to comply with any of these covenants or to meet any debt payment obligations could result in an event of default which,
if not cured or waived, would result in any amounts outstanding, including any accrued interest and/or unpaid fees, becoming immediately
due and payable. We might not have sufficient working capital or liquidity to satisfy any repayment obligations in the event of an acceleration
of those obligations. In addition, if we are not in compliance with the financial and operating covenants under the credit facility at
the time we wish to borrow funds, we will be unable to borrow funds. The financial and operating covenants under the credit facility may
limit our ability to borrow funds or capital, including for general corporate purposes and strategic acquisitions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We may experience difficulties resulting from our relatively new
and evolving management structure and executive team.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have made a number of changes to our management structure throughout
the organization in recent years and have filled a number of these positions while we are actively recruiting to fill others. &#160;Although,
we believe the persons who currently and will serve in these positions are and will be qualified to do so, they may take time to integrate
into the organization and with each other, if at all. &#160;Many of these persons have or will have had little to no experience with our
company prior to joining us, which may result in delays in our ability to implement our business plans. &#160;If we are unable to integrate,
motivate and retain the services of our new executives and other managers, or if integration takes longer than we expect, it may have
an adverse effect on our business and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Changes in tax or labor laws or exposure to additional income tax
liabilities could increase our costs and reduce our margins.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Changes to the tax and labor laws in the U.S. or other countries in which
we operate could have an adverse effect on our operating results. &#160;Certain changes in tax rates, deductibility of interest, deductibility
of executive compensation expense, expensing of capital expenditures, the ability to use certain tax credits, taxation on earnings from
international business operations, and the system of taxation (from worldwide to territorial) could adversely affect our financial condition
and results of operations. &#160;Taxing authorities may audit us from time to time and disagree with certain positions we have taken in
respect of our tax liabilities. &#160;We regularly assess the likely outcomes of these audits in order to determine the appropriateness
of our tax provision. &#160;However, we may not accurately predict the outcome of these audits, and as a result the actual outcome of
these audits may have an adverse impact on our financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our manufacturing operations depend on low-cost labor. &#160;Recent increases
in U.S. minimum wage requirements, as well as those imposed by the state of New York and New Jersey will increase our costs for employees
to support those operations, reduce our margins and negatively impact our profit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>A downturn in global economic conditions could adversely affect our
operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deterioration in the global economic environment, particularly in countries
with government-sponsored healthcare systems, may cause decreased demand for our products and increased competition, which could result
in lower sales volume and downward pressure on the prices for our products, longer sales cycles, and slower adoption of new technologies.
&#160;A weakening of economic conditions in the U.S. and/or abroad may also adversely affect our suppliers, which could result in interruptions
in supply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to foreign currency exchange risk.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A portion of our revenues is currently, and we expect in the future to
be, derived from international operations. &#160;Our revenues from sales outside the U.S. may be adversely affected by fluctuations in
foreign currency exchange rates. &#160;We cannot predict with any certainty changes in foreign currency exchange rates or our ability
to mitigate these risks. &#160;We may experience additional volatility as a result of inflationary pressures and other macroeconomic factors.
&#160;If we cannot adequately mitigate foreign currency exchange rates, our revenues and profit may suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our distribution network and other operations outside the U.S. subject
us to certain risks.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Approximately 17% of our net revenues in the year ended December 31, 2023,
came from our operations outside the U.S., and we intend to continue to pursue growth opportunities in foreign markets. &#160;Our foreign
operations subject us to certain risks, including, among others, the effects of fluctuations in foreign currency exchange, uncertainties
with respect to local economic and political</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 19 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">conditions, competition from local companies, trade protectionism and restrictions
on the transfer of goods across borders, U.S. diplomatic and trade relations with the governments of the foreign countries in which we
operate, foreign regulatory requirements or changes in such requirements, local product preferences and product requirements, longer payment
terms for accounts receivable than we experience in the U.S., difficulty in establishing, staffing and managing foreign operations, changes
to international trade agreements and treaties, changes in tax laws, weakening or loss of the protection of intellectual property rights
in some countries, and import or export licensing requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are dependent on information technology systems and subject to
privacy and security laws, and our systems and infrastructure face certain risks, including from cyber security breaches and data leakage.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Despite the implementation of security measures, our internal computer
systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism,
war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside
our organization, or persons with access to systems inside our organization. &#160;While we do not believe that we have experienced any
such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our systems, it could
result in a material disruption of our operations. &#160;To the extent that any disruption or security breach results in a loss of or
damage to our data or applications or other data applications relating to our technology, or inappropriate disclosure of confidential
or proprietary information, we could incur liabilities, damage to our reputation, and the further development of our product candidates
could be delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We cannot guarantee that any of our strategic acquisitions, investments
or alliances will be successful.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may seek to supplement our internal growth through strategic acquisitions,
investments and alliances. &#160;Such transactions are inherently risky, and the integration of any newly acquired business requires significant
effort and management attention. &#160;The success of any acquisition, investment or alliance may be affected by a number of factors,
including our ability to properly assess and value the potential business opportunity or to successfully integrate any business we may
acquire into our existing business. &#160;There can be no assurance that any past or future transaction will be successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our operating results and financial condition may fluctuate.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our operating results and financial condition may fluctuate from quarter
to quarter and year to year for a number of reasons. &#160;Events such as a delay in product development, increases in litigation expenses,
changes to our expectations or strategy or even a relatively small revenue shortfall may cause financial results for a period to be below
our expectations or projections. &#160;As a result, we believe that period-to-period comparisons of our results of operations should not
be relied upon as an indication of future performance. &#160;Our operating results and financial condition are also subject to fluctuation
from all of the risks described throughout this section. &#160;These fluctuations may adversely affect our results of operations and financial
conditions and our stock price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Future material impairments in the value of our long-lived assets
could negatively affect our operating results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We review our long-lived assets, including identifiable intangible assets
and property, plant and equipment, for impairment. &#160;Long-lived assets are reviewed when there is an indication or triggering event
that impairment may have occurred. &#160;Changes in market conditions or other changes in the future outlook of value may lead to impairment
charges in the future. &#160;In addition, we may from time to time sell assets that we determine are not critical to our strategy. &#160;Future
events or decisions may lead to asset impairments and/or related charges. Certain non-cash impairments may result from a change in our
strategic goals, business direction or other factors relating to the overall business environment. &#160;Material impairment charges could
negatively affect our results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Actions of activist stockholders could have an adverse effect on
our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">From time to time, we may be subject to proposals by stockholders urging
us to take certain corporate actions. &#160;If activist stockholder activities ensue, our business could be adversely affected because
responding to proxy contests and reacting to other actions by activist stockholders can be costly and time-consuming, disrupt our operations
and divert the attention of management and our employees. For example, we may be required to retain the services of various professionals
to advise us on activist stockholder matters, including legal, financial and communications advisors, the costs of which may negatively
impact our future financial results. &#160;In addition, perceived uncertainties as to our future direction, strategy or leadership created
as a consequence of activist stockholder initiatives may result in the loss of potential business opportunities, harm our ability to attract
new investors, customers, employees, and joint venture partners, and cause our stock price to experience periods of volatility or stagnation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 20 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Natural disasters, war and other events could adversely affect our
suppliers and customers.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Natural disasters (including pandemics), war, terrorism, labor disruptions
and international conflicts, and actions taken by the U.S. and other governments or by our customers or suppliers in response to such
events, could cause significant economic disruption and political and social instability in the U.S. and areas outside of the U.S. in
which we operate. &#160;Most of our products are assembled and packaged in Nicaragua, where there is currently civil unrest whose outcome
cannot be predicted. &#160;This and similar events could increase the costs for or cause interruptions in the supply of materials, result
in decreased demand for our products or adversely affect our manufacturing and distribution capabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our insurance coverage may be inadequate to cover all the liabilities
we may incur.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We face the risk of exposure to liability claims if any product that we
develop causes injury. &#160;Although we carry insurance at levels customary for companies in our industry, such coverage may become unavailable
or be inadequate to cover all liabilities we may incur. &#160;There can be no assurance that we will be able to continue to maintain such
insurance, or obtain comparable insurance at a reasonable cost, if at all. &#160;If we are unable to obtain sufficient insurance coverage
at an acceptable cost or otherwise, or if the amount of any claim against us exceeds the coverage under our policies, we may face significant
expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Rising inflation increases economic uncertainty and may require us
to raise prices in order to maintain our operating margins.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For much of the past two years, inflation rates have risen or held steady
at rates not seen in a generation or more. Higher level of inflation not only reduces the real value of the profits we generate from our
business (and in turn our returns to investors), but it also increases the costs of goods and services, including those from our single-source
suppliers, that we need to run our business. Should such trends continue, it would not only have a destabilizing macroeconomic effect
on the broader U.S. and global economy, but it may also require us to increase the price of our products in order to maintain sufficient
operations margins. Any increase in the prices we charge our customers could reduce the demand for our products, perhaps significantly.
We will continue to monitor inflation trends and will make adjustments to our business as necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Brexit may impact our business in the United Kingdom.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">One of our two most significant international distributors is located in
the United Kingdom (&#8220;UK&#8221;), and the other is in Finland, a member of the European Union (&#8220;EU&#8221;). &#160;The June
2016 referendum result in the UK to exit the EU (commonly known as &#8220;Brexit&#8221;), and the subsequent commencement of the official
withdrawal process by the UK government in March 2017, has created uncertainties affecting business operations in the UK and the EU. &#160;On
January 31, 2020, the UK withdrew from the EU. Under the withdrawal agreement agreed between the UK and the EU, the UK was subject to
a transition period until December 31, 2020 (the &#8220;Transition Period&#8221;) during which EU rules continued to apply. &#160;During
the Transition Period, negotiations between the UK and the EU continued in relation to the future customs and trading relationship between
the UK and the EU following the expiration of the Transition Period. Due to the current COVID-19 global pandemic, negotiations between
the UK and the EU scheduled have either been postponed or occurred in a reduced forum via video conference. &#160;However, on December
24, 2020, the negotiators from the EU and UK reached an agreement on a new partnership. &#160;This agreement sets out the rules that apply
between the EU and the UK as of January 1, 2021. &#160;New regulations require medical device registration with the Medicines and Healthcare
Products Regulatory Agency (&#8220;MHRA") before being placed on the Great Britain market (England, Wales, and Scotland). Additionally,
all medical devices will require a UK Conformity Assessment mark (&#8220;UKCA&#8221;) by December 31, 2024. CE marks issued by Notified
Bodies will remain valid until this time. Therefore, we must be compliant with applicable legislation in order to identify our devices
with the UKCA mark and continue to market and sell our devices in Great Britain beyond December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We could be adversely affected, directly or indirectly, by the effects
of an increased focus on environmental, social and governance issues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recently, shareholders generally have increased their focus on environmental,
social and governance ("ESG") issues, specifically regarding how companies are addressing climate change, diversity, and human
rights, among other ESG-related issues. Our failure to comply with shareholder expectations and standards regarding ESG issues, which
are still evolving and can vary considerably, or the perception that we have not responded appropriately to ESG-related issues, could
result in reputational harm, and could have an adverse effect on our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 21 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Climate change could present immediate and long-term risks to our industry
and our customers. The potential for increased severe weather events could have a material adverse effect on our operations and infrastructure
or the operations and infrastructure of our suppliers. In addition, the effects of climate change could include long-term changes in temperature
levels and water availability, increased energy costs, and increased supply costs impacted by those increasing energy costs. The cost
of mitigating or responding to ESG issues could be significant; however, these costs are too uncertain to predict. In addition, the approaches
taken by the U.S. or foreign governments to regulate ESG issues, which may include legislative or regulatory changes, could adversely
impact our business, results of operations, financial condition, and prospects, and are too uncertain to predict.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Risks Related to Ownership of Our Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>There may be circumstances in which the interests of our significant
stockholders could be in conflict with your interests as a stockholder.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Three stockholders, together with their respective affiliates, beneficially
own approximately 17%, 11%, and 7% of our outstanding common stock, respectively. &#160;An affiliate of Horton Capital Management LLP.
currently serves on our Board of Directors. &#160;Circumstances may arise in which these stockholders may have an interest in exerting
influence to pursue or prevent acquisitions, divestitures or other transactions, including the issuance of additional shares or debt,
that, in their judgment, could enhance their investment in us or another company in which they invest. &#160;Such transactions might adversely
affect us or other holders of our common stock. Furthermore, our significant concentration of share ownership may adversely affect the
trading price of our common stock because investors may perceive disadvantages in owning shares in companies with significant stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We do not currently intend to pay dividends on our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have never paid dividends on our common stock, and we do not intend
to pay any dividends to holders of our common stock for the foreseeable future. &#160;We currently intend to invest our future earnings,
if any, to fund our growth. &#160;Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Future sales and issuances of shares of our common stock or rights
to purchase our common stock, including pursuant to our equity compensation plans, could result in additional dilution of the percentage
ownership of our stockholders.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may need additional capital in the future to continue our planned operations.
&#160;To the extent we raise additional capital by issuing equity and/or convertible securities, our stockholders may experience substantial
dilution. &#160;We may sell our common stock, convertible securities or other equity securities in one or more transactions at prices
and in a manner, we determine from time to time. If we sell our common stock, convertible securities or other equity securities, investors
may be materially diluted. &#160;These sales may also result in material dilution to our existing stockholders, and new investors could
gain rights superior to our existing stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We provide and intend to continue to provide additional equity-based compensation
to our employees, directors and consultants under our three equity compensation plans. We may issue equity-based compensation outside
of our equity compensation plans as inducement for new employees. &#160;If our Board elects to issue additional stock options or other
equity-based compensation, our stockholders may experience additional dilution, which could cause our stock price to decline. &#160;Because
stock options granted under our equity compensation plans will generally only be exercised when the exercise price for such option is
below the then market value of the common stock, the exercise of such options or the issuance of shares will cause dilution to the book
value per share of our common stock and to existing and new investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>There has been volatility in the price of shares of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Since our common stock was listed on the Nasdaq Capital Market on October
17, 2019, it has traded between $1.82 per share to $12.84 per share. &#160;Our stock price is subject to wide fluctuations in response
to a variety of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">quarterly variations in operating results;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>announcement of new products or customers by our competitors;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>changes in financial estimates by securities analysts;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>trading volume on the Nasdaq Capital Market;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>announcements related to litigation;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>general economic conditions; or</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>other events or factors that are beyond our control.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 22 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, the stock market has experienced significant price and volume
fluctuations that have particularly affected the trading prices of equity securities of many biotechnology companies. &#160;These fluctuations
have often been unrelated or disproportionate to the operating performance of these companies. &#160;Any negative change in the public&#8217;s
perception of the prospects of medical device companies could further depress our stock price regardless of our results. &#160;Sales of
substantial amounts of our common stock, particularly by our two most significant stockholders, or the perception that such sales might
occur, could adversely affect prevailing market prices of our common stock and our stock price may decline substantially in a short time
and our stockholders could suffer losses or be unable to liquidate their holdings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If we do not maintain compliance with the listing standards of the
Nasdaq Capital Market, Nasdaq may delist our common stock from trading on its exchange</i></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Nasdaq Capital Market on which our common stock trades has continued
listing standards that we must maintain on an ongoing basis in order to continue the listing of our common stock. &#160;If we fail to
meet these continued listing requirements, our common stock may be subject to delisting. &#160;If our common stock is delisted and we
are not able to list our common stock on another national securities exchange, we expect our securities would be quoted on an over-the-counter
market. &#160;If this were to occur, our stockholders could face significant material adverse consequences, including limited availability
of market quotations for our common stock and reduced liquidity for the trading of our common stock. &#160;In addition, we could experience
a decreased ability to issue additional securities and obtain additional financing in the future, if or when needed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are a smaller reporting company and non-accelerated filer, and
we cannot be certain if the reduced disclosure requirements applicable to us will make our common stock less attractive to investors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are currently a &#8220;smaller reporting company&#8221; and a &#8220;non-accelerated
filer&#8221;, as those terms are defined in the Securities Act. &#160;Accordingly, we take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not &#8220;smaller reporting companies&#8221; and &#8220;non-accelerated
filers,&#8221; including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports
and proxy statements and exemptions from the provisions of Section&#160;404(b) of the Sarbanes-Oxley Act of 2002 requiring that independent
registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting. &#160;Decreased
disclosures in our SEC filings due to our status as a &#8220;smaller reporting company&#8221; and &#8220;non-accelerated filer&#8221;
may make it harder for investors to analyze our results of operations and financial prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We cannot predict if investors will find our common stock less attractive
if we rely on these exemptions. &#160;If some investors find our common stock less attractive as a result, there may be a less active
trading market for our common stock and our share price may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>The price of our common stock may be adversely affected by the future
issuance and sale of shares of our common stock or other equity securities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We cannot predict the size of future issuances or sales of our common stock
or other equity securities future acquisitions or capital raising activities, or the effect, if any, that such issuances or sales may
have on the market price of our common stock. The issuance and sale of substantial amounts of common stock or other equity securities
or announcement that such issuances and sales may occur, could adversely affect the market price of our common stock. Any decline in the
price of our common stock may encourage short sales, which could place further downward pressure on the price of our common stock and
may impair our ability to raise additional capital through the sale of equity securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>You may find it difficult to sell our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Only recently has there been any active trading market in our common stock.
&#160;We cannot assure you that such an active trading market for our common stock will be sustained. &#160;Regardless of whether an active
and liquid public market exists, negative fluctuations in our actual or anticipated operating results will likely cause the market price
of our common stock to fall, making it more difficult for you to sell our common stock at a favorable price, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_1B"></span><b>ITEM 1B. UNRESOLVED STAFF COMMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 23 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_1C"></span><b>ITEM 1C. CYBERSECURITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management has responsibility for developing and coordinating the Company&#8217;s
cybersecurity policy and strategy, and for managing the prevention, detection, mitigation and remediation of cybersecurity incidents.
We utilize various risk assessment tools and technologies to identify potential cyber and information security threats and risks, including
engaging a third-party information technology services provider to perform risk evaluation and testing. In addition, the Company is in
the process of implementing a program for all team members to participate in ongoing training and awareness programs that include periodic
assessments to drive adoption and awareness of cybersecurity processes and controls.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We promote a company-wide culture of cybersecurity risk management intended
to protect the confidentiality, integrity, and availability of our critical systems and the information contained therein. No risks from
cybersecurity threats or previous cybersecurity incidents have materially affected, or are reasonably likely to materially affect, our
business strategy, financial condition or results of operations. However, there can be no assurance that the controls and procedures in
place to monitor and mitigate the risks of cyber threats will be successful or sufficient to avoid material losses or consequences in
the future. Additionally, while we have insurance coverage in place that is designed to address certain aspects of cyber risks, such insurance
coverage may be insufficient to cover all insured losses or all types of claims that may arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our Board of Directors, as a whole and through its committees, oversees
risk management, including cybersecurity risks. The Board has delegated risk management responsibilities, including but not limited to
cybersecurity risk, to the Nominating and Governance Committee. Specifically, the Nominating and Governance Committee periodically reviews
our cybersecurity policies, data security programs and plans that management has established to monitor compliance and assess preparedness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_2"></span><b>ITEM 2. PROPERTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We currently rent 43,975 square feet of a building located at 100 Corporate
Drive, Mahwah, New Jersey with the lease having commenced on March 1, 2022 and expiring August 31, 2032. This facility is used as our
headquarters and for our in-house manufacturing operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_3"></span><b>ITEM 3. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_4"></span><b>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_5"></span><b>ITEM 5. MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Market Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our common stock is traded on the Nasdaq Capital Market under the symbol
&#8220;KRMD.&#8221; &#160;We have not paid any cash dividends on our common stock and do not plan to pay any such dividends in the foreseeable
future. &#160;We currently intend to use all available funds for our business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are authorized to issue 77,000,000 shares of capital stock, of which
75,000,000 are designated common stock, $0.01 par value per share, and 2,000,000 are designated preferred stock. &#160;As of March 13,
2024, 45,669,362 shares of our common stock were issued and outstanding held by approximately 471 stockholders of record. &#160;There
were no shares of preferred stock issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_6"></span><b>ITEM 6. SELECTED FINANCIAL DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 24 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_7"></span><b>ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>The following discussion and analysis of our financial condition and
results of operations should be read together with our consolidated financial statements and related notes included under ITEM 8 of this
Annual Report on Form 10-K. &#160;This discussion contains forward-looking statements about our business and operations. &#160;Our actual
results may differ materially from those we currently anticipate as a result of many factors, including those described under Part I &#8211;
FORWARD LOOKING STATEMENTS and elsewhere in this Annual Report.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OVERVIEW</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company develops, manufactures and commercializes innovative patient-centric
large volume subcutaneous solutions primarily for the subcutaneous drug delivery market as governed by the United States Food and Drug
Administration (the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues derive from three business sources: (i) domestic core (which
consists of US and Canada), (ii) international core, and (iii) novel therapies.&#160; Our domestic core and international core revenues
consist of sales of our products for the delivery of subcutaneous drugs that are FDA cleared for use with the FREEDOM Infusion System,
with the primary delivery for immunoglobulin to treat Primary Immunodeficiency Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory
Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies revenues consist of product revenues from our infusion system (syringe
drivers, tubing and needles) for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical
companies in the drug development process as well as non-recurring engineering services revenues (&#8220;NRE&#8221;) received from biopharmaceutical
companies to ready or customize the FREEDOM System for clinical and commercial use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company completed its transition of substantially all finished goods
manufacturing of its needle and tubing sets to Command Medical Products, a third-party contract manufacturing organization which also
provides subassemblies for all of the Company&#8217;s products, in the second quarter of 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company entered into a lease commencing March 1, 2022 for a new corporate
headquarters and manufacturing facility located in Mahwah, NJ. During the quarter ended June 30, 2022, the Company completed the first
phase of the move, the headquarters and office staff to the new location, and completed the move of its manufacturing facility at the
end of the first quarter 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company ended the 2023 fiscal year with $28.5 million in net revenues,
a 2.2% increase compared with $27.9 million in the same period last year driven by volume growth in our core domestic and international
business of 5.9% and 10.4% respectively, offset by a 41.6% decline in our novel therapies business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Gross profit, for the year ended December 31, 2023, was $16.7 million,
an increase of 8.7% or $1.3 million from the same period last year, and stated as a percentage of net revenues was 58.6%, an increase
from 55.1% in the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating expenses for the year ended December 31, 2023, were $27 million,
up from $26.1 million for the same period last year, the increase was driven primarily by research and development and depreciation, partially
offset by selling, general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Year Ended December 31, 2023 compared to Year Ended December 31, 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Net Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes our net revenues for the years ended December
31, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td>
    <td>&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><b>% of Net Revenues</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 25%"><b>Net Revenues</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 10.7pt">Domestic Core</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">22,446,519</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">21,205,204</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">1,241,315</td>
    <td>&#160;</td>
    <td style="text-align: right">5.9%</td>
    <td>&#160;</td>
    <td style="text-align: right">78.7%</td>
    <td>&#160;</td>
    <td style="text-align: right">76.0%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.7pt">International Core</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,596,097</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,164,714</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">431,383</td>
    <td>&#160;</td>
    <td style="text-align: right">10.4%</td>
    <td>&#160;</td>
    <td style="text-align: right">16.1%</td>
    <td>&#160;</td>
    <td style="text-align: right">14.9%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 10.7pt">Novel Therapies</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">1,475,050</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">2,526,119</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(1,051,069</td>
    <td>)</td>
    <td style="text-align: right">(41.6%</td>
    <td>)</td>
    <td style="text-align: right">5.2%</td>
    <td>&#160;</td>
    <td style="text-align: right">9.1%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">28,517,666</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">27,896,037</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">621,629</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="text-align: right">2.2%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 25 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total net revenues increased $0.6 million, or 2.2%, for the year ended
December 31, 2023, as compared with the same period last year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Domestic core growth of 5.9% was primarily driven
by volume growth in pumps and consumables attributed to overall SCIG market growth and new account share gains. International core growth
of 10.4% was driven by increased volume across several EU markets and the entry into multiple new geographic markets. Novel therapies
net revenues declined by 41.6% driven primarily by lower NRE revenue of $0.9 million and fewer clinical trial supply shipments of $0.2
million than in the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Gross Profit</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our gross profit for the years ended December 31, 2023, and 2022 is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="width: 43%">Gross Profit</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">$</td>
    <td style="vertical-align: bottom; width: 12%; text-align: right">16,708,282</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">$</td>
    <td style="vertical-align: bottom; width: 12%; text-align: right">15,368,986</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">$</td>
    <td style="vertical-align: bottom; width: 12%; text-align: right">1,339,296</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: right">8.7%</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 11.9pt">Stated as a Percentage of Net Revenues</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">58.6%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">55.1%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Gross profit increased $1.3 million or 8.7% in the year ended December
31, 2023, compared to the same period in 2022 driven by the increase in net revenues of $0.6 million coupled with a favorable cost of
goods sold impact of $0.7 million. Gross profit as a percentage of net revenues increased to 58.6% in the year ended 2023 compared to
55.1% for the year ended 2022 primarily driven by increased manufacturing productivity and product mix versus the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our selling, general and administrative, research and development and depreciation
and amortization costs for the years ended December 31, 2023, and 2022 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>%</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 43%">Selling, general and administrative</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">20,365,617</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">20,606,507</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">(240,890</td>
    <td style="width: 3%">)</td>
    <td style="width: 8%; text-align: right">(1.2%)</td></tr>
  <tr style="vertical-align: bottom">
    <td>Research and development</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,742,254</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,956,215</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">786,039</td>
    <td>&#160;</td>
    <td style="text-align: right">15.9%&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">870,390</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">587,137</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">283,253</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">48.2%&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Total Operating Expense</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">26,978,261</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">26,149,859</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">828,402</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">3.2%&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Selling, general and administrative expenses decreased $0.2 million, or
1.2%, during the year ended December 31, 2023 compared with the same period last year, primarily due to a $0.4 million decrease in compensation
and benefits related to executive management restructuring costs that took place in the prior year, and a decrease in stock compensation
costs of $0.2 million, partially offset by $0.4 million increase in compensation costs related to business development and medical affairs
new hires.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Research and development expenses increased $0.8 million, or 15.9% during
the year ended December 31, 2023 compared with the same period last year, primarily due to $0.5 million in compensation and benefits,
$0.1 million in stock compensation and $0.1 million in expenses, to support acceleration and insourcing of our innovation efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Depreciation and amortization expense increased by 48.2% to $0.9 million
in the year ended December 31, 2023 compared with $0.6 million in the year ended December 31, 2022 resulting from prior year investments
in our Mahwah, NJ facility which includes our corporate office, in-house manufacturing, and research and development labs and the associated
annualized depreciation impact.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><b>Change from Prior Year</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 43%">Net Loss</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">(13,741,062</td>
    <td style="width: 3%">)</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">(8,661,142</td>
    <td style="width: 3%">)</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">5,079,920</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 8%; text-align: right">58.7%</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 11.7pt">Stated as a Percentage of Net Revenues</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(48.2%</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(31.0%</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our net loss increased $5.1 million in the year ended December 31, 2023
compared with the same period last year mostly driven by the establishment of an allowance for the nonrealization of deferred tax assets
of $6.0 million offset by a higher gross profit of $1.3 million, an increase in other income of $0.4 million due to higher interest and
dividend income from our treasury bill investments, which was partially offset by higher operating expenses of $0.8 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 26 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LIQUIDITY AND CAPITAL RESOURCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our principal source of liquidity is our cash on hand of $11.5 million
as of December 31, 2023. &#160;Our principal source of operating cash inflows is from sales of our products and NRE services to customers.
Our principal cash outflows relate to the purchase and production of inventory, funding of research and development, and selling, general
and administrative expenses. To develop new products, support future growth, achieve operating efficiencies, and maintain product quality,
we are continuing to invest in research and development, innovation, and equipment. Operating expenses for the 2023 fiscal year were $27.0
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our inventory position was $3.5 million at December 31, 2023, which reflected
a decrease of $2.9 million from December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In October 2023, the Company received a payroll tax credit under the Coronavirus
Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) of $0.7 million. This credit was previously recorded as a receivable..</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect that our cash on hand and cash flows from operations will be
sufficient to meet our requirements at least through the next twelve months. Continued execution on our longer-term strategic plan may
require the Company to draw on our new credit facility, take on additional debt or raise capital through issuance of equity, or a combination
of both. Our future capital requirements may vary from those currently planned and will depend on many factors, including our rate of
sales growth, the timing and extent of spending on various strategic initiatives including research and development, our international
expansion, the timing of new product introductions, market acceptance of our solutions, and overall economic conditions including inflation
and the potential impact of global supply imbalances on the global financial markets. To the extent that current and anticipated future
sources of liquidity are or are expected to be insufficient to fund our future business activities and requirements, we may be required
to draw on our existing credit facility, seek additional equity or debt financing sooner. There can be no assurance the Company will be
able to obtain the financing or raise the capital required to fund its operations or planned expansion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes our cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31, 2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31, 2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 56%">Net cash (used in) operating activities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 18%; text-align: right">(4,892,553</td>
    <td style="width: 4%">)</td>
    <td style="width: 1%">$</td>
    <td style="width: 18%; text-align: right">(5,404,549</td>
    <td style="width: 1%">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>Net cash (used in) investing activities</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(814,597</td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(2,801,568</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net cash (used in)/ provided by financing activities</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(218,867</td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">279,485</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Operating Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in operating activities was $4.9 million for the year ended
December 31, 2023. This net cash usage was primarily due to the net loss of $13.7, plus cash flows used to reduce accrued expenses of
$1.2 million primarily from the payment of 2023 employee bonuses, and a decrease in accounts payable of $1.4 million. Partially offsetting
these increases were cash flows generated from a decrease in inventory of $2.9 million, a decrease in accounts receivable of $0.5 million,
and changes in working capital of $0.4 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Further contributing to this change were non-cash items including a deferred
tax asset increase of $2.0 million partially offset by the establishment of an allowance for non-realization of deferred tax assets of
$6.0 million, stock-based compensation expense of $2.8 million, depreciation and amortization expense of $0.9 million and a loss on disposal
of fixed assets of $0.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in operating activities of $5.4 million for the year ended
December 31, 2022 was primarily due to the net loss of $8.7 million, working capital changes which included an increase in accounts payable
and other liabilities of $1.3 million, an increase in accrued payroll of $0.4 million increase in inventory of $0.3 million, an increase
in accrued expenses of $0.2 million. Further contributing were deferred tax assets of $2.0 million increased for book to tax differences
related to stock option expense. &#160;Offsetting these were primarily non-cash charges for stock-based compensation of $3.1 million,
and depreciation and amortization of $0.6 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 27 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Investing Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in investing activities of $0.8 million for the year ended
December 31, 2023, was for capital expenditures for research and development and manufacturing equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in investing activities of $2.8 million for the year ended
December 31, 2022, was for capital expenditures for manufacturing space, research and development laboratories and office equipment for
our corporate office and manufacturing facilities move.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Financing Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in financing activities for the year ended December 31, 2023
of $0.2 million, was from a net between borrowings and payments on our note payable for insurance premium financing of $0.1 million, and
$0.1 million for payments on our finance leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The $0.3 million provided by financing activities
for the year ended December 31, 2022, was from $0.4 million in option exercises offset by $0.08 million in net borrowings on our indebtedness
for a note payable for insurance premium financing and $0.05 million in </span><span style="font-size: 8pt">&#160;</span><span style="font-size: 10pt">equipment
financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Debt and Borrowing Capacity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 10 &#8212; DEBT OBLIGATIONS&#8221; and &#8220;NOTE
11 &#8212; SUBSEQUENT EVENT&#8221; in the accompanying &#8220;Notes to Financial Statements&#8221; appearing in this Annual Report on
Form 10-K for further details regarding debt and borrowing capacity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lease Commitments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;Our two operating leases have remaining lease terms of 8.6 years and 5 years, respectively. Our three
finance leases have remaining lease terms of 3.4 years, 3 years, and 4.75 years, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 5 &#8212; LEASES&#8221; in the accompanying &#8220;Notes
to Financial Statements&#8221; appearing in this Annual Report on Form 10-K for further details regarding our operating and finance leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Subsequent Event</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In March 2024, the Company received an assessment report from its notified
body in the EU, BSI, stating that, following BSI&#8217;s review of technical documentation submitted by the Company in connection with
a prior audit nonconformance, a recommendation for continued certification cannot be made.&#160; The Company has filed an appeal to this
determination.&#160; If the Company&#8217;s appeal is denied, then its EU certification may be suspended with respect to some or all of
the Company&#8217;s products as determined by a BSI review panel.&#160; Management believes that the Company&#8217;s appeal will be successful
in limiting the scope of the suspension to have minimal impact on the Company&#8217;s revenues, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>SIGNIFICANT ACCOUNTING POLICIES AND CRITICAL ACCOUNTING ESTIMATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with generally accepted
accounting principles of the United States (&#8220;GAAP&#8221;) requires estimates and assumptions that affect the reported amounts of
assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the financial statements and accompanying
notes. &#160;The SEC has defined a company&#8217;s critical accounting policies as the ones that are most important to the portrayal of
the company&#8217;s financial condition and results of operations, and which require the company to make its most difficult and subjective
judgments, often as a result of the need to make estimates of matters that are inherently uncertain. &#160;Based on this definition, we
have identified some of our more critical accounting estimates below. &#160;We also have other key accounting policies, which involve
the use of estimates, judgments, and assumptions that are significant to understanding our results. &#160;For additional information,
see &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&#8221; in the accompanying &#8220;Notes
to Financial Statements&#8221; appearing in this Annual Report on Form 10-K. &#160;Although we believe that our estimates, assumptions,
and judgments are reasonable, they are based upon information presently available. &#160;Actual results may differ significantly from
these estimates under different assumptions, judgments, or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 28 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers and are included
in Product Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#8217;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#8217;s revenue recognition criteria described above. As of December 31, 2023, the Company has recognized
a contract asset of zero which is included in other accounts receivable in the accompanying balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Inventory</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. We make estimates regarding the future recoverability
of the costs of these products and record provisions based on historical experience, expiration of sterilization dates and expected future
trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than
projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 29 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#8221; in the accompanying &#8220;Notes to Financial Statements&#8221; appearing in this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#8221; in the accompanying &#8220;Notes to Financial Statements&#8221; appearing in this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_7A"></span><b>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_8"></span><b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="index_to_fs"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>INDEX TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: bottom">
    <td style="width: 7in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 0.5in; text-align: center">Page</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Audit_Report">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID <span id="xdx_900_edei--AuditorFirmId_c20230101__20231231_zdep5f6brIZi"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorFirmId" id="ixv-7786">256</ix:nonNumeric></span>)</td>
    <td style="text-align: center">31</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financial Statements</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Balance_Sheets">Balance Sheets as of December 31, 2023 and 2022</a></td>
    <td style="text-align: center">33</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Statements_Of_Operations">Statements of Operations for the years ended December 31, 2023 and 2022</a></td>
    <td style="text-align: center">34</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Stockholders_Equity">Statements of Stockholders&#8217; Equity as of December 31, 2023 and 2022</a></td>
    <td style="text-align: center">35</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Cash_Flows">Statements of Cash Flows for the years ended December 31, 2023 and 2022</a></td>
    <td style="text-align: center">36</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Notes_To_Financial_Statements">Notes to Financial Statements</a></td>
    <td style="text-align: center">37</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 30 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Audit_Report"></span><b>Report of Independent Registered Public Accounting
Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To the Shareholders and the Board of Directors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU Medical Systems, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mahwah, New Jersey</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have audited the accompanying balance sheets of KORU Medical Systems,
Inc. (the Company) as of December 31, 2023 and 2022, the related statements of operations, stockholders&#8217; equity and cash flows for
the years then ended, and the related notes to the financial statements (collectively, the financial statements). In our opinion, the
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022,
and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted
in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These financial statements are the responsibility of the Company&#8217;s
management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent
with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit
of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control
over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control
over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our audits included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Critical Audit Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The critical audit matters communicated below are matters arising from
the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and
that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,
subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements,
taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit
matters or on the accounts or disclosures to which they relate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><i>Deferred Tax Valuation Allowance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Description of the Matter:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As discussed in Note 1 to the financial statements, the Company recorded
a $6 million deferred tax valuation allowance during the year ended December 31, 2023. Management is required to evaluate deferred tax
assets to determine if they are more likely than not to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We identified the valuation allowance as a critical audit matter. Management&#8217;s
estimate regarding the valuation allowance results in the application of a high degree of auditor judgment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 31 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">How We Addressed the Matter in Our Audit:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We applied auditor judgment to determine the nature and extent of procedures
to be performed over the valuation allowance. We obtained an understanding of the Company&#8217;s processes and controls in place for
determining the qualitative factors used in the calculation of the allowance. We evaluated the valuation allowance by testing the completeness
and accuracy of the data utilized in the determination of the qualitative factors and the reasonableness of management&#8217;s judgments
and significant assumptions used in the development of the qualitative factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ <span id="xdx_908_edei--AuditorName_c20230101__20231231_zXgyE02JP3w5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorName" id="ixv-7787">McGrail Merkel Quinn &amp; Associates, P.C.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have served as the Company's auditor since 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_901_edei--AuditorLocation_c20230101__20231231_zFdRzVb4LvMd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorLocation" id="ixv-7788">Scranton, Pennsylvania</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">March 13, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 32 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Balance_Sheets"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_304_111_zOQVuJV9lAUg" summary="xdx: Statement - BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 72%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_49A_20231231_zkWzSo5l318d" style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_492_20221231_zjUHvFcPYXwl" style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsAbstract_iB_zfNsjW4ugSE8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>ASSETS</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrentAbstract_i01B_zp6N250AeyF5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CURRENT ASSETS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACz2MT_z6gTsWDAACh8" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Cash and cash equivalents</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7789">11,482,240</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7790">17,408,257</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_i02I_maACz2MT_zmi5EEBIFrhc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accounts receivable less allowance for doubtful accounts of $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zLF1ip0JYMik" title="Accounts receivable, allowance for credit loss, current"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7791">24,777</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zHUppZS2IpH1" title="Accounts receivable, allowance for credit loss, current"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7792">21,459</ix:nonFraction></span> for December 31, 2023, and December 31, 2022, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7793">4,045,211</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7794">3,558,884</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryNet_i02I_maACz2MT_zfn3RTYDkFO4" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Inventory</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7795">3,481,301</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7796">6,404,867</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherReceivables_i02I_maACz2MT_zNXZgDI0HGB5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Other receivables</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7797">28,889</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7798">972,396</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseCurrent_i02I_maACz2MT_ztcO1Fl2w2l5" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Prepaid expenses and other</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7799">1,218,288</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7800">1,457,232</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrent_i02TI_mtACz2MT_maAzRLg_zRjihZaOtsKl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL CURRENT ASSETS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7801">20,255,929</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7802">29,801,636</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzRLg_zSCTPS7tdqB2" style="vertical-align: bottom">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7803">3,837,657</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7804">3,886,975</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maAzRLg_z8zWBffBhKFk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Intangible assets, net of accumulated amortization of $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231_ztHaNTK8zsjc" title="Finite-lived intangible assets, accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7805">390,341</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_z1iOcoxZ22y6" title="Finite-lived intangible assets, accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7806">325,872</ix:nonFraction></span> at December 31, 2023 and December 31, 2022, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7807">754,361</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7808">787,182</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzRLg_zOyEvFrbvRx3" style="vertical-align: bottom">
    <td style="padding-left: 45.5pt; text-indent: -45.5pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7809">3,514,055</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7810">3,786,545</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxAssetsNet_i01I_maAzRLg_zdlv09Eki7x4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 7.9pt; text-indent: -7.9pt">Deferred income tax assets, net allowance for non-realization of deferred tax assets of $<span id="xdx_906_eus-gaap--DeferredRentReceivablesNetNoncurrent_iI_c20231231_zkoaFRAD9M4l"><ix:nonFraction name="us-gaap:DeferredRentReceivablesNetNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7811">6,002,777</ix:nonFraction></span> and <span id="xdx_90F_eus-gaap--DeferredRentReceivablesNetNoncurrent_iI_dxL_c20221231_z7zPJYuiwiW5" title="::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0091">zero</span></span> for December 31, 2023 and December 31, 2022, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0088">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7812">3,967,480</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherAssetsNoncurrent_i01I_maAzRLg_zGgTHjsQ7As9" style="vertical-align: bottom">
    <td style="padding-left: 45.5pt; text-indent: -45.5pt">Other assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7813">98,970</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7814">102,625</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_i01TI_mtAzRLg_zuIe4GZW2Ixd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL ASSETS</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7815">28,460,972</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7816">42,332,443</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zxWXkOdHxpo6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrentAbstract_i01B_zLeQ8Odu4ENj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CURRENT LIABILITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_i02I_maLCzz6f_z7rhrIWzpQF9" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accounts payable</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7817">975,193</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7818">2,391,799</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzz6f_zCrYBfzZQyIb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accrued expenses</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7819">1,711,427</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7820">2,889,941</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NotesPayableCurrent_i02I_maLCzz6f_z6KNM1oE36E6" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Note Payable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7821">314,344</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7822">433,295</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherLiabilitiesCurrent_i02I_maLCzz6f_zgNPIX9pNK5c" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Other liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7823">512,520</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7824">257,337</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_maLCzz6f_zOgDgnQjmuMg" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accrued payroll and related taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7825">462,941</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7826">542,399</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maLCzz6f_zXlYT1JRYji4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7827">109,540</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7828">98,335</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzz6f_zrmuqzPt6wA9" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease liability &#8211; current</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7829">368,313</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7830">345,834</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzz6f_maLzCwA_zaoptMSp3oO4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL CURRENT LIABILITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7831">4,454,278</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7832">6,958,940</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_maLzCwA_zNrh5I8WJcJi" style="vertical-align: bottom">
    <td>Finance lease liability, net current portion</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7833">316,623</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7834">394,283</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzCwA_zGaR2MIzEPN5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 45.5pt; text-indent: -45.5pt">Operating lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7835">3,336,300</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7836">3,653,257</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Liabilities_i01TI_mtLzCwA_maLASEzkql_zP3LQTeZxHKd" style="vertical-align: bottom">
    <td>TOTAL LIABILITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7837">8,107,201</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7838">11,006,480</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_zSIRSXrdfhIj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Commitments and contingencies (Refer to Note 8)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquityAbstract_i01B_zKWv5WNSDi01" style="vertical-align: bottom">
    <td>STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CommonStockValue_i02I_maSEz6tY_z8TKdZtGnV31" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Common stock, $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20221231_zi88w8lNDxa1" title="Common stock, par or stated value per share"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20231231_zVrYg0aL1kZ6" title="Common stock, par or stated value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-7839"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-7840">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20231231_zNrLbhJPNjek" title="Common stock, shares authorized"><span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221231_zkiEWW6CFtt7" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7841"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7842">75,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20231231_zlwHAtCLsVOi" title="Common stock, shares, issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7843">49,089,864</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20221231_zrCFerdB7WUi" title="Common stock, shares, issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7844">48,861,891</ix:nonFraction></span> shares issued; <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20231231_zYB5dnEtNgb1" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7845">45,669,362</ix:nonFraction></span> and <span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20221231_zlQUqFlnVizc" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7846">45,441,389</ix:nonFraction></span> shares outstanding at December 31, 2023, and December 31, 2022, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7847">490,899</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7848">488,619</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maSEz6tY_zP8kaPdWAhJ1" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Additional paid-in capital</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7849">47,018,707</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7850">44,252,117</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--TreasuryStockValue_i02NI_di_msSEz6tY_z8oySIxmOrb3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Treasury stock, <span id="xdx_900_eus-gaap--TreasuryStockPreferredShares_iI_pid_uShares_c20231231_zuObyQdd5rN8" title="Treasury stock, shares"><span id="xdx_903_eus-gaap--TreasuryStockPreferredShares_iI_pid_uShares_c20221231_zhJza4pXE0Ue" title="Treasury stock, shares"><ix:nonFraction name="us-gaap:TreasuryStockPreferredShares" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7851"><ix:nonFraction name="us-gaap:TreasuryStockPreferredShares" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7852">3,420,502</ix:nonFraction></ix:nonFraction></span></span> shares at December 31, 2023 and December 31, 2022, at cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7853">3,843,562</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7854">3,843,562</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEz6tY_zm7po8KDxjx4" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Retained Deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7855">23,312,273</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7856">9,571,211</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquity_i02TI_mtSEz6tY_maLASEzkql_zw0AeXmclNok" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7857">20,353,771</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7858">31,325,963</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzkql_zOOvMfeEnpm7" style="vertical-align: bottom">
    <td>TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7859">28,460,972</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7860">42,332,443</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 33 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Statements_Of_Operations"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_30F_113_z8JDjkeWcx1a" summary="xdx: Statement - STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 72%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_495_20230101__20231231_zWjddIrUreI3" style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_499_20220101__20221231_zSvnKwTXxjsb" style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>For the Years Ended<br/>
December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_maGPzCxH_zpDXRJdTCtFl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET REVENUES</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7861">28,517,666</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7862">27,896,037</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CostOfGoodsAndServicesSold_msGPzCxH_zRIa6aZa7H4f" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Cost of goods sold</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7863">11,809,384</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7864">12,527,051</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GrossProfit_iT_mtGPzCxH_maOILzGGH_zrvQ6mujaPfd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Gross Profit</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7865">16,708,282</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7866">15,368,986</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_zFXpGnnZoU6e" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>OPERATING EXPENSES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maOEzFJl_zhzHEqXqd645" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Selling, general and administrative</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7867">20,365,617</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7868">20,606,507</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzFJl_zxTp9GHTP3a9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Research and development</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7869">5,742,254</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7870">4,956,215</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_i01_maOEzFJl_zVzTOzLtSbRj" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7871">870,390</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7872">587,137</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_i01T_mtOEzFJl_msOILzGGH_zwifRgI9daf6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total Operating Expenses</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7873">26,978,261</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7874">26,149,859</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_iT_mtOILzGGH_maILFCOzJCF_z6drrFC178nk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net Operating Loss</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7875">10,269,979</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7876">10,780,873</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zC2ZISiZ2HYc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Non-Operating Income</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maNIEzv41_zXcI7hw4sUn4" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Loss on foreign currency exchange</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7877">5,124</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7878">39,874</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40F_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i01_maNIEzv41_zW949KJL0dwg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Loss on disposal of fixed assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7879">59,807</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0216">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEzv41_z9yMjMsWUxP6" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Interest income, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7880">561,328</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7881">145,587</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzv41_maILFCOzJCF_zQruVi7CF82a" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL OTHER INCOME</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7882">496,397</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7883">105,713</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_iT_mtILFCOzJCF_maNILz2Mm_zbl3LDwawFW2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>LOSS BEFORE TAXES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7884">9,773,582</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7885">10,675,160</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILz2Mm_zOOg7k9TWmVe" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Income (tax)/benefit</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7886">3,967,480</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7887">2,014,018</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_iT_mtNILz2Mm_zBmteAlTPVOl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET LOSS</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7888">13,741,062</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7889">8,661,142</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareAbstract_iB_zeEETMaVp5W5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET LOSS PER SHARE</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_i01_zRHl7JjuY7Ld" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-7890">0.30</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-7891">0.19</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_i01_zfan07at7Xe1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-7892">0.30</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-7893">0.19</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zu5Gexp4sSv2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_z2exwKqjxWP8" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7894">45,601,346</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7895">45,002,074</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pid_uShares_zQRUOo8Hj3x2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7896">45,601,346</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7897">45,002,074</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 34 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Stockholders_Equity"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_309_114_zHbY9iHQ7K0c" summary="xdx: Statement - STATEMENTS OF STOCKHOLDERS' EQUITY" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 29%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 9%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zTxot0hFI0Nk" style="width: 7%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zbMImvIGTxEc" style="width: 9%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zrTewQHIXDyi" style="width: 10%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_zGJBzyr9Bcjh" style="width: 9%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_4B2_zmpP7CbMfpR" style="width: 10%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="4"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Additional</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Common Stock</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Paid-in</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Retained</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Treasury</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Stockholders&#8217;</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Amount</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Capital</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>(Deficit)</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Stock</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Equity</b></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43D_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zw9exNmx8TQ7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">BALANCE, DECEMBER 31, 2021</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zITzNKWpqt92" title="Beginning balance (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7898">48,044,162</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7899">480,441</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7900">40,774,245</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7901">910,069</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7902">3,843,562</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7903">36,501,055</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43A_c20220101__20221231_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zmkwKWiWjFg1" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">Accrued compensation paid in shares</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbzkffoioEvi" title="Issuance upon options exercised (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7904">206,570</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7905">2,066</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7906">511,016</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7907">513,082</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43E_c20220101__20221231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zBInNpWCs3Uj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">Compensation expense related to stock options</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7908">2,083,396</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7909">2,083,396</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_430_c20220101__20221231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zOCj59MQmUkc" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">Compensation expense related to restricted stock
    awards</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_980_ecustom--CompensationeExpenseRelatedToRestrictedStockAwards_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8ZsyxTqi4Al" title="Compensation expense related to restricted stock awards (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="krmd:CompensationeExpenseRelatedToRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7910">50,000</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7911">500</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7912">482,449</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7913">482,949</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_436_c20220101__20221231_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zMnxhrEeMohg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">Issuance upon options exercised</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3Jsy0g13CQj" title="Issuance upon options exercised (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7914">561,159</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7915">5,612</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7916">401,011</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7917">406,623</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_437_c20220101__20221231_eus-gaap--NetIncomeLoss_zXDaRHiq0Azh" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">Net loss</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7918">8,661,142</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7919">8,661,142</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zdNOoceQyMsk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">BALANCE, DECEMBER 31, 2022</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGtWFwZieW9f" title="Beginning balance (in shares)" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7920">48,861,891</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7921">488,619</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7922">44,252,117</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7923">9,571,211</ix:nonFraction></span></td>
    <td style="border-bottom: white 2.25pt double"><span style="font-size: 10pt">)</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7924">3,843,562</ix:nonFraction></span></td>
    <td style="border-bottom: white 2.25pt double"><span style="font-size: 10pt">)</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7925">31,325,963</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_438_c20230101__20231231_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zgtoVqTLNLak" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">Accrued compensation paid in shares</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwMexLDNTdVc" title="Accrued compensation paid in shares (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7926">127,973</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7927">1,280</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7928">445,069</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7929">446,349</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_435_c20230101__20231231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_z4zFfEpH4bx7" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">Compensation expense related to stock options</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7930">1,940,720</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7931">1,940,720</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43A_c20230101__20231231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ztd45aXVBjJ8" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">Compensation expense related to restricted stock
    awards</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_988_ecustom--CompensationeExpenseRelatedToRestrictedStockAwards_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3ncsfhAoJN3" title="Compensation expense related to restricted stock awards (in shares)" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="krmd:CompensationeExpenseRelatedToRestrictedStockAwards" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7932">100,000</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7933">1,000</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7934">380,801</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7935">381,801</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zlIpBa0cMT34" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">Issuance upon options exercised</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43A_c20230101__20231231_eus-gaap--NetIncomeLoss_zpLRBiBGtO8b" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">Net loss</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7936">13,741,062</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7937">13,741,062</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_43D_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zLDJuxJtRpS5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in"><span style="font-size: 10pt">BALANCE, DECEMBER 31, 2023</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNLbqwoy0Ssi" title="Ending balance (in shares)" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7938">49,089,864</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7939">490,899</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7940">47,018,707</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7941">23,312,273</ix:nonFraction></span></td>
    <td style="border-bottom: white 2.25pt double"><span style="font-size: 10pt">)</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7942">3,843,562</ix:nonFraction></span></td>
    <td style="border-bottom: white 2.25pt double"><span style="font-size: 10pt">)</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7943">20,353,771</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 35 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Cash_Flows"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_30B_112_z9velxENyZV3" summary="xdx: Statement - STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 72%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_491_20230101__20231231_zv1AE30dGSe8" style="width: 10%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_49A_20220101__20221231_zqKBf8sTNXi9" style="width: 10%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>For the Years Ended<br/>
December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zpM1BNYFX3tj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_maCzA0C_maNCPBUzcMq_zeXzPCGQoQ8c" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Net Loss</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7944">13,741,062</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7945">8,661,142</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zCvHCD7yZ219" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Adjustments to reconcile net loss to net cash used in operating activities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i02_maCzA0C_maNCPBUzcMq_ztSHOkyFf0E5" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Stock-based compensation expense</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7946">2,768,870</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7947">3,079,427</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DepreciationDepletionAndAmortization_i02_maCzA0C_maNCPBUzcMq_zQJqGFfs6l6c" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Depreciation and amortization</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7948">870,390</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7949">587,137</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GainLossOnSaleOfOtherAssets_i02N_di_msCzA0C_msNCPBUzcMq_zkiND61VUHVk">
    <td style="vertical-align: bottom; padding-left: 41.15pt; text-indent: -8.25pt">Loss on disposal of fixed assets</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7950">59,807</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxesAndTaxCredits_i02_maCzA0C_maNCPBUzcMq_zRHQRG063hMi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Deferred income taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7951">2,035,297</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7952">2,026,226</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredPurchasedPowerCosts_i02_maNCPBUzcMq_zzNxAdQPcfk3" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Allowance for non-realization of deferred tax asset</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredPurchasedPowerCosts" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7953">6,002,777</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_ecustom--RouLandlordCredit_i02_maNCPBUzcMq_z6JiYRYsrrb9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">ROU landlord credit</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:RouLandlordCredit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7954">21,988</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:RouLandlordCredit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7955">212,546</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zP5luyS4iHJ7" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Changes in operating assets and liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msNCPBUzcMq_zqTMBHHlnJm1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">(Increase)/Decrease in accounts receivable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7956">486,327</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7957">34,002</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInInventories_i02N_di_msNCPBUzcMq_zfrCtMR29S55" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Decrease/(Increase) in inventory</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7958">2,923,566</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7959">298,529</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOtherReceivables_i02N_di_msNCPBUzcMq_z5GMXr2nwBri" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Decrease/(Increase) in other receivables</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7960">943,507</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7961">254,176</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msNCPBUzcMq_z3yGCIzXsRxk" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Decrease in prepaid expenses and other assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7962">242,599</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7963">28,776</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maNCPBUzcMq_zCRASo2jTpUh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">(Decrease)/Increase in accounts payable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7964">1,416,606</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7965">1,164,266</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i02_maNCPBUzcMq_zggOLCFgBaog" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">(Decrease)/Increase in accrued payroll and related taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7966">79,458</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7967">381,796</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i02_maNCPBUzcMq_zONHztcn4vn6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Increase in other liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7968">255,183</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7969">167,337</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i02_maNCPBUzcMq_zQKN8XsJb7qa" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">(Decrease)/Increase in accrued expenses</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7970">1,178,514</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7971">180,237</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzcMq_maCCERCzpOk_zSwWbx4O7iIg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET CASH USED IN OPERATING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7972">4,892,553</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7973">5,404,549</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zBYHqyYVzwm1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CASH FLOWS FROM INVESTING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquireProductiveAssets_i01N_di_msNCPBUzzvK_zmEKUzPaXAwl" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Purchases of property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7974">782,949</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7975">2,761,056</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUzzvK_z05J4aSeIDUi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Purchases of intangible assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7976">31,648</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7977">40,512</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzzvK_maCCERCzpOk_zIpayEAzouIg" style="vertical-align: bottom">
    <td>NET CASH USED IN INVESTING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7978">814,597</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7979">2,801,568</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z3MlFVLHVqW2" style="vertical-align: bottom">
    <td>CASH FLOWS FROM FINANCING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzm6z_z73OeJtPKGX1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Proceeds from issuance of equity</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7980">406,623</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--BorrowingsFromIndebtedness_i01_maNCPBUzm6z_zt9hi4eShak4" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Borrowings from indebtedness</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:BorrowingsFromIndebtedness" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7981">565,172</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:BorrowingsFromIndebtedness" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7982">783,799</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--PaymentsOnIndebtedness_i01N_di_msNCPBUzm6z_zll8HMQ9szz3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Payments on indebtedness</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:PaymentsOnIndebtedness" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7983">684,123</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:PaymentsOnIndebtedness" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7984">859,087</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_400_ecustom--FinanceLeaseROUAsset_i01N_di_msNCPBUzm6z_zacVgZfOU3al" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Finance lease ROU asset</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:FinanceLeaseROUAsset" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7985">33,461</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msNCPBUzm6z_zQeKvdMaeI13" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Payments on finance lease liability</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7986">66,455</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7987">51,850</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_mtNCPBUzm6z_maCCERCzpOk_z6UnOjL8oVI7" style="vertical-align: bottom">
    <td>NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7988">218,867</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7989">279,485</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzpOk_zjpC30Q5dKE3" style="vertical-align: bottom">
    <td>NET DECREASE IN CASH AND CASH EQUIVALENTS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7990">5,926,017</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-7991">7,926,632</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zNuZRo4nyU33" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7992">17,408,257</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7993">25,334,889</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_z4rf33boR9b1" style="vertical-align: bottom">
    <td>CASH AND CASH EQUIVALENTS, END OF YEAR</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7994">11,482,240</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7995">17,408,257</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zunAUurdEl02" style="vertical-align: bottom">
    <td>Supplemental Information</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CashPaidDuringPeriodsForAbstract_iB_zIYGJn1QVYJ3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Cash paid during the years for:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestPaidNet_i01_zLaWHgVTvgJh" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Interest</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7996">50,832</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7997">28,490</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxesPaidNet_i01_zgZgvB7Wlwcl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Income taxes</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7998">3,160</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zg4z3mYI7T3c" style="vertical-align: bottom">
    <td>Schedule of Non-Cash Operating, Investing and Financing Activities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IssuanceOfCommonStockCompensation_i01_zS53IhST8Zz" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Issuance of common stock as compensation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:IssuanceOfCommonStockCompensation" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-7999">446,349</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:IssuanceOfCommonStockCompensation" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8000">513,082</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 36 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Notes_To_Financial_Statements"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="ixv-4119"><p id="xdx_80C_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zLKDHnybvnVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; <span id="xdx_820_zs762yR0Y2dk">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:NatureOfOperations" id="ixv-4124"><p id="xdx_843_eus-gaap--NatureOfOperations_zRRRz9m674vk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_zrYF4NWrhPF6">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) develops, manufactures and commercializes innovative and
patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United
States Food and Drug Administration (the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system
management. &#160;The Company operates as <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxH_uN_c20230101__20231231_zZ9xrjClTPk7" title="Number of segments::XDX::1">one</span> segment.</p>

</ix:nonNumeric><p id="xdx_853_zMIe7tIiDdu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-4131"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbn4X8lTGPme" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_z3Y0F1FhUOdb">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We prepare our financial statements and accompanying notes in accordance
with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). &#160;Certain prior year amounts have
been reclassified to conform to the current year presentation in our Financial Statements.</p>

</ix:nonNumeric><p id="xdx_853_zrCUXeIPMf9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-4137"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z2QYCi9sxaV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_zTqFTpDCew02">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For purposes of the statements of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company has historically held
cash balances in excess of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zAWPnCTIiF41" title="FDIC cash insurance limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8001">250,000</ix:nonFraction></span> at its primary commercial bank, which exceeds FDIC insurance limits. To reduce the risk of uninsured
deposits, the Company entered an insured cash sweep program with KeyBank during the second quarter of 2023 to automatically invest its
uninsured bank cash balances over $250,000 into FDIC insured banks so there is no more than $250,000 maintained at any one bank. Further,
as of December 31, 2023 the Company had invested $<span id="xdx_90C_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20230101__20231231_zv5GLwAzoGZ" title="Investment securities treasury bill"><ix:nonFraction name="us-gaap:InterestIncomeSecuritiesUSTreasury" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD" id="ixv-8002">10.2</ix:nonFraction> million</span> in a US Treasury bill that matures every 90 days.</p>

</ix:nonNumeric><p id="xdx_853_zDD9WrxjHK89" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-4145"><p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zLy0eLjaRDX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_860_z0sXNcja7QFh">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

</ix:nonNumeric><p id="xdx_853_zfJIwzfaU0W5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="ixv-4153"><p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zITQ163r6qLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zqyfSbinHex6">INTANGIBLE ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_z6RzZC0sqY6k" title="Estimated useful lives::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0480">6</span></span> to <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zfnkxoE5vxd9" title="Estimated useful lives::XDX::P20Y"><span style="-sec-ix-hidden: xdx2ixbrl0482">20</span></span> years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2023 and 2022 was $<span id="xdx_903_ecustom--AmortizationOfIntangibleAssets1_c20230101__20231231_zXukqMc8c7Hg" title="Amortization expense of intangible assets"><ix:nonFraction name="krmd:AmortizationOfIntangibleAssets1" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8003">64,469</ix:nonFraction></span> and
$<span id="xdx_90C_ecustom--AmortizationOfIntangibleAssets1_c20220101__20221231_zgUYqRRQcSW3"><ix:nonFraction name="krmd:AmortizationOfIntangibleAssets1" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8004">62,143</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="ixv-4165"><p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zksHIEC1OdYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zOrGNsW3BTte">The estimated amortization expense for the succeeding years for the intangible
assets is approximately:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_494_20231231_zDrzIiBttqZ5" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zpLNLu9FFqQ6" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 68%">2024</td>
    <td style="vertical-align: top; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; width: 4%">$</td>
    <td style="vertical-align: bottom; width: 24%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8005">65,869</ix:nonFraction></td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zz7zWibfl9Cg" style="vertical-align: bottom; background-color: white">
    <td>2025</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8006">65,729</ix:nonFraction></td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zh5sEDXZveSa" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8007">64,674</ix:nonFraction></td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zmJwnFnhwN54" style="background-color: white">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8008">64,242</ix:nonFraction></td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zKXXXIq6HIb7" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8009">64,242</ix:nonFraction></td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zLHLDXaIUDv9" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8010">429,605</ix:nonFraction></td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zYPWgwFKa1jj" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8011">754,361</ix:nonFraction></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_znSzBPf6D04d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_853_z3yWxcUzGDOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><div id="xdx_238_zS0MdUsDi7hg">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 37 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-4222"><p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zShXOqtPrub8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">INCOME TAXES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For interim income tax reporting, the Company estimates its annual effective
tax rate and applies it to fiscal year-to-date pretax loss, excluding unusual or infrequently occurring discrete items. Tax jurisdictions
with losses for which tax benefits cannot be realized are excluded. The Company reported an income tax expense of $<span id="xdx_90A_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20230101__20231231_zXmOncdOr4Rl" title="Income tax benefit::XDX::3967480"><span style="-sec-ix-hidden: xdx2ixbrl0506">4.0</span></span> million and income
tax benefit of $<span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20220101__20221231_zoh7fVjM73E2" title="Income tax benefit::XDX::-2014018"><span style="-sec-ix-hidden: xdx2ixbrl0508">2.0</span></span> million for the years ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We evaluate our deferred tax assets to determine if they are more likely
than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income Taxes.&#160; After considering
our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all available evidence,&#160; we
have recorded a valuation allowance of $<span id="xdx_905_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dm_c20231231_zq2OWt9v3MCf" title="Valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD" id="ixv-8012">6.0</ix:nonFraction> million</span> against our net deferred tax assets during the year ended December 31, 2023.&#160;
As we continue to assess the realizability of our deferred tax assets, reported pretax income and new evidence may result in a partial
or full reduction of the valuation allowance in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recurring items cause our effective tax rate to differ from the U.S. federal
statutory rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zpGbrAiKG3qc" title="Statutory rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8013">21</ix:nonFraction></span>%, including U.S. federal R&amp;D credits, U.S. state tax rates, and stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Beginning in 2022, certain research and development costs are required
to be capitalized and amortized over a five-year period under the Tax Cuts and Jobs Act enacted in December 2017. This change will impact
the expected U.S. federal and state income tax expense and cash taxes to be paid for our fiscal 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company files income tax returns in the U.S. federal jurisdiction and
in various state jurisdictions. Income tax returns for years prior to fiscal 2019 are no longer subject to examination by tax authorities.</p>

</ix:nonNumeric><p id="xdx_853_zG2DqhxrMm5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-4241"><p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgArdpYLNeI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zmoMv5cFWNEa">PROPERTY AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zR7gwH0bQ3Oe" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0516">3</span></span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zl14xJrx2uqc" title="::XDX::P10Y0M0D"><span style="-sec-ix-hidden: xdx2ixbrl0517">10</span></span> years for furniture
and office equipment, <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zBTCv7TEdGFd" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0518">3</span></span>-<span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zPML4eKFwqsd" title="::XDX::P12Y"><span style="-sec-ix-hidden: xdx2ixbrl0519">12</span></span> years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2023
and 2022 was $<span id="xdx_90F_ecustom--DepreciationAndAmortizationPropertyAndEquipment_c20230101__20231231_ziA6P2npF5v" title="Depreciation and amortization, property and equipment"><ix:nonFraction name="krmd:DepreciationAndAmortizationPropertyAndEquipment" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8014">805,921</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--DepreciationAndAmortizationPropertyAndEquipment_c20220101__20221231_zNRekgHPDcna" title="Depreciation and amortization, property and equipment"><ix:nonFraction name="krmd:DepreciationAndAmortizationPropertyAndEquipment" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8015">524,994</ix:nonFraction></span>, respectively.</p>

</ix:nonNumeric><p id="xdx_853_zHfZIY2IkFT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-4257"><p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zQ2zPvVkCaM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_861_zwjIzp2ufOF2">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock options outside
of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing
model. &#160;All options are charged against income at their fair value. &#160;The entire compensation expense of the award is recognized
over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares of stock granted for director fees under the non-employee director
compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted stock awards under its omnibus equity incentive
plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at the fair market value of
the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization thresholds
were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of other restricted stock awards
were estimated on the date of grant at the current stock price. We recognize restricted stock expense using the straight-line attribution
method over the requisite service period and account for forfeitures as they occur.</p>

</ix:nonNumeric><p id="xdx_853_zL0dqwu47sgb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-4267"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_z1hUayy5s3X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_zaZI5CgC3olc">NET LOSS PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic net loss per common share is calculated by dividing net loss by the
weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net
loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company&#8217;s potentially
dilutive common shares are those that result from diluted common stock options and unvested restricted stock awards. The calculation of
diluted loss per share excluded stock options of <span id="xdx_90C_ecustom--AntiDilutiveStockOptions_pid_uShares_c20230101__20231231_zziGeBajGgUk" title="Anti-dilutive stock options"><ix:nonFraction name="krmd:AntiDilutiveStockOptions" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8016">12,335</ix:nonFraction></span> and <span id="xdx_904_ecustom--AntiDilutiveStockOptions_pid_dxL_uShares_c20220101__20221231_z5tD5FVp81p4" title="Anti-dilutive stock options::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0531">zero</span></span> in weighted-average shares for each of the years ended
December 31, 2023 and 2022, respectively, as their effect was anti-dilutive as a result of the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_23E_zzC1fxdnJ0Gl">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 38 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The calculation of diluted loss per share excluded performance-based restricted
stock and time-based restricted stock of <span id="xdx_904_ecustom--AntiDilutiveRestrictedStock_pid_uShares_c20230101__20231231_z8W4A0kYm7m6" title="Anti-dilutive restricted stock"><ix:nonFraction name="krmd:AntiDilutiveRestrictedStock" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8017">904,496</ix:nonFraction></span> and <span id="xdx_905_ecustom--AntiDilutiveRestrictedStock_pid_uShares_c20220101__20221231_zYsUlyhb8ALh" title="Anti-dilutive restricted stock"><ix:nonFraction name="krmd:AntiDilutiveRestrictedStock" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8018">950,000</ix:nonFraction></span> in weighted-average shares for each of the years ended December
31, 2023 and 2022, respectively, as their effect was anti-dilutive as a result of the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="krmd:ScheduleOfSecuritiesTextBlock" id="ixv-4289"><p id="xdx_89C_ecustom--ScheduleOfSecuritiesTextBlock_zCAYv9Hd6LWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zEUvOauTXLBj">The following securities were not included in the computation of diluted
shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td id="xdx_498_20230101__20231231_zvTejDmQtR0c" style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td id="xdx_49D_20220101__20221231_z5ouRlWwl5gg" style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockOptions_pid_uShares_ztWXeR7pq7rd" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Stock options</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:StockOptions" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8019">12,335</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8212;</span></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_402_ecustom--RestrictedStockUnits_pid_uShares_zB7X80sRCGLl" style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Restricted stock</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:RestrictedStockUnits" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8020">904,496</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:RestrictedStockUnits" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8021">950,000</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_uShares_zcuV9Hh5wmM3" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:AntiDilutedSecurities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8022">916,831</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:AntiDilutedSecurities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8023">950,000</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zDqCtW4WYiEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-4347"><p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNaXvfvueqkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B3_zcL7Io9SHgCd" style="display: none; visibility: hidden">Schedule of net income per common share</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_ztU38QDRs1il" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_z5NhXHxgA985" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 69%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zGYjl5DfEOx4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8024">13,741,062</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8025">8,661,142</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zbX0ho5sfmT8" style="vertical-align: bottom; background-color: white">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo1PThvKWyg8" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Basic weighted average shares outstanding</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8026">45,601,346</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8027">45,002,074</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zqRV9gTQ3b8f" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.2in">Dilutive effect of outstanding stock options and unvested restricted stock</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziVtziaxQivj" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Diluted weighted average shares outstanding</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8028">45,601,346</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8029">45,020,074</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zLKU6CbTJXmg" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zvEIXmwPQtFk" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-8030">0.30</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-8031">0.19</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zgo7lA10NY5a" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-8032">0.30</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-8033">0.19</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zUiOb4deb5ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Therefore, diluted weighted average number of shares outstanding and diluted
net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the years ended December
31, 2023 and 2022. See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221; for further detail.</p>

</ix:nonNumeric><p id="xdx_853_znY2BDTAcEPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:UseOfEstimates" id="ixv-4477"><p id="xdx_844_eus-gaap--UseOfEstimates_zNFNFYuQAZI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_zjJSsksRpBe5">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.</p>

</ix:nonNumeric><p id="xdx_853_znUV9ope84m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-4483"><p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zOtO34xIQuE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_861_zzayRpQjOfy5">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting
Standards Update (&#8220;ASU&#8221;) No. 2014-09, <i>Revenue from Contracts with Customers</i>, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_239_zjFe5L6qt3ud">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 39 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers and are included
in Product Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#8217;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#8217;s revenue recognition criteria described above. As of December 31, 2023, the Company has recognized
a contract asset of zero which is included in other accounts receivable in the accompanying balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="krmd:ScheduleOfNetRevenuesByGeography" id="ixv-4513"><p id="xdx_898_ecustom--ScheduleOfNetRevenuesByGeography_zgOk39Kpl3P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B4_zzLqgxExCEz2">The following table summarizes net revenues by geography for the years
ended December 31, 2023 and 2022:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zlJvfdkf0eva" title="Net Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8034">23,676,039</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zxd3On1nZsl7" title="Net Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8035">23,586,254</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z9WJMe07cdac" title="Net Revenues" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_us-gaap_NonUsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8036">4,841,627</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zWLgskHZsh1h" title="Net Revenues" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_us-gaap_NonUsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8037">4,309,783</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20230101__20231231_zjh9E8vQnmA2" title="Revenues" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8038">28,517,666</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20220101__20221231_zuQ3cmZ8ak6a" title="Revenues" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8039">27,896,037</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_zJHH3WsFODQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_853_zRYrPM1r0gkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-4581"><p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zutAeD5nwoZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zVguakYwV0S9">LEASES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#8220;NOTE 5 <b>&#8212; </b>LEASES&#8221; for further detail.</p>

</ix:nonNumeric><p id="xdx_853_znNPxFFGSCwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_23F_zTwmy1NNRDd">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 40 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-4597"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBQ7gh9jSITg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zCzypJsogS6i">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company adopted this standard on January 1, 2023, and it did not have a
significant impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

</ix:nonNumeric><p id="xdx_853_zdycsE4UWRe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-4606"><p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zfpebkPQILed" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zqY8Tw8pNwb9">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2023.</p>

</ix:nonNumeric><p id="xdx_853_zS0TbtpWyY9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="krmd:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" id="ixv-4631"><p id="xdx_842_ecustom--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc_zNaHnezOrga1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">IMPAIRMENT OF LONG-LIVED ASSETS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2023.</p>

</ix:nonNumeric><p id="xdx_853_znYMkSVW9tHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_818_zpqcxHp9HEPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 41 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-4644"><p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zAZN0q0lV7g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_829_zMF3gAEHYfw">INVENTORY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-4649"><p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zX61zdvEhwd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_z3jmSyQGRb25">Inventory consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Raw materials and work-in-process</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20231231_ziUbnwr5bKH9" title="Raw materials and work-in-process" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcessAndRawMaterials" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8040">1,869,356</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20221231_z18xyOI1Xrli" title="Raw materials and work-in-process" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcessAndRawMaterials" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8041">3,853,034</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Finished goods</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20231231_zLAfc6m67f0c" title="Finished goods" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8042">1,862,525</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20221231_zURHm1TjbASa" title="Finished goods" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8043">2,611,951</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;&#160;&#160;Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--InventoryGross_iI_c20231231_zWyuTK3Nl3Yl" title="Inventory, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8044">3,731,881</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryGross_iI_c20221231_zEljUY9NZ9Il" title="Inventory, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8045">6,464,985</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Less: reserve for obsolete inventory</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryValuationReserves_iNI_di_c20231231_zThgvIKcoY1j" title="Less: reserve for obsolete inventory" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8046">250,580</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--InventoryValuationReserves_iNI_di_c20221231_zm7BmshG5f29" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8047">60,118</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Inventory, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--InventoryNet_iI_c20231231_zI0bFlNRqbFb" title="Inventory" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8048">3,481,301</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--InventoryNet_iI_c20221231_zHXuNssReZHh" title="Inventory" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8049">6,404,867</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zUuKdZTb19Wc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_81C_z9qqEAwZsFa9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-4719"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z6ZnPVaegca" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8212; <span id="xdx_825_zm2p7COcH577">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-4724"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWkScz5mmSN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zqsL5fj7Yt7d">Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zjYZmReSfphf" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8050">1,412,164</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z7IveEZuNol4" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_FurnitureAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8051">1,456,745</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6rdrelA7794" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8052">1,953,653</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWLszAyseh2g" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8053">2,413,820</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zGAhw6PPKAhj" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8054">3,193,113</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zQjvAVCRM5Y3" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_ManufacturingEquipmentAndToolingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8055">2,810,813</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zCiLDQVZ8Pe5" title="Total property and equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8056">6,558,930</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_ziqRGyjJPcvj" title="Total property and equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8057">6,681,378</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zSoBNiLqIM11" title="Less: accumulated depreciation and amortization" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8058">2,721,273</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_znwnqS9d6snk" title="Less: accumulated depreciation and amortization" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8059">2,794,403</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_z6QzVcp39uX4" title="Property and equipment, net" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8060">3,837,657</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zarNcWLbaTlg" title="Property and equipment, net" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8061">3,886,975</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zhRm7KyvCy03" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_819_zeJpiZLu1xnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-4803"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z1NaC8021y5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 &#8212; <span id="xdx_823_zZTNnGoCxnUa">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has three equity incentive plans: the 2015 Stock Option Plan,
as amended (the &#8220;2015 Plan&#8221;), the 2021 Omnibus Equity Incentive Plan (the &#8220;2021 Plan&#8221;), and the Non-Employee Director
Compensation Plan. The Company has also issued restricted stock and stock options as employment inducement awards to its Chief Executive
Officer and Chief Commercial Officer, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The 2015 plan provides for the grant of up to <span id="xdx_904_ecustom--StockBasedCompensationSharesIssuable_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zT0QROv0DeC4" title="Stock issuable under plan (in shares)"><ix:nonFraction name="krmd:StockBasedCompensationSharesIssuable" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8062">6,000,000</ix:nonFraction></span> incentive stock
options and nonqualified stock options. As of December 31, 2023, there were options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutivesEmployeesConsultantsMember_zUB55jKbf5gf" title="Common stock outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8063">2,436,250</ix:nonFraction></span> shares of the Company&#8217;s
common stock outstanding to certain executives, key employees and consultants under the 2015 Plan, of which <span id="xdx_906_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutivesEmployeesConsultantsMember_z0WHvqJLij82" title="Shares issued under plan"><ix:nonFraction name="krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8064">85,000</ix:nonFraction></span> were issued during
the year ended December 31, 2023 and <span id="xdx_900_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutivesEmployeesConsultantsMember_zo7SftfeuDc" title="Shares issued under plan"><ix:nonFraction name="krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8065">445,000</ix:nonFraction></span> were issued during the year ended December 31, 2022. Additional options may be issued under
the 2015 Plan as outstanding options are forfeited. As of December 31, 2023, there were <span id="xdx_908_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zwSJfCutYt32" title="Shares available for issuance"><ix:nonFraction name="krmd:SharesAvailableForIssuanceShareBasedCompensation" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8066">2,724,250</ix:nonFraction></span> shares reserved for outstanding awards
and available for issuance under the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The 2021 Plan provides for the grant of up to <span id="xdx_900_ecustom--StockBasedCompensationSharesIssuable_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBlr2lwki6B1" title="Stock issuable under plan (in shares)"><ix:nonFraction name="krmd:StockBasedCompensationSharesIssuable" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8067">1,000,000</ix:nonFraction></span> incentive stock
options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units and/or stock appreciation rights to
employees, consultants and directors. During the years ended December 31, 2023 and 2022, there were awards with respect to <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zHwCbWgbCZHj" title="Issuance of common stock awards (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8068">21,100</ix:nonFraction></span> and
<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMobm31jjFc4" title="Issuance of common stock awards (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8069">97,100</ix:nonFraction></span> shares of common stock, respectively, issued under the 2021 Plan. Additional awards may be issued under the 2021 Plan as outstanding
awards are forfeited. As of December 31, 2023, there were <span id="xdx_90D_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLsYA3sXInul" title="Shares available for issuance"><ix:nonFraction name="krmd:SharesAvailableForIssuanceShareBasedCompensation" contextRef="AsOf2023-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8070">822,142</ix:nonFraction></span> shares reserved for outstanding awards and available for issuance under
the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Each non-employee director of the Company (other than the Chairman of the
Board) is eligible to receive $<span id="xdx_907_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zzU90Xag2hN5" title="Nonemployee services transaction cost"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2023-01-012023-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8071">110,000</ix:nonFraction></span> annually, <span id="xdx_90E_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zBJCRRoZx3Sd" title="Share-based goods and non-employee services transaction"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction" id="ixv-8072">to be paid quarterly $12,500 in cash and $15,000 in common stock.</ix:nonNumeric></span> &#160;The Chairman
of the Board is eligible to receive $<span id="xdx_905_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20230101__20231231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zbtLZW3tBcua" title="Nonemployee services transaction cost"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2023-01-012023-12-31_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8073">140,000</ix:nonFraction></span> annually, <span id="xdx_909_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20230101__20231231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zrsn21IWhGT5" title="Share-based goods and non-employee services transaction"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_BoardOfDirectorsChairmanMember" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction" id="ixv-8074">to be paid quarterly $12,500 in cash and $22,500 in common stock.</ix:nonNumeric></span> From May 18,
2021 to May 6, 2022, non-employee director compensation was paid pursuant to the 2021 Plan. Since May 6, 2022, non-employee director compensation
has been paid pursuant to the Non-Employee Director Compensation Plan. All payments were and are pro-rated for partial service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The per share weighted average fair value of stock options granted during
the year ended December 31, 2023 and December 31, 2022 was $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zMtzRLd4mVTb" title="Per share weighted average fair value of stock options granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8075">1.84</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zkRmBYMMMtg3" title="Per share weighted average fair value of stock options granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8076">1.98</ix:nonFraction></span>, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
year ended December 31, 2023 and December 31, 2022. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued. We have recognized tax benefits associated with
stock-based compensation of $<span id="xdx_903_ecustom--TaxBenefitFromStockBasedCompensation_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zPdNFe7dVFp8" title="Tax benefit from stock-based compensation"><ix:nonFraction name="krmd:TaxBenefitFromStockBasedCompensation" contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8077">256,315</ix:nonFraction></span> and $<span id="xdx_900_ecustom--TaxBenefitFromStockBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zIRnF23Rv2z2" title="Tax benefit from stock-based compensation"><ix:nonFraction name="krmd:TaxBenefitFromStockBasedCompensation" contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8078">231,341</ix:nonFraction></span> for the year ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_23D_zIMjTDvE0rp6">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 42 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Time Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-4847"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zNNM5iwpmL2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the activities for our stock options with
time based vesting for the years ended December 31, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8B2_ziuflerqMOHi" style="display: none; visibility: hidden">Schedule of time based stock options</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 44%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zimUbs6WZcF6" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8079">0.00</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5YA1TzdK49c" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8080">0.00</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z2vcbNA95U5k" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8081">51.9</ix:nonFraction></span>% - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zwZ6FEgiJBCk" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8082">61.3</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zig3jesCAfTj" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8083">65.29</ix:nonFraction></span>% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zNyFUhbYt9oh" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8084">77.5</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zp3fRJqsu2x2" title="Weighted-average volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8085">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zPgzCrXzqFOd" title="Weighted-average volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8086">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zr6v1ZKIKVx5" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:zerodash" decimals="0" unitRef="USD" id="ixv-8087">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxYlkrjitIT" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:zerodash" decimals="0" unitRef="USD" id="ixv-8088">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z1jOmn5MPA17" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0707">10</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJPw7MTmiVhe" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0709">10</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z94OrWsBFtQ1" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8089">3.50</ix:nonFraction></span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_z2myhkGzx1s7" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8090">4.53</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zrlTY08nfwRf" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8091">1.81</ix:nonFraction></span>% - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zaZdGXGs6nf2" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8092">4.02</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A7_zMZeEPBfEfkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-4949"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3skaw4hoX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the time-based stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8BD_zoOm84bn8TLe" style="display: none; visibility: hidden">Schedule of status of time based stock options</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 54%">Outstanding at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoLlsLS6XsAh" title="Outstanding at beginning (in shares)" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8093">3,035,000</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zPSMutrubaIb" title="Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8094">3.93</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zXasPHkR3FDg" title="Outstanding at beginning (in shares)" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8095">3,672,500</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zkzXZZM8cv0c" title="Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8096">3.42</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zjte071jhx2" title="Granted (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8097">430,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z8sNdtWX97a5" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8098">2.66</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLIog2GcPmef" title="Granted (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8099">920,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zsSlCgKCXM5j" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8100">2.62</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zHXx0yI8QvGd" title="Exercised (in shares)" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoUfFM3QUx5d" title="Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoW0l8NJRtB2" title="Exercised (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8101">1,031,250</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z8g7ILueyDl7" title="Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8102">1.57</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zD9OhpaXZyH1" title="Forfeited (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8103">208,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zOFlnx4XYOI3" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8104">5.45</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDhc90Lf6hag" title="Forfeited (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8105">526,250</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdMkB7B1eYnf" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8106">2.73</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at December 31</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zkGQr6YVYqE9" title="Outstanding at ending (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8107">3,256,250</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJQIAoa2Qxzd" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8108">3.66</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDQ6iHbmxkTl" title="Outstanding at ending (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8109">3,035,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMEXyyRdawhc" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8110">3.93</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Options exercisable at December 31</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zWOHeaN7VNRe" title="Options exercisable (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8111">1,458,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQGgYc11tSgi" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8112">4.42</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5jwCQQwe2Xg" title="Options exercisable (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8113">737,500</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zD00fFY3ETEd" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8114">4.93</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZfHcarGtsB7" title="Weighted average fair value of options granted during the period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8115">1.84</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJHZIM1njtld" title="Weighted average fair value of options granted during the period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8116">1.99</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zh2JESU6bYW6" title="Stock-based compensation expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8117">1,940,720</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJErI9jW98fl" title="Stock-based compensation expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8118">2,083,397</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zugjYjiqXz27" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense was $<span id="xdx_901_ecustom--StockBasedCompensationStockOptions_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zmqwQXtA5Ez9" title="Stock-based compensation expense"><ix:nonFraction name="krmd:StockBasedCompensationStockOptions" contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8119">1,940,720</ix:nonFraction></span> and $<span id="xdx_909_ecustom--StockBasedCompensationStockOptions_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zsAFaeFyrCs4" title="Stock-based compensation expense"><ix:nonFraction name="krmd:StockBasedCompensationStockOptions" contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8120">2,083,397</ix:nonFraction></span> for
the years ended December 31, 2023, and 2022, respectively. Net cash received from option exercises for the years ended December 31, 2023,
and 2022 was <span id="xdx_909_ecustom--CashReceivedFromOptionExercise_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMzzHm6IFemc" title="Cash received from option exercise::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0781">zero</span></span> and $<span id="xdx_900_ecustom--CashReceivedFromOptionExercise_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zk5E17xjVo1f" title="Cash received from option exercise"><ix:nonFraction name="krmd:CashReceivedFromOptionExercise" contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8121">406,623</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The weighted-average grant-date fair value of options granted during the
years ended December 31, 2023, and 2022 was $<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_iI_dm_c20231231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zydFj7nRr8T" title="Weighted-average grant-date fair value options granted"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD" id="ixv-8122">0.8</ix:nonFraction> million</span> and $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_iI_dm_c20221231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_z2AIsRS2c9R1" title="Weighted-average grant-date fair value options granted"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD" id="ixv-8123">1.8</ix:nonFraction> million</span>, respectively. &#160;There were <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_do_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zJ6iy1rgrUy9" title="Number of options exercised"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares" id="ixv-8124">no</ix:nonFraction></span> options exercised during
the year ended December 31,2023 and <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zMwVooYBO5B1" title="Number of options exercised"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8125">1,031,250</ix:nonFraction></span> options exercised during the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" id="ixv-5121"><p id="xdx_895_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_za2BNGCvvJj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to time- based stock
options outstanding at December 31, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8B9_zJbw7ma0vV06" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 29%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.18-$9.49</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zX5ktyylRsTc" title="Number outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8126">3,256,250</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zW5jUzrzHVGe" title="Weighted average remaining contractual life::XDX::P8Y3M19D"><span style="-sec-ix-hidden: xdx2ixbrl0797">8.3</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zj1nuAG2OW51" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8127">3.66</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z8blGC4c8V35" title="Number exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8128">1,458,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zqcISb4booHa" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8129">4.42</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_zxB7BceAd42b" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2023, there was $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zKWtJMB4iuPb" title="Total unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8130">3,145,616</ix:nonFraction></span> of total unrecognized compensation
cost related to non-vested time- based stock options granted under the Company&#8217;s plans. &#160;That cost is expected to be recognized
over a weighted-average period of<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zqjj9fintAD" title="Weighted-average period::XDX::P46M"> <span style="-sec-ix-hidden: xdx2ixbrl0807">46</span></span> months. &#160;The total fair value of shares vested as of December 31, 2023, and December 31, 2022,
was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAFzJB4auBdf" title="Total fair value of shares vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2023-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8131">4,819,658</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zqA49jZqYHN4" title="Total fair value of shares vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2022-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8132">2,703,002</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_233_zZSRZ4ekZ9r3">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 43 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Performance Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" id="ixv-5209"><p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zhPAnldze47a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to an employment agreement entered into on November 6, 2023, with
the Company&#8217;s Chief Commercial Officer, and as an inducement to his employment, the Company issued a non-qualified option to purchase
200,000 shares of common stock that vest upon achievement of sales growth milestones.&#160;<span id="xdx_8BA_zEyadYIGzkfl">The following table summarizes the activities
for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Twelve Months Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 46%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z45l6opaHkll" title="Unvested at beginning (in shares)" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zVkxT1f68a5f" title="Unvested at beginning" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0818">&#8212;</span></td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4NIoIoBzZ79" title="Unvested at beginning (in shares)" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">&#8212;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zy16y6lOlPo5" title="Unvested at beginning" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0822">&#8212;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zzlB3j8bjNae" title="Granted (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8133">200,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zt0o7PVVYzDl" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8134">1.48</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXRSLbJaIxN2" title="Granted (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares" id="ixv-8135">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4M0NLYOVe3i" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares" id="ixv-8136">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4ipmvUnHem" title="Vested (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares" id="ixv-8137">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zxDr35xjmIXc" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares" id="ixv-8138">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zFBn1TpWV5D5" title="Vested (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares" id="ixv-8139">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zyVAZ3aERA02" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares" id="ixv-8140">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zxpEVIJUV7Oa" title="Forfeited/canceled (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares" id="ixv-8141">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zkIABLM6hxxi" title="Forfeited/canceled" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares" id="ixv-8142">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zfwDAGdsgE73" title="Forfeited/canceled (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" unitRef="Shares" id="ixv-8143">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z736TyxeOos3" title="Forfeited/canceled" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares" id="ixv-8144">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zlwqeSmQQTEc" title="Unvested at ending (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions" contextRef="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8145">200,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zwFHpgH3Ya5a" title="Unvested at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8146">1.48</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zum9GSPaaM4j" title="Unvested at ending (in shares)" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zKSPREQa99M3" title="Unvested at ending" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zLOFqNNWsLv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2023, there was $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zvYjw3LvAWG2" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8147">176,345</ix:nonFraction></span> of unrecognized compensation
cost related to unvested employee performance options. This amount is expected to be recognized over a weighted-average period of<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zJJj6XPZO0r1" title="Weighted-average period::XDX::P36M"> <span style="-sec-ix-hidden: xdx2ixbrl0858">36</span></span> months.
We have recognized tax benefits associated with restricted stock award compensation of $<span id="xdx_908_ecustom--TaxBenefitFromRestrictedStockCompensation_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXXCK7rQ3YG3" title="Tax benefit from restricted stock award compensation"><ix:nonFraction name="krmd:TaxBenefitFromRestrictedStockCompensation" contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8148">1,137</ix:nonFraction></span> and <span id="xdx_90E_ecustom--TaxBenefitFromRestrictedStockCompensation_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z28UFQnymdH6" title="Tax benefit from restricted stock compensation::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0862">zero</span></span> for the twelve months ended December
31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESTRICTED STOCK AWARDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="ixv-5344"><p id="xdx_898_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zfunpkl4nUhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B6_zyDtnkQEFQkc">The following table summarizes the activities for our unvested restricted
stock awards for the twelve months ended December 31, 2023, and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Twelve Months Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 46%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhJVfbeXIxP8" title="Outstanding at beginning (in shares)" style="width: 10%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8149">950,000</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBPjvkLNa7yj" title="Outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8150">3.04</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z07BwXSgZmz6" title="Outstanding at beginning (in shares)" style="width: 10%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8151">1,000,000</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zgeVGhrvxVX7" title="Outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8152">3.01</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3LAi9s9XCTe" title="Granted (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8153">54,496</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zGzrTMrGQcXk" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8154">3.68</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zbQfXLgHb5W1" title="Granted (in shares)" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zllcecbW3drk" title="Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXK55JfgMdHi" title="Vested (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8155">100,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zvmqSZ98yUEd" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8156">3.31</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zl6HFN0Tc3rl" title="Vested (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8157">50,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zlFjXfmwisW4" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8158">3.31</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zpKU0AmugtS5" title="Forfeited/canceled (in shares)" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0890">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zTdUZszxmIkc" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z7wMYrP3Yz3c" title="Forfeited/canceled (in shares)" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJEyiezOocf6" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z143DXigTUDe" title="Outstanding at ending (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8159">904,496</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLfz9jPJh54f" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8160">2.77</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zq79WcillT5d" title="Outstanding at ending (in shares)" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-8161">950,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zimyf8K4Ts39" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-8162">3.04</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zjoX3RCTXjc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2023, there was $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zAFg7ENbg7Od" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8163">1,076,664</ix:nonFraction></span> of unrecognized compensation
cost related to unvested employee restricted shares. This amount is expected to be recognized over a weighted-average period of 21 months.
We have recognized tax benefits associated with restricted stock award compensation of $<span id="xdx_90F_ecustom--TaxBenefitFromRestrictedStockCompensation_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zN1uwWnsezSg" title="Tax benefit from restricted stock compensation"><ix:nonFraction name="krmd:TaxBenefitFromRestrictedStockCompensation" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8164">79,326</ix:nonFraction></span> and $<span id="xdx_90E_ecustom--TaxBenefitFromRestrictedStockCompensation_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zCLpMEWruJI4" title="Tax benefit from restricted stock compensation"><ix:nonFraction name="krmd:TaxBenefitFromRestrictedStockCompensation" contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8165">101,419</ix:nonFraction></span> for the twelve months ended
December 31, 2023 and 2022, respectively.</p>

</ix:nonNumeric><p id="xdx_81F_zudRbAxvMnK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 44 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" id="ixv-5480"><p id="xdx_801_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zGBiJgAYhFWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8212; <span id="xdx_821_ztigHibf5dbb">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;Our two operating leases have remaining lease terms of <span id="xdx_900_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zxwLY8V60Ktd" title="Operating lease remaining term::XDX::P8Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0914">8.6</span></span> years and <span id="xdx_906_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_z3rmYnhRglh6" title="Operating lease remaining term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0916">5</span></span> years, respectively. Our three
finance leases have remaining lease terms of <span id="xdx_90C_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zGoMWa0ih2Nj" title="Finance lease remaining term::XDX::P3Y4M24D"><span style="-sec-ix-hidden: xdx2ixbrl0918">3.4</span></span> years, <span id="xdx_90D_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zNLYlSx7evQ" title="Finance lease remaining term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0920">3</span></span> years, and <span id="xdx_906_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseThreeMember_zWmdu9M5xyWh" title="Finance lease remaining term::XDX::P4Y9M0D"><span style="-sec-ix-hidden: xdx2ixbrl0922">4.75</span></span> years, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At contract inception, we evaluate whether an arrangement is or contains
a lease for which we are the lessee (that is, arrangements which provide us with the right to control a physical asset for a period of
time). &#160;Operating leases are accounted for on the balance sheets with ROU assets being recognized in &#8220;Operating lease right-of-use
assets&#8221; and lease liabilities recognized in &#8220;Operating lease liability &#8211; current&#8221; and &#8220;Operating lease liability,
net of current portion.&#8221; Finance leases are accounted for on the balance sheets recognized in &#8220;Property and equipment, net&#8221;
and lease liabilities recognized in &#8220;Finance lease liability &#8211; current&#8221; and &#8220;Finance lease liability, net of current
portion.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating lease expenses are recognized on a straight-line basis over the
lease term. &#160;With respect to finance leases, amortization of the ROU asset is presented separately from interest expense related
to the finance lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have elected to combine lease and non-lease components for all lease
contracts where we are the lessee. &#160;Additionally, for arrangements with lease terms of 12 months or less, we do not recognize ROU
assets and lease liabilities and lease payments are recognized on a straight-line basis over the lease term with variable lease payments
recognized in the period in which the obligation is incurred. &#160;ROU assets are measured for impairment when a triggering event occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-5503"><p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_znhwFvHPWxwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of lease expense were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BE_zDfk5fgcQbcj" style="display: none; visibility: hidden">Schedule of components of lease expenses</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 57%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_494_20230101__20231231_zKiB6cGbWRp4" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 3%; text-align: center">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_49D_20220101__20221231_zjAAY9T4ZDc9" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zaS1RlIt9pb9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8166">448,630</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8167">514,294</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zIdwXxVc5UYa" style="vertical-align: bottom; background-color: white">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8168">130,483</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8169">131,490</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zdOriZH6Oifk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8170">579,113</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8171">645,784</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zkMAAx5sE1fi" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zMeYf5mxIzA9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8172">110,566</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8173">50,895</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zdq5GiOb9S3a" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8174">25,343</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8175">5,393</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zE4V3Y4Eq1ec" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8176">135,909</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8177">56,288</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z5LFep38Wfsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="ixv-5620"><p id="xdx_89A_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zselWVrMP4bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental cash flow information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zZ1w5yy5QMH1" style="display: none; visibility: hidden">Schedule of cash flow information related to leases</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 72%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td id="xdx_495_20230101__20231231_zzRbf8rXOXUa" style="width: 11%; text-align: center">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td id="xdx_491_20220101__20221231_zhS65FBULqld" style="width: 11%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.45pt; text-indent: -9.45pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zdZi16PauUj1" style="vertical-align: bottom; background-color: white">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8178">464,104</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8179">247,504</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zUeDqJG34f1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8180">125,259</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8181">57,243</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_zZC3ZIqdAXid" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_234_zVwx9jxL19kf">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 45 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock" id="ixv-5701"><p id="xdx_897_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z2E5mzBdPO79" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental balance sheet information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zc7YbtpSNOu6" style="display: none; visibility: hidden">Schedule of balance sheet information related to leases</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zB62PhKNaONd" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zKOJjTjXRV29" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zl9jr5wwyhvf" style="vertical-align: bottom; background-color: white">
    <td style="width: 59%; padding-left: 9.1pt; text-indent: -9.1pt"><b>Operating Leases</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 15%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 16%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zgg4N1jXmim4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8182">3,514,055</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8183">3,786,545</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_zOkwuHUya5Nd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8184">368,313</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8185">345,834</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zNNxsHNUxT1g" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8186">3,336,300</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8187">3,653,257</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_zr1ggNoOPBwl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8188">3,704,613</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8189">3,999,091</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_z1yayVn0aEU5" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_zZ7rpgB4edL4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8190">577,929</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8191">544,468</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_zgo6WFpvwXi3" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8192">161,461</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8193">50,895</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zHdscoHEbKW4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8194">416,468</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8195">493,573</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zkwmxWl3bXMj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8196">109,540</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8197">98,335</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zTfOwEsNtFF6" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8198">316,623</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8199">394,283</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zSEELGZNZst8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8200">426,163</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8201">492,618</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 58%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td style="vertical-align: top; width: 1%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_zZf4F5Q30GP4" title="Operating leases term::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0997">6.9</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20221231_zcYRctEfugE8" title="::XDX::P9Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0998">9.7</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_zeaQD2VStw4d" title="Finance leases  term::XDX::P3Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl1000">3.7</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_900_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20221231_zsvcgphj12G8" title="::XDX::P4Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl1001">4.6 </span></span>Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zT9ehFPKl5pf" title="Operating leases discount rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8202">5.76</ix:nonFraction></span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zGaketmYUWu3"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8203">4.00</ix:nonFraction></span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zFhp9PN6K93e" title="Finance leases discount rate"><ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8204">6.19</ix:nonFraction></span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_906_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20221231_z2Q80shkk67j"><ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8205">4.25</ix:nonFraction></span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zLVASEBRsQil" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-5945"><p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z17mlvILdsol" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Maturities of lease liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8B7_zUFFKPAqsp18" style="display: none; visibility: hidden">Schedule of maturities of lease liabilities</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 57%">2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zQcC8joE0WEi" title="2024 - Operating Leases" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8206">512,055</ix:nonFraction></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zJd3hfl0udD" title="2024 - Finance Leases" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8207">131,437</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zXUdyqsuMf2c" title="2025 - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8208">512,055</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zVmq6vyxjuW4" title="2025 - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8209">131,437</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zRyIIkYxIrb" title="2026 - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8210">512,055</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zwmZ6ay8nu6i" title="2026 - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8211">131,437</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zvkcp4xvrMuj" title="2027 - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8212">512,055</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zo0pWx6vMXck" title="2027 - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8213">74,194</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20231231_zPLHgDfCcVjl" title="2028 - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8214">512,055</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20231231_zyvqrNESrjI6" title="2028 - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8215">6,181</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20231231_zxlaI2rrxQ8e" title="Thereafter - Operating Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8216">1,832,557</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20231231_zzgiBFk0TZE9" title="Thereafter - Finance Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_986_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20231231_zpU0MdldqvZ6" title="Total undiscounted lease payments - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8217">4,392,832</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_987_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20231231_zJwCtKSR541j" title="Total undiscounted lease payments - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8218">474,686</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 18.8pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20231231_zKdtxCiyRnU" title="Less: imputed interest - Operating Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(<ix:nonFraction name="krmd:LesseeOperatingLeaseImputedInterest" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8219">688,220</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20231231_zzQ0Zerpow2b" title="Less: imputed interest - Finance Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(<ix:nonFraction name="krmd:LesseeFinancingLeaseImputedInterest" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8220">48,523</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20231231_zwvCLHDBLtte" title="Total lease liabilities - Operating Leases" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8221">3,704,613</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_986_eus-gaap--FinanceLeaseLiability_iI_c20231231_zkxSLnpFa6A" title="Total lease liabilities - Finance Leases" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8222">426,163</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_znRQ2nVEkIP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_81B_z2v4qDWlCT1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 46 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-6051"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zkUXaGaEBiL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8212; <span id="xdx_821_zRi2M8gtiuVk">FEDERAL AND STATE INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-6056"><p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJTmOBimS5r" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_zxRW4mZ3lUN2" style="display: none; visibility: hidden">Schedule of provision for income taxes</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zHctlo41dmwi" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zlzqc0OUWIsk" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z2yKTLcu8wf7" style="vertical-align: bottom; background-color: white">
    <td>State income tax:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_z51hzqwRstWb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 51%; padding-left: 21.8pt">Current, net of refund</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">$</td>
    <td style="width: 19%; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8223">0</ix:nonFraction></td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 2%">$</td>
    <td style="width: 19%; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8224">0</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z46egG0kC9ga" style="vertical-align: bottom; background-color: white">
    <td>Federal income tax:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zSX11M5F9p13" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Deferred</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8225">2,035,297</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8226">2,014,018</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_zu7w9rb70Pl9" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 21.8pt">Current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WriteoffOfDeferredTaxAsset_zK8xrqvwSSDk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Write-off of deferred tax asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="krmd:WriteoffOfDeferredTaxAsset" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8227">6,002,777</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20230101__20231231_ztAptpNmii0a" title="Income tax benefit/(expense)" style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8228">3,967,480</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98B_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zgxeqZGjwYSk" title="Income tax benefit/(expense)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8229">2,014,018</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_zYsVoTGoj5ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-6146"><p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zNPI1xPbzeml" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The reconciliation of income taxes shown in the financial statements and
amounts computed by applying the Federal expected tax rate of 21% for year 2023 and 2022 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B8_zg34NCCUtSid" style="display: none; visibility: hidden">Schedule of reconciliation of income taxes</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_zO2ZcN6jHd09" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zbJYaSwTn3Z1" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_zYAwaTqqPUS6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 60%">Loss before taxes</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; width: 1%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8230">9,773,582</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double; width: 4%">)</td>
    <td style="border-bottom: black 2.25pt double; width: 1%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8231">10,675,160</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double; width: 1%">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zbSzbna7zBt7" style="vertical-align: bottom; background-color: white">
    <td>Income taxes computed at the federal statutory rate</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8232">2,052,452</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8233">2,241,784</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_z2ktpkq5KsR8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>State income and franchise tax</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1082">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zSRYt6WqZjI5" style="vertical-align: bottom; background-color: white">
    <td>Permanent differences and other</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8234">17,155</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8235">227,766</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40D_ecustom--WriteoffOfDeferredTaxAsset_zvWKIs9VFZeb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Write-off of deferred tax asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="krmd:WriteoffOfDeferredTaxAsset" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8236">6,002,777</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1088">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20230101__20231231_ztoiOvHdE2D8" title="Income tax benefit/(expense)" style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8237">3,967,480</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zWeBKg45pzwj" title="Income tax benefit/(expense)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8238">2,014,018</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_zhXaeMsAZSTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-6236"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKFGMN3Kcpyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The significant components of deferred income tax assets, net are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8BC_z4sTd2qvGpIb" style="display: none; visibility: hidden">Schedule of components of deferred tax assets</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zR7qybW8bxCl" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zcdy3sOF9V5b" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredCompensationPlanAssets_iI_zrqwDl1ZBlZi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 60%">Deferred compensation cost</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredCompensationPlanAssets" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8239">1,047,608</ix:nonFraction></td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredCompensationPlanAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8240">557,931</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DepreciationDepletionAndAmortization1_iI_zVkK6CbK4oBf" style="vertical-align: bottom; background-color: white">
    <td>Depreciation and amortization</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:DepreciationDepletionAndAmortization1" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8241">913,671</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:DepreciationDepletionAndAmortization1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8242">624,184</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_403_ecustom--RdCredit_z3DOhi3YsAmc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>R&amp;D credit</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:RdCredit" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8243">142,030</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:RdCredit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8244">142,030</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--Nol_zHaKxqsnpMX4" style="vertical-align: bottom; background-color: white">
    <td>NOL</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:Nol" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8245">3,566,630</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:Nol" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8246">2,956,685</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AllowanceForDoubtfulOtherReceivables1Current_zsM4g8zG4Dq2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Allowance for bad debts and other</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:AllowanceForDoubtfulOtherReceivables1Current" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8247">2,160,180</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:AllowanceForDoubtfulOtherReceivables1Current" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8248">935,018</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--AllowanceForNonRealizationOfDeferredTaxAsset_iI_zxkfYdFg8anb" style="vertical-align: bottom; background-color: white">
    <td>Allowance for non-realization of deferred tax asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="krmd:AllowanceForNonRealizationOfDeferredTaxAsset" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD" id="ixv-8249">6,002,777</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_zRu5Hm81Eft8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Deferred income tax assets, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">&#8212;</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8250">3,967,480</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_zvFWfXmIMEMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our U.S. federal and state income tax returns remain open to examination
for the tax years 2020 through 2022.</p>

</ix:nonNumeric><p id="xdx_81B_zix3eii9QjVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="ixv-6327"><p id="xdx_80A_eus-gaap--ConcentrationRiskDisclosureTextBlock_zbdQMjwffKEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8212; <span id="xdx_82F_zgajdSoN0Jb">MAJOR CUSTOMERS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For the years ended December 31, 2023 and December 31, 2022, approximately
<span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zue1I2mINIcb" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8251">66</ix:nonFraction></span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zWqBZLOe73Kj" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8252">64</ix:nonFraction></span>%, respectively, of the Company&#8217;s net product revenues were derived from three major customers that are distributors.
&#160;As of December 31, 2023 and December 31, 2022, accounts receivable due from the three major customers was $<span id="xdx_906_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20231231_zXl35KrkL7e9" title="Account eceivable from customers"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD" id="ixv-8253">2.6</ix:nonFraction> million</span> and $<span id="xdx_90C_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20221231_zpRC4ulyR6r6" title="Account eceivable from customers"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD" id="ixv-8254">2.2</ix:nonFraction>
million</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The largest customer in both years is a domestic medical products and supplies
distributor. &#160;Although a number of larger infusion customers have elected to consolidate their purchases through one or more distributors
in recent years, we continue to maintain strong direct relationships with them. &#160;We do not believe that their continued purchase
of FREEDOM System products and related supplies is contingent upon the distributor.</p>

</ix:nonNumeric><p id="xdx_813_zaRtCUzlPVKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 47 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-6347"><p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zblDifXjcZ2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8212; <span id="xdx_82C_zzipdBmphPsa">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OTHER</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#8220;Command&#8221;), pursuant to which Command has agreed to manufacture and supply
the Company&#8217;s subassemblies, needle sets and tubing products pursuant to the Company&#8217;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#8220;Effective
Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.</p>

</ix:nonNumeric><p id="xdx_81C_zgNPz27O0wNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="ixv-6366"><p id="xdx_803_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zNb2Zq5vbV14" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 &#8212; <span id="xdx_821_zO312PiFznTd">EMPLOYEE BENEFITS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We provide a safe harbor 401(k) plan for our employees that allows for
employee elective contributions, Company matching contributions and discretionary profit-sharing contributions. &#160;Employee elective
contributions are funded through voluntary payroll deductions. &#160;<span id="xdx_900_ecustom--DescriptionOfMatchingContribution_c20230101__20231231_zrf827PcORCk" title="Description of matching contribution"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="krmd:DescriptionOfMatchingContribution" id="ixv-8255">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#8217;s contribution, not to exceed 3% of employee&#8217;s compensation plus 50% of employee&#8217;s pay
contributed between 3% and 5% of employee&#8217;s compensation.</ix:nonNumeric></span> &#160;Company matching expense for the years ended December 31, 2023 and
December 31, 2022 was $<span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zxurb7Sk0cua" title="Matching expense"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8256">227,447</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zJcu9TGniUsg" title="Matching expense"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8257">214,931</ix:nonFraction></span>, respectively. &#160;The Company has not provided for a discretionary profit-sharing contribution.</p>

</ix:nonNumeric><p id="xdx_815_zIrVLp44q3Og" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-6376"><p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zugbuc7j3H03" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 &#8212; <span id="xdx_829_zgKwPlf1lqGe">DEBT OBLIGATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On July 28, 2023, the Company entered into a commercial insurance premium
finance and security agreement with AON Premium Finance, LLC in the aggregate principal amount of $<span id="xdx_906_eus-gaap--NotesPayable_iI_dm_c20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z1pMWEqXixPi" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD" id="ixv-8258">0.57</ix:nonFraction> million</span> bearing an annual percentage
rate of <span id="xdx_90B_ecustom--NotePayableTerms_pid_dp_uPure_c20230726__20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zHqHEfQG4iq2" title="Note payable terms"><ix:nonFraction name="krmd:NotePayableTerms" contextRef="From2023-07-262023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8259">9.5</ix:nonFraction></span>%, to finance its insurance premiums. <span id="xdx_90C_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_c20230726__20230728_zsJcE1SMlza8" title="Description of the frequency of periodic payments"><ix:nonNumeric contextRef="From2023-07-262023-07-28" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" id="ixv-8260">Monthly payments are due on the first of each month beginning August 1, 2023 through
June 1, 2024.</ix:nonNumeric></span> The balance of AON note was $<span id="xdx_903_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember_zwelvbDfXZ6k" title="Balance of AON note"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="AsOf2023-12-31_custom_AONPremiumFinanceLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8261">314,344</ix:nonFraction></span> as of December 31, 2023 and $<span id="xdx_90A_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20221231__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember_zxU9rAK8pzra" title="Balance of AON note"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="AsOf2022-12-31_custom_AONPremiumFinanceLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8262">433,295</ix:nonFraction></span> as of December 31, 2022, respectively.</p>

</ix:nonNumeric><p id="xdx_817_zxp1dj6FpC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-6388"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zezBPiQjjKuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 11 &#8212; <span id="xdx_829_zY5BsxqjBb3i">SUBSEQUENT EVENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 8, 2024, the Company entered into a loan and security agreement
with HSBC Ventures USA Inc., as lender, providing for a $<span id="xdx_904_eus-gaap--InvestmentOwnedAtFairValue_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zur2qbkjrTVj" title="Loan provided, as lender"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2024-03-08_us-gaap_SubsequentEventMember_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8263">5,000,000</ix:nonFraction></span> revolving credit facility and a $<span id="xdx_903_eus-gaap--InvestmentOwnedAtFairValue_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zyuGQCjxXys5"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_TermLoanFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-8264">5,000,000</ix:nonFraction></span> term loan facility. Borrowings
are secured by a first-priority lien on substantially all of the assets of the Company, subject to customary exceptions. The revolving
credit facility matures on December 31, 2025 and the term loan matures on December 1, 2028. Our former revolving credit facility with
Key Bank expired during the quarter ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Borrowings under the revolving credit facility will bear interest at the
greater of Prime or <span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_uPure_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zCTBf0SQorwb" title="Inteest rate on borrowings"><ix:nonFraction name="us-gaap:InvestmentInterestRate" contextRef="AsOf2024-03-08_us-gaap_SubsequentEventMember_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-8265">6.50</ix:nonFraction></span>%, payable in arrears on a monthly basis and at maturity. <span id="xdx_90F_eus-gaap--SubsequentEventDescription_c20240306__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLquczIIIEW7" title="Description of subsequent event"><ix:nonNumeric contextRef="From2024-03-062024-03-08_us-gaap_SubsequentEventMember" name="us-gaap:SubsequentEventDescription" id="ixv-8266">Borrowings under the term loan will bear interest at
the greater of Prime minus 0.50% or 6.50% and will be interest-only through December 31, 2025, followed by 24 equal monthly payments of
principal plus interest.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The loan and security agreement contains customary affirmative covenants
a financial maintenance covenant that requires the Company to maintain a minimum Adjusted Quick Ratio (defined as the ratio of the Company&#8217;s
(i) unrestricted and unencumbered cash and cash equivalents maintained with the lender and its affiliates, plus eligible accounts receivable,
to (ii) current liabilities) of not less than 1.50 to 1.00 tested on the last day of each month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There are no outstanding borrowings under the facility as of March 13,
2024.</p>

</ix:nonNumeric><p id="xdx_819_z3XwiRJ19xP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 48 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_9"></span><b>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_9A"></span><b>ITEM 9A. CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">An evaluation was performed under the supervision and with the participation
of our management, including our principal executive officer or CEO, and principal financial officer or CFO, of the effectiveness of our
disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;)) as of December 31, 2023. &#160;Based on that evaluation, our management, including our CEO and CFO, concluded that as of
December 31, 2023, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports
that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
SEC&#8217;s rules and forms, and is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions
regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management of the Company is responsible for establishing and maintaining
adequate internal control over financial reporting. &#160;The Company&#8217;s internal control over financial reporting is a process designed
under the supervision of the Company&#8217;s principal executive officer and principal financial officer, and implemented in conjunction
with management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of the Company&#8217;s financial statements for external purposes in accordance with generally accepted accounting principles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There are inherent limitations in the effectiveness of any internal control,
including the possibility of human error and the circumvention or overriding of controls. &#160;Accordingly, even effective internal control
can provide only reasonable assurance with respect to financial statement preparation. Further, because of changes in conditions, the
effectiveness of internal control may vary over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management assessed the effectiveness of the Company&#8217;s internal control
over financial reporting as of December 31, 2023. &#160;This assessment was based on criteria for effective internal control over financial
reporting described in &#8220;Internal Control - Integrated Framework,&#8221; issued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO). &#160;Based on this assessment, management determined that, as of December 31, 2023, the Company maintained
effective internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There has been no change in our internal control over financial reporting
(as defined in Rule 13a-15(f) under the Exchange Act) during the year ended December 31, 2023, that has materially affected, or that is
reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_9B"></span><b>ITEM 9B. OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_9C"></span><b>ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 49 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_10"></span><b>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information regarding our executive officers required by Item 10 of Part
III is set forth in Item 1 of Part I &#8220;Business &#8212; Executive Officers.&#8221; &#160;Information required by Item 10 of Part
III regarding our directors and any material changes to the process by which security holders may recommend nominees to the Board of Directors
is included in our Proxy Statement relating to our 2024 Annual Meeting of Shareholders, and is incorporated herein by reference. &#160;Information
relating to our Code of Ethics and to compliance with Section 16(a) of the 1934 Act is set forth in our Proxy Statement relating to our
2024 Annual Meeting of Shareholders and is incorporated herein by reference. &#160;We intend to disclose amendments to our Code of Ethics,
as well as waivers of the provisions thereof, on our website under the heading &#8220;Investors - Governance&#8221; at www.korumedical.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_11"></span><b>ITEM 11. EXECUTIVE COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 11 of Part III is included in our Proxy Statement
relating to our 2024 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_12"></span><b>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 12 of Part III is included in our Proxy Statement
relating to our 2024 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_13"></span><b>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 13 of Part III is included in our Proxy Statement
relating to our 2024 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_14"></span><b>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 14 of Part III is included in our Proxy Statement
relating to our 2024 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 50 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_15"></span><b>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">All financial statement schedules have been omitted because they are not
required, not applicable, not present in amounts sufficient to require submission of the schedule, or the required information is otherwise
included.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following exhibits are filed herewith or incorporated by reference
as part of this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 0.8in"><b>Exhibit&#160;No.</b></td>
    <td style="width: 0.2in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 6.5in"><b>Description</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>2.1</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169723000302/ex_2-1.htm">Agreement and Plan of Merger by and between KORU Medical Systems, Inc., a New York corporation, and KORU Medical Systems, Inc., a Delaware corporation</a> (incorporated by reference to our Form 8-K filed with the SEC on May 17, 2023).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>3.1(i)</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169719000090/ex_3-i.htm">Certificate of Incorporation of KORU Medical Systems, Inc. effective May 16, 2023</a> (incorporated by reference to our Form 8-K filed with the SEC on May 17, 2023).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>3.1(ii)</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169718000565/ex_3iii.htm">Bylaws of KORU Medical Systems, Inc.</a> (incorporated by reference to our Form 8-K filed with the SEC on May 17, 2023).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>4.1</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_4-1.htm">Description of Securities</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.1</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169716001008/schedule_14a.htm">2015 Stock Option Plan, as amended</a> (incorporated by reference to the Company&#8217;s Proxy Statement on Schedule 14A filed with the SEC on July 28, 2016).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.2</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000196/schedule_14a.htm#Koru2021OmnibusEquityIncentivePlan">2021 Omnibus Equity Incentive Plan</a> (incorporated by reference to the Company&#8217;s Proxy Statement on Schedule 14A filed with the SEC on April 5, 2021).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.3</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_10-5.htm">Form of Non-Qualified Stock Option</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.4</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_10-6.htm">Form of Incentive Stock Option</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.5</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169722000140/schedule_14a.htm#a_021">Non-Employee Director Compensation Plan</a> (incorporated by reference to the Company&#8217;s Proxy Statement on Schedule 14A filed with the SEC on March 18, 2022).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.6</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169720000481/ex_10-1.htm">Manufacturing and Supply Agreement dated as of November 11, 2020 between KORU Medical Systems, Inc. and Command Medical Products</a> (incorporated by reference to the Company&#8217;s Form 10-Q filed with the SEC on November 12, 2020). &#160;Certain information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.7</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_10-15.htm">Employment Agreement effective as of March 15, 2021 between KORU Medical Systems, Inc. and Linda Tharby</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).* &#8224;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.8</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169723000158/ex_10-15.htm">Employment Agreement effective as of March 18, 2022 between KORU Medical Systems, Inc. and Brian Case</a> (incorporated by reference to the Company's Form 10-K filed with the SEC on March 8, 2023).*</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.9</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169722000377/ex_10-1.htm">Employment Agreement effective as of October 20, 2021 between KORU Medical Systems, Inc. and Thomas Adams</a> (incorporated by reference to the Company&#8217;s Form 10-Q filed with the SEC on August 3, 2022).*</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.10</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169723000429/ex_10-1.htm">First Amendment to Employment Agreement effective as of August 1, 2023 between Thomas Adams and KORU Medical Systems, Inc.</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on August 2, 2023).*</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>continued</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 51 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 0.8in"><b>Exhibit&#160;No.</b></td>
    <td style="width: 0.2in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 6.5in"><b>Description</b></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.11</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169723000567/ex_10-1.htm">Employment Agreement effective as of November 6, 2023 between KORU Medical Systems, Inc. and Kenneth Miller</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on November 8, 2023).*</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.12</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169722000133/ex_10-16.htm">Lease dated as of January 21, 2022 between the Company and Breit Industrial Canyon NJ1W05 LLC</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 2, 2022).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.13</td>
    <td>&#160;</td>
    <td>Loan and Security Agreement dated as of March 8, 2024 by and between KORU Medical Systems, Inc. and HSBC Ventures USA Inc. (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on March 13, 2024).+</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.14</td>
    <td>&#160;</td>
    <td>Stock Purchase Warrant issued to HSBC Ventures USA Inc. issued on March 8, 2024 (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on March 13, 2024).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>23.1</td>
    <td>&#160;</td>
    <td><a href="ex_23-1.htm">Consent of Independent Auditors</a> (filed herewith).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>31.1</td>
    <td>&#160;</td>
    <td><a href="ex_31-1.htm">Certification of the Principal Executive Officer of registrant required under Section 302 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>31.2</td>
    <td>&#160;</td>
    <td><a href="ex_31-2.htm">Certification of the Principal Financial Officer of registrant required under Section 302 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>32.1</td>
    <td>&#160;</td>
    <td><a href="ex_32-1.htm">Certification of the Principal Executive Officer of registrant required under Section 906 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>32.2</td>
    <td>&#160;</td>
    <td><a href="ex_32-2.htm">Certification of the Principal Financial Officer of registrant required under Section 906 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.INS</td>
    <td>&#160;</td>
    <td>Inline XBRL Instance Document - the XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.SCH</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Schema Document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.CAL</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.DEF</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Definition Linkbase Document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.LAB</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Label Linkbase Document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.PRE</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>104</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.2in">+</td>
    <td style="width: 7.3in">Certain schedules, appendices and/or exhibits to this agreement have been omitted in accordance with Item 601 of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished supplementally to the Securities and Exchange Commission staff upon request.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>*</td>
    <td>Denotes management compensatory agreement or arrangement.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#8224;</td>
    <td>Certain information has been omitted from this exhibit because it is not material and would be competitively harmful if publicly disclosed.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_16"></span><b>ITEM 16. FORM 10-K SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 52 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Signatures"></span><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March
13, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU MEDICAL SYSTEMS, INC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Linda Tharby</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby, President and Chief Executive Officer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Thomas Adams</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Thomas Adams, Chief Financial Officer and Treasurer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on March 13, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ R. John Fletcher</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">R. John Fletcher, Chairman of the Board</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Edward Wholihan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Edward Wholihan, Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Robert A. Casella</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Robert A. Casella, Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Joseph M. Manko, Jr.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Joseph M. Manko, Jr., Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Shahriar Matin</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shahriar Matin, Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Donna French</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Donna French, Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Linda Tharby</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby, Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 53 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>2
<FILENAME>ex_23-1.htm
<DESCRIPTION>CONSENT OF INDEPENDENT AUDITORS
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 23.1</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="mmq_logo-header.jpg">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference in the
Registration Statement on Form S-1 (No. 333-229498), Registration Statement on Form S-3 (No. 333-238242), Registration Statement on Form
S-3 (No. 333-272026), Registration Statement on form S-8 (No. 333-265943), Registration Statement on Form S-8 (No. 333-273300) and related
Prospectuses of KORU Medical Systems, Inc. of our report dated March 13, 2024, with respect to the financial statements of KORU Medical
Systems, Inc., appearing in this Annual Report on Form 10-K for the fiscal year ended December 31, 2023.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">/s/ McGrail Merkel Quinn &amp; Associates, P.C.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Scranton, Pennsylvania</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">March 13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="mmq_logo-footer.jpg">&nbsp;</P>

<HR NOSHADE ALIGN="CENTER" WIDTH="100%" SIZE="2">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>ex_31-1.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 31.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Linda Tharby, Principal Executive Officer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>1)</TD>
    <TD COLSPAN="2">I have reviewed this Annual Report on Form 10-K of KORU MEDICAL SYSTEMS, INC.;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>2)</TD>
    <TD COLSPAN="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3)</TD>
    <TD COLSPAN="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(a)</TD>
    <TD STYLE="width: 7in">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(c)</TD>
    <TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(d)</TD>
    <TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>5)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Linda Tharby</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>ex_31-2.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 31.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRINCIPAL FINANCIAL OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Thomas Adams, Principal Financial Officer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>1)</TD>
    <TD COLSPAN="2">I have reviewed this Annual Report on Form 10-K of KORU MEDICAL SYSTEMS, INC.;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>2)</TD>
    <TD COLSPAN="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3)</TD>
    <TD COLSPAN="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(a)</TD>
    <TD STYLE="width: 7in">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(c)</TD>
    <TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(d)</TD>
    <TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>5)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Thomas Adams</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Thomas Adams</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer and Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>ex_32-1.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 32.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Annual Report of KORU MEDICAL SYSTEMS, INC. (the
&ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;),
I, Linda Tharby, Principal Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">(1)</TD>
    <TD STYLE="width: 7in">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Linda Tharby</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Executive Officer and President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>ex_32-2.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 32.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Annual Report of KORU MEDICAL SYSTEMS, INC. (the
&ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;),
I, Thomas Adams, Principal Financial Officer and Treasurer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">(1)</TD>
    <TD STYLE="width: 7in">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Thomas Adams</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Thomas Adams</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer and Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>mmq_logo-footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmq_logo-footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  \ G # 2(  A$! Q$!_\0
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M=?#6#Q&WBK19/%'A[2=1TR]\+Z)IVOZKI^HRZ_J6E:9H9M].UK0)[K5=?O\
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M(NM7EEI=G=ZA'X8U/0]>%HUC9>+G\,]9XB_9,^"?B7P%I'PQN] U&R\$>%_
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MXRZ9K+^(1:WUO<7<5]H/Q^^*?ARYM89[6UN-"UW3K*YAF/A3PE+H8(]=T_\
M:*^!.JW^F:5IOQ:\!7NI:Q<V-GI]A;^(].DNY;K4]?A\*:9!+;K-YMI)J?BB
MZL?#>FB\6W^WZ_JFD:/:>=J&L:9;W?):S^U=\'=(TSX*^*VU\3_#CXYZ9XEU
MSPO\37:UTKP=I6@>&/ FH_$>YU_Q//KUQI.J:1HEQX5T?5=0.J/ILEKI5O8S
MWNO/I6G127B6;[]E_P"&>J7OAO4]7F\7ZKJ/A;3OAWIFGWMWXHOEFN+?X6?%
M/P]\9/!CZFMHMK!J%W8^.?"NAWM]>3Q&XUNQM)=-UF2^M+Z_2ZK:K^R=\&];
M^&7@CX1ZEIOB"X\%_#SPMXC\"^%+3_A*-9BO]/\ !'BSP5JOPVUWPM+JD5RE
M[>6%S\/]:U#PI;WEW+-KFFVCP:KIFK6?B6SL]<@ .YA^//P8N;^/2;?XG>#)
M]5FU/4=$M]-@URRFU"XUC1_%GB_P+K.EVUE'(US<ZAHGB_P!XXT#6K."*2?2
M-0\(^(H]2CM4TB]>'G] _::^".M6ND-=?$KP+HFIZMI":XNCZAXU\)7$UGIT
MVB^./$]O<W>IZ3K.H:"L-UX7^&?Q%\26D\6JR07>A> ?&VJ6\DEIX3\02Z=P
M-W^P_P#L\WTUV;CPQJCV%UJFIZLFACQ#J@T'3[K5OBKXC^-]Q-I&E^=Y&DWU
MG\5O%OB'QOX=UZP$'B;P=K-W8/X.UO0(/#7A2'0\_4_V"_V<->L#I/B+PWXA
M\0Z/+H4WA:]TG5_&/B*:PU'PU=^"OVAOAYJ&AWT4-[;O+9:EX0_:F^-6E7C)
M+'>,?$MA>PW4.H>&?#EUI8![%%^T5\"[B&YN+?XK>"+B.R6V-Z(-=M)YK*2]
MU^[\*V%K>V\3O<6>H:CXCT_4=%TW3;F*+4-1U#3M1M[*VG>PNQ#IVWQR^#M[
MXB?PC8_$SP7?>*8]9'AY_#UCX@TZ]UE=8_M76M DM#IUK/+=?Z/X@\-^(_#M
MW<B(VEGXB\/ZYH-U/#J^D:A9V_E?C;]C?X'_ !*$,GQ!T74O&5_'X&N_AS-J
M^NW\-SJNH>$+_6=/U^^TC4KJ.RA^W6ESK&DZ7J_V2=&LK7Q#ING>+K&UM?&&
MG6/B"VTK+]DGX*6&F^%M$AT+49-"\#_%&7XQ>#-)O-9O+^+PKX[G\7:GX\EU
M30M0O6GUNP+>*]<UZ^5H]5^U1:3K^N>"H;J/P%J]_P"%IP#T/5_C=\)-!U&\
MT?6?B%X8TW5[+4-&TB72KK4HH]2FU7Q%JFK:'H.F:?8\W6JZAK&O:#K>@:;9
MZ7%>7%YK^DZAH<$;ZK:RVB\@/VF/A7J'C[X7> /"OB"Q\=7?Q6^WMH^M>#-6
MT'7="T>&#X;?\+8TBXUR\M]5\V.#Q3X'DLM=T%M.M]1DFTW6/#VJW45KH_B'
M2-0N\B^_9,^$NI?$*^^*%ZWC:Z\7ZAXE\->*+B]N_'/B&]@%YX-\6+XW\)Z=
M%:7MW<PQZ!X<\2->W>CZ$!_9MC9ZG>Z)# NA"RTVSJ?#?]CKX(?":^\"7W@;
M2O$6E#X=W6DZGX>L7\6Z[>:?)K6C? _1_P!G*TUS6K>ZNY3K>IO\'_#GAGPO
M</J3SVTMQH%EXB^RKXEN=7U?4@>FM]^AP_[2OP__ &3/%?B_4YOCY\&/'WQ,
MU_QE\ /'_P  =:N?#OP*_:,^+/A[5/@3\6M;T74/'WP[U>Z^$_@KQ3X/MU\0
MZUX(T#4KF"^EM_&&F'2]-U#3I].M;N":Z^98O@3_ ,$Y1\4O#'QEOOV?_P!J
M;Q#X_P#!DOAN\\,7GC'X'_\ !2CQMX=T?7/!_@ZU\!>%O%]MX"\7^$=;\ MX
M^T#PM9VUAI?Q"F\,2^-[2ZC.LQ>(!KDDFI/^;?\ P<:_\%4OVQ_^";_C/]D#
M1_V5O%G@CPU8?&+PU\=]2\<IXO\ A]H_C>6\N_ .I_"&V\./I\NJ2Q-IL=O#
MXQUP74<&5NVFMVDP;=,^&?MK_P#!8O\ ;I^"/_!&S_@FG^V=\/O&GP_L?CS^
MTSXOAT?XM:UJ7PST/5O#VJ6+^"/BCKA31O"]Q,MAH,G]H>%='?S+-V8Q131'
M*SN0%J,K)K:3LM;:Z^7D?M!X4^!W_!-;P/<^%KWPG^RK\9]#O?!D?[,\/AR_
ML_V2/VZ_M]E'^QU8:OI?[-2SWTOPMDNM3_X57IVNZG9:4=6FOFU>WEMX_$QU
MM=/T\6NSXT^&'_!/7XB?'O3/VF_&7[.'Q[UGXT:7X@\ >,/^$D;]E7]O*QT3
M6O&OPG55^%?COQA\.],^&%E\-?'7CSX9"*V_X5YXW\9^$->\5>"?[/TH^&=7
MTPZ3IIM?X;?^(G[_ (*\?]%4^"__ (87PE_\EU^OVA_\%NO^"@M]_P $-/''
M[==QXZ^'#?M%Z'^WIIWP#T_7U^%6@)X9C^&UQX0\&:O+I\OA$3_V=+JAOM;O
MY%UAI/M2QR1Q8VQ+04Z<U9OJU'XN_P MC^A+X0_#']@#X%?%K4_CI\-_@-^T
MY8_%?4M.\4:1#XP\4?L\_P#!1+XDW7AO2?&VLVGB#QAI?@+3OB5X#\7:+\-]
M.\4:OI^GW>OV7P_TWPS;:J+"RMKV.:TM8((\?5/@;_P3:UGP)X<^&U_^R]\=
M&\*>$KOX^7V@QVO[*W[>^G>(+6]_:B\-_$OPE\?[NX\::=\-+7QIJES\3M"^
M,'Q$MM?FU7Q!>R1W6OQZMI;:?K&B>'[_ $K^(?\ XB?O^"O'_15/@O\ ^&%\
M)?\ R71_Q$__ /!7?_HJGP7_ /#"^$O_ )+H#V4^W_DW_ /[--"_8Y_X)2>&
MO#FK>%=$_92_:.LM+UB34;B:X_X4-_P4IN?$&FWVI^(?@;XMEU;PSXNN_"<_
MBOP?KEGXH_9K^"'B'0]>\)ZUHNL^'-9\ V.I>'[[3+O4]?EU;M]._9__ .":
M>E^'/%/A.U_9C_:#DT3QMX8F\'^+H=0_9I_X*$ZO?>(O#]S\<?$?[2=W:ZKK
M6J_#^]UN[N[SXX^+O$?Q$O=7DU$ZS>:OJMQ;76H2Z2L.G1?Q*?\ $3__ ,%=
M_P#HJGP7_P##"^$O_DNC_B)__P""N_\ T53X+_\ AA?"7_R70'LIO_\ :_X!
M_;%K'[.W_!-;79OB1)J'[.G[4"VOQ5\82?$?Q1HFF_ S_@I3HGA73/B;/XXM
M?B5<_%/X;^#]%\)6'A;X-_%6[\?6H\67GQ-^$.C^!_'EWK5WJMW<^(96UG5Q
M>_HS^S[;?#W3/A?H?AWX76/Q5T_P9X7EO]%TR'XSZ=\=K3Q^\ANY-5O;C5=2
M_:1MX_BSXF2>[U.22'Q'K]YJ\5V3):6>J31V+6]M_G"?\1/W_!7C_HJGP7_\
M,+X2_P#DNO[L/^".7[3?Q<_;)_X)P?LW?M*_';5-%UKXK_$RT^*,OBW4_#V@
MVGAC1[J3PK\;/B5X'T<V>AV+O:V(B\/>&M)MYQ$Q$]S%-=OB2X<4$3A**3>V
MV]SU#XW>$OVC(/CU9^/O@MI,2:)J/PZ\ ^!?%_B-Y_"VHZA9Z+:_$OQ)K'B(
M>%/"OB7Q-HFG:GXLTFPU32M02;Q!';Z,/"=UXNBT:]O_ !C'H>AWW@#?&/\
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MFEZ#K/B6+X1VEYXB\-1?%OPSX@\ ^';_ %O1M2O[KPA=>(OAY-XG\/Q^*8_
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M?AUXWTA+_5?&/P%UW2-8ET6\^"^E>*KGXN^(_P!EWP99P>'=-OXM4B\,:/\
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ML^+[_P  >)-*\4LEMXCO;S50#Z^?]G#X$R1>)H'^%7@LP>-=/UO2O&5O_8T
MM_%NG^(O&?C?XBZK:^)X!B+7TD\>_$SXB^,;1M62[ETOQ+XZ\7:SI,EC?^(=
M5GN>F\4?"7X<>-=)T;0_&7A'2/%.E>'Y-=DT:U\0PRZP+&;Q1X1\3^ ?$5PD
MU]-/<RW6N>#/&GBWPSJ=U<32W%[H_B/6+*:1X[^X$GP1XA_9J_;:U'P-K>GV
MW[1J7/Q*O-;U>2#QO!\0_B#X-TB[TB+]AJ^^%6B7,?@W1/">J:#X3NM1_;4O
M9/V@=2T+1[34[+0?"XM=*MM;\36.EZ?X!BZ+Q%\"?VRM7N+O2=,^*OA[1?#,
MOB+XORPZDGQ=^+%SXJ'@[X@>&OC?H?A'P]*%\&6MJ)O &L>/OA]XSTK54OO^
M$D@U#P)9Z!I?B;3=(TO29) #ZB\/? ']GFPO]8F\,_#GX?I?V^N:'+KRZ?86
M=S)9^(_#/C"P^,'AS^T;=9)DLM7T/QQ=V/Q'TJ.>**ZL=?U1O$MLD=SK%Q=7
M?4#X*?"I?!NO?#Q? OA]/ OB6YO;S6?"4=HT?A^>XU#6)_$5V]MIB2K:Z6)/
M$%U<ZXL>E1V4<.KW$VHPI'>2/,?CC3?V?_VO[.Y\1/9_&?1/#-AJ ">%]/M/
M&/C/Q>?"FKQ?#C]ECPMI7C/4M1USPAI>H>/O[ \0_"[X[:E)\//$4JZ!XKM/
MBAI\NKZ[97C2+X=ZWP;\&_VI]$\&?''1-<^*EG?Z]XX^"^H>'/AIJ3_$?QKK
M;^#OB[/XM_: NK/Q1_:^J^"+?4- TB'P7XN^!NCG4-#M]1N8=2\!:K=KX9N+
MN,:QXF /?+3]FWX%6%CJFF6/PN\(6>G:TVARZK96FF_9[6^O/"_B>7QIX4U6
M:&*5$_MSPEXKE&O^$M>0+K/A?4[:PN= O].;3K 6VI<_ CX0WL/B>VO/A_X=
MNK/QM.UWXRL+BTDET[Q7=S>&;;P5?7?B+3GF-CK5UK'@^SM/"NOW.HV]S/XA
M\.6MMHNN2:CIT$5NOQ[XY^%W[57@W1_'/B31/B-XK\73?VS\&(_AWX.T?XA>
M)IK:#3;OQ#\%K+XJ^$/&$<GPQ\2^+KS1;[7]'^*/BR3XM:!XCM_%^B?#[XA7
M_A+1_"WAC3O!.@W<?#^$_@]^VSXD\.^ ]3LOB%J_A#24\%>#-.\0:3\1OBQX
M^M_BAXAU_3?&G[+OB?Q1XH\71:9X6\4^'_"^K:G8?#K]HKPOI^C^#KS3M,O/
M"WQ4T ZU8:5>W6KZ1X6 /O"^\#? [38&\&ZEI?@;3SJ/B;PA\0&T:_NK&UU>
M_P#%GA_6?"6A>!O%S-<7<>LW>LZ7K.@>"/#'AK5S-)/!)I7AOPSITHAMM/TY
M;8^!'P;/@[QC\/Q\-?!P\$?$'PI_P@?C/PNFB6BZ+XC\"#1KWPY#X&U*R5!%
M+X+L_#^HZAH>F^$T$>@:7H]_?:;IVG6MG>7,,OQ/<?LL?M++\3M!\<1_$?PW
MK,^B>*-5LQXHUSQYX^/B*;X1O^VO\&?C=X9\"1:%=>$_$.F6LNA?LV> -7^"
M>N7J:\;CQYXLL=,\;^);Z75O%_B'7M&\P\:_#?\ ;B^''P_\,:)/XQ\>_$F^
MF\+^!T\72_#+XE^-=8\5W&L^$/A1XBT3XI:SX<U_6_ >DRV/BOQ;XI;P9J7P
MOT#6M8T+X=ZMK4'B/5O&T>DWYA_M  ^^C\(?V:-+\::E"?"GPQT_QYXMU+3?
M$FM:7NTNUU[Q9JL$6@R:9K.LZ&+I)_$ETP^%_AN\BN]1L;Y[RZ\!:9J,CS7G
MAZ&YM;&@?#K]FV#Q-X0U;PSH/PN_X3+PK?ZM+X/U'1Y-%G\2VNK6O@72? FL
MSVMS:W,FJ:CJMC\-X]$\*WUQ=/>7MCX172]+DD@TL6L5?+?QS_9*^*_Q"_:?
M\.?'OPG>?#F[\+^$_#7[--O!\/\ Q[K.O0-XRUWX+?%3XQ^,YY/$>MZ-X-UK
MQ!X9NO!\?Q/T;QQ\.M?T+Q1K=IKGCCPC<^%/B#X-U'PKXC;7M&X3P]^PG\7O
M#=KX LO#OCOPSH"?![XI>&?B1\!M3UK7=9^)'B/X'Z79^$_"'P\\<?"W3O$N
MK>!_#OBGXI?#CQ=\,[OXK?#CPU#\2O$5YXL^'WA_5_#$C^)_%]GIFA^'/ P/
MU/LB]^#'[*NIR:IKE]X/^$UX_P 1/$WC71]4U65M'<>,/%_CO4_!T7CW19+L
M7835M>\1ZO\ "#P1!KVD1/+>W-]\/-$MY[;SO#\"6^E'\+/V:Y[_ %:&#0/A
ML^H>.[?XB^%-;M+6]T\3^,;/Q;XD\3ZO\2?#&I6=O?#^WK2Y\8>)O&VK:OH=
MQ#=0:3XG\2^+]1AM+#5]=UR:[^8?"'['_CWPE^SS\"?AO:)\.8O%GP*_:IU_
MX_:1H<>N>(+SP;J/AS5OC7\5?&%IX<B\6W/@NVUVPU^P\!?$QB-4?P9<P3>+
M](.FS2'2M1E\0P=GJO[,/Q F^,_P]^+GA77M$\"ZEI.LV-S\1X=/\0:GK_AK
MX@^#[WXG?%3XF:UX#\2_#C7/!O\ PC^KZEX3U3XAW5]\)OBYX=U3X<_$+PWX
MG\0^*]7U>XU3PJ]_\/O%P(]7\2_!_P#92\1:;XHOO%?A7X2ZGI.FM#X6\97^
MKSZ.]EI-Q9> -;^$L&A^(+V:]6'2K^W^'/C_ %_P,MG?2VU\GA_Q;?:85\K5
M76:U)\%/V8+'Q%8Z1/X,^&$'BFZN8=?LM$O#IAU?4[H^+/'OCBVU8Z)=7;7&
MK-_PF'CSXE^(K:ZGL[M?[6\5^,;J)M^KZMYWR?\ $+]E;X^:_P###]L7X;>'
M]%^!D\/[1OQ]U7XJ>'=0USX@>--/CM-!/AOX1Z?I4/BC3['X+ZPEOXBN]6^'
M%U+J(L9]>L]/L;BR:VU#5+II%M?5M=_9E\2?%/\ :@M/C%\7-"\#)X#\/> _
M 6E^&M#\,>./$VI>(+CQW\*OC3:?&+X>^(-<\[X?>$@-,T;7[6WUH:?9>)C:
MOJ5C!I6K:7X@TBZO'8 ]YN/V;/@-=P&VN?A3X+N(FTK4=#D\[1XI)9]&U6U\
M V%]I=S<,QN+FPFTWX5?#/3$M+B66"WTOP!X0TVU2&P\/Z7;VU70O@;^SWX"
M\6>'M1T#P)X"\,>,_M^KZWX5:V@M;+67U&/2-<TK6M2T&TDG$LL]IX?\8:WI
M=Y/8P.;#1=9DL&,&GO!"G@WB+X/_ +5^O_%+6M8B^(.@Z)\+M4\;^!+Z/PYH
MOQ;^*&GZRO@[PSXX\8ZCXEX3P;,-(UKQQX'\4:?H.HZ%X:\0:1H.FWGA719;
M._>[CCUZVYCX3_LY?M/Z7\0O@5X[^.'Q&\)_$K4_ANEF=?U:+Q7XL,MI'??L
MJ>#_ (6>+=/\->&I?!6F^']7NM7^.ND>-/B+<^+-0;PSK.K>'O'TEK=V]H/#
M6E>&V /T9HHHH *_ S_@YPECA_X(R?M.R2R)&B^,OV8<O(P11G]J/X.@99B
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MMYK37V6T%GY"MKEK<W%MK#",'4[>>:&],\<KJP!\#_&W]N;6?#WA.'Q5\*/
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4NL  Z?YSR?UH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>mmq_logo-header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmq_logo-header.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !A G # 2(  A$! Q$!_\0
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MD:_B]@L+5E0Q61_5:\.7GHXG,L30K0YES1YJ5;!4JD5*/O1<J<5*+33L]/\
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MO#/CS6M>C\>Z9X5U.[\7:MXCN?&'@G1-,U7V;X?_  E^+&B_&7PQ\0-1\/\
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M[P+X@\0:AJEFVBW'Q?\ $]QX\U_1/&^E6VG7$^K+X9\6:UK?]A76D:F9-?\
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MW7=AIOB*YT/PS<:Y9VTF8H-3F\/Z-)>1HL[:;:%S$(_L[ _] U/_ ,GZZ_\
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M  BOBW4-6\&/J&EZWJNBZU>>';S6_#^J:IX?O]*U"^^N<CU%']G8'_H%I?\
MD_\ \LO^(?6*W_/Q_P#@-/\ ^5'\_?\ Q#N_LP?]%Y_:1_\  _X4>F,_\DNZ
M^]'_ !#N_LP'K\>?VD3];_X4?_.NK^@3(]??\/6OB;QW^TY\7?"O[:_P=_9?
MT3]E+XJ^,?A!\2_A;XV\>^+_ -K[2+R"+X1?!_Q+X8.N#1OASXLM9=#G277?
M$_\ 9-BMNTGB/3+^*7Q1X>;3-#\062:_>:&/+L"]\-3?37G>G;6IL-8BO=6J
M/_P&G^E*Y^:?_$.Y^R]S_P 7X_:1_P# [X4'\L_"T@>G3ID5J^'O^#?[]G_P
MCK^F>*?"'[2_[5OA+Q3HDZW6C>)?"_B7X;^'_$&D7*?=N-,UO1_AO9ZI83#&
M/,M+J(OPLOF1EHV^D_V*/^"B_C_]JC]L;]N/]D'X@_LYQ_ ;Q+^Q'_PI^+7-
M4'Q>TWXI'QY-\8;'Q5KVC75I%I'@;PQIFA::GA31]!UNVV:QK>H23>()=-U2
MVTB]TJ>WDZS_ (*6?M^^*_\ @G'\&M1_:+U+]GK6_CE\(-#OO#6B^)+CP)\0
M])T+QQX=UOQ1JFH:99W%WX0U[PI)87?@ZTFBT:/4?$MCXMN-3LYM:=KCPK'I
M.D7VME_V?@M$\/3:6R?.TODY\NME?W=;+70GV]9/^(]).37+!Q<MKN+I\K?3
M6,KK3;0^F_A9\$_BC\-= 7P_J?[3GQ)^+B6UNMOIVM_%KPK\,]1\460C0+ )
MM<\$>$_ ,NM[,!I;CQ%#K&IW3%OM.I2*S*?GOPW_ ,$[](L_VP?#/[:WCG]H
M7XX?%+XJ^$].U[1-$T?Q7'\-=.\":9H&M>$_$GA&+P_I6@^%/ 6@3:3I.D6O
MBG5-1L8K*_2YN]:FN-6UN[U:_P!1U2XOOIK]E;]HKP'^UM^SI\&/VE?AI<O+
MX(^-7P\\-^/M%M[F:&:_T9M9L(WU;PQK#6^(4\0>$=<34O"_B*WC4+:ZYI-_
M;<&+%?G9^VY_P6"\$_LA_MG?LT?L+^'/@KXO^._QP_:7_L6'2;?P[XS\+>"_
M#7@:\\7^+;7PIX,MO%NL^(H+A0=5,.O:]J<=C'<:GH>@:78WITK4#XDT:.;?
MV%+3W%[LE-7<F^:+;BV^:\G%MVYG*R=DDM"%*4;\KM>+B]%K%I)K;2Z2NU9R
M>K;9^R*C&?<C]%4?TIU8'ABY\07>@Z/=>+--T[1?$ESIEC/KFC:1K,OB/2M*
MU66!7O\ 3M-\07&B^&Y]<L[.Y,D%OJLWA_19;Z*-+F32[%Y#;1;^1ZUJ2%%?
MF/\ \%8/V_O&_P#P32_97\0?M6^'_P!G@_M">#_!-]H]AX]L(_BWI'PKD\)I
MXM\3^&_!'@[5)&OO!WC34/$%AJOC'Q1I6BW\>AZ7+?:.ES%J$UM-8&[N;']$
M?!>N3^)?"/ACQ)=01VDWB'P]HFN26D<QN([5]7TNUU%[5+AH;8SI;M<-"LQM
MX#,L8E,,1<Q( =/129'J/SK\IO\ @I/_ ,%%/B#^P!KG[,C:?^SA#\7OA]^T
M=^T!\+?V<)?B$WQCT[P*OP[\>?$_6[VWT[^T?!C>!/%>M^);1/#FCZUKEE=:
M?>Z=87=Y8-HFH7>DR2VM]= )-['ZM44P95.278 Y/ +D9Z#@ GTZ#IT%?FU=
M?\%#M/\ B=^T/\1?V7/V-/AC<_M-?$SX'7MCI7[0_CF]\;V/PK_9J^ _B2]^
MW-'\._&WQC;PS\0M>\2?%EAI]PMQX ^$?PP^)$_AR6WU"T\>:MX,O].NK5 #
M]***_*OXW_\ !274OV,/%'@<?MY?!2+X(_!/XE^*=/\  WA[]JCX3?$NY^.W
MP%\%^-=4A+:3X;^.]UJWPQ^#WQ%^$ UN6&YCTOQ<_@#Q/\.D2'[3KOC7P\AN
M4M/U'T^_M=3M+>^L9XKNRNX8KFSO;>6*XM;RTN(UEM[JUN('DAN;6XB=)K>X
MB=HIX726-F1U8@%VBBOBSX._M+?%[XE?M5?M0? +Q7^RE\6?A/\ #+X"0_#6
M;X<_M*>*;JSN/AQ^T<_C?1GU+78/ $$.D6L,(\'7"K9Z@=.\0^*)XW+1^(8_
M!^J>7HET ?:=%)D8SD?F*,CU'KU[>M "T49'J** "BOC[XP?M/:IX6^/'@C]
MEKX/^"]$^)WQ_P#&?PS\7?'"\T'Q?X]G^%_@#P'\'/!OB+PYX(NO&/C+QKIG
M@/XH>((]0\3>.?%>E^&? GAK0/A_X@N=>N-/\5:EJ=YX=T?PQ=ZA/3_8C_:_
MTW]L7X?_ !'UZ7P+K7PL^)'P,^.OQ-_9E^//PMUK5K'Q+_P@/QK^$EUI<?BC
M2-#\8Z9::;8>-O"&J:3KOAWQ9X,\7PZ1HS^(/"_B+2K^ZT71KR2YTVV /LVB
MBOE']N+]JCPS^Q)^R?\ '3]JCQ;IDWB#2_@SX"U3Q/9>$[>^.EW/C;Q3+);Z
M1X)\#VVJKINL'2)_&?C#4M#\,IK)TK4TT8:H^K3:9J$-E);. ?5U%?/?[*'[
M0_@_]K/]F[X)_M*^ 9@WA+XV?#CPM\0=+LFNH;RYT*;7M+M[C6/"NHW$%O:)
M)K'A#7!J?A?7%-M;O%K&D7T3P0F/RU^A,CU'_P"OI^= !11D>HHR/44 %%)D
M>H_.C(]1^= "T5\5:O\ M+_%W3?VY?"/[*MI^RI\5M8^"_B+X&ZO\5M5_;,M
M+VR7X.^%?&FG^);_ $:W^#>JV:Z1-GQ/>6%G#J43S>)[+6V;5---IX2O]#74
M?$=A]J# '7IW/Y<].?7WH 6BJEU>VUE&9KJ6*"!%:26XFFBAAAC3&9)9)714
MC!(#.?E3(WD9&;>1ZB@ HI,CU'YTN1ZB@ HI#T/;@\CJ*_&7]JC_ (*I^/OV
M5?VR_P!G3]C/7_V5X_&/BG]KS6]3TK]GSQYH?QYTJP\&:DNCZ]!HFH/\2K?4
M?A>GB3P!?6,&H:/JFH66AZ7\0K%?[5M[#3-8U6[ANHXP+7_/[C]FZ*_*/6O^
M"H>E? _]JWX,?LC?MG?!#Q7^SCXR_:6NI]'_ &<OBCI/C'P[\7OV??BMXKM]
M0TC1Y? 2>.M,T[PCXT\&>/7UGQ!X=TJRTGQG\-M'T34+SQ%HD-KXC>;4K.*;
MZ8_;7_;E_9__ &!_A&GQ?^/_ (@UFSL=7U[3?!GP_P# G@S1)?%OQ2^+GQ#U
MUS%H'P\^%_@BTF@O/%'BS5I581VYN+'2M/@5[_7-7TK38I;U +7V/L2BOAKP
M_P#&/]N/6_ =KX]O/V-_ACX9FOK-M6@^$OB']K=?^%TV]CCSHM U6#1/V?M8
M^"UC\1)((Y+=O#UO\:-3\$P:J\5K>?%&SLEN=1M.U_8\_:Q\,?MB_#CQ3\2?
M"W@CXC?#>'PC\5O'OP=\0>"/BWI.E>'_ (C>&O&WPROK?1/&NB>*_#^C:KKE
MAHVI:-XE;4=',%MK&J6=[#IT6LZ7J6H:1JFG7DX!]84444 %%%% !1110 4A
M&>PR.F?\_GZCBEJ&<3%"8"HD )&_.S.#C?@$[0<%@H+$948SN _(#YYE_:-\
M.'PKJ?BZS\"?&B^L=+\1Z?X572H?@U\0;;Q/KVIWE_+;SW/@WP]JNCZ=JGC7
M0--TZVF\177BGPM;:MX7G\.YU/2M9U+[)J4%C/I/[2/P^U2PL[RY'B7PR9D@
MN=2TSQCX5UKPSKOA;3KWQM>?#G2]5\8:-J4*7WAK2]:\9Z??Z-I%UJ<,(O$T
M[5M8$:Z'HVJ:C;>;6'P8^+&@2>./'7@B;X?>!?B'J?[/%K\.?#/A:TUOQ+KO
MP[N_B]ILOB#5]%^('C/5KO0K77-8TW0M6O=-TK3+N71;GQ/=>&[C74UJXN99
M=,L[/"\:_LD76M:;XQ\,:-XCB?0/B7\$?@;\"/%^J:Q=7G]OV/ASX/>,?'.N
M:AKVGK#:746J:YXST+XD^*+6[,]UI:6?B*"RU>66^74;S[/B_:)VLI/:]DJ=
MTI7E9-RM*24E&S:?*N]F^1*Z?2]D[V;M9.]K<K:OOLU=Z'T?XV^,7@KP!>WU
MCXAU>.VGT/P;??$/Q0(K.ZO$\*^ M,O5T_4/&?B)X0$TWP_;70N5$SM)?7,.
MG:U>V5C<Z;X<\1WNDZ%A\1M+U75[C1](M-:UDV\OB>SDU72M$U"Y\,?VSX-N
M].T[Q%X>;Q/\NAVNN6.I:DFFQ6>H7UE%?ZGIWB#3-/N[G4O#'B6UTKQSX_?
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MA7J/A3Q1_P )IH/ACXI>(_&?@U?$.H'SO!C:MX8C-]:%(==70=5EBLY?N?\
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M:-\%/AUK5A)&@TW7/A5^S]X9^%7P]\1V,($3^-M \3ZT5-UK%W*WZ:_MU?\
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M+P]/X_M-,34+VX34M-6&P'A^RU'7]4N-'T?1-!\.IK-S9Z1:75 '\\G[0/\
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M<0V\<4UQ%8P/+#8QS2(TJV<,LD5L&\J.215\QM.@!NQ=I7:H4]@ !Z=,8X&
M..@%"HJ_=4#  X ' )(' ' ).!T&3CK3J* &!$'15'7HJC.3DDX'7.3]2?6@
M1H.BK_WRO)P1DX R<$CFGT4 ,$<8SA$&3DX4<D=">.HQQZ4>5'P0B@@8!"KP
M.!@9!P.!P/2GT4 ,"( 0% #=0  #SW&,'T^G%(8HR02B$J<C*J>0" <D9R 3
M@Y[GUJ2B@"/RH\%=J[222,#'(P>W<8S]!08HCG,:$'.1M&#D@GMZ@?7O4E%
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MT7^34R#_ %K_ .Z]%%>=+_?*?^-_G(O[+_PK_P!*9!>]$_W(_P#T=;U8MO\
M5'_KK+_,445O/_E__BI_G Q^W\G_ .E(>/NG_KI'_P"BQ3$^\OU3_P!'FBBN
MF?QS]5_Z0.'Q0_PS_(MIU'^Z?_0C4E%%*'PQ]$-;1_PK\@HHHJAA1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>krmd-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6I5w7xRiXgen8uPa3csWa2GKaPtzJZyWekxvmx5Hek6byIju4vBoi8yCUamkTMG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:krmd="http://korumedical.com/20231231" elementFormDefault="qualified" targetNamespace="http://korumedical.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://korumedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - BALANCE SHEETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - STATEMENTS OF OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPolicies">
          <link:definition>00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Inventory" id="Inventory">
          <link:definition>00000008 - Disclosure - INVENTORY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>00000009 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>00000010 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Leases" id="Leases">
          <link:definition>00000011 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" id="FederalAndStateIncomeTaxes">
          <link:definition>00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/MajorCustomers" id="MajorCustomers">
          <link:definition>00000013 - Disclosure - MAJOR CUSTOMERS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/EmployeeBenefits" id="EmployeeBenefits">
          <link:definition>00000015 - Disclosure - EMPLOYEE BENEFITS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/DebtObligations" id="DebtObligations">
          <link:definition>00000016 - Disclosure - DEBT OBLIGATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/SubsequentEvent" id="SubsequentEvent">
          <link:definition>00000017 - Disclosure - SUBSEQUENT EVENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000019 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/InventoryTables" id="InventoryTables">
          <link:definition>00000020 - Disclosure - INVENTORY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/LeasesTables" id="LeasesTables">
          <link:definition>00000023 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" id="FederalAndStateIncomeTaxesTables">
          <link:definition>00000024 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" id="EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails">
          <link:definition>00000025 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails" id="FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails">
          <link:definition>00000026 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" id="ScheduleOfNetIncomePerCommonShareDetails">
          <link:definition>00000027 - Disclosure - Schedule of net income per common share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details" id="FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details">
          <link:definition>00000028 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000029 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" id="InventoryConsistsOfDetails">
          <link:definition>00000030 - Disclosure - Inventory consists of: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" id="PropertyAndEquipmentConsistsOfFollowingAtDetails">
          <link:definition>00000031 - Disclosure - Property and equipment consists of the following at: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" id="ScheduleOfTimeBasedStockOptionsDetails">
          <link:definition>00000032 - Disclosure - Schedule of time based stock options (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" id="ScheduleOfStatusOfTimeBasedStockOptionsDetails">
          <link:definition>00000033 - Disclosure - Schedule of status of time based stock options (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" id="ScheduleOfInformationPertainingToOptionsOutstandingDetails">
          <link:definition>00000034 - Disclosure - Schedule of information pertaining to options outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details" id="FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details">
          <link:definition>00000035 - Disclosure - The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022. (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details" id="FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details">
          <link:definition>00000036 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022. (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" id="ScheduleOfComponentsOfLeaseExpensesDetails">
          <link:definition>00000038 - Disclosure - Schedule of components of lease expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" id="ScheduleOfCashFlowInformationRelatedToLeasesDetails">
          <link:definition>00000039 - Disclosure - Schedule of cash flow information related to leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" id="ScheduleOfBalanceSheetInformationRelatedToLeasesDetails">
          <link:definition>00000040 - Disclosure - Schedule of balance sheet information related to leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" id="ScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
          <link:definition>00000041 - Disclosure - Schedule of maturities of lease liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>00000042 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" id="ScheduleOfProvisionForIncomeTaxesDetails">
          <link:definition>00000043 - Disclosure - Schedule of provision for income taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" id="ScheduleOfReconciliationOfIncomeTaxesDetails">
          <link:definition>00000044 - Disclosure - Schedule of reconciliation of income taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" id="ScheduleOfComponentsOfDeferredTaxAssetsDetails">
          <link:definition>00000045 - Disclosure - Schedule of components of deferred tax assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" id="MajorCustomersDetailsNarrative">
          <link:definition>00000046 - Disclosure - MAJOR CUSTOMERS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" id="EmployeeBenefitsDetailsNarrative">
          <link:definition>00000047 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" id="DebtObligationsDetailsNarrative">
          <link:definition>00000048 - Disclosure - DEBT OBLIGATIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/SubsequentEventDetailsNarrative" id="SubsequentEventDetailsNarrative">
          <link:definition>00000049 - Disclosure - SUBSEQUENT EVENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="krmd_PatentsAndTrademarksMember" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_EquipmentAndToolingMember" name="EquipmentAndToolingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ManufacturingEquipmentAndToolingMember" name="ManufacturingEquipmentAndToolingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExecutivesEmployeesConsultantsMember" name="ExecutivesEmployeesConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptionPlan2021Member" name="StockOptionPlan2021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NonEmployeeDirectorAndBoardAdvisorMember" name="NonEmployeeDirectorAndBoardAdvisorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptionPlans2015And2021CombinedMember" name="StockOptionPlans2015And2021CombinedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TimeBasedSharesOptionsMember" name="TimeBasedSharesOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PerformanceBasedSharesOptionsMember" name="PerformanceBasedSharesOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RestrictedStockAwardsMember" name="RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExercisePrice1Member" name="ExercisePrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LeaseOneMember" name="LeaseOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LeaseTwoMember" name="LeaseTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LeaseThreeMember" name="LeaseThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AONPremiumFinanceLLCMember" name="AONPremiumFinanceLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TermLoanFacilityMember" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CompensationeExpenseRelatedToRestrictedStockAwards" name="CompensationeExpenseRelatedToRestrictedStockAwards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RouLandlordCredit" name="RouLandlordCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_BorrowingsFromIndebtedness" name="BorrowingsFromIndebtedness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PaymentsOnIndebtedness" name="PaymentsOnIndebtedness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseROUAsset" name="FinanceLeaseROUAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CashPaidDuringPeriodsForAbstract" name="CashPaidDuringPeriodsForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_IssuanceOfCommonStockCompensation" name="IssuanceOfCommonStockCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" name="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfSecuritiesTextBlock" name="ScheduleOfSecuritiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfNetRevenuesByGeography" name="ScheduleOfNetRevenuesByGeography" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" name="ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptions" name="StockOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RestrictedStockUnits" name="RestrictedStockUnits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutedSecurities" name="AntiDilutedSecurities" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" name="DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AmortizationOfIntangibleAssets1" name="AmortizationOfIntangibleAssets1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DepreciationAndAmortizationPropertyAndEquipment" name="DepreciationAndAmortizationPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutiveStockOptions" name="AntiDilutiveStockOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutiveRestrictedStock" name="AntiDilutiveRestrictedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" name="ShareBasedCompensationArrangementByUnvestedAwardOptions" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockBasedCompensationSharesIssuable" name="StockBasedCompensationSharesIssuable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" name="SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SharesAvailableForIssuanceShareBasedCompensation" name="SharesAvailableForIssuanceShareBasedCompensation" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NonemployeeServicesTransactionCost" name="NonemployeeServicesTransactionCost" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TaxBenefitFromStockBasedCompensation" name="TaxBenefitFromStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockBasedCompensationStockOptions" name="StockBasedCompensationStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CashReceivedFromOptionExercise" name="CashReceivedFromOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" name="StockIssuedDuringPeriodSharesStockOptionsExercised1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TaxBenefitFromRestrictedStockCompensation" name="TaxBenefitFromRestrictedStockCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseCost1Abstract" name="FinanceLeaseCost1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseCost" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" name="AssetsAndLiabilitiesOperatingLesseeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" name="AssetsAndLiabilitiesLesseeFinanceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" name="LesseeOperatingLeaseLiabilityPaymentsDueTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" name="LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseImputedInterest" name="LesseeOperatingLeaseImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseImputedInterest" name="LesseeFinancingLeaseImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseRemainingTerm" name="LesseeOperatingLeaseRemainingTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinanceLeaseRemainingTerm" name="LesseeFinanceLeaseRemainingTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_WriteoffOfDeferredTaxAsset" name="WriteoffOfDeferredTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DepreciationDepletionAndAmortization1" name="DepreciationDepletionAndAmortization1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RdCredit" name="RdCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_Nol" name="Nol" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AllowanceForDoubtfulOtherReceivables1Current" name="AllowanceForDoubtfulOtherReceivables1Current" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AllowanceForNonRealizationOfDeferredTaxAsset" name="AllowanceForNonRealizationOfDeferredTaxAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DescriptionOfMatchingContribution" name="DescriptionOfMatchingContribution" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NotePayableTerms" name="NotePayableTerms" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" name="LesseeFinancingLeaseLeaseLiabilityPaymentsDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LessorOperatingLeaseOptionToTerminate1" name="LessorOperatingLeaseOptionToTerminate1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DescriptionOfLessorOperatingLeaseTerm" name="DescriptionOfLessorOperatingLeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_UnrecognizedCompensationCost" name="UnrecognizedCompensationCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FDICBankMember" name="FDICBankMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CommonStockOptions" name="CommonStockOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutedSecuritiesPerformancBased" name="AntiDilutedSecuritiesPerformancBased" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntiDilutedSecuritiesTimeBased" name="AntiDilutedSecuritiesTimeBased" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>krmd-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20231231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Inventory" xlink:href="krmd-20231231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20231231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:href="krmd-20231231.xsd#FederalAndStateIncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomers" xlink:href="krmd-20231231.xsd#MajorCustomers" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefits" xlink:href="krmd-20231231.xsd#EmployeeBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20231231.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SubsequentEvent" xlink:href="krmd-20231231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryTables" xlink:href="krmd-20231231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20231231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:href="krmd-20231231.xsd#FederalAndStateIncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:href="krmd-20231231.xsd#EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails" xlink:href="krmd-20231231.xsd#FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:href="krmd-20231231.xsd#ScheduleOfNetIncomePerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details" xlink:href="krmd-20231231.xsd#FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:href="krmd-20231231.xsd#InventoryConsistsOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20231231.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:href="krmd-20231231.xsd#ScheduleOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:href="krmd-20231231.xsd#ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:href="krmd-20231231.xsd#ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:href="krmd-20231231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:href="krmd-20231231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20231231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfComponentsOfLeaseExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesDetailsNarrative" xlink:href="krmd-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="krmd-20231231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:href="krmd-20231231.xsd#MajorCustomersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:href="krmd-20231231.xsd#EmployeeBenefitsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20231231.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SubsequentEventDetailsNarrative" xlink:href="krmd-20231231.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredPurchasedPowerCosts" xlink:label="loc_us-gaapDeferredPurchasedPowerCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredPurchasedPowerCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RouLandlordCredit" xlink:label="loc_krmdRouLandlordCredit" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_krmdRouLandlordCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="loc_krmdBorrowingsFromIndebtedness" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_krmdBorrowingsFromIndebtedness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PaymentsOnIndebtedness" xlink:label="loc_krmdPaymentsOnIndebtedness" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_krmdPaymentsOnIndebtedness" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FinanceLeaseROUAsset" xlink:label="loc_krmdFinanceLeaseROUAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_krmdFinanceLeaseROUAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Inventory" xlink:title="00000008 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:title="00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomers" xlink:title="00000013 - Disclosure - MAJOR CUSTOMERS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefits" xlink:title="00000015 - Disclosure - EMPLOYEE BENEFITS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="00000016 - Disclosure - DEBT OBLIGATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SubsequentEvent" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryTables" xlink:title="00000020 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="00000023 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:title="00000024 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:title="00000025 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails" xlink:title="00000026 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:title="00000027 - Disclosure - Schedule of net income per common share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details" xlink:title="00000028 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:title="00000030 - Disclosure - Inventory consists of: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="00000031 - Disclosure - Property and equipment consists of the following at: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:title="00000032 - Disclosure - Schedule of time based stock options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:title="00000033 - Disclosure - Schedule of status of time based stock options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:title="00000034 - Disclosure - Schedule of information pertaining to options outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:title="00000035 - Disclosure - The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:title="00000036 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:title="00000038 - Disclosure - Schedule of components of lease expenses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:title="00000039 - Disclosure - Schedule of cash flow information related to leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:title="00000040 - Disclosure - Schedule of balance sheet information related to leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="00000041 - Disclosure - Schedule of maturities of lease liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesDetailsNarrative" xlink:title="00000042 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000043 - Disclosure - Schedule of provision for income taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:title="00000044 - Disclosure - Schedule of reconciliation of income taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000045 - Disclosure - Schedule of components of deferred tax assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:title="00000046 - Disclosure - MAJOR CUSTOMERS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:title="00000047 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="00000048 - Disclosure - DEBT OBLIGATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SubsequentEventDetailsNarrative" xlink:title="00000049 - Disclosure - SUBSEQUENT EVENT (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>krmd-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20231231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Inventory" xlink:href="krmd-20231231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20231231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:href="krmd-20231231.xsd#FederalAndStateIncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomers" xlink:href="krmd-20231231.xsd#MajorCustomers" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefits" xlink:href="krmd-20231231.xsd#EmployeeBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20231231.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SubsequentEvent" xlink:href="krmd-20231231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryTables" xlink:href="krmd-20231231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20231231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:href="krmd-20231231.xsd#FederalAndStateIncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:href="krmd-20231231.xsd#EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails" xlink:href="krmd-20231231.xsd#FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:href="krmd-20231231.xsd#ScheduleOfNetIncomePerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details" xlink:href="krmd-20231231.xsd#FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:href="krmd-20231231.xsd#InventoryConsistsOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20231231.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:href="krmd-20231231.xsd#ScheduleOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:href="krmd-20231231.xsd#ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:href="krmd-20231231.xsd#ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:href="krmd-20231231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:href="krmd-20231231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20231231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfComponentsOfLeaseExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesDetailsNarrative" xlink:href="krmd-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="krmd-20231231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:href="krmd-20231231.xsd#MajorCustomersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:href="krmd-20231231.xsd#EmployeeBenefitsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20231231.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SubsequentEventDetailsNarrative" xlink:href="krmd-20231231.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CompensationeExpenseRelatedToRestrictedStockAwards" xlink:label="loc_krmdCompensationeExpenseRelatedToRestrictedStockAwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdCompensationeExpenseRelatedToRestrictedStockAwards_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Inventory" xlink:title="00000008 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:title="00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomers" xlink:title="00000013 - Disclosure - MAJOR CUSTOMERS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefits" xlink:title="00000015 - Disclosure - EMPLOYEE BENEFITS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="00000016 - Disclosure - DEBT OBLIGATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/SubsequentEvent" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryTables" xlink:title="00000020 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="00000023 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:title="00000024 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:title="00000025 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails" xlink:title="00000026 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:title="00000027 - Disclosure - Schedule of net income per common share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:label="loc_krmdDilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdDilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details" xlink:title="00000028 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PatentsAndTrademarksMember" xlink:label="loc_krmdPatentsAndTrademarksMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_krmdPatentsAndTrademarksMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_EquipmentAndToolingMember" xlink:label="loc_krmdEquipmentAndToolingMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdEquipmentAndToolingMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="loc_us-gaapInterestIncomeSecuritiesUSTreasury_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInterestIncomeSecuritiesUSTreasury_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AmortizationOfIntangibleAssets1" xlink:label="loc_krmdAmortizationOfIntangibleAssets1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdAmortizationOfIntangibleAssets1_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_DepreciationAndAmortizationPropertyAndEquipment" xlink:label="loc_krmdDepreciationAndAmortizationPropertyAndEquipment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdDepreciationAndAmortizationPropertyAndEquipment_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AntiDilutiveStockOptions" xlink:label="loc_krmdAntiDilutiveStockOptions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdAntiDilutiveStockOptions_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AntiDilutiveRestrictedStock" xlink:label="loc_krmdAntiDilutiveRestrictedStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdAntiDilutiveRestrictedStock_100" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:title="00000030 - Disclosure - Inventory consists of: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="00000031 - Disclosure - Property and equipment consists of the following at: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="loc_krmdManufacturingEquipmentAndToolingMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdManufacturingEquipmentAndToolingMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:title="00000032 - Disclosure - Schedule of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:title="00000033 - Disclosure - Schedule of status of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:title="00000034 - Disclosure - Schedule of information pertaining to options outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ExercisePrice1Member" xlink:label="loc_krmdExercisePrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_krmdExercisePrice1Member_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:title="00000035 - Disclosure - The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PerformanceBasedSharesOptionsMember" xlink:label="loc_krmdPerformanceBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdPerformanceBasedSharesOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:title="00000036 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlans2015And2021CombinedMember" xlink:label="loc_krmdStockOptionPlans2015And2021CombinedMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlans2015And2021CombinedMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ExecutivesEmployeesConsultantsMember" xlink:label="loc_krmdExecutivesEmployeesConsultantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdExecutivesEmployeesConsultantsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PerformanceBasedSharesOptionsMember" xlink:label="loc_krmdPerformanceBasedSharesOptionsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdPerformanceBasedSharesOptionsMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockBasedCompensationSharesIssuable" xlink:label="loc_krmdStockBasedCompensationSharesIssuable_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockBasedCompensationSharesIssuable_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:label="loc_krmdSharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:label="loc_krmdSharesAvailableForIssuanceShareBasedCompensation_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesAvailableForIssuanceShareBasedCompensation_230" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_230" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="loc_krmdNonemployeeServicesTransactionCost_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdNonemployeeServicesTransactionCost_230" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction_230" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_230" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TaxBenefitFromStockBasedCompensation" xlink:label="loc_krmdTaxBenefitFromStockBasedCompensation_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdTaxBenefitFromStockBasedCompensation_230" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockBasedCompensationStockOptions" xlink:label="loc_krmdStockBasedCompensationStockOptions_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockBasedCompensationStockOptions_230" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CashReceivedFromOptionExercise" xlink:label="loc_krmdCashReceivedFromOptionExercise_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdCashReceivedFromOptionExercise_230" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_230" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1_230" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_230" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_230" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_230" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TaxBenefitFromRestrictedStockCompensation" xlink:label="loc_krmdTaxBenefitFromRestrictedStockCompensation_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdTaxBenefitFromRestrictedStockCompensation_230" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:title="00000038 - Disclosure - Schedule of components of lease expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:title="00000039 - Disclosure - Schedule of cash flow information related to leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:title="00000040 - Disclosure - Schedule of balance sheet information related to leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="00000041 - Disclosure - Schedule of maturities of lease liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesDetailsNarrative" xlink:title="00000042 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LeaseOneMember" xlink:label="loc_krmdLeaseOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LeaseTwoMember" xlink:label="loc_krmdLeaseTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LeaseThreeMember" xlink:label="loc_krmdLeaseThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeOperatingLeaseRemainingTerm" xlink:label="loc_krmdLesseeOperatingLeaseRemainingTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_krmdLesseeOperatingLeaseRemainingTerm_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeFinanceLeaseRemainingTerm" xlink:label="loc_krmdLesseeFinanceLeaseRemainingTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_krmdLesseeFinanceLeaseRemainingTerm_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000043 - Disclosure - Schedule of provision for income taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:title="00000044 - Disclosure - Schedule of reconciliation of income taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000045 - Disclosure - Schedule of components of deferred tax assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:title="00000046 - Disclosure - MAJOR CUSTOMERS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CustomerOneMember" xlink:label="loc_krmdCustomerOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_krmdCustomerOneMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:title="00000047 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="00000048 - Disclosure - DEBT OBLIGATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AONPremiumFinanceLLCMember" xlink:label="loc_krmdAONPremiumFinanceLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdAONPremiumFinanceLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PromissoryNoteMember" xlink:label="loc_krmdPromissoryNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_krmdPromissoryNoteMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaapLineOfCreditMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapLineOfCreditMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_NotePayableTerms" xlink:label="loc_krmdNotePayableTerms_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_krmdNotePayableTerms_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaapOtherLongTermDebtNoncurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherLongTermDebtNoncurrent_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/SubsequentEventDetailsNarrative" xlink:title="00000049 - Disclosure - SUBSEQUENT EVENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TermLoanFacilityMember" xlink:label="loc_krmdTermLoanFacilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_krmdTermLoanFacilityMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate" xlink:label="loc_us-gaapInvestmentInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInvestmentInterestRate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventDescription_40" xlink:type="arc" order="2" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>krmd-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PatentsAndTrademarksMember" xlink:label="krmd_PatentsAndTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PatentsAndTrademarksMember" xlink:to="krmd_PatentsAndTrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PatentsAndTrademarksMember_lbl" xml:lang="en-US">Patents and Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="krmd_FurnitureAndOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FurnitureAndOfficeEquipmentMember" xlink:to="krmd_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US">Furniture and Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_EquipmentAndToolingMember" xlink:label="krmd_EquipmentAndToolingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EquipmentAndToolingMember" xlink:to="krmd_EquipmentAndToolingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_EquipmentAndToolingMember_lbl" xml:lang="en-US">Equipment and Tooling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US">Non-US [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="krmd_ManufacturingEquipmentAndToolingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ManufacturingEquipmentAndToolingMember" xlink:to="krmd_ManufacturingEquipmentAndToolingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ManufacturingEquipmentAndToolingMember_lbl" xml:lang="en-US">Manufacturing Equipment and Tooling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2015Member" xlink:label="krmd_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2015Member" xlink:to="krmd_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ExecutivesEmployeesConsultantsMember" xlink:label="krmd_ExecutivesEmployeesConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExecutivesEmployeesConsultantsMember" xlink:to="krmd_ExecutivesEmployeesConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ExecutivesEmployeesConsultantsMember_lbl" xml:lang="en-US">Executives Employees Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2021Member" xlink:label="krmd_StockOptionPlan2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2021Member" xlink:to="krmd_StockOptionPlan2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptionPlan2021Member_lbl" xml:lang="en-US">Stock Option Plan 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:to="krmd_NonEmployeeDirectorAndBoardAdvisorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember_lbl" xml:lang="en-US">Non Employee Director and Board Advisor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlans2015And2021CombinedMember" xlink:label="krmd_StockOptionPlans2015And2021CombinedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlans2015And2021CombinedMember" xlink:to="krmd_StockOptionPlans2015And2021CombinedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptionPlans2015And2021CombinedMember_lbl" xml:lang="en-US">Stock Option Plans 2015 and 2021 Combined [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="krmd_TimeBasedSharesOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TimeBasedSharesOptionsMember" xlink:to="krmd_TimeBasedSharesOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_TimeBasedSharesOptionsMember_lbl" xml:lang="en-US">Time Based Shares Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PerformanceBasedSharesOptionsMember" xlink:label="krmd_PerformanceBasedSharesOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PerformanceBasedSharesOptionsMember" xlink:to="krmd_PerformanceBasedSharesOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PerformanceBasedSharesOptionsMember_lbl" xml:lang="en-US">Performance Based Shares Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="krmd_RestrictedStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockAwardsMember" xlink:to="krmd_RestrictedStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ExercisePrice1Member" xlink:label="krmd_ExercisePrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice1Member" xlink:to="krmd_ExercisePrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ExercisePrice1Member_lbl" xml:lang="en-US">Exercise Price1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LeaseOneMember" xlink:label="krmd_LeaseOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseOneMember" xlink:to="krmd_LeaseOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LeaseOneMember_lbl" xml:lang="en-US">Lease One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LeaseTwoMember" xlink:label="krmd_LeaseTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseTwoMember" xlink:to="krmd_LeaseTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LeaseTwoMember_lbl" xml:lang="en-US">Lease Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LeaseThreeMember" xlink:label="krmd_LeaseThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseThreeMember" xlink:to="krmd_LeaseThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LeaseThreeMember_lbl" xml:lang="en-US">Lease Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CustomerOneMember" xlink:label="krmd_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CustomerOneMember" xlink:to="krmd_CustomerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CustomerOneMember_lbl" xml:lang="en-US">Customer One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AONPremiumFinanceLLCMember" xlink:label="krmd_AONPremiumFinanceLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AONPremiumFinanceLLCMember" xlink:to="krmd_AONPremiumFinanceLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AONPremiumFinanceLLCMember_lbl" xml:lang="en-US">AON Premium Finance LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PromissoryNoteMember" xlink:label="krmd_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PromissoryNoteMember" xlink:to="krmd_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US">Line of Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TermLoanFacilityMember" xlink:label="krmd_TermLoanFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TermLoanFacilityMember" xlink:to="krmd_TermLoanFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_TermLoanFacilityMember_lbl" xml:lang="en-US">Term Loan Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable less allowance for doubtful accounts of $24,777 and $21,459 for December 31, 2023, and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization of $390,341 and $325,872 at December 31, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax assets, net allowance for non-realization of deferred tax assets of $6,002,777 and zero for December 31, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll and related taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liability &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease liability, net current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Refer to Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value, 75,000,000 shares authorized, 49,089,864 and 48,861,891 shares issued; 45,669,362 and 45,441,389 shares outstanding at December 31, 2023, and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, 3,420,502 shares at December 31, 2023 and December 31, 2022, at cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Accounts receivable, allowance for credit loss, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentReceivablesNetNoncurrent" xlink:label="us-gaap_DeferredRentReceivablesNetNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentReceivablesNetNoncurrent" xlink:to="us-gaap_DeferredRentReceivablesNetNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentReceivablesNetNoncurrent_lbl" xml:lang="en-US">Deferred Rent Receivables, Net, Noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par or stated value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockPreferredShares" xlink:label="us-gaap_TreasuryStockPreferredShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockPreferredShares" xlink:to="us-gaap_TreasuryStockPreferredShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockPreferredShares_lbl" xml:lang="en-US">Treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">NET REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Net Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Non-Operating Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Loss on foreign currency exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">TOTAL OTHER INCOME</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">LOSS BEFORE TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income (tax)/benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Accrued compensation paid in shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Accrued compensation paid in shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Compensation expense related to stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Compensation expense related to restricted stock awards</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CompensationeExpenseRelatedToRestrictedStockAwards" xlink:label="krmd_CompensationeExpenseRelatedToRestrictedStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CompensationeExpenseRelatedToRestrictedStockAwards" xlink:to="krmd_CompensationeExpenseRelatedToRestrictedStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CompensationeExpenseRelatedToRestrictedStockAwards_lbl" xml:lang="en-US">Compensation expense related to restricted stock awards (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance upon options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance upon options exercised (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xml:lang="en-US">Deferred income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredPurchasedPowerCosts" xlink:label="us-gaap_DeferredPurchasedPowerCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredPurchasedPowerCosts" xlink:to="us-gaap_DeferredPurchasedPowerCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredPurchasedPowerCosts_lbl" xml:lang="en-US">Allowance for non-realization of deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RouLandlordCredit" xlink:label="krmd_RouLandlordCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RouLandlordCredit" xlink:to="krmd_RouLandlordCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RouLandlordCredit_lbl" xml:lang="en-US">ROU landlord credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">(Increase)/Decrease in accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease/(Increase) in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Decrease/(Increase) in other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Decrease in prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">(Decrease)/Increase in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">(Decrease)/Increase in accrued payroll and related taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Increase in other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">(Decrease)/Increase in accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchases of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="krmd_BorrowingsFromIndebtedness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_BorrowingsFromIndebtedness" xlink:to="krmd_BorrowingsFromIndebtedness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_BorrowingsFromIndebtedness_lbl" xml:lang="en-US">Borrowings from indebtedness</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PaymentsOnIndebtedness" xlink:label="krmd_PaymentsOnIndebtedness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsOnIndebtedness" xlink:to="krmd_PaymentsOnIndebtedness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_PaymentsOnIndebtedness_lbl" xml:lang="en-US">Payments on indebtedness</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FinanceLeaseROUAsset" xlink:label="krmd_FinanceLeaseROUAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseROUAsset" xlink:to="krmd_FinanceLeaseROUAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_FinanceLeaseROUAsset_lbl" xml:lang="en-US">Finance lease ROU asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF YEAR</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Information</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CashPaidDuringPeriodsForAbstract" xlink:label="krmd_CashPaidDuringPeriodsForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashPaidDuringPeriodsForAbstract" xlink:to="krmd_CashPaidDuringPeriodsForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CashPaidDuringPeriodsForAbstract_lbl" xml:lang="en-US">Cash paid during the years for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Schedule of Non-Cash Operating, Investing and Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_IssuanceOfCommonStockCompensation" xlink:label="krmd_IssuanceOfCommonStockCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IssuanceOfCommonStockCompensation" xlink:to="krmd_IssuanceOfCommonStockCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_IssuanceOfCommonStockCompensation_lbl" xml:lang="en-US">Issuance of common stock as compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">FEDERAL AND STATE INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">MAJOR CUSTOMERS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT OBLIGATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">REVENUE RECOGNITION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" xlink:label="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" xlink:to="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc_lbl" xml:lang="en-US">IMPAIRMENT OF LONG-LIVED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">The estimated amortization expense for the succeeding years for the intangible assets is approximately:</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ScheduleOfSecuritiesTextBlock" xlink:label="krmd_ScheduleOfSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfSecuritiesTextBlock" xlink:to="krmd_ScheduleOfSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfSecuritiesTextBlock_lbl" xml:lang="en-US">The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of net income per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ScheduleOfNetRevenuesByGeography" xlink:label="krmd_ScheduleOfNetRevenuesByGeography" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfNetRevenuesByGeography" xlink:to="krmd_ScheduleOfNetRevenuesByGeography_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfNetRevenuesByGeography_lbl" xml:lang="en-US">The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Inventory consists of:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property and equipment consists of the following at:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of time based stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of status of time based stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_lbl" xml:lang="en-US">Schedule of information pertaining to options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of cash flow information related to leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of balance sheet information related to leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of components of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Total amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptions" xlink:label="krmd_StockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptions" xlink:to="krmd_StockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptions_lbl" xml:lang="en-US">Stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RestrictedStockUnits" xlink:label="krmd_RestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockUnits" xlink:to="krmd_RestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RestrictedStockUnits_lbl" xml:lang="en-US">Restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AntiDilutedSecurities" xlink:label="krmd_AntiDilutedSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutedSecurities" xlink:to="krmd_AntiDilutedSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AntiDilutedSecurities_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Weighted Average Outstanding Shares:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Basic weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:label="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:to="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_lbl" xml:lang="en-US">Dilutive effect of outstanding stock options and unvested restricted stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Diluted weighted average shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_2_lbl" xml:lang="en-US">Net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">FDIC cash insurance limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="us-gaap_InterestIncomeSecuritiesUSTreasury" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:to="us-gaap_InterestIncomeSecuritiesUSTreasury_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeSecuritiesUSTreasury_lbl" xml:lang="en-US">Investment securities treasury bill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AmortizationOfIntangibleAssets1" xlink:label="krmd_AmortizationOfIntangibleAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AmortizationOfIntangibleAssets1" xlink:to="krmd_AmortizationOfIntangibleAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AmortizationOfIntangibleAssets1_lbl" xml:lang="en-US">Amortization expense of intangible assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_DepreciationAndAmortizationPropertyAndEquipment" xlink:label="krmd_DepreciationAndAmortizationPropertyAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DepreciationAndAmortizationPropertyAndEquipment" xlink:to="krmd_DepreciationAndAmortizationPropertyAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DepreciationAndAmortizationPropertyAndEquipment_lbl" xml:lang="en-US">Depreciation and amortization, property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AntiDilutiveStockOptions" xlink:label="krmd_AntiDilutiveStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutiveStockOptions" xlink:to="krmd_AntiDilutiveStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AntiDilutiveStockOptions_lbl" xml:lang="en-US">Anti-dilutive stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AntiDilutiveRestrictedStock" xlink:label="krmd_AntiDilutiveRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutiveRestrictedStock" xlink:to="krmd_AntiDilutiveRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AntiDilutiveRestrictedStock_lbl" xml:lang="en-US">Anti-dilutive restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xml:lang="en-US">Raw materials and work-in-process</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Inventory, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Less: reserve for obsolete inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Weighted-average volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at ending (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value of options granted during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_lbl" xml:lang="en-US">Unvested at beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Unvested at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl" xml:lang="en-US">Granted (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_lbl" xml:lang="en-US">Vested (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_lbl" xml:lang="en-US">Forfeited/canceled (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Forfeited/canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_2_lbl" xml:lang="en-US">Unvested at ending (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Unvested at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_lbl" xml:lang="en-US">Outstanding at beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_lbl" xml:lang="en-US">Granted (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xml:lang="en-US">Vested (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_lbl" xml:lang="en-US">Forfeited/canceled</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Forfeited/canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2_lbl" xml:lang="en-US">Outstanding at ending (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockBasedCompensationSharesIssuable" xlink:label="krmd_StockBasedCompensationSharesIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockBasedCompensationSharesIssuable" xlink:to="krmd_StockBasedCompensationSharesIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockBasedCompensationSharesIssuable_lbl" xml:lang="en-US">Stock issuable under plan (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_2_lbl" xml:lang="en-US">Common stock outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:label="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:to="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Shares issued under plan</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:label="krmd_SharesAvailableForIssuanceShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:to="krmd_SharesAvailableForIssuanceShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_SharesAvailableForIssuanceShareBasedCompensation_lbl" xml:lang="en-US">Shares available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common stock awards (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="krmd_NonemployeeServicesTransactionCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonemployeeServicesTransactionCost" xlink:to="krmd_NonemployeeServicesTransactionCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NonemployeeServicesTransactionCost_lbl" xml:lang="en-US">Nonemployee services transaction cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction_lbl" xml:lang="en-US">Share-based goods and non-employee services transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Per share weighted average fair value of stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TaxBenefitFromStockBasedCompensation" xlink:label="krmd_TaxBenefitFromStockBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TaxBenefitFromStockBasedCompensation" xlink:to="krmd_TaxBenefitFromStockBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_TaxBenefitFromStockBasedCompensation_lbl" xml:lang="en-US">Tax benefit from stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockBasedCompensationStockOptions" xlink:label="krmd_StockBasedCompensationStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockBasedCompensationStockOptions" xlink:to="krmd_StockBasedCompensationStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_StockBasedCompensationStockOptions_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CashReceivedFromOptionExercise" xlink:label="krmd_CashReceivedFromOptionExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashReceivedFromOptionExercise" xlink:to="krmd_CashReceivedFromOptionExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CashReceivedFromOptionExercise_lbl" xml:lang="en-US">Cash received from option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_lbl" xml:lang="en-US">Number of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Total fair value of shares vested</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TaxBenefitFromRestrictedStockCompensation" xlink:label="krmd_TaxBenefitFromRestrictedStockCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TaxBenefitFromRestrictedStockCompensation" xlink:to="krmd_TaxBenefitFromRestrictedStockCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_TaxBenefitFromRestrictedStockCompensation_lbl" xml:lang="en-US">Tax benefit from restricted stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FinanceLeaseCost1Abstract" xlink:label="krmd_FinanceLeaseCost1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost1Abstract" xlink:to="krmd_FinanceLeaseCost1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseCost1Abstract_lbl" xml:lang="en-US">Finance lease cost:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FinanceLeaseCost" xlink:label="krmd_FinanceLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost" xlink:to="krmd_FinanceLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Financing cash flows from finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:label="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:label="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_lbl" xml:lang="en-US">Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOther" xlink:to="us-gaap_PropertyPlantAndEquipmentOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOther_lbl" xml:lang="en-US">Property and equipment, at cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Finance lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Total finance lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating leases term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US">Finance leases term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Operating leases discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US">Finance leases discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_lbl" xml:lang="en-US">Total undiscounted lease payments - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_lbl" xml:lang="en-US">Total undiscounted lease payments - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeOperatingLeaseImputedInterest" xlink:label="krmd_LesseeOperatingLeaseImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_lbl" xml:lang="en-US">Less: imputed interest - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeFinancingLeaseImputedInterest" xlink:label="krmd_LesseeFinancingLeaseImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_lbl" xml:lang="en-US">Less: imputed interest - Finance Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total lease liabilities - Operating Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_2_lbl" xml:lang="en-US">Total lease liabilities - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeOperatingLeaseRemainingTerm" xlink:label="krmd_LesseeOperatingLeaseRemainingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseRemainingTerm" xlink:to="krmd_LesseeOperatingLeaseRemainingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseRemainingTerm_lbl" xml:lang="en-US">Operating lease remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeFinanceLeaseRemainingTerm" xlink:label="krmd_LesseeFinanceLeaseRemainingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinanceLeaseRemainingTerm" xlink:to="krmd_LesseeFinanceLeaseRemainingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeFinanceLeaseRemainingTerm_lbl" xml:lang="en-US">Finance lease remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">State income tax:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current, net of refund</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Federal income tax:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_WriteoffOfDeferredTaxAsset" xlink:label="krmd_WriteoffOfDeferredTaxAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_WriteoffOfDeferredTaxAsset" xlink:to="krmd_WriteoffOfDeferredTaxAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_WriteoffOfDeferredTaxAsset_lbl" xml:lang="en-US">Write-off of deferred tax asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income tax benefit/(expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xml:lang="en-US">Loss before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income taxes computed at the federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income and franchise tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent differences and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationPlanAssets" xlink:label="us-gaap_DeferredCompensationPlanAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationPlanAssets" xlink:to="us-gaap_DeferredCompensationPlanAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationPlanAssets_lbl" xml:lang="en-US">Deferred compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_DepreciationDepletionAndAmortization1" xlink:label="krmd_DepreciationDepletionAndAmortization1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DepreciationDepletionAndAmortization1" xlink:to="krmd_DepreciationDepletionAndAmortization1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_DepreciationDepletionAndAmortization1_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RdCredit" xlink:label="krmd_RdCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RdCredit" xlink:to="krmd_RdCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RdCredit_lbl" xml:lang="en-US">R&amp;D credit</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_Nol" xlink:label="krmd_Nol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_Nol" xlink:to="krmd_Nol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_Nol_lbl" xml:lang="en-US">NOL</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AllowanceForDoubtfulOtherReceivables1Current" xlink:label="krmd_AllowanceForDoubtfulOtherReceivables1Current" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllowanceForDoubtfulOtherReceivables1Current" xlink:to="krmd_AllowanceForDoubtfulOtherReceivables1Current_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AllowanceForDoubtfulOtherReceivables1Current_lbl" xml:lang="en-US">Allowance for bad debts and other</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AllowanceForNonRealizationOfDeferredTaxAsset" xlink:label="krmd_AllowanceForNonRealizationOfDeferredTaxAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllowanceForNonRealizationOfDeferredTaxAsset" xlink:to="krmd_AllowanceForNonRealizationOfDeferredTaxAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_AllowanceForNonRealizationOfDeferredTaxAsset_lbl" xml:lang="en-US">Allowance for non-realization of deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Account eceivable from customers</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_DescriptionOfMatchingContribution" xlink:label="krmd_DescriptionOfMatchingContribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DescriptionOfMatchingContribution" xlink:to="krmd_DescriptionOfMatchingContribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DescriptionOfMatchingContribution_lbl" xml:lang="en-US">Description of matching contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Matching expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_NotePayableTerms" xlink:label="krmd_NotePayableTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NotePayableTerms" xlink:to="krmd_NotePayableTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NotePayableTerms_lbl" xml:lang="en-US">Note payable terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xml:lang="en-US">Description of the frequency of periodic payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="us-gaap_OtherLongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebtNoncurrent" xlink:to="us-gaap_OtherLongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebtNoncurrent_lbl" xml:lang="en-US">Balance of AON note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xml:lang="en-US">Loan provided, as lender</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Inteest rate on borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventDescription" xlink:label="us-gaap_SubsequentEventDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Description of subsequent event</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FurnitureAndOfficeEquipmentMember" xlink:to="krmd_FurnitureAndOfficeEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FurnitureAndOfficeEquipmentMember_doc" xml:lang="en-US">The element represents furniture and office equipment member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ManufacturingEquipmentAndToolingMember" xlink:to="krmd_ManufacturingEquipmentAndToolingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ManufacturingEquipmentAndToolingMember_doc" xml:lang="en-US">The element represents manufacturing equipment and tooling member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsOnIndebtedness" xlink:to="krmd_PaymentsOnIndebtedness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PaymentsOnIndebtedness_doc" xml:lang="en-US">The element represents payments on indebtedness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IssuanceOfCommonStockCompensation" xlink:to="krmd_IssuanceOfCommonStockCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_IssuanceOfCommonStockCompensation_doc" xml:lang="en-US">The element represents issuance of common stock compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2015Member" xlink:to="krmd_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptionPlan2015Member_doc" xml:lang="en-US">The element represents stock option plan2015 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2021Member" xlink:to="krmd_StockOptionPlan2021Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptionPlan2021Member_doc" xml:lang="en-US">The element represents stock option plan2021 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:to="krmd_NonEmployeeDirectorAndBoardAdvisorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember_doc" xml:lang="en-US">The element represents non employee director and board advisor member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonemployeeServicesTransactionCost" xlink:to="krmd_NonemployeeServicesTransactionCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NonemployeeServicesTransactionCost_doc" xml:lang="en-US">The element represents nonemployee services transaction cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TimeBasedSharesOptionsMember" xlink:to="krmd_TimeBasedSharesOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TimeBasedSharesOptionsMember_doc" xml:lang="en-US">The element represents time based shares options member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award grants in period weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xml:lang="en-US">The element represents stock issued during period shares stock options exercised1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice1Member" xlink:to="krmd_ExercisePrice1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ExercisePrice1Member_doc" xml:lang="en-US">The element represents exercise price1 member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants in period gross1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashPaidDuringPeriodsForAbstract" xlink:to="krmd_CashPaidDuringPeriodsForAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CashPaidDuringPeriodsForAbstract_doc" xml:lang="en-US">The element represents cash paid during periods for abstract.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options forfeitures in period2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding number unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockAwardsMember" xlink:to="krmd_RestrictedStockAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RestrictedStockAwardsMember_doc" xml:lang="en-US">The element represents restricted stock awards member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options vested in period gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost1Abstract" xlink:to="krmd_FinanceLeaseCost1Abstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseCost1Abstract_doc" xml:lang="en-US">The element represents finance lease cost1 abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost" xlink:to="krmd_FinanceLeaseCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseCost_doc" xml:lang="en-US">The element represents finance lease cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_doc" xml:lang="en-US">The element represents assets and liabilities operating lessee abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_doc" xml:lang="en-US">The element represents assets and liabilities lessee finance abstract.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue_doc" xml:lang="en-US">The element represents lessee financing lease lease liability payments due.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_doc" xml:lang="en-US">The element represents lessee operating lease imputed interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_doc" xml:lang="en-US">The element represents lessee financing lease imputed interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AONPremiumFinanceLLCMember" xlink:to="krmd_AONPremiumFinanceLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AONPremiumFinanceLLCMember_doc" xml:lang="en-US">The element represents a o n premium finance l l c member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PromissoryNoteMember" xlink:to="krmd_PromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PromissoryNoteMember_doc" xml:lang="en-US">The element represents promissory note member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NotePayableTerms" xlink:to="krmd_NotePayableTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NotePayableTerms_doc" xml:lang="en-US">The element represents note payable terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_doc" xml:lang="en-US">The element represents lessee operating lease liability payments due total.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_doc" xml:lang="en-US">The element represents schedule of share based compensation stock options activity amended table text block.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LessorOperatingLeaseOptionToTerminate1" xlink:label="krmd_LessorOperatingLeaseOptionToTerminate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LessorOperatingLeaseOptionToTerminate1" xlink:to="krmd_LessorOperatingLeaseOptionToTerminate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LessorOperatingLeaseOptionToTerminate1_doc" xml:lang="en-US">The element represents lessor operating lease option to terminate1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RouLandlordCredit" xlink:to="krmd_RouLandlordCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RouLandlordCredit_doc" xml:lang="en-US">The element represents rou landlord credit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_BorrowingsFromIndebtedness" xlink:to="krmd_BorrowingsFromIndebtedness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_BorrowingsFromIndebtedness_doc" xml:lang="en-US">The element represents borrowings from indebtedness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AmortizationOfIntangibleAssets1" xlink:to="krmd_AmortizationOfIntangibleAssets1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AmortizationOfIntangibleAssets1_doc" xml:lang="en-US">The element represents amortization of intangible assets1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DepreciationDepletionAndAmortization1" xlink:to="krmd_DepreciationDepletionAndAmortization1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DepreciationDepletionAndAmortization1_doc" xml:lang="en-US">The element represents depreciation depletion and amortization1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RdCredit" xlink:to="krmd_RdCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RdCredit_doc" xml:lang="en-US">The element represents rd credit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_Nol" xlink:to="krmd_Nol_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_Nol_doc" xml:lang="en-US">The element represents nol.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllowanceForDoubtfulOtherReceivables1Current" xlink:to="krmd_AllowanceForDoubtfulOtherReceivables1Current_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AllowanceForDoubtfulOtherReceivables1Current_doc" xml:lang="en-US">The element represents allowance for doubtful other receivables1 current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DescriptionOfMatchingContribution" xlink:to="krmd_DescriptionOfMatchingContribution_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DescriptionOfMatchingContribution_doc" xml:lang="en-US">The element represents description of matching contribution.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_DescriptionOfLessorOperatingLeaseTerm" xlink:label="krmd_DescriptionOfLessorOperatingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DescriptionOfLessorOperatingLeaseTerm" xlink:to="krmd_DescriptionOfLessorOperatingLeaseTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DescriptionOfLessorOperatingLeaseTerm_doc" xml:lang="en-US">The element represents description of lessor operating lease term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EquipmentAndToolingMember" xlink:to="krmd_EquipmentAndToolingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_EquipmentAndToolingMember_doc" xml:lang="en-US">The element represents equipment and tooling member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_UnrecognizedCompensationCost" xlink:label="krmd_UnrecognizedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_UnrecognizedCompensationCost" xlink:to="krmd_UnrecognizedCompensationCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_UnrecognizedCompensationCost_doc" xml:lang="en-US">The element represents unrecognized compensation cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfNetRevenuesByGeography" xlink:to="krmd_ScheduleOfNetRevenuesByGeography_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfNetRevenuesByGeography_doc" xml:lang="en-US">The element represents schedule of net revenues by geography.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CompensationeExpenseRelatedToRestrictedStockAwards" xlink:to="krmd_CompensationeExpenseRelatedToRestrictedStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CompensationeExpenseRelatedToRestrictedStockAwards_doc" xml:lang="en-US">The element represents compensatione expense related to restricted stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:to="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_doc" xml:lang="en-US">The element represents shares issued under plan in total shares employee stock ownership plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:to="krmd_SharesAvailableForIssuanceShareBasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_SharesAvailableForIssuanceShareBasedCompensation_doc" xml:lang="en-US">The element represents shares available for issuance share based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TaxBenefitFromStockBasedCompensation" xlink:to="krmd_TaxBenefitFromStockBasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TaxBenefitFromStockBasedCompensation_doc" xml:lang="en-US">The element represents tax benefit from stock based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlans2015And2021CombinedMember" xlink:to="krmd_StockOptionPlans2015And2021CombinedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptionPlans2015And2021CombinedMember_doc" xml:lang="en-US">The element represents stock option plans2015 and2021 combined member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TaxBenefitFromRestrictedStockCompensation" xlink:to="krmd_TaxBenefitFromRestrictedStockCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TaxBenefitFromRestrictedStockCompensation_doc" xml:lang="en-US">The element represents tax benefit from restricted stock compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockBasedCompensationSharesIssuable" xlink:to="krmd_StockBasedCompensationSharesIssuable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockBasedCompensationSharesIssuable_doc" xml:lang="en-US">The element represents stock based compensation shares issuable.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FDICBankMember" xlink:label="krmd_FDICBankMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FDICBankMember" xlink:to="krmd_FDICBankMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FDICBankMember_doc" xml:lang="en-US">The element represents f d i c bank member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CommonStockOptions" xlink:label="krmd_CommonStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CommonStockOptions" xlink:to="krmd_CommonStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CommonStockOptions_doc" xml:lang="en-US">The element represents common stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockUnits" xlink:to="krmd_RestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RestrictedStockUnits_doc" xml:lang="en-US">The element represents restricted stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfSecuritiesTextBlock" xlink:to="krmd_ScheduleOfSecuritiesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfSecuritiesTextBlock_doc" xml:lang="en-US">The element represents schedule of securities text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutedSecurities" xlink:to="krmd_AntiDilutedSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutedSecurities_doc" xml:lang="en-US">The element represents anti diluted securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:to="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_doc" xml:lang="en-US">The element represents dilutive effect of outstanding stock options and unvested restricted stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashReceivedFromOptionExercise" xlink:to="krmd_CashReceivedFromOptionExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CashReceivedFromOptionExercise_doc" xml:lang="en-US">The element represents cash received from option exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockBasedCompensationStockOptions" xlink:to="krmd_StockBasedCompensationStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockBasedCompensationStockOptions_doc" xml:lang="en-US">The element represents stock based compensation stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" xlink:to="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc_doc" xml:lang="en-US">The element represents impairment or disposal of long lived assets policy text bloc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PatentsAndTrademarksMember" xlink:to="krmd_PatentsAndTrademarksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PatentsAndTrademarksMember_doc" xml:lang="en-US">The element represents patents and trademarks member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AntiDilutedSecuritiesPerformancBased" xlink:label="krmd_AntiDilutedSecuritiesPerformancBased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutedSecuritiesPerformancBased" xlink:to="krmd_AntiDilutedSecuritiesPerformancBased_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutedSecuritiesPerformancBased_doc" xml:lang="en-US">The element represents anti diluted securities performanc based.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AntiDilutedSecuritiesTimeBased" xlink:label="krmd_AntiDilutedSecuritiesTimeBased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntiDilutedSecuritiesTimeBased" xlink:to="krmd_AntiDilutedSecuritiesTimeBased_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AntiDilutedSecuritiesTimeBased_doc" xml:lang="en-US">The element represents anti diluted securities time based.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptions" xlink:to="krmd_StockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptions_doc" xml:lang="en-US">The element represents stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PerformanceBasedSharesOptionsMember" xlink:to="krmd_PerformanceBasedSharesOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PerformanceBasedSharesOptionsMember_doc" xml:lang="en-US">The element represents performance based shares options member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_doc" xml:lang="en-US">The element represents share based compensation arrangement by unvested award options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options forfeitures.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options unvested weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseOneMember" xlink:to="krmd_LeaseOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LeaseOneMember_doc" xml:lang="en-US">The element represents lease one member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseTwoMember" xlink:to="krmd_LeaseTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LeaseTwoMember_doc" xml:lang="en-US">The element represents lease two member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LeaseThreeMember" xlink:to="krmd_LeaseThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LeaseThreeMember_doc" xml:lang="en-US">The element represents lease three member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_WriteoffOfDeferredTaxAsset" xlink:to="krmd_WriteoffOfDeferredTaxAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_WriteoffOfDeferredTaxAsset_doc" xml:lang="en-US">The element represents writeoff of deferred tax asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllowanceForNonRealizationOfDeferredTaxAsset" xlink:to="krmd_AllowanceForNonRealizationOfDeferredTaxAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AllowanceForNonRealizationOfDeferredTaxAsset_doc" xml:lang="en-US">The element represents allowance for non realization of deferred tax asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CustomerOneMember" xlink:to="krmd_CustomerOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CustomerOneMember_doc" xml:lang="en-US">The element represents customer one member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TermLoanFacilityMember" xlink:to="krmd_TermLoanFacilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TermLoanFacilityMember_doc" xml:lang="en-US">The element represents term loan facility member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseROUAsset" xlink:to="krmd_FinanceLeaseROUAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseROUAsset_doc" xml:lang="en-US">The element represents finance lease rou asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_doc" xml:lang="en-US">The element represents lessee financing lease lease liability payments due total.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsOnIndebtedness" xlink:to="krmd_PaymentsOnIndebtedness_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PaymentsOnIndebtedness_3_lbl" xml:lang="en-US">Payments on Indebtedness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseROUAsset" xlink:to="krmd_FinanceLeaseROUAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseROUAsset_3_lbl" xml:lang="en-US">Finance Lease ROU Asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_2_lbl" xml:lang="en-US">Inventory Valuation Reserves</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Unvested Award Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Unvested Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Grants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award Options Grants in Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Number Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period Gross Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award Options Grants in Period Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Vested in Period Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award Options Vested in Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options forfeitures in Period Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award Options forfeitures in Period Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockBasedCompensationStockOptions" xlink:to="krmd_StockBasedCompensationStockOptions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockBasedCompensationStockOptions_3_lbl" xml:lang="en-US">Stock Based Compensation Stock Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Other, Accumulated Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Other, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_3_lbl" xml:lang="en-US">Lessee Operating Lease Imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_3_lbl" xml:lang="en-US">Lessee Financing Lease Imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DepreciationDepletionAndAmortization1" xlink:to="krmd_DepreciationDepletionAndAmortization1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DepreciationDepletionAndAmortization1_3_lbl" xml:lang="en-US">Depreciation Depletion and Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllowanceForNonRealizationOfDeferredTaxAsset" xlink:to="krmd_AllowanceForNonRealizationOfDeferredTaxAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AllowanceForNonRealizationOfDeferredTaxAsset_3_lbl" xml:lang="en-US">Allowance for Non Realization of Deferred Tax Asset</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>krmd-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20231231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Inventory" xlink:href="krmd-20231231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20231231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:href="krmd-20231231.xsd#FederalAndStateIncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomers" xlink:href="krmd-20231231.xsd#MajorCustomers" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefits" xlink:href="krmd-20231231.xsd#EmployeeBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20231231.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SubsequentEvent" xlink:href="krmd-20231231.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryTables" xlink:href="krmd-20231231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20231231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:href="krmd-20231231.xsd#FederalAndStateIncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:href="krmd-20231231.xsd#EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails" xlink:href="krmd-20231231.xsd#FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:href="krmd-20231231.xsd#ScheduleOfNetIncomePerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details" xlink:href="krmd-20231231.xsd#FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20231231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:href="krmd-20231231.xsd#InventoryConsistsOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20231231.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:href="krmd-20231231.xsd#ScheduleOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:href="krmd-20231231.xsd#ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:href="krmd-20231231.xsd#ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:href="krmd-20231231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:href="krmd-20231231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20231231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfComponentsOfLeaseExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesDetailsNarrative" xlink:href="krmd-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:href="krmd-20231231.xsd#ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="krmd-20231231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:href="krmd-20231231.xsd#MajorCustomersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:href="krmd-20231231.xsd#EmployeeBenefitsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20231231.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SubsequentEventDetailsNarrative" xlink:href="krmd-20231231.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRentReceivablesNetNoncurrent" xlink:label="loc_us-gaapDeferredRentReceivablesNetNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapDeferredRentReceivablesNetNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockPreferredShares" xlink:label="loc_us-gaapTreasuryStockPreferredShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockPreferredShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CompensationeExpenseRelatedToRestrictedStockAwards" xlink:label="loc_krmdCompensationeExpenseRelatedToRestrictedStockAwards" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdCompensationeExpenseRelatedToRestrictedStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredPurchasedPowerCosts" xlink:label="loc_us-gaapDeferredPurchasedPowerCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredPurchasedPowerCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RouLandlordCredit" xlink:label="loc_krmdRouLandlordCredit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_krmdRouLandlordCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="loc_krmdBorrowingsFromIndebtedness" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_krmdBorrowingsFromIndebtedness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PaymentsOnIndebtedness" xlink:label="loc_krmdPaymentsOnIndebtedness" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_krmdPaymentsOnIndebtedness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FinanceLeaseROUAsset" xlink:label="loc_krmdFinanceLeaseROUAsset" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_krmdFinanceLeaseROUAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CashPaidDuringPeriodsForAbstract" xlink:label="loc_krmdCashPaidDuringPeriodsForAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_IssuanceOfCommonStockCompensation" xlink:label="loc_krmdIssuanceOfCommonStockCompensation" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_krmdIssuanceOfCommonStockCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Inventory" xlink:title="00000008 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:title="00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomers" xlink:title="00000013 - Disclosure - MAJOR CUSTOMERS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefits" xlink:title="00000015 - Disclosure - EMPLOYEE BENEFITS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="00000016 - Disclosure - DEBT OBLIGATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SubsequentEvent" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" xlink:label="loc_krmdImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ScheduleOfSecuritiesTextBlock" xlink:label="loc_krmdScheduleOfSecuritiesTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdScheduleOfSecuritiesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ScheduleOfNetRevenuesByGeography" xlink:label="loc_krmdScheduleOfNetRevenuesByGeography" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdScheduleOfNetRevenuesByGeography" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryTables" xlink:title="00000020 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:label="loc_krmdScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_krmdScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="00000023 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:title="00000024 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:title="00000025 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails" xlink:title="00000026 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptions" xlink:label="loc_krmdStockOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RestrictedStockUnits" xlink:label="loc_krmdRestrictedStockUnits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AntiDilutedSecurities" xlink:label="loc_krmdAntiDilutedSecurities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdAntiDilutedSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:title="00000027 - Disclosure - Schedule of net income per common share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:label="loc_krmdDilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdDilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details" xlink:title="00000028 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PatentsAndTrademarksMember" xlink:label="loc_krmdPatentsAndTrademarksMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_krmdPatentsAndTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_EquipmentAndToolingMember" xlink:label="loc_krmdEquipmentAndToolingMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdEquipmentAndToolingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="loc_us-gaapInterestIncomeSecuritiesUSTreasury" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInterestIncomeSecuritiesUSTreasury" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AmortizationOfIntangibleAssets1" xlink:label="loc_krmdAmortizationOfIntangibleAssets1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdAmortizationOfIntangibleAssets1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_DepreciationAndAmortizationPropertyAndEquipment" xlink:label="loc_krmdDepreciationAndAmortizationPropertyAndEquipment" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdDepreciationAndAmortizationPropertyAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AntiDilutiveStockOptions" xlink:label="loc_krmdAntiDilutiveStockOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdAntiDilutiveStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AntiDilutiveRestrictedStock" xlink:label="loc_krmdAntiDilutiveRestrictedStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdAntiDilutiveRestrictedStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:title="00000030 - Disclosure - Inventory consists of: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="loc_us-gaapInventoryWorkInProcessAndRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcessAndRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="00000031 - Disclosure - Property and equipment consists of the following at: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="loc_krmdManufacturingEquipmentAndToolingMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdManufacturingEquipmentAndToolingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:title="00000032 - Disclosure - Schedule of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:title="00000033 - Disclosure - Schedule of status of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:title="00000034 - Disclosure - Schedule of information pertaining to options outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ExercisePrice1Member" xlink:label="loc_krmdExercisePrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_krmdExercisePrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:title="00000035 - Disclosure - The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PerformanceBasedSharesOptionsMember" xlink:label="loc_krmdPerformanceBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdPerformanceBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details" xlink:title="00000036 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockOptionPlans2015And2021CombinedMember" xlink:label="loc_krmdStockOptionPlans2015And2021CombinedMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlans2015And2021CombinedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ExecutivesEmployeesConsultantsMember" xlink:label="loc_krmdExecutivesEmployeesConsultantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdExecutivesEmployeesConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PerformanceBasedSharesOptionsMember" xlink:label="loc_krmdPerformanceBasedSharesOptionsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdPerformanceBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockBasedCompensationSharesIssuable" xlink:label="loc_krmdStockBasedCompensationSharesIssuable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockBasedCompensationSharesIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:label="loc_krmdSharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:label="loc_krmdSharesAvailableForIssuanceShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesAvailableForIssuanceShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="loc_krmdNonemployeeServicesTransactionCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdNonemployeeServicesTransactionCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TaxBenefitFromStockBasedCompensation" xlink:label="loc_krmdTaxBenefitFromStockBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdTaxBenefitFromStockBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockBasedCompensationStockOptions" xlink:label="loc_krmdStockBasedCompensationStockOptions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockBasedCompensationStockOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CashReceivedFromOptionExercise" xlink:label="loc_krmdCashReceivedFromOptionExercise" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdCashReceivedFromOptionExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TaxBenefitFromRestrictedStockCompensation" xlink:label="loc_krmdTaxBenefitFromRestrictedStockCompensation" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdTaxBenefitFromRestrictedStockCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails" xlink:title="00000038 - Disclosure - Schedule of components of lease expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FinanceLeaseCost1Abstract" xlink:label="loc_krmdFinanceLeaseCost1Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdFinanceLeaseCost1Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_FinanceLeaseCost" xlink:label="loc_krmdFinanceLeaseCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_krmdFinanceLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:title="00000039 - Disclosure - Schedule of cash flow information related to leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:title="00000040 - Disclosure - Schedule of balance sheet information related to leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:label="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:label="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="loc_us-gaapLesseeFinanceLeaseDiscountRate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeFinanceLeaseDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="00000041 - Disclosure - Schedule of maturities of lease liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:label="loc_krmdLesseeOperatingLeaseLiabilityPaymentsDueTotal" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:label="loc_krmdLesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeOperatingLeaseImputedInterest" xlink:label="loc_krmdLesseeOperatingLeaseImputedInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeOperatingLeaseImputedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeFinancingLeaseImputedInterest" xlink:label="loc_krmdLesseeFinancingLeaseImputedInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeFinancingLeaseImputedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesDetailsNarrative" xlink:title="00000042 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLesseeLeaseDescriptionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LeaseOneMember" xlink:label="loc_krmdLeaseOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LeaseTwoMember" xlink:label="loc_krmdLeaseTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LeaseThreeMember" xlink:label="loc_krmdLeaseThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_krmdLeaseThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeOperatingLeaseRemainingTerm" xlink:label="loc_krmdLesseeOperatingLeaseRemainingTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_krmdLesseeOperatingLeaseRemainingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_LesseeFinanceLeaseRemainingTerm" xlink:label="loc_krmdLesseeFinanceLeaseRemainingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_krmdLesseeFinanceLeaseRemainingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000043 - Disclosure - Schedule of provision for income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_WriteoffOfDeferredTaxAsset" xlink:label="loc_krmdWriteoffOfDeferredTaxAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdWriteoffOfDeferredTaxAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:title="00000044 - Disclosure - Schedule of reconciliation of income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_WriteoffOfDeferredTaxAsset" xlink:label="loc_krmdWriteoffOfDeferredTaxAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdWriteoffOfDeferredTaxAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000045 - Disclosure - Schedule of components of deferred tax assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationPlanAssets" xlink:label="loc_us-gaapDeferredCompensationPlanAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredCompensationPlanAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_DepreciationDepletionAndAmortization1" xlink:label="loc_krmdDepreciationDepletionAndAmortization1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdDepreciationDepletionAndAmortization1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_RdCredit" xlink:label="loc_krmdRdCredit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdRdCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_Nol" xlink:label="loc_krmdNol" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdNol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AllowanceForDoubtfulOtherReceivables1Current" xlink:label="loc_krmdAllowanceForDoubtfulOtherReceivables1Current" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdAllowanceForDoubtfulOtherReceivables1Current" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AllowanceForNonRealizationOfDeferredTaxAsset" xlink:label="loc_krmdAllowanceForNonRealizationOfDeferredTaxAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdAllowanceForNonRealizationOfDeferredTaxAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:title="00000046 - Disclosure - MAJOR CUSTOMERS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_CustomerOneMember" xlink:label="loc_krmdCustomerOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_krmdCustomerOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:title="00000047 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_DescriptionOfMatchingContribution" xlink:label="loc_krmdDescriptionOfMatchingContribution" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_krmdDescriptionOfMatchingContribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="00000048 - Disclosure - DEBT OBLIGATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_AONPremiumFinanceLLCMember" xlink:label="loc_krmdAONPremiumFinanceLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdAONPremiumFinanceLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_PromissoryNoteMember" xlink:label="loc_krmdPromissoryNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_krmdPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaapLineOfCreditMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapLineOfCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_NotePayableTerms" xlink:label="loc_krmdNotePayableTerms" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_krmdNotePayableTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaapOtherLongTermDebtNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherLongTermDebtNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SubsequentEventDetailsNarrative" xlink:title="00000049 - Disclosure - SUBSEQUENT EVENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20231231.xsd#krmd_TermLoanFacilityMember" xlink:label="loc_krmdTermLoanFacilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_krmdTermLoanFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate" xlink:label="loc_us-gaapInvestmentInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInvestmentInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaapSubsequentEventDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventDescription" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541725088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 13, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-12305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KORU MEDICAL SYSTEMS, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000704440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3044880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mahwah<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">469-2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,191,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,710,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,420,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">McGrail Merkel Quinn & Associates, P.C.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Scranton, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295540242288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,482,240<span></span>
</td>
<td class="nump">$ 17,408,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable less allowance for doubtful accounts of $24,777 and $21,459 for December 31, 2023, and December 31, 2022, respectively</a></td>
<td class="nump">4,045,211<span></span>
</td>
<td class="nump">3,558,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,481,301<span></span>
</td>
<td class="nump">6,404,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">28,889<span></span>
</td>
<td class="nump">972,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">1,218,288<span></span>
</td>
<td class="nump">1,457,232<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">20,255,929<span></span>
</td>
<td class="nump">29,801,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,837,657<span></span>
</td>
<td class="nump">3,886,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net of accumulated amortization of $390,341 and $325,872 at December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">754,361<span></span>
</td>
<td class="nump">787,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,514,055<span></span>
</td>
<td class="nump">3,786,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets, net allowance for non-realization of deferred tax assets of $6,002,777 and zero for December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,967,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">98,970<span></span>
</td>
<td class="nump">102,625<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">28,460,972<span></span>
</td>
<td class="nump">42,332,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">975,193<span></span>
</td>
<td class="nump">2,391,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,711,427<span></span>
</td>
<td class="nump">2,889,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note Payable</a></td>
<td class="nump">314,344<span></span>
</td>
<td class="nump">433,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">512,520<span></span>
</td>
<td class="nump">257,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related taxes</a></td>
<td class="nump">462,941<span></span>
</td>
<td class="nump">542,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability &#8211; current</a></td>
<td class="nump">109,540<span></span>
</td>
<td class="nump">98,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability &#8211; current</a></td>
<td class="nump">368,313<span></span>
</td>
<td class="nump">345,834<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">4,454,278<span></span>
</td>
<td class="nump">6,958,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liability, net current portion</a></td>
<td class="nump">316,623<span></span>
</td>
<td class="nump">394,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">3,336,300<span></span>
</td>
<td class="nump">3,653,257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">8,107,201<span></span>
</td>
<td class="nump">11,006,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 75,000,000 shares authorized, 49,089,864 and 48,861,891 shares issued; 45,669,362 and 45,441,389 shares outstanding at December 31, 2023, and December 31, 2022, respectively</a></td>
<td class="nump">490,899<span></span>
</td>
<td class="nump">488,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">47,018,707<span></span>
</td>
<td class="nump">44,252,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 3,420,502 shares at December 31, 2023 and December 31, 2022, at cost</a></td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Deficit</a></td>
<td class="num">(23,312,273)<span></span>
</td>
<td class="num">(9,571,211)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">20,353,771<span></span>
</td>
<td class="nump">31,325,963<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 28,460,972<span></span>
</td>
<td class="nump">$ 42,332,443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541564848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit loss, current</a></td>
<td class="nump">$ 24,777<span></span>
</td>
<td class="nump">$ 21,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">390,341<span></span>
</td>
<td class="nump">325,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNetNoncurrent', window );">Deferred Rent Receivables, Net, Noncurrent</a></td>
<td class="nump">$ 6,002,777<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">49,089,864<span></span>
</td>
<td class="nump">48,861,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">45,669,362<span></span>
</td>
<td class="nump">45,441,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockPreferredShares', window );">Treasury stock, shares</a></td>
<td class="nump">3,420,502<span></span>
</td>
<td class="nump">3,420,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental income recognized over rental payment required by lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479341/842-30-25-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued preferred shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295655095840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">NET REVENUES</a></td>
<td class="nump">$ 28,517,666<span></span>
</td>
<td class="nump">$ 27,896,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">11,809,384<span></span>
</td>
<td class="nump">12,527,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">16,708,282<span></span>
</td>
<td class="nump">15,368,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">20,365,617<span></span>
</td>
<td class="nump">20,606,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,742,254<span></span>
</td>
<td class="nump">4,956,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">870,390<span></span>
</td>
<td class="nump">587,137<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">26,978,261<span></span>
</td>
<td class="nump">26,149,859<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net Operating Loss</a></td>
<td class="num">(10,269,979)<span></span>
</td>
<td class="num">(10,780,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-Operating Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Loss on foreign currency exchange</a></td>
<td class="num">(5,124)<span></span>
</td>
<td class="num">(39,874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="num">(59,807)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income, net</a></td>
<td class="nump">561,328<span></span>
</td>
<td class="nump">145,587<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME</a></td>
<td class="nump">496,397<span></span>
</td>
<td class="nump">105,713<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">LOSS BEFORE TAXES</a></td>
<td class="num">(9,773,582)<span></span>
</td>
<td class="num">(10,675,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income (tax)/benefit</a></td>
<td class="num">(3,967,480)<span></span>
</td>
<td class="nump">2,014,018<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (13,741,062)<span></span>
</td>
<td class="num">$ (8,661,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">45,601,346<span></span>
</td>
<td class="nump">45,002,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">45,601,346<span></span>
</td>
<td class="nump">45,002,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541949952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Treasury Stock, Common [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 480,441<span></span>
</td>
<td class="nump">$ 40,774,245<span></span>
</td>
<td class="num">$ (910,069)<span></span>
</td>
<td class="num">$ (3,843,562)<span></span>
</td>
<td class="nump">$ 36,501,055<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">48,044,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Accrued compensation paid in shares</a></td>
<td class="nump">$ 2,066<span></span>
</td>
<td class="nump">511,016<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">513,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Accrued compensation paid in shares (in shares)</a></td>
<td class="nump">206,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,083,396<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,083,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Compensation expense related to restricted stock awards</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">482,449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">482,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CompensationeExpenseRelatedToRestrictedStockAwards', window );">Compensation expense related to restricted stock awards (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon options exercised</a></td>
<td class="nump">$ 5,612<span></span>
</td>
<td class="nump">401,011<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">406,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance upon options exercised (in shares)</a></td>
<td class="nump">561,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,661,142)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,661,142)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 488,619<span></span>
</td>
<td class="nump">44,252,117<span></span>
</td>
<td class="num">(9,571,211)<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="nump">31,325,963<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">48,861,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Accrued compensation paid in shares</a></td>
<td class="nump">$ 1,280<span></span>
</td>
<td class="nump">445,069<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">446,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Accrued compensation paid in shares (in shares)</a></td>
<td class="nump">127,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,940,720<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,940,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Compensation expense related to restricted stock awards</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">380,801<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">381,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CompensationeExpenseRelatedToRestrictedStockAwards', window );">Compensation expense related to restricted stock awards (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,741,062)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,741,062)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 490,899<span></span>
</td>
<td class="nump">$ 47,018,707<span></span>
</td>
<td class="num">$ (23,312,273)<span></span>
</td>
<td class="num">$ (3,843,562)<span></span>
</td>
<td class="nump">$ 20,353,771<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">49,089,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CompensationeExpenseRelatedToRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents compensatione expense related to restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CompensationeExpenseRelatedToRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295540243760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (13,741,062)<span></span>
</td>
<td class="num">$ (8,661,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,768,870<span></span>
</td>
<td class="nump">3,079,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">870,390<span></span>
</td>
<td class="nump">587,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">59,807<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(2,035,297)<span></span>
</td>
<td class="num">(2,026,226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredPurchasedPowerCosts', window );">Allowance for non-realization of deferred tax asset</a></td>
<td class="nump">6,002,777<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_RouLandlordCredit', window );">ROU landlord credit</a></td>
<td class="num">(21,988)<span></span>
</td>
<td class="nump">212,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase)/Decrease in accounts receivable</a></td>
<td class="num">(486,327)<span></span>
</td>
<td class="nump">34,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease/(Increase) in inventory</a></td>
<td class="nump">2,923,566<span></span>
</td>
<td class="num">(298,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease/(Increase) in other receivables</a></td>
<td class="nump">943,507<span></span>
</td>
<td class="num">(254,176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease in prepaid expenses and other assets</a></td>
<td class="nump">242,599<span></span>
</td>
<td class="nump">28,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">(Decrease)/Increase in accounts payable</a></td>
<td class="num">(1,416,606)<span></span>
</td>
<td class="nump">1,164,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">(Decrease)/Increase in accrued payroll and related taxes</a></td>
<td class="num">(79,458)<span></span>
</td>
<td class="nump">381,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Increase in other liabilities</a></td>
<td class="nump">255,183<span></span>
</td>
<td class="nump">167,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">(Decrease)/Increase in accrued expenses</a></td>
<td class="num">(1,178,514)<span></span>
</td>
<td class="nump">180,237<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(4,892,553)<span></span>
</td>
<td class="num">(5,404,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchases of property and equipment</a></td>
<td class="num">(782,949)<span></span>
</td>
<td class="num">(2,761,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="num">(31,648)<span></span>
</td>
<td class="num">(40,512)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(814,597)<span></span>
</td>
<td class="num">(2,801,568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">406,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_BorrowingsFromIndebtedness', window );">Borrowings from indebtedness</a></td>
<td class="nump">565,172<span></span>
</td>
<td class="nump">783,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_PaymentsOnIndebtedness', window );">Payments on indebtedness</a></td>
<td class="num">(684,123)<span></span>
</td>
<td class="num">(859,087)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_FinanceLeaseROUAsset', window );">Finance lease ROU asset</a></td>
<td class="num">(33,461)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease liability</a></td>
<td class="num">(66,455)<span></span>
</td>
<td class="num">(51,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="num">(218,867)<span></span>
</td>
<td class="nump">279,485<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(5,926,017)<span></span>
</td>
<td class="num">(7,926,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</a></td>
<td class="nump">17,408,257<span></span>
</td>
<td class="nump">25,334,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS, END OF YEAR</a></td>
<td class="nump">11,482,240<span></span>
</td>
<td class="nump">17,408,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CashPaidDuringPeriodsForAbstract', window );"><strong>Cash paid during the years for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">50,832<span></span>
</td>
<td class="nump">28,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">3,160<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Schedule of Non-Cash Operating, Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_IssuanceOfCommonStockCompensation', window );">Issuance of common stock as compensation</a></td>
<td class="nump">$ 446,349<span></span>
</td>
<td class="nump">$ 513,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_BorrowingsFromIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents borrowings from indebtedness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_BorrowingsFromIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CashPaidDuringPeriodsForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents cash paid during periods for abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CashPaidDuringPeriodsForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseROUAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents finance lease rou asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseROUAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_IssuanceOfCommonStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents issuance of common stock compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_IssuanceOfCommonStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_PaymentsOnIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents payments on indebtedness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_PaymentsOnIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_RouLandlordCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents rou landlord credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_RouLandlordCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredPurchasedPowerCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of power used for operations in prior periods that were expected to be recovered from customers in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredPurchasedPowerCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295543531472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zLKDHnybvnVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; <span id="xdx_820_zs762yR0Y2dk">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_843_eus-gaap--NatureOfOperations_zRRRz9m674vk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_zrYF4NWrhPF6">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) develops, manufactures and commercializes innovative and
patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United
States Food and Drug Administration (the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system
management. &#160;The Company operates as <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxH_uN_c20230101__20231231_zZ9xrjClTPk7" title="Number of segments::XDX::1">one</span> segment.</p>

<p id="xdx_853_zMIe7tIiDdu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbn4X8lTGPme" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_z3Y0F1FhUOdb">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We prepare our financial statements and accompanying notes in accordance
with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). &#160;Certain prior year amounts have
been reclassified to conform to the current year presentation in our Financial Statements.</p>

<p id="xdx_853_zrCUXeIPMf9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z2QYCi9sxaV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_zTqFTpDCew02">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For purposes of the statements of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company has historically held
cash balances in excess of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zAWPnCTIiF41" title="FDIC cash insurance limit">250,000</span> at its primary commercial bank, which exceeds FDIC insurance limits. To reduce the risk of uninsured
deposits, the Company entered an insured cash sweep program with KeyBank during the second quarter of 2023 to automatically invest its
uninsured bank cash balances over $250,000 into FDIC insured banks so there is no more than $250,000 maintained at any one bank. Further,
as of December 31, 2023 the Company had invested $<span id="xdx_90C_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20230101__20231231_zv5GLwAzoGZ" title="Investment securities treasury bill">10.2 million</span> in a US Treasury bill that matures every 90 days.</p>

<p id="xdx_853_zDD9WrxjHK89" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zLy0eLjaRDX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_860_z0sXNcja7QFh">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

<p id="xdx_853_zfJIwzfaU0W5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zITQ163r6qLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zqyfSbinHex6">INTANGIBLE ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_z6RzZC0sqY6k" title="Estimated useful lives::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0480">6</span></span> to <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zfnkxoE5vxd9" title="Estimated useful lives::XDX::P20Y"><span style="-sec-ix-hidden: xdx2ixbrl0482">20</span></span> years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2023 and 2022 was $<span id="xdx_903_ecustom--AmortizationOfIntangibleAssets1_c20230101__20231231_zXukqMc8c7Hg" title="Amortization expense of intangible assets">64,469</span> and
$<span id="xdx_90C_ecustom--AmortizationOfIntangibleAssets1_c20220101__20221231_zgUYqRRQcSW3">62,143</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zksHIEC1OdYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zOrGNsW3BTte">The estimated amortization expense for the succeeding years for the intangible
assets is approximately:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_494_20231231_zDrzIiBttqZ5" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zpLNLu9FFqQ6" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 68%">2024</td>
    <td style="vertical-align: top; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; width: 4%">$</td>
    <td style="vertical-align: bottom; width: 24%; text-align: right">65,869</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zz7zWibfl9Cg" style="vertical-align: bottom; background-color: white">
    <td>2025</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">65,729</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zh5sEDXZveSa" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">64,674</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zmJwnFnhwN54" style="background-color: white">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">64,242</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zKXXXIq6HIb7" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">64,242</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zLHLDXaIUDv9" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">429,605</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zYPWgwFKa1jj" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">754,361</td></tr>
  </table>
<p id="xdx_8A1_znSzBPf6D04d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_853_z3yWxcUzGDOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zShXOqtPrub8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">INCOME TAXES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For interim income tax reporting, the Company estimates its annual effective
tax rate and applies it to fiscal year-to-date pretax loss, excluding unusual or infrequently occurring discrete items. Tax jurisdictions
with losses for which tax benefits cannot be realized are excluded. The Company reported an income tax expense of $<span id="xdx_90A_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20230101__20231231_zXmOncdOr4Rl" title="Income tax benefit::XDX::3967480"><span style="-sec-ix-hidden: xdx2ixbrl0506">4.0</span></span> million and income
tax benefit of $<span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20220101__20221231_zoh7fVjM73E2" title="Income tax benefit::XDX::-2014018"><span style="-sec-ix-hidden: xdx2ixbrl0508">2.0</span></span> million for the years ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We evaluate our deferred tax assets to determine if they are more likely
than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income Taxes.&#160; After considering
our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all available evidence,&#160; we
have recorded a valuation allowance of $<span id="xdx_905_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dm_c20231231_zq2OWt9v3MCf" title="Valuation allowance">6.0 million</span> against our net deferred tax assets during the year ended December 31, 2023.&#160;
As we continue to assess the realizability of our deferred tax assets, reported pretax income and new evidence may result in a partial
or full reduction of the valuation allowance in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recurring items cause our effective tax rate to differ from the U.S. federal
statutory rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zpGbrAiKG3qc" title="Statutory rate">21</span>%, including U.S. federal R&amp;D credits, U.S. state tax rates, and stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Beginning in 2022, certain research and development costs are required
to be capitalized and amortized over a five-year period under the Tax Cuts and Jobs Act enacted in December 2017. This change will impact
the expected U.S. federal and state income tax expense and cash taxes to be paid for our fiscal 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company files income tax returns in the U.S. federal jurisdiction and
in various state jurisdictions. Income tax returns for years prior to fiscal 2019 are no longer subject to examination by tax authorities.</p>

<p id="xdx_853_zG2DqhxrMm5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgArdpYLNeI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zmoMv5cFWNEa">PROPERTY AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zR7gwH0bQ3Oe" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0516">3</span></span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zl14xJrx2uqc" title="::XDX::P10Y0M0D"><span style="-sec-ix-hidden: xdx2ixbrl0517">10</span></span> years for furniture
and office equipment, <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zBTCv7TEdGFd" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0518">3</span></span>-<span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zPML4eKFwqsd" title="::XDX::P12Y"><span style="-sec-ix-hidden: xdx2ixbrl0519">12</span></span> years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2023
and 2022 was $<span id="xdx_90F_ecustom--DepreciationAndAmortizationPropertyAndEquipment_c20230101__20231231_ziA6P2npF5v" title="Depreciation and amortization, property and equipment">805,921</span> and $<span id="xdx_90D_ecustom--DepreciationAndAmortizationPropertyAndEquipment_c20220101__20221231_zNRekgHPDcna" title="Depreciation and amortization, property and equipment">524,994</span>, respectively.</p>

<p id="xdx_853_zHfZIY2IkFT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zQ2zPvVkCaM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_861_zwjIzp2ufOF2">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock options outside
of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing
model. &#160;All options are charged against income at their fair value. &#160;The entire compensation expense of the award is recognized
over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares of stock granted for director fees under the non-employee director
compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted stock awards under its omnibus equity incentive
plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at the fair market value of
the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization thresholds
were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of other restricted stock awards
were estimated on the date of grant at the current stock price. We recognize restricted stock expense using the straight-line attribution
method over the requisite service period and account for forfeitures as they occur.</p>

<p id="xdx_853_zL0dqwu47sgb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_z1hUayy5s3X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_zaZI5CgC3olc">NET LOSS PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic net loss per common share is calculated by dividing net loss by the
weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net
loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company&#8217;s potentially
dilutive common shares are those that result from diluted common stock options and unvested restricted stock awards. The calculation of
diluted loss per share excluded stock options of <span id="xdx_90C_ecustom--AntiDilutiveStockOptions_pid_uShares_c20230101__20231231_zziGeBajGgUk" title="Anti-dilutive stock options">12,335</span> and <span id="xdx_904_ecustom--AntiDilutiveStockOptions_pid_dxL_uShares_c20220101__20221231_z5tD5FVp81p4" title="Anti-dilutive stock options::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0531">zero</span></span> in weighted-average shares for each of the years ended
December 31, 2023 and 2022, respectively, as their effect was anti-dilutive as a result of the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The calculation of diluted loss per share excluded performance-based restricted
stock and time-based restricted stock of <span id="xdx_904_ecustom--AntiDilutiveRestrictedStock_pid_uShares_c20230101__20231231_z8W4A0kYm7m6" title="Anti-dilutive restricted stock">904,496</span> and <span id="xdx_905_ecustom--AntiDilutiveRestrictedStock_pid_uShares_c20220101__20221231_zYsUlyhb8ALh" title="Anti-dilutive restricted stock">950,000</span> in weighted-average shares for each of the years ended December
31, 2023 and 2022, respectively, as their effect was anti-dilutive as a result of the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89C_ecustom--ScheduleOfSecuritiesTextBlock_zCAYv9Hd6LWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zEUvOauTXLBj">The following securities were not included in the computation of diluted
shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td id="xdx_498_20230101__20231231_zvTejDmQtR0c" style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td id="xdx_49D_20220101__20221231_z5ouRlWwl5gg" style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockOptions_pid_uShares_ztWXeR7pq7rd" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Stock options</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td style="vertical-align: bottom; text-align: right">12,335</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8212;</span></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_402_ecustom--RestrictedStockUnits_pid_uShares_zB7X80sRCGLl" style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Restricted stock</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">904,496</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">950,000</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_uShares_zcuV9Hh5wmM3" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">916,831</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">950,000</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zDqCtW4WYiEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNaXvfvueqkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B3_zcL7Io9SHgCd" style="display: none; visibility: hidden">Schedule of net income per common share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_ztU38QDRs1il" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_z5NhXHxgA985" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 69%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zGYjl5DfEOx4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(13,741,062</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(8,661,142</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zbX0ho5sfmT8" style="vertical-align: bottom; background-color: white">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo1PThvKWyg8" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Basic weighted average shares outstanding</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,601,346</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,002,074</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zqRV9gTQ3b8f" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.2in">Dilutive effect of outstanding stock options and unvested restricted stock</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziVtziaxQivj" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Diluted weighted average shares outstanding</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,601,346</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,020,074</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zLKU6CbTJXmg" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zvEIXmwPQtFk" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.30</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zgo7lA10NY5a" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.30</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
<p id="xdx_8AD_zUiOb4deb5ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Therefore, diluted weighted average number of shares outstanding and diluted
net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the years ended December
31, 2023 and 2022. See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221; for further detail.</p>

<p id="xdx_853_znY2BDTAcEPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_eus-gaap--UseOfEstimates_zNFNFYuQAZI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_zjJSsksRpBe5">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.</p>

<p id="xdx_853_znUV9ope84m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zOtO34xIQuE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_861_zzayRpQjOfy5">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting
Standards Update (&#8220;ASU&#8221;) No. 2014-09, <i>Revenue from Contracts with Customers</i>, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers and are included
in Product Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#8217;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#8217;s revenue recognition criteria described above. As of December 31, 2023, the Company has recognized
a contract asset of zero which is included in other accounts receivable in the accompanying balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_898_ecustom--ScheduleOfNetRevenuesByGeography_zgOk39Kpl3P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B4_zzLqgxExCEz2">The following table summarizes net revenues by geography for the years
ended December 31, 2023 and 2022:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zlJvfdkf0eva" style="text-align: right" title="Net Revenue">23,676,039</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zxd3On1nZsl7" style="text-align: right" title="Net Revenue">23,586,254</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z9WJMe07cdac" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,841,627</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zWLgskHZsh1h" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,309,783</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20230101__20231231_zjh9E8vQnmA2" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">28,517,666</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20220101__20221231_zuQ3cmZ8ak6a" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">27,896,037</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<p id="xdx_8A5_zJHH3WsFODQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_853_zRYrPM1r0gkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zutAeD5nwoZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zVguakYwV0S9">LEASES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#8220;NOTE 5 <b>&#8212; </b>LEASES&#8221; for further detail.</p>

<p id="xdx_853_znNPxFFGSCwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBQ7gh9jSITg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zCzypJsogS6i">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company adopted this standard on January 1, 2023, and it did not have a
significant impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

<p id="xdx_853_zdycsE4UWRe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zfpebkPQILed" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zqY8Tw8pNwb9">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2023.</p>

<p id="xdx_853_zS0TbtpWyY9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_842_ecustom--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc_zNaHnezOrga1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">IMPAIRMENT OF LONG-LIVED ASSETS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2023.</p>

<p id="xdx_853_znYMkSVW9tHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295548020640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zAZN0q0lV7g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_829_zMF3gAEHYfw">INVENTORY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zX61zdvEhwd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_z3jmSyQGRb25">Inventory consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Raw materials and work-in-process</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20231231_ziUbnwr5bKH9" style="text-align: right" title="Raw materials and work-in-process">1,869,356</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20221231_z18xyOI1Xrli" style="text-align: right" title="Raw materials and work-in-process">3,853,034</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Finished goods</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20231231_zLAfc6m67f0c" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">1,862,525</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20221231_zURHm1TjbASa" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">2,611,951</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;&#160;&#160;Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--InventoryGross_iI_c20231231_zWyuTK3Nl3Yl" style="text-align: right" title="Inventory, Gross">3,731,881</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryGross_iI_c20221231_zEljUY9NZ9Il" style="text-align: right" title="Inventory, Gross">6,464,985</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Less: reserve for obsolete inventory</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryValuationReserves_iNI_di_c20231231_zThgvIKcoY1j" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory">(250,580</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--InventoryValuationReserves_iNI_di_c20221231_zm7BmshG5f29" style="border-bottom: black 1pt solid; text-align: right">(60,118</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Inventory, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--InventoryNet_iI_c20231231_zI0bFlNRqbFb" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory">3,481,301</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--InventoryNet_iI_c20221231_zHXuNssReZHh" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory">6,404,867</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A4_zUuKdZTb19Wc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295635730096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z6ZnPVaegca" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8212; <span id="xdx_825_zm2p7COcH577">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWkScz5mmSN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zqsL5fj7Yt7d">Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zjYZmReSfphf" style="text-align: right">1,412,164</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z7IveEZuNol4" style="text-align: right">1,456,745</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6rdrelA7794" style="text-align: right">1,953,653</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWLszAyseh2g" style="text-align: right">2,413,820</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zGAhw6PPKAhj" style="border-bottom: black 1pt solid; text-align: right">3,193,113</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zQjvAVCRM5Y3" style="border-bottom: black 1pt solid; text-align: right">2,810,813</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zCiLDQVZ8Pe5" style="text-align: right" title="Total property and equipment">6,558,930</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_ziqRGyjJPcvj" style="text-align: right" title="Total property and equipment">6,681,378</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zSoBNiLqIM11" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,721,273</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_znwnqS9d6snk" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,794,403</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_z6QzVcp39uX4" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">3,837,657</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zarNcWLbaTlg" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">3,886,975</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AE_zhRm7KyvCy03" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295543512480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z1NaC8021y5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 &#8212; <span id="xdx_823_zZTNnGoCxnUa">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has three equity incentive plans: the 2015 Stock Option Plan,
as amended (the &#8220;2015 Plan&#8221;), the 2021 Omnibus Equity Incentive Plan (the &#8220;2021 Plan&#8221;), and the Non-Employee Director
Compensation Plan. The Company has also issued restricted stock and stock options as employment inducement awards to its Chief Executive
Officer and Chief Commercial Officer, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The 2015 plan provides for the grant of up to <span id="xdx_904_ecustom--StockBasedCompensationSharesIssuable_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zT0QROv0DeC4" title="Stock issuable under plan (in shares)">6,000,000</span> incentive stock
options and nonqualified stock options. As of December 31, 2023, there were options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutivesEmployeesConsultantsMember_zUB55jKbf5gf" title="Common stock outstanding">2,436,250</span> shares of the Company&#8217;s
common stock outstanding to certain executives, key employees and consultants under the 2015 Plan, of which <span id="xdx_906_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutivesEmployeesConsultantsMember_z0WHvqJLij82" title="Shares issued under plan">85,000</span> were issued during
the year ended December 31, 2023 and <span id="xdx_900_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutivesEmployeesConsultantsMember_zo7SftfeuDc" title="Shares issued under plan">445,000</span> were issued during the year ended December 31, 2022. Additional options may be issued under
the 2015 Plan as outstanding options are forfeited. As of December 31, 2023, there were <span id="xdx_908_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zwSJfCutYt32" title="Shares available for issuance">2,724,250</span> shares reserved for outstanding awards
and available for issuance under the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The 2021 Plan provides for the grant of up to <span id="xdx_900_ecustom--StockBasedCompensationSharesIssuable_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBlr2lwki6B1" title="Stock issuable under plan (in shares)">1,000,000</span> incentive stock
options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units and/or stock appreciation rights to
employees, consultants and directors. During the years ended December 31, 2023 and 2022, there were awards with respect to <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zHwCbWgbCZHj" title="Issuance of common stock awards (in shares)">21,100</span> and
<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMobm31jjFc4" title="Issuance of common stock awards (in shares)">97,100</span> shares of common stock, respectively, issued under the 2021 Plan. Additional awards may be issued under the 2021 Plan as outstanding
awards are forfeited. As of December 31, 2023, there were <span id="xdx_90D_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLsYA3sXInul" title="Shares available for issuance">822,142</span> shares reserved for outstanding awards and available for issuance under
the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Each non-employee director of the Company (other than the Chairman of the
Board) is eligible to receive $<span id="xdx_907_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zzU90Xag2hN5" title="Nonemployee services transaction cost">110,000</span> annually, <span id="xdx_90E_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zBJCRRoZx3Sd" title="Share-based goods and non-employee services transaction">to be paid quarterly $12,500 in cash and $15,000 in common stock.</span> &#160;The Chairman
of the Board is eligible to receive $<span id="xdx_905_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20230101__20231231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zbtLZW3tBcua" title="Nonemployee services transaction cost">140,000</span> annually, <span id="xdx_909_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20230101__20231231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zrsn21IWhGT5" title="Share-based goods and non-employee services transaction">to be paid quarterly $12,500 in cash and $22,500 in common stock.</span> From May 18,
2021 to May 6, 2022, non-employee director compensation was paid pursuant to the 2021 Plan. Since May 6, 2022, non-employee director compensation
has been paid pursuant to the Non-Employee Director Compensation Plan. All payments were and are pro-rated for partial service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The per share weighted average fair value of stock options granted during
the year ended December 31, 2023 and December 31, 2022 was $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zMtzRLd4mVTb" title="Per share weighted average fair value of stock options granted">1.84</span> and $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zkRmBYMMMtg3" title="Per share weighted average fair value of stock options granted">1.98</span>, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
year ended December 31, 2023 and December 31, 2022. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued. We have recognized tax benefits associated with
stock-based compensation of $<span id="xdx_903_ecustom--TaxBenefitFromStockBasedCompensation_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zPdNFe7dVFp8" title="Tax benefit from stock-based compensation">256,315</span> and $<span id="xdx_900_ecustom--TaxBenefitFromStockBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zIRnF23Rv2z2" title="Tax benefit from stock-based compensation">231,341</span> for the year ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Time Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zNNM5iwpmL2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the activities for our stock options with
time based vesting for the years ended December 31, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8B2_ziuflerqMOHi" style="display: none; visibility: hidden">Schedule of time based stock options</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 44%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zimUbs6WZcF6" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5YA1TzdK49c" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z2vcbNA95U5k" title="Expected volatility">51.9</span>% - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zwZ6FEgiJBCk" title="Expected volatility">61.3</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zig3jesCAfTj" title="Expected volatility">65.29</span>% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zNyFUhbYt9oh" title="Expected volatility">77.5</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zp3fRJqsu2x2" title="Weighted-average volatility">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zPgzCrXzqFOd" title="Weighted-average volatility">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zr6v1ZKIKVx5" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxYlkrjitIT" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z1jOmn5MPA17" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0707">10</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJPw7MTmiVhe" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0709">10</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z94OrWsBFtQ1" title="Risk-free rate">3.50</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_z2myhkGzx1s7" title="Risk-free rate">4.53</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zrlTY08nfwRf" title="Risk-free rate">1.81</span>% - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zaZdGXGs6nf2" title="Risk-free rate">4.02</span>%</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A7_zMZeEPBfEfkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3skaw4hoX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the time-based stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8BD_zoOm84bn8TLe" style="display: none; visibility: hidden">Schedule of status of time based stock options</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 54%">Outstanding at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoLlsLS6XsAh" style="width: 9%; text-align: right" title="Outstanding at beginning (in shares)">3,035,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zPSMutrubaIb" style="width: 9%; text-align: right" title="Outstanding at beginning">3.93</td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zXasPHkR3FDg" style="width: 9%; text-align: right" title="Outstanding at beginning (in shares)">3,672,500</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zkzXZZM8cv0c" style="width: 9%; text-align: right" title="Outstanding at beginning">3.42</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zjte071jhx2" style="text-align: right" title="Granted (in shares)">430,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z8sNdtWX97a5" style="text-align: right" title="Granted">2.66</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLIog2GcPmef" style="text-align: right" title="Granted (in shares)">920,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zsSlCgKCXM5j" style="text-align: right" title="Granted">2.62</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zHXx0yI8QvGd" style="text-align: right" title="Exercised (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoUfFM3QUx5d" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoW0l8NJRtB2" style="text-align: right" title="Exercised (in shares)">1,031,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z8g7ILueyDl7" style="text-align: right" title="Exercised">1.57</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zD9OhpaXZyH1" style="text-align: right" title="Forfeited (in shares)">208,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zOFlnx4XYOI3" style="text-align: right" title="Forfeited">5.45</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDhc90Lf6hag" style="text-align: right" title="Forfeited (in shares)">526,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdMkB7B1eYnf" style="text-align: right" title="Forfeited">2.73</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at December 31</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zkGQr6YVYqE9" style="text-align: right" title="Outstanding at ending (in shares)">3,256,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJQIAoa2Qxzd" style="text-align: right" title="Outstanding at ending">3.66</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDQ6iHbmxkTl" style="text-align: right" title="Outstanding at ending (in shares)">3,035,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMEXyyRdawhc" style="text-align: right" title="Outstanding at ending">3.93</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Options exercisable at December 31</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zWOHeaN7VNRe" style="text-align: right" title="Options exercisable (in shares)">1,458,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQGgYc11tSgi" style="text-align: right" title="Options exercisable">4.42</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5jwCQQwe2Xg" style="text-align: right" title="Options exercisable (in shares)">737,500</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zD00fFY3ETEd" style="text-align: right" title="Options exercisable">4.93</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZfHcarGtsB7" style="text-align: right" title="Weighted average fair value of options granted during the period">1.84</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJHZIM1njtld" style="text-align: right" title="Weighted average fair value of options granted during the period">1.99</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zh2JESU6bYW6" style="text-align: right" title="Stock-based compensation expense">1,940,720</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJErI9jW98fl" style="text-align: right" title="Stock-based compensation expense">2,083,397</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AC_zugjYjiqXz27" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense was $<span id="xdx_901_ecustom--StockBasedCompensationStockOptions_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zmqwQXtA5Ez9" title="Stock-based compensation expense">1,940,720</span> and $<span id="xdx_909_ecustom--StockBasedCompensationStockOptions_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zsAFaeFyrCs4" title="Stock-based compensation expense">2,083,397</span> for
the years ended December 31, 2023, and 2022, respectively. Net cash received from option exercises for the years ended December 31, 2023,
and 2022 was <span id="xdx_909_ecustom--CashReceivedFromOptionExercise_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMzzHm6IFemc" title="Cash received from option exercise::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0781">zero</span></span> and $<span id="xdx_900_ecustom--CashReceivedFromOptionExercise_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zk5E17xjVo1f" title="Cash received from option exercise">406,623</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The weighted-average grant-date fair value of options granted during the
years ended December 31, 2023, and 2022 was $<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_iI_dm_c20231231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zydFj7nRr8T" title="Weighted-average grant-date fair value options granted">0.8 million</span> and $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_iI_dm_c20221231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_z2AIsRS2c9R1" title="Weighted-average grant-date fair value options granted">1.8 million</span>, respectively. &#160;There were <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_do_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zJ6iy1rgrUy9" title="Number of options exercised">no</span> options exercised during
the year ended December 31,2023 and <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zMwVooYBO5B1" title="Number of options exercised">1,031,250</span> options exercised during the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_895_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_za2BNGCvvJj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to time- based stock
options outstanding at December 31, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8B9_zJbw7ma0vV06" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 29%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.18-$9.49</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zX5ktyylRsTc" style="text-align: right" title="Number outstanding">3,256,250</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zW5jUzrzHVGe" title="Weighted average remaining contractual life::XDX::P8Y3M19D"><span style="-sec-ix-hidden: xdx2ixbrl0797">8.3</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zj1nuAG2OW51" style="text-align: right" title="Weighted average exercise price">3.66</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z8blGC4c8V35" style="text-align: right" title="Number exercisable">1,458,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zqcISb4booHa" style="text-align: right" title="Weighted average exercise price">4.42</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A3_zxB7BceAd42b" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2023, there was $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zKWtJMB4iuPb" title="Total unrecognized compensation cost">3,145,616</span> of total unrecognized compensation
cost related to non-vested time- based stock options granted under the Company&#8217;s plans. &#160;That cost is expected to be recognized
over a weighted-average period of<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zqjj9fintAD" title="Weighted-average period::XDX::P46M"> <span style="-sec-ix-hidden: xdx2ixbrl0807">46</span></span> months. &#160;The total fair value of shares vested as of December 31, 2023, and December 31, 2022,
was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAFzJB4auBdf" title="Total fair value of shares vested">4,819,658</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zqA49jZqYHN4" title="Total fair value of shares vested">2,703,002</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Performance Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zhPAnldze47a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to an employment agreement entered into on November 6, 2023, with
the Company&#8217;s Chief Commercial Officer, and as an inducement to his employment, the Company issued a non-qualified option to purchase
200,000 shares of common stock that vest upon achievement of sales growth milestones.&#160;<span id="xdx_8BA_zEyadYIGzkfl">The following table summarizes the activities
for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Twelve Months Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 46%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z45l6opaHkll" style="width: 10%; text-align: right" title="Unvested at beginning (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zVkxT1f68a5f" style="width: 12%; text-align: right" title="Unvested at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0818">&#8212;</span></td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4NIoIoBzZ79" style="width: 10%; text-align: right" title="Unvested at beginning (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0820">&#8212;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zy16y6lOlPo5" style="width: 12%; text-align: right" title="Unvested at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0822">&#8212;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zzlB3j8bjNae" style="text-align: right" title="Granted (in shares)">200,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zt0o7PVVYzDl" style="text-align: right" title="Granted">1.48</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXRSLbJaIxN2" style="text-align: right" title="Granted (in shares)">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4M0NLYOVe3i" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4ipmvUnHem" style="text-align: right" title="Vested (in shares)">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zxDr35xjmIXc" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zFBn1TpWV5D5" style="text-align: right" title="Vested (in shares)">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zyVAZ3aERA02" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zxpEVIJUV7Oa" style="text-align: right" title="Forfeited/canceled (in shares)">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zkIABLM6hxxi" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zfwDAGdsgE73" style="text-align: right" title="Forfeited/canceled (in shares)">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z736TyxeOos3" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zlwqeSmQQTEc" style="text-align: right" title="Unvested at ending (in shares)">200,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zwFHpgH3Ya5a" style="text-align: right" title="Unvested at ending">1.48</td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zum9GSPaaM4j" style="text-align: right" title="Unvested at ending (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zKSPREQa99M3" style="text-align: right" title="Unvested at ending"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A4_zLOFqNNWsLv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2023, there was $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zvYjw3LvAWG2" title="Unrecognized compensation cost">176,345</span> of unrecognized compensation
cost related to unvested employee performance options. This amount is expected to be recognized over a weighted-average period of<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zJJj6XPZO0r1" title="Weighted-average period::XDX::P36M"> <span style="-sec-ix-hidden: xdx2ixbrl0858">36</span></span> months.
We have recognized tax benefits associated with restricted stock award compensation of $<span id="xdx_908_ecustom--TaxBenefitFromRestrictedStockCompensation_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXXCK7rQ3YG3" title="Tax benefit from restricted stock award compensation">1,137</span> and <span id="xdx_90E_ecustom--TaxBenefitFromRestrictedStockCompensation_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z28UFQnymdH6" title="Tax benefit from restricted stock compensation::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0862">zero</span></span> for the twelve months ended December
31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESTRICTED STOCK AWARDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_898_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zfunpkl4nUhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B6_zyDtnkQEFQkc">The following table summarizes the activities for our unvested restricted
stock awards for the twelve months ended December 31, 2023, and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Twelve Months Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 46%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhJVfbeXIxP8" style="width: 10%; text-align: right" title="Outstanding at beginning (in shares)">950,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBPjvkLNa7yj" style="width: 12%; text-align: right" title="Outstanding at beginning">3.04</td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z07BwXSgZmz6" style="width: 10%; text-align: right" title="Outstanding at beginning (in shares)">1,000,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zgeVGhrvxVX7" style="width: 12%; text-align: right" title="Outstanding at beginning">3.01</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3LAi9s9XCTe" style="text-align: right" title="Granted (in shares)">54,496</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zGzrTMrGQcXk" style="text-align: right" title="Granted">3.68</td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zbQfXLgHb5W1" style="text-align: right" title="Granted (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0878">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zllcecbW3drk" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0880">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXK55JfgMdHi" style="text-align: right" title="Vested (in shares)">100,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zvmqSZ98yUEd" style="text-align: right" title="Vested">3.31</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zl6HFN0Tc3rl" style="text-align: right" title="Vested (in shares)">50,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zlFjXfmwisW4" style="text-align: right" title="Vested">3.31</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zpKU0AmugtS5" style="text-align: right" title="Forfeited/canceled (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0890">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zTdUZszxmIkc" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0892">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z7wMYrP3Yz3c" style="text-align: right" title="Forfeited/canceled (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0894">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJEyiezOocf6" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0896">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z143DXigTUDe" style="text-align: right" title="Outstanding at ending (in shares)">904,496</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLfz9jPJh54f" style="text-align: right" title="Outstanding at ending">2.77</td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zq79WcillT5d" style="text-align: right" title="Outstanding at ending (in shares)">950,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zimyf8K4Ts39" style="text-align: right" title="Outstanding at ending">3.04</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AC_zjoX3RCTXjc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2023, there was $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zAFg7ENbg7Od" title="Unrecognized compensation cost">1,076,664</span> of unrecognized compensation
cost related to unvested employee restricted shares. This amount is expected to be recognized over a weighted-average period of 21 months.
We have recognized tax benefits associated with restricted stock award compensation of $<span id="xdx_90F_ecustom--TaxBenefitFromRestrictedStockCompensation_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zN1uwWnsezSg" title="Tax benefit from restricted stock compensation">79,326</span> and $<span id="xdx_90E_ecustom--TaxBenefitFromRestrictedStockCompensation_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zCLpMEWruJI4" title="Tax benefit from restricted stock compensation">101,419</span> for the twelve months ended
December 31, 2023 and 2022, respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295544331872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zGBiJgAYhFWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8212; <span id="xdx_821_ztigHibf5dbb">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;Our two operating leases have remaining lease terms of <span id="xdx_900_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zxwLY8V60Ktd" title="Operating lease remaining term::XDX::P8Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0914">8.6</span></span> years and <span id="xdx_906_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_z3rmYnhRglh6" title="Operating lease remaining term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0916">5</span></span> years, respectively. Our three
finance leases have remaining lease terms of <span id="xdx_90C_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zGoMWa0ih2Nj" title="Finance lease remaining term::XDX::P3Y4M24D"><span style="-sec-ix-hidden: xdx2ixbrl0918">3.4</span></span> years, <span id="xdx_90D_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zNLYlSx7evQ" title="Finance lease remaining term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0920">3</span></span> years, and <span id="xdx_906_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseThreeMember_zWmdu9M5xyWh" title="Finance lease remaining term::XDX::P4Y9M0D"><span style="-sec-ix-hidden: xdx2ixbrl0922">4.75</span></span> years, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At contract inception, we evaluate whether an arrangement is or contains
a lease for which we are the lessee (that is, arrangements which provide us with the right to control a physical asset for a period of
time). &#160;Operating leases are accounted for on the balance sheets with ROU assets being recognized in &#8220;Operating lease right-of-use
assets&#8221; and lease liabilities recognized in &#8220;Operating lease liability &#8211; current&#8221; and &#8220;Operating lease liability,
net of current portion.&#8221; Finance leases are accounted for on the balance sheets recognized in &#8220;Property and equipment, net&#8221;
and lease liabilities recognized in &#8220;Finance lease liability &#8211; current&#8221; and &#8220;Finance lease liability, net of current
portion.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating lease expenses are recognized on a straight-line basis over the
lease term. &#160;With respect to finance leases, amortization of the ROU asset is presented separately from interest expense related
to the finance lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have elected to combine lease and non-lease components for all lease
contracts where we are the lessee. &#160;Additionally, for arrangements with lease terms of 12 months or less, we do not recognize ROU
assets and lease liabilities and lease payments are recognized on a straight-line basis over the lease term with variable lease payments
recognized in the period in which the obligation is incurred. &#160;ROU assets are measured for impairment when a triggering event occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_znhwFvHPWxwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of lease expense were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BE_zDfk5fgcQbcj" style="display: none; visibility: hidden">Schedule of components of lease expenses</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 57%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_494_20230101__20231231_zKiB6cGbWRp4" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 3%; text-align: center">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_49D_20220101__20221231_zjAAY9T4ZDc9" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zaS1RlIt9pb9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">448,630</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">514,294</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zIdwXxVc5UYa" style="vertical-align: bottom; background-color: white">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">130,483</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">131,490</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zdOriZH6Oifk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">579,113</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">645,784</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zkMAAx5sE1fi" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zMeYf5mxIzA9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">110,566</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">50,895</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zdq5GiOb9S3a" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,343</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,393</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zE4V3Y4Eq1ec" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">135,909</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">56,288</td>
    <td>&#160;</td></tr>
  </table>

<p id="xdx_8AD_z5LFep38Wfsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89A_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zselWVrMP4bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental cash flow information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zZ1w5yy5QMH1" style="display: none; visibility: hidden">Schedule of cash flow information related to leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 72%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td id="xdx_495_20230101__20231231_zzRbf8rXOXUa" style="width: 11%; text-align: center">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td id="xdx_491_20220101__20221231_zhS65FBULqld" style="width: 11%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.45pt; text-indent: -9.45pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zdZi16PauUj1" style="vertical-align: bottom; background-color: white">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">464,104</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">247,504</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zUeDqJG34f1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">125,259</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">57,243</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A5_zZC3ZIqdAXid" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p id="xdx_897_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z2E5mzBdPO79" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental balance sheet information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zc7YbtpSNOu6" style="display: none; visibility: hidden">Schedule of balance sheet information related to leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zB62PhKNaONd" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zKOJjTjXRV29" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zl9jr5wwyhvf" style="vertical-align: bottom; background-color: white">
    <td style="width: 59%; padding-left: 9.1pt; text-indent: -9.1pt"><b>Operating Leases</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 15%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 16%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zgg4N1jXmim4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,514,055</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,786,545</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_zOkwuHUya5Nd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">368,313</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">345,834</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zNNxsHNUxT1g" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,336,300</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,653,257</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_zr1ggNoOPBwl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,704,613</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,999,091</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_z1yayVn0aEU5" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_zZ7rpgB4edL4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">577,929</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">544,468</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_zgo6WFpvwXi3" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(161,461</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(50,895</td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zHdscoHEbKW4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">416,468</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">493,573</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zkwmxWl3bXMj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">109,540</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">98,335</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zTfOwEsNtFF6" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">316,623</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">394,283</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zSEELGZNZst8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">426,163</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">492,618</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 58%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td style="vertical-align: top; width: 1%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_zZf4F5Q30GP4" title="Operating leases term::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0997">6.9</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20221231_zcYRctEfugE8" title="::XDX::P9Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0998">9.7</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_zeaQD2VStw4d" title="Finance leases  term::XDX::P3Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl1000">3.7</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_900_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20221231_zsvcgphj12G8" title="::XDX::P4Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl1001">4.6 </span></span>Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zT9ehFPKl5pf" title="Operating leases discount rate">5.76</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zGaketmYUWu3">4.00</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zFhp9PN6K93e" title="Finance leases discount rate">6.19</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_906_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20221231_z2Q80shkk67j">4.25</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<p id="xdx_8AE_zLVASEBRsQil" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z17mlvILdsol" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Maturities of lease liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8B7_zUFFKPAqsp18" style="display: none; visibility: hidden">Schedule of maturities of lease liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 57%">2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zQcC8joE0WEi" style="width: 18%; text-align: right" title="2024 - Operating Leases">512,055</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zJd3hfl0udD" style="width: 18%; text-align: right" title="2024 - Finance Leases">131,437</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zXUdyqsuMf2c" style="vertical-align: bottom; text-align: right" title="2025 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zVmq6vyxjuW4" style="vertical-align: bottom; text-align: right" title="2025 - Finance Leases">131,437</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zRyIIkYxIrb" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zwmZ6ay8nu6i" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases">131,437</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zvkcp4xvrMuj" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zo0pWx6vMXck" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases">74,194</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20231231_zPLHgDfCcVjl" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20231231_zyvqrNESrjI6" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases">6,181</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20231231_zxlaI2rrxQ8e" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases">1,832,557</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20231231_zzgiBFk0TZE9" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_986_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20231231_zpU0MdldqvZ6" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases">4,392,832</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_987_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20231231_zJwCtKSR541j" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases">474,686</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 18.8pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20231231_zKdtxCiyRnU" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases">(688,220</td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20231231_zzQ0Zerpow2b" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases">(48,523</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20231231_zwvCLHDBLtte" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases">3,704,613</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_986_eus-gaap--FinanceLeaseLiability_iI_c20231231_zkxSLnpFa6A" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases">426,163</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<p id="xdx_8AF_znRQ2nVEkIP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//840/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295635730096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FEDERAL AND STATE INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">FEDERAL AND STATE INCOME TAXES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zkUXaGaEBiL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8212; <span id="xdx_821_zRi2M8gtiuVk">FEDERAL AND STATE INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJTmOBimS5r" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_zxRW4mZ3lUN2" style="display: none; visibility: hidden">Schedule of provision for income taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zHctlo41dmwi" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zlzqc0OUWIsk" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z2yKTLcu8wf7" style="vertical-align: bottom; background-color: white">
    <td>State income tax:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_z51hzqwRstWb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 51%; padding-left: 21.8pt">Current, net of refund</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">$</td>
    <td style="width: 19%; text-align: right">0</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 2%">$</td>
    <td style="width: 19%; text-align: right">0</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z46egG0kC9ga" style="vertical-align: bottom; background-color: white">
    <td>Federal income tax:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zSX11M5F9p13" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Deferred</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,035,297</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,014,018</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_zu7w9rb70Pl9" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 21.8pt">Current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WriteoffOfDeferredTaxAsset_zK8xrqvwSSDk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Write-off of deferred tax asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(6,002,777</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20230101__20231231_ztAptpNmii0a" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">(3,967,480</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98B_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zgxeqZGjwYSk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">2,014,018</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<p id="xdx_8A0_zYsVoTGoj5ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zNPI1xPbzeml" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The reconciliation of income taxes shown in the financial statements and
amounts computed by applying the Federal expected tax rate of 21% for year 2023 and 2022 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B8_zg34NCCUtSid" style="display: none; visibility: hidden">Schedule of reconciliation of income taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_zO2ZcN6jHd09" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zbJYaSwTn3Z1" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_zYAwaTqqPUS6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 60%">Loss before taxes</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; width: 1%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 16%; text-align: right">(9,773,582</td>
    <td style="border-bottom: white 2.25pt double; width: 4%">)</td>
    <td style="border-bottom: black 2.25pt double; width: 1%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 16%; text-align: right">(10,675,160</td>
    <td style="border-bottom: white 2.25pt double; width: 1%">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zbSzbna7zBt7" style="vertical-align: bottom; background-color: white">
    <td>Income taxes computed at the federal statutory rate</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,052,452</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,241,784</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_z2ktpkq5KsR8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>State income and franchise tax</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1082">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zSRYt6WqZjI5" style="vertical-align: bottom; background-color: white">
    <td>Permanent differences and other</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(17,155</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(227,766</td>
    <td>)</td></tr>
  <tr id="xdx_40D_ecustom--WriteoffOfDeferredTaxAsset_zvWKIs9VFZeb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Write-off of deferred tax asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(6,002,777</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1088">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20230101__20231231_ztoiOvHdE2D8" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">(3,967,480</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zWeBKg45pzwj" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">2,014,018</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<p id="xdx_8A0_zhXaeMsAZSTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKFGMN3Kcpyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The significant components of deferred income tax assets, net are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8BC_z4sTd2qvGpIb" style="display: none; visibility: hidden">Schedule of components of deferred tax assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zR7qybW8bxCl" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zcdy3sOF9V5b" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredCompensationPlanAssets_iI_zrqwDl1ZBlZi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 60%">Deferred compensation cost</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 16%; text-align: right">1,047,608</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 16%; text-align: right">557,931</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DepreciationDepletionAndAmortization1_iI_zVkK6CbK4oBf" style="vertical-align: bottom; background-color: white">
    <td>Depreciation and amortization</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(913,671</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(624,184</td>
    <td>)</td></tr>
  <tr id="xdx_403_ecustom--RdCredit_z3DOhi3YsAmc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>R&amp;D credit</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,030</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,030</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--Nol_zHaKxqsnpMX4" style="vertical-align: bottom; background-color: white">
    <td>NOL</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">3,566,630</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,956,685</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AllowanceForDoubtfulOtherReceivables1Current_zsM4g8zG4Dq2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Allowance for bad debts and other</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,160,180</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">935,018</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--AllowanceForNonRealizationOfDeferredTaxAsset_iI_zxkfYdFg8anb" style="vertical-align: bottom; background-color: white">
    <td>Allowance for non-realization of deferred tax asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(6,002,777</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_zRu5Hm81Eft8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Deferred income tax assets, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">&#8212;</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,967,480</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<p id="xdx_8A0_zvFWfXmIMEMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our U.S. federal and state income tax returns remain open to examination
for the tax years 2020 through 2022.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295547671040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">MAJOR CUSTOMERS</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--ConcentrationRiskDisclosureTextBlock_zbdQMjwffKEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8212; <span id="xdx_82F_zgajdSoN0Jb">MAJOR CUSTOMERS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For the years ended December 31, 2023 and December 31, 2022, approximately
<span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zue1I2mINIcb" title="Concentration risk, percentage">66</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zWqBZLOe73Kj" title="Concentration risk, percentage">64</span>%, respectively, of the Company&#8217;s net product revenues were derived from three major customers that are distributors.
&#160;As of December 31, 2023 and December 31, 2022, accounts receivable due from the three major customers was $<span id="xdx_906_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20231231_zXl35KrkL7e9" title="Account eceivable from customers">2.6 million</span> and $<span id="xdx_90C_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20221231_zpRC4ulyR6r6" title="Account eceivable from customers">2.2
million</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The largest customer in both years is a domestic medical products and supplies
distributor. &#160;Although a number of larger infusion customers have elected to consolidate their purchases through one or more distributors
in recent years, we continue to maintain strong direct relationships with them. &#160;We do not believe that their continued purchase
of FREEDOM System products and related supplies is contingent upon the distributor.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295547599024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zblDifXjcZ2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8212; <span id="xdx_82C_zzipdBmphPsa">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OTHER</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#8220;Command&#8221;), pursuant to which Command has agreed to manufacture and supply
the Company&#8217;s subassemblies, needle sets and tubing products pursuant to the Company&#8217;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#8220;Effective
Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295543508944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">EMPLOYEE BENEFITS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zNb2Zq5vbV14" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 &#8212; <span id="xdx_821_zO312PiFznTd">EMPLOYEE BENEFITS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We provide a safe harbor 401(k) plan for our employees that allows for
employee elective contributions, Company matching contributions and discretionary profit-sharing contributions. &#160;Employee elective
contributions are funded through voluntary payroll deductions. &#160;<span id="xdx_900_ecustom--DescriptionOfMatchingContribution_c20230101__20231231_zrf827PcORCk" title="Description of matching contribution">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#8217;s contribution, not to exceed 3% of employee&#8217;s compensation plus 50% of employee&#8217;s pay
contributed between 3% and 5% of employee&#8217;s compensation.</span> &#160;Company matching expense for the years ended December 31, 2023 and
December 31, 2022 was $<span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zxurb7Sk0cua" title="Matching expense">227,447</span> and $<span id="xdx_902_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zJcu9TGniUsg" title="Matching expense">214,931</span>, respectively. &#160;The Company has not provided for a discretionary profit-sharing contribution.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295547599024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT OBLIGATIONS</a></td>
<td class="text"><p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zugbuc7j3H03" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 &#8212; <span id="xdx_829_zgKwPlf1lqGe">DEBT OBLIGATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On July 28, 2023, the Company entered into a commercial insurance premium
finance and security agreement with AON Premium Finance, LLC in the aggregate principal amount of $<span id="xdx_906_eus-gaap--NotesPayable_iI_dm_c20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z1pMWEqXixPi" title="Notes payable">0.57 million</span> bearing an annual percentage
rate of <span id="xdx_90B_ecustom--NotePayableTerms_pid_dp_uPure_c20230726__20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zHqHEfQG4iq2" title="Note payable terms">9.5</span>%, to finance its insurance premiums. <span id="xdx_90C_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_c20230726__20230728_zsJcE1SMlza8" title="Description of the frequency of periodic payments">Monthly payments are due on the first of each month beginning August 1, 2023 through
June 1, 2024.</span> The balance of AON note was $<span id="xdx_903_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember_zwelvbDfXZ6k" title="Balance of AON note">314,344</span> as of December 31, 2023 and $<span id="xdx_90A_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20221231__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember_zxU9rAK8pzra" title="Balance of AON note">433,295</span> as of December 31, 2022, respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295543440448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zezBPiQjjKuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 11 &#8212; <span id="xdx_829_zY5BsxqjBb3i">SUBSEQUENT EVENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 8, 2024, the Company entered into a loan and security agreement
with HSBC Ventures USA Inc., as lender, providing for a $<span id="xdx_904_eus-gaap--InvestmentOwnedAtFairValue_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zur2qbkjrTVj" title="Loan provided, as lender">5,000,000</span> revolving credit facility and a $<span id="xdx_903_eus-gaap--InvestmentOwnedAtFairValue_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zyuGQCjxXys5">5,000,000</span> term loan facility. Borrowings
are secured by a first-priority lien on substantially all of the assets of the Company, subject to customary exceptions. The revolving
credit facility matures on December 31, 2025 and the term loan matures on December 1, 2028. Our former revolving credit facility with
Key Bank expired during the quarter ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Borrowings under the revolving credit facility will bear interest at the
greater of Prime or <span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_uPure_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zCTBf0SQorwb" title="Inteest rate on borrowings">6.50</span>%, payable in arrears on a monthly basis and at maturity. <span id="xdx_90F_eus-gaap--SubsequentEventDescription_c20240306__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLquczIIIEW7" title="Description of subsequent event">Borrowings under the term loan will bear interest at
the greater of Prime minus 0.50% or 6.50% and will be interest-only through December 31, 2025, followed by 24 equal monthly payments of
principal plus interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The loan and security agreement contains customary affirmative covenants
a financial maintenance covenant that requires the Company to maintain a minimum Adjusted Quick Ratio (defined as the ratio of the Company&#8217;s
(i) unrestricted and unencumbered cash and cash equivalents maintained with the lender and its affiliates, plus eligible accounts receivable,
to (ii) current liabilities) of not less than 1.50 to 1.00 tested on the last day of each month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There are no outstanding borrowings under the facility as of March 13,
2024.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295655078784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p id="xdx_843_eus-gaap--NatureOfOperations_zRRRz9m674vk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_zrYF4NWrhPF6">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) develops, manufactures and commercializes innovative and
patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United
States Food and Drug Administration (the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system
management. &#160;The Company operates as <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxH_uN_c20230101__20231231_zZ9xrjClTPk7" title="Number of segments::XDX::1">one</span> segment.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbn4X8lTGPme" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_z3Y0F1FhUOdb">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We prepare our financial statements and accompanying notes in accordance
with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). &#160;Certain prior year amounts have
been reclassified to conform to the current year presentation in our Financial Statements.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z2QYCi9sxaV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_zTqFTpDCew02">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For purposes of the statements of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company has historically held
cash balances in excess of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zAWPnCTIiF41" title="FDIC cash insurance limit">250,000</span> at its primary commercial bank, which exceeds FDIC insurance limits. To reduce the risk of uninsured
deposits, the Company entered an insured cash sweep program with KeyBank during the second quarter of 2023 to automatically invest its
uninsured bank cash balances over $250,000 into FDIC insured banks so there is no more than $250,000 maintained at any one bank. Further,
as of December 31, 2023 the Company had invested $<span id="xdx_90C_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20230101__20231231_zv5GLwAzoGZ" title="Investment securities treasury bill">10.2 million</span> in a US Treasury bill that matures every 90 days.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zLy0eLjaRDX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_860_z0sXNcja7QFh">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zITQ163r6qLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zqyfSbinHex6">INTANGIBLE ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_z6RzZC0sqY6k" title="Estimated useful lives::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0480">6</span></span> to <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zfnkxoE5vxd9" title="Estimated useful lives::XDX::P20Y"><span style="-sec-ix-hidden: xdx2ixbrl0482">20</span></span> years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2023 and 2022 was $<span id="xdx_903_ecustom--AmortizationOfIntangibleAssets1_c20230101__20231231_zXukqMc8c7Hg" title="Amortization expense of intangible assets">64,469</span> and
$<span id="xdx_90C_ecustom--AmortizationOfIntangibleAssets1_c20220101__20221231_zgUYqRRQcSW3">62,143</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zksHIEC1OdYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zOrGNsW3BTte">The estimated amortization expense for the succeeding years for the intangible
assets is approximately:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_494_20231231_zDrzIiBttqZ5" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zpLNLu9FFqQ6" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 68%">2024</td>
    <td style="vertical-align: top; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; width: 4%">$</td>
    <td style="vertical-align: bottom; width: 24%; text-align: right">65,869</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zz7zWibfl9Cg" style="vertical-align: bottom; background-color: white">
    <td>2025</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">65,729</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zh5sEDXZveSa" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">64,674</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zmJwnFnhwN54" style="background-color: white">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">64,242</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zKXXXIq6HIb7" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">64,242</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zLHLDXaIUDv9" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">429,605</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zYPWgwFKa1jj" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">754,361</td></tr>
  </table>
<p id="xdx_8A1_znSzBPf6D04d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zShXOqtPrub8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">INCOME TAXES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For interim income tax reporting, the Company estimates its annual effective
tax rate and applies it to fiscal year-to-date pretax loss, excluding unusual or infrequently occurring discrete items. Tax jurisdictions
with losses for which tax benefits cannot be realized are excluded. The Company reported an income tax expense of $<span id="xdx_90A_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20230101__20231231_zXmOncdOr4Rl" title="Income tax benefit::XDX::3967480"><span style="-sec-ix-hidden: xdx2ixbrl0506">4.0</span></span> million and income
tax benefit of $<span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20220101__20221231_zoh7fVjM73E2" title="Income tax benefit::XDX::-2014018"><span style="-sec-ix-hidden: xdx2ixbrl0508">2.0</span></span> million for the years ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We evaluate our deferred tax assets to determine if they are more likely
than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income Taxes.&#160; After considering
our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all available evidence,&#160; we
have recorded a valuation allowance of $<span id="xdx_905_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dm_c20231231_zq2OWt9v3MCf" title="Valuation allowance">6.0 million</span> against our net deferred tax assets during the year ended December 31, 2023.&#160;
As we continue to assess the realizability of our deferred tax assets, reported pretax income and new evidence may result in a partial
or full reduction of the valuation allowance in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recurring items cause our effective tax rate to differ from the U.S. federal
statutory rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zpGbrAiKG3qc" title="Statutory rate">21</span>%, including U.S. federal R&amp;D credits, U.S. state tax rates, and stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Beginning in 2022, certain research and development costs are required
to be capitalized and amortized over a five-year period under the Tax Cuts and Jobs Act enacted in December 2017. This change will impact
the expected U.S. federal and state income tax expense and cash taxes to be paid for our fiscal 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company files income tax returns in the U.S. federal jurisdiction and
in various state jurisdictions. Income tax returns for years prior to fiscal 2019 are no longer subject to examination by tax authorities.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgArdpYLNeI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zmoMv5cFWNEa">PROPERTY AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zR7gwH0bQ3Oe" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0516">3</span></span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zl14xJrx2uqc" title="::XDX::P10Y0M0D"><span style="-sec-ix-hidden: xdx2ixbrl0517">10</span></span> years for furniture
and office equipment, <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zBTCv7TEdGFd" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0518">3</span></span>-<span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zPML4eKFwqsd" title="::XDX::P12Y"><span style="-sec-ix-hidden: xdx2ixbrl0519">12</span></span> years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2023
and 2022 was $<span id="xdx_90F_ecustom--DepreciationAndAmortizationPropertyAndEquipment_c20230101__20231231_ziA6P2npF5v" title="Depreciation and amortization, property and equipment">805,921</span> and $<span id="xdx_90D_ecustom--DepreciationAndAmortizationPropertyAndEquipment_c20220101__20221231_zNRekgHPDcna" title="Depreciation and amortization, property and equipment">524,994</span>, respectively.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zQ2zPvVkCaM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_861_zwjIzp2ufOF2">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock options outside
of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing
model. &#160;All options are charged against income at their fair value. &#160;The entire compensation expense of the award is recognized
over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares of stock granted for director fees under the non-employee director
compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted stock awards under its omnibus equity incentive
plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at the fair market value of
the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization thresholds
were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of other restricted stock awards
were estimated on the date of grant at the current stock price. We recognize restricted stock expense using the straight-line attribution
method over the requisite service period and account for forfeitures as they occur.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_z1hUayy5s3X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_zaZI5CgC3olc">NET LOSS PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic net loss per common share is calculated by dividing net loss by the
weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net
loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company&#8217;s potentially
dilutive common shares are those that result from diluted common stock options and unvested restricted stock awards. The calculation of
diluted loss per share excluded stock options of <span id="xdx_90C_ecustom--AntiDilutiveStockOptions_pid_uShares_c20230101__20231231_zziGeBajGgUk" title="Anti-dilutive stock options">12,335</span> and <span id="xdx_904_ecustom--AntiDilutiveStockOptions_pid_dxL_uShares_c20220101__20221231_z5tD5FVp81p4" title="Anti-dilutive stock options::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0531">zero</span></span> in weighted-average shares for each of the years ended
December 31, 2023 and 2022, respectively, as their effect was anti-dilutive as a result of the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The calculation of diluted loss per share excluded performance-based restricted
stock and time-based restricted stock of <span id="xdx_904_ecustom--AntiDilutiveRestrictedStock_pid_uShares_c20230101__20231231_z8W4A0kYm7m6" title="Anti-dilutive restricted stock">904,496</span> and <span id="xdx_905_ecustom--AntiDilutiveRestrictedStock_pid_uShares_c20220101__20221231_zYsUlyhb8ALh" title="Anti-dilutive restricted stock">950,000</span> in weighted-average shares for each of the years ended December
31, 2023 and 2022, respectively, as their effect was anti-dilutive as a result of the net loss incurred for those periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89C_ecustom--ScheduleOfSecuritiesTextBlock_zCAYv9Hd6LWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zEUvOauTXLBj">The following securities were not included in the computation of diluted
shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td id="xdx_498_20230101__20231231_zvTejDmQtR0c" style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td id="xdx_49D_20220101__20221231_z5ouRlWwl5gg" style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockOptions_pid_uShares_ztWXeR7pq7rd" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Stock options</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td style="vertical-align: bottom; text-align: right">12,335</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8212;</span></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_402_ecustom--RestrictedStockUnits_pid_uShares_zB7X80sRCGLl" style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Restricted stock</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">904,496</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">950,000</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_uShares_zcuV9Hh5wmM3" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">916,831</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">950,000</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zDqCtW4WYiEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNaXvfvueqkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B3_zcL7Io9SHgCd" style="display: none; visibility: hidden">Schedule of net income per common share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_ztU38QDRs1il" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_z5NhXHxgA985" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 69%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zGYjl5DfEOx4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(13,741,062</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(8,661,142</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zbX0ho5sfmT8" style="vertical-align: bottom; background-color: white">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo1PThvKWyg8" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Basic weighted average shares outstanding</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,601,346</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,002,074</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zqRV9gTQ3b8f" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.2in">Dilutive effect of outstanding stock options and unvested restricted stock</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziVtziaxQivj" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Diluted weighted average shares outstanding</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,601,346</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,020,074</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zLKU6CbTJXmg" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zvEIXmwPQtFk" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.30</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zgo7lA10NY5a" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.30</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
<p id="xdx_8AD_zUiOb4deb5ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Therefore, diluted weighted average number of shares outstanding and diluted
net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the years ended December
31, 2023 and 2022. See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221; for further detail.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</a></td>
<td class="text"><p id="xdx_844_eus-gaap--UseOfEstimates_zNFNFYuQAZI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_zjJSsksRpBe5">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zOtO34xIQuE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_861_zzayRpQjOfy5">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting
Standards Update (&#8220;ASU&#8221;) No. 2014-09, <i>Revenue from Contracts with Customers</i>, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers and are included
in Product Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#8217;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#8217;s revenue recognition criteria described above. As of December 31, 2023, the Company has recognized
a contract asset of zero which is included in other accounts receivable in the accompanying balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_898_ecustom--ScheduleOfNetRevenuesByGeography_zgOk39Kpl3P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B4_zzLqgxExCEz2">The following table summarizes net revenues by geography for the years
ended December 31, 2023 and 2022:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zlJvfdkf0eva" style="text-align: right" title="Net Revenue">23,676,039</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zxd3On1nZsl7" style="text-align: right" title="Net Revenue">23,586,254</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z9WJMe07cdac" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,841,627</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zWLgskHZsh1h" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,309,783</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20230101__20231231_zjh9E8vQnmA2" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">28,517,666</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20220101__20221231_zuQ3cmZ8ak6a" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">27,896,037</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<p id="xdx_8A5_zJHH3WsFODQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zutAeD5nwoZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zVguakYwV0S9">LEASES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#8220;NOTE 5 <b>&#8212; </b>LEASES&#8221; for further detail.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</a></td>
<td class="text"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBQ7gh9jSITg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zCzypJsogS6i">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company adopted this standard on January 1, 2023, and it did not have a
significant impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zfpebkPQILed" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zqY8Tw8pNwb9">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2023.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc', window );">IMPAIRMENT OF LONG-LIVED ASSETS</a></td>
<td class="text"><p id="xdx_842_ecustom--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc_zNaHnezOrga1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">IMPAIRMENT OF LONG-LIVED ASSETS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2023.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents impairment or disposal of long lived assets policy text bloc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295540189536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">The estimated amortization expense for the succeeding years for the intangible assets is approximately:</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zksHIEC1OdYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zOrGNsW3BTte">The estimated amortization expense for the succeeding years for the intangible
assets is approximately:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_494_20231231_zDrzIiBttqZ5" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zpLNLu9FFqQ6" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 68%">2024</td>
    <td style="vertical-align: top; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; width: 4%">$</td>
    <td style="vertical-align: bottom; width: 24%; text-align: right">65,869</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zz7zWibfl9Cg" style="vertical-align: bottom; background-color: white">
    <td>2025</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">65,729</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zh5sEDXZveSa" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">64,674</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zmJwnFnhwN54" style="background-color: white">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">64,242</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zKXXXIq6HIb7" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">64,242</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zLHLDXaIUDv9" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">429,605</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zYPWgwFKa1jj" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">754,361</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfSecuritiesTextBlock', window );">The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive:</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfSecuritiesTextBlock_zCAYv9Hd6LWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zEUvOauTXLBj">The following securities were not included in the computation of diluted
shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td id="xdx_498_20230101__20231231_zvTejDmQtR0c" style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td id="xdx_49D_20220101__20221231_z5ouRlWwl5gg" style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockOptions_pid_uShares_ztWXeR7pq7rd" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Stock options</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td style="vertical-align: bottom; text-align: right">12,335</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8212;</span></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_402_ecustom--RestrictedStockUnits_pid_uShares_zB7X80sRCGLl" style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Restricted stock</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">904,496</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">950,000</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_uShares_zcuV9Hh5wmM3" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">916,831</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">950,000</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net income per common share</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNaXvfvueqkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B3_zcL7Io9SHgCd" style="display: none; visibility: hidden">Schedule of net income per common share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_ztU38QDRs1il" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_z5NhXHxgA985" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 69%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zGYjl5DfEOx4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(13,741,062</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(8,661,142</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zbX0ho5sfmT8" style="vertical-align: bottom; background-color: white">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo1PThvKWyg8" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Basic weighted average shares outstanding</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,601,346</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,002,074</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zqRV9gTQ3b8f" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.2in">Dilutive effect of outstanding stock options and unvested restricted stock</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziVtziaxQivj" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Diluted weighted average shares outstanding</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,601,346</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,020,074</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zLKU6CbTJXmg" style="vertical-align: bottom; background-color: #E7E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zvEIXmwPQtFk" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.2in">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.30</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zgo7lA10NY5a" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.2in">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.30</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfNetRevenuesByGeography', window );">The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022:</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfNetRevenuesByGeography_zgOk39Kpl3P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B4_zzLqgxExCEz2">The following table summarizes net revenues by geography for the years
ended December 31, 2023 and 2022:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zlJvfdkf0eva" style="text-align: right" title="Net Revenue">23,676,039</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zxd3On1nZsl7" style="text-align: right" title="Net Revenue">23,586,254</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z9WJMe07cdac" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,841,627</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zWLgskHZsh1h" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,309,783</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20230101__20231231_zjh9E8vQnmA2" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">28,517,666</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--Revenues_c20220101__20221231_zuQ3cmZ8ak6a" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">27,896,037</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfNetRevenuesByGeography">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of net revenues by geography.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfNetRevenuesByGeography</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of securities text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295543517072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory consists of:</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zX61zdvEhwd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_z3jmSyQGRb25">Inventory consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Raw materials and work-in-process</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20231231_ziUbnwr5bKH9" style="text-align: right" title="Raw materials and work-in-process">1,869,356</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20221231_z18xyOI1Xrli" style="text-align: right" title="Raw materials and work-in-process">3,853,034</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Finished goods</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20231231_zLAfc6m67f0c" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">1,862,525</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20221231_zURHm1TjbASa" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">2,611,951</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;&#160;&#160;Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--InventoryGross_iI_c20231231_zWyuTK3Nl3Yl" style="text-align: right" title="Inventory, Gross">3,731,881</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryGross_iI_c20221231_zEljUY9NZ9Il" style="text-align: right" title="Inventory, Gross">6,464,985</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Less: reserve for obsolete inventory</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryValuationReserves_iNI_di_c20231231_zThgvIKcoY1j" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory">(250,580</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--InventoryValuationReserves_iNI_di_c20221231_zm7BmshG5f29" style="border-bottom: black 1pt solid; text-align: right">(60,118</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Inventory, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--InventoryNet_iI_c20231231_zI0bFlNRqbFb" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory">3,481,301</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--InventoryNet_iI_c20221231_zHXuNssReZHh" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory">6,404,867</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295543512480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment consists of the following at:</a></td>
<td class="text"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWkScz5mmSN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zqsL5fj7Yt7d">Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 55%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zjYZmReSfphf" style="text-align: right">1,412,164</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z7IveEZuNol4" style="text-align: right">1,456,745</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6rdrelA7794" style="text-align: right">1,953,653</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWLszAyseh2g" style="text-align: right">2,413,820</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zGAhw6PPKAhj" style="border-bottom: black 1pt solid; text-align: right">3,193,113</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zQjvAVCRM5Y3" style="border-bottom: black 1pt solid; text-align: right">2,810,813</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zCiLDQVZ8Pe5" style="text-align: right" title="Total property and equipment">6,558,930</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_ziqRGyjJPcvj" style="text-align: right" title="Total property and equipment">6,681,378</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zSoBNiLqIM11" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,721,273</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_znwnqS9d6snk" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,794,403</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_z6QzVcp39uX4" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">3,837,657</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zarNcWLbaTlg" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">3,886,975</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295546679312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of time based stock options</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zNNM5iwpmL2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the activities for our stock options with
time based vesting for the years ended December 31, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8B2_ziuflerqMOHi" style="display: none; visibility: hidden">Schedule of time based stock options</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 44%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 22%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zimUbs6WZcF6" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5YA1TzdK49c" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z2vcbNA95U5k" title="Expected volatility">51.9</span>% - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zwZ6FEgiJBCk" title="Expected volatility">61.3</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zig3jesCAfTj" title="Expected volatility">65.29</span>% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zNyFUhbYt9oh" title="Expected volatility">77.5</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zp3fRJqsu2x2" title="Weighted-average volatility">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zPgzCrXzqFOd" title="Weighted-average volatility">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zr6v1ZKIKVx5" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxYlkrjitIT" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z1jOmn5MPA17" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0707">10</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJPw7MTmiVhe" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0709">10</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z94OrWsBFtQ1" title="Risk-free rate">3.50</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_z2myhkGzx1s7" title="Risk-free rate">4.53</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zrlTY08nfwRf" title="Risk-free rate">1.81</span>% - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zaZdGXGs6nf2" title="Risk-free rate">4.02</span>%</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of status of time based stock options</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3skaw4hoX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the time-based stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8BD_zoOm84bn8TLe" style="display: none; visibility: hidden">Schedule of status of time based stock options</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 54%">Outstanding at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoLlsLS6XsAh" style="width: 9%; text-align: right" title="Outstanding at beginning (in shares)">3,035,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zPSMutrubaIb" style="width: 9%; text-align: right" title="Outstanding at beginning">3.93</td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zXasPHkR3FDg" style="width: 9%; text-align: right" title="Outstanding at beginning (in shares)">3,672,500</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zkzXZZM8cv0c" style="width: 9%; text-align: right" title="Outstanding at beginning">3.42</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zjte071jhx2" style="text-align: right" title="Granted (in shares)">430,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z8sNdtWX97a5" style="text-align: right" title="Granted">2.66</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLIog2GcPmef" style="text-align: right" title="Granted (in shares)">920,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zsSlCgKCXM5j" style="text-align: right" title="Granted">2.62</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zHXx0yI8QvGd" style="text-align: right" title="Exercised (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoUfFM3QUx5d" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoW0l8NJRtB2" style="text-align: right" title="Exercised (in shares)">1,031,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z8g7ILueyDl7" style="text-align: right" title="Exercised">1.57</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zD9OhpaXZyH1" style="text-align: right" title="Forfeited (in shares)">208,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zOFlnx4XYOI3" style="text-align: right" title="Forfeited">5.45</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDhc90Lf6hag" style="text-align: right" title="Forfeited (in shares)">526,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdMkB7B1eYnf" style="text-align: right" title="Forfeited">2.73</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at December 31</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zkGQr6YVYqE9" style="text-align: right" title="Outstanding at ending (in shares)">3,256,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJQIAoa2Qxzd" style="text-align: right" title="Outstanding at ending">3.66</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDQ6iHbmxkTl" style="text-align: right" title="Outstanding at ending (in shares)">3,035,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMEXyyRdawhc" style="text-align: right" title="Outstanding at ending">3.93</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Options exercisable at December 31</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zWOHeaN7VNRe" style="text-align: right" title="Options exercisable (in shares)">1,458,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQGgYc11tSgi" style="text-align: right" title="Options exercisable">4.42</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5jwCQQwe2Xg" style="text-align: right" title="Options exercisable (in shares)">737,500</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zD00fFY3ETEd" style="text-align: right" title="Options exercisable">4.93</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZfHcarGtsB7" style="text-align: right" title="Weighted average fair value of options granted during the period">1.84</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJHZIM1njtld" style="text-align: right" title="Weighted average fair value of options granted during the period">1.99</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zh2JESU6bYW6" style="text-align: right" title="Stock-based compensation expense">1,940,720</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJErI9jW98fl" style="text-align: right" title="Stock-based compensation expense">2,083,397</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock', window );">Schedule of information pertaining to options outstanding</a></td>
<td class="text"><p id="xdx_895_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_za2BNGCvvJj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to time- based stock
options outstanding at December 31, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8B9_zJbw7ma0vV06" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 29%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.18-$9.49</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zX5ktyylRsTc" style="text-align: right" title="Number outstanding">3,256,250</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zW5jUzrzHVGe" title="Weighted average remaining contractual life::XDX::P8Y3M19D"><span style="-sec-ix-hidden: xdx2ixbrl0797">8.3</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zj1nuAG2OW51" style="text-align: right" title="Weighted average exercise price">3.66</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z8blGC4c8V35" style="text-align: right" title="Number exercisable">1,458,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zqcISb4booHa" style="text-align: right" title="Weighted average exercise price">4.42</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022.</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zhPAnldze47a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to an employment agreement entered into on November 6, 2023, with
the Company&#8217;s Chief Commercial Officer, and as an inducement to his employment, the Company issued a non-qualified option to purchase
200,000 shares of common stock that vest upon achievement of sales growth milestones.&#160;<span id="xdx_8BA_zEyadYIGzkfl">The following table summarizes the activities
for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Twelve Months Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 46%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z45l6opaHkll" style="width: 10%; text-align: right" title="Unvested at beginning (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zVkxT1f68a5f" style="width: 12%; text-align: right" title="Unvested at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0818">&#8212;</span></td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4NIoIoBzZ79" style="width: 10%; text-align: right" title="Unvested at beginning (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0820">&#8212;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zy16y6lOlPo5" style="width: 12%; text-align: right" title="Unvested at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0822">&#8212;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zzlB3j8bjNae" style="text-align: right" title="Granted (in shares)">200,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zt0o7PVVYzDl" style="text-align: right" title="Granted">1.48</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXRSLbJaIxN2" style="text-align: right" title="Granted (in shares)">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4M0NLYOVe3i" style="text-align: right" title="Granted">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4ipmvUnHem" style="text-align: right" title="Vested (in shares)">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zxDr35xjmIXc" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zFBn1TpWV5D5" style="text-align: right" title="Vested (in shares)">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zyVAZ3aERA02" style="text-align: right" title="Vested">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zxpEVIJUV7Oa" style="text-align: right" title="Forfeited/canceled (in shares)">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zkIABLM6hxxi" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zfwDAGdsgE73" style="text-align: right" title="Forfeited/canceled (in shares)">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z736TyxeOos3" style="text-align: right" title="Forfeited/canceled">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zlwqeSmQQTEc" style="text-align: right" title="Unvested at ending (in shares)">200,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zwFHpgH3Ya5a" style="text-align: right" title="Unvested at ending">1.48</td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zum9GSPaaM4j" style="text-align: right" title="Unvested at ending (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zKSPREQa99M3" style="text-align: right" title="Unvested at ending"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022.</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zfunpkl4nUhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B6_zyDtnkQEFQkc">The following table summarizes the activities for our unvested restricted
stock awards for the twelve months ended December 31, 2023, and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Twelve Months Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 46%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhJVfbeXIxP8" style="width: 10%; text-align: right" title="Outstanding at beginning (in shares)">950,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBPjvkLNa7yj" style="width: 12%; text-align: right" title="Outstanding at beginning">3.04</td>
    <td style="width: 2%">&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z07BwXSgZmz6" style="width: 10%; text-align: right" title="Outstanding at beginning (in shares)">1,000,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zgeVGhrvxVX7" style="width: 12%; text-align: right" title="Outstanding at beginning">3.01</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3LAi9s9XCTe" style="text-align: right" title="Granted (in shares)">54,496</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zGzrTMrGQcXk" style="text-align: right" title="Granted">3.68</td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zbQfXLgHb5W1" style="text-align: right" title="Granted (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0878">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zllcecbW3drk" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0880">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXK55JfgMdHi" style="text-align: right" title="Vested (in shares)">100,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zvmqSZ98yUEd" style="text-align: right" title="Vested">3.31</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zl6HFN0Tc3rl" style="text-align: right" title="Vested (in shares)">50,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zlFjXfmwisW4" style="text-align: right" title="Vested">3.31</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zpKU0AmugtS5" style="text-align: right" title="Forfeited/canceled (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0890">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zTdUZszxmIkc" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0892">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z7wMYrP3Yz3c" style="text-align: right" title="Forfeited/canceled (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl0894">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJEyiezOocf6" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0896">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z143DXigTUDe" style="text-align: right" title="Outstanding at ending (in shares)">904,496</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLfz9jPJh54f" style="text-align: right" title="Outstanding at ending">2.77</td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zq79WcillT5d" style="text-align: right" title="Outstanding at ending (in shares)">950,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zimyf8K4Ts39" style="text-align: right" title="Outstanding at ending">3.04</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of share based compensation stock options activity amended table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541627376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expenses</a></td>
<td class="text"><p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_znhwFvHPWxwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of lease expense were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BE_zDfk5fgcQbcj" style="display: none; visibility: hidden">Schedule of components of lease expenses</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 57%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_494_20230101__20231231_zKiB6cGbWRp4" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 3%; text-align: center">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_49D_20220101__20221231_zjAAY9T4ZDc9" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zaS1RlIt9pb9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">448,630</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">514,294</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zIdwXxVc5UYa" style="vertical-align: bottom; background-color: white">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">130,483</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">131,490</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zdOriZH6Oifk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">579,113</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">645,784</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zkMAAx5sE1fi" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zMeYf5mxIzA9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">110,566</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">50,895</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zdq5GiOb9S3a" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,343</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,393</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zE4V3Y4Eq1ec" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">135,909</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">56,288</td>
    <td>&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of cash flow information related to leases</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zselWVrMP4bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental cash flow information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zZ1w5yy5QMH1" style="display: none; visibility: hidden">Schedule of cash flow information related to leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 72%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td id="xdx_495_20230101__20231231_zzRbf8rXOXUa" style="width: 11%; text-align: center">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td id="xdx_491_20220101__20221231_zhS65FBULqld" style="width: 11%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.45pt; text-indent: -9.45pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zdZi16PauUj1" style="vertical-align: bottom; background-color: white">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">464,104</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">247,504</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zUeDqJG34f1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">125,259</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">57,243</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of balance sheet information related to leases</a></td>
<td class="text"><p id="xdx_897_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z2E5mzBdPO79" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental balance sheet information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zc7YbtpSNOu6" style="display: none; visibility: hidden">Schedule of balance sheet information related to leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zB62PhKNaONd" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zKOJjTjXRV29" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zl9jr5wwyhvf" style="vertical-align: bottom; background-color: white">
    <td style="width: 59%; padding-left: 9.1pt; text-indent: -9.1pt"><b>Operating Leases</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 15%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 16%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zgg4N1jXmim4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,514,055</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,786,545</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_zOkwuHUya5Nd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">368,313</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">345,834</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zNNxsHNUxT1g" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,336,300</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,653,257</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_zr1ggNoOPBwl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,704,613</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,999,091</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_z1yayVn0aEU5" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_zZ7rpgB4edL4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">577,929</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">544,468</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_zgo6WFpvwXi3" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(161,461</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(50,895</td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zHdscoHEbKW4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">416,468</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">493,573</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zkwmxWl3bXMj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">109,540</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">98,335</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zTfOwEsNtFF6" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">316,623</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">394,283</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zSEELGZNZst8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">426,163</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">492,618</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 58%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td style="vertical-align: top; width: 1%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_zZf4F5Q30GP4" title="Operating leases term::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0997">6.9</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20221231_zcYRctEfugE8" title="::XDX::P9Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0998">9.7</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_zeaQD2VStw4d" title="Finance leases  term::XDX::P3Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl1000">3.7</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_900_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20221231_zsvcgphj12G8" title="::XDX::P4Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl1001">4.6 </span></span>Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zT9ehFPKl5pf" title="Operating leases discount rate">5.76</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zGaketmYUWu3">4.00</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zFhp9PN6K93e" title="Finance leases discount rate">6.19</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_906_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20221231_z2Q80shkk67j">4.25</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z17mlvILdsol" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Maturities of lease liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8B7_zUFFKPAqsp18" style="display: none; visibility: hidden">Schedule of maturities of lease liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 57%">2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zQcC8joE0WEi" style="width: 18%; text-align: right" title="2024 - Operating Leases">512,055</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zJd3hfl0udD" style="width: 18%; text-align: right" title="2024 - Finance Leases">131,437</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zXUdyqsuMf2c" style="vertical-align: bottom; text-align: right" title="2025 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zVmq6vyxjuW4" style="vertical-align: bottom; text-align: right" title="2025 - Finance Leases">131,437</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zRyIIkYxIrb" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zwmZ6ay8nu6i" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases">131,437</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zvkcp4xvrMuj" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zo0pWx6vMXck" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases">74,194</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20231231_zPLHgDfCcVjl" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases">512,055</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20231231_zyvqrNESrjI6" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases">6,181</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20231231_zxlaI2rrxQ8e" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases">1,832,557</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20231231_zzgiBFk0TZE9" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_986_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20231231_zpU0MdldqvZ6" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases">4,392,832</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_987_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20231231_zJwCtKSR541j" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases">474,686</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 18.8pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20231231_zKdtxCiyRnU" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases">(688,220</td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20231231_zzQ0Zerpow2b" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases">(48,523</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20231231_zwvCLHDBLtte" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases">3,704,613</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_986_eus-gaap--FinanceLeaseLiability_iI_c20231231_zkxSLnpFa6A" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases">426,163</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481440/840-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541791488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FEDERAL AND STATE INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision for income taxes</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJTmOBimS5r" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_zxRW4mZ3lUN2" style="display: none; visibility: hidden">Schedule of provision for income taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zHctlo41dmwi" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zlzqc0OUWIsk" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z2yKTLcu8wf7" style="vertical-align: bottom; background-color: white">
    <td>State income tax:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_z51hzqwRstWb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 51%; padding-left: 21.8pt">Current, net of refund</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">$</td>
    <td style="width: 19%; text-align: right">0</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 2%">$</td>
    <td style="width: 19%; text-align: right">0</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z46egG0kC9ga" style="vertical-align: bottom; background-color: white">
    <td>Federal income tax:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zSX11M5F9p13" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Deferred</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,035,297</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,014,018</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_zu7w9rb70Pl9" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 21.8pt">Current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WriteoffOfDeferredTaxAsset_zK8xrqvwSSDk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Write-off of deferred tax asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(6,002,777</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20230101__20231231_ztAptpNmii0a" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">(3,967,480</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98B_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zgxeqZGjwYSk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">2,014,018</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income taxes</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zNPI1xPbzeml" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The reconciliation of income taxes shown in the financial statements and
amounts computed by applying the Federal expected tax rate of 21% for year 2023 and 2022 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B8_zg34NCCUtSid" style="display: none; visibility: hidden">Schedule of reconciliation of income taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_zO2ZcN6jHd09" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zbJYaSwTn3Z1" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_zYAwaTqqPUS6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 60%">Loss before taxes</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; width: 1%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 16%; text-align: right">(9,773,582</td>
    <td style="border-bottom: white 2.25pt double; width: 4%">)</td>
    <td style="border-bottom: black 2.25pt double; width: 1%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 16%; text-align: right">(10,675,160</td>
    <td style="border-bottom: white 2.25pt double; width: 1%">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zbSzbna7zBt7" style="vertical-align: bottom; background-color: white">
    <td>Income taxes computed at the federal statutory rate</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,052,452</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,241,784</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_z2ktpkq5KsR8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>State income and franchise tax</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1082">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zSRYt6WqZjI5" style="vertical-align: bottom; background-color: white">
    <td>Permanent differences and other</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(17,155</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(227,766</td>
    <td>)</td></tr>
  <tr id="xdx_40D_ecustom--WriteoffOfDeferredTaxAsset_zvWKIs9VFZeb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Write-off of deferred tax asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(6,002,777</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1088">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20230101__20231231_ztoiOvHdE2D8" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">(3,967,480</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_984_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zWeBKg45pzwj" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">2,014,018</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of deferred tax assets</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKFGMN3Kcpyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The significant components of deferred income tax assets, net are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_8BC_z4sTd2qvGpIb" style="display: none; visibility: hidden">Schedule of components of deferred tax assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_zR7qybW8bxCl" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zcdy3sOF9V5b" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredCompensationPlanAssets_iI_zrqwDl1ZBlZi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 60%">Deferred compensation cost</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 16%; text-align: right">1,047,608</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 16%; text-align: right">557,931</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DepreciationDepletionAndAmortization1_iI_zVkK6CbK4oBf" style="vertical-align: bottom; background-color: white">
    <td>Depreciation and amortization</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(913,671</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(624,184</td>
    <td>)</td></tr>
  <tr id="xdx_403_ecustom--RdCredit_z3DOhi3YsAmc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>R&amp;D credit</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,030</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,030</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--Nol_zHaKxqsnpMX4" style="vertical-align: bottom; background-color: white">
    <td>NOL</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">3,566,630</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,956,685</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AllowanceForDoubtfulOtherReceivables1Current_zsM4g8zG4Dq2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Allowance for bad debts and other</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,160,180</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">935,018</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--AllowanceForNonRealizationOfDeferredTaxAsset_iI_zxkfYdFg8anb" style="vertical-align: bottom; background-color: white">
    <td>Allowance for non-realization of deferred tax asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(6,002,777</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_zRu5Hm81Eft8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Deferred income tax assets, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">&#8212;</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,967,480</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295540100416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 65,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">65,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">64,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">64,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">64,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">429,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization expense</a></td>
<td class="nump">$ 754,361<span></span>
</td>
<td class="nump">$ 787,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295546854864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive: (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockOptions', window );">Stock options</a></td>
<td class="nump">12,335<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_RestrictedStockUnits', window );">Restricted stock</a></td>
<td class="nump">904,496<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AntiDilutedSecurities', window );">Total</a></td>
<td class="nump">916,831<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AntiDilutedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents anti diluted securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AntiDilutedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_RestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_RestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541762704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of net income per common share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,741,062)<span></span>
</td>
<td class="num">$ (8,661,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted Average Outstanding Shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding</a></td>
<td class="nump">45,601,346<span></span>
</td>
<td class="nump">45,002,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock', window );">Dilutive effect of outstanding stock options and unvested restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding</a></td>
<td class="nump">45,601,346<span></span>
</td>
<td class="nump">45,002,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted Average Outstanding Shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding</a></td>
<td class="nump">45,601,346<span></span>
</td>
<td class="nump">45,002,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding</a></td>
<td class="nump">45,601,346<span></span>
</td>
<td class="nump">45,020,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents dilutive effect of outstanding stock options and unvested restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541575824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 28,517,666<span></span>
</td>
<td class="nump">$ 27,896,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">23,676,039<span></span>
</td>
<td class="nump">23,586,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 4,841,627<span></span>
</td>
<td class="nump">$ 4,309,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541813856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Number </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of segments | Number</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC cash insurance limit</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeSecuritiesUSTreasury', window );">Investment securities treasury bill</a></td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AmortizationOfIntangibleAssets1', window );">Amortization expense of intangible assets</a></td>
<td class="nump">64,469<span></span>
</td>
<td class="nump">$ 62,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">3,967,480<span></span>
</td>
<td class="num">(2,014,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DepreciationAndAmortizationPropertyAndEquipment', window );">Depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 805,921<span></span>
</td>
<td class="nump">$ 524,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AntiDilutiveStockOptions', window );">Anti-dilutive stock options | shares</a></td>
<td class="nump">12,335<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AntiDilutiveRestrictedStock', window );">Anti-dilutive restricted stock | shares</a></td>
<td class="nump">904,496<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Equipment and Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Equipment and Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember', window );">Patents and Trademarks [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember', window );">Patents and Trademarks [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AmortizationOfIntangibleAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents amortization of intangible assets1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AmortizationOfIntangibleAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AntiDilutiveRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AntiDilutiveRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AntiDilutiveStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AntiDilutiveStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DepreciationAndAmortizationPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DepreciationAndAmortizationPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeSecuritiesUSTreasury">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeSecuritiesUSTreasury</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_EquipmentAndToolingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_EquipmentAndToolingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541850928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory consists of: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Raw materials and work-in-process</a></td>
<td class="nump">$ 1,869,356<span></span>
</td>
<td class="nump">$ 3,853,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,862,525<span></span>
</td>
<td class="nump">2,611,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">3,731,881<span></span>
</td>
<td class="nump">6,464,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: reserve for obsolete inventory</a></td>
<td class="num">(250,580)<span></span>
</td>
<td class="num">(60,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 3,481,301<span></span>
</td>
<td class="nump">$ 6,404,867<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295543059904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment consists of the following at: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 6,558,930<span></span>
</td>
<td class="nump">$ 6,681,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,721,273)<span></span>
</td>
<td class="num">(2,794,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,837,657<span></span>
</td>
<td class="nump">3,886,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,412,164<span></span>
</td>
<td class="nump">1,456,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,953,653<span></span>
</td>
<td class="nump">2,413,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember', window );">Manufacturing Equipment and Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 3,193,113<span></span>
</td>
<td class="nump">$ 2,810,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295543059360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of time based stock options (Details) - Stock Option Plan 2015 [Member] - Time Based Shares Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">51.90%<span></span>
</td>
<td class="nump">65.29%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.81%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">61.30%<span></span>
</td>
<td class="nump">77.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.53%<span></span>
</td>
<td class="nump">4.02%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295543101152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of status of time based stock options (Details) - Stock Option Plan 2015 [Member] - Time Based Shares Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning (in shares)</a></td>
<td class="nump">3,035,000<span></span>
</td>
<td class="nump">3,672,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning</a></td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">430,000<span></span>
</td>
<td class="nump">920,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="nump">$ 2.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,031,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">208,750<span></span>
</td>
<td class="nump">526,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">$ 5.45<span></span>
</td>
<td class="nump">$ 2.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending (in shares)</a></td>
<td class="nump">3,256,250<span></span>
</td>
<td class="nump">3,035,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending</a></td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">1,458,750<span></span>
</td>
<td class="nump">737,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable</a></td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted during the period</a></td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,940,720<span></span>
</td>
<td class="nump">$ 2,083,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295535987536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of information pertaining to options outstanding (Details) - Stock Option Plan 2015 [Member] - Time Based Shares Options [Member] - Exercise Price1 [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">3,256,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 3 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number exercisable | shares</a></td>
<td class="nump">1,458,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 4.42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=krmd_ExercisePrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=krmd_ExercisePrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295543081936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022. (Details) - Performance Based Shares Options [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions', window );">Unvested at beginning (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice', window );">Unvested at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants', window );">Granted (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1', window );">Granted</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested', window );">Vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1', window );">Vested</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures', window );">Forfeited/canceled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1', window );">Forfeited/canceled</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions', window );">Unvested at ending (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice', window );">Unvested at ending</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options forfeitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options unvested weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by unvested award options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_PerformanceBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_PerformanceBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541988128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022. (Details) - Restricted Stock Awards [Member] - Stock Option Plan 2021 [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at beginning (in shares)</a></td>
<td class="nump">950,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at beginning</a></td>
<td class="nump">$ 3.04<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested', window );">Granted (in shares)</a></td>
<td class="nump">54,496<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested', window );">Granted</a></td>
<td class="nump">$ 3.68<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross', window );">Vested (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice', window );">Vested</a></td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="nump">$ 3.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested', window );">Forfeited/canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested', window );">Forfeited/canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at ending (in shares)</a></td>
<td class="nump">904,496<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at ending</a></td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding number unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options vested in period gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295538274672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 1,076,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_TaxBenefitFromRestrictedStockCompensation', window );">Tax benefit from restricted stock compensation</a></td>
<td class="nump">$ 79,326<span></span>
</td>
<td class="nump">$ 101,419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember', window );">Non Employee Director and Board Advisor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NonemployeeServicesTransactionCost', window );">Nonemployee services transaction cost</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction', window );">Share-based goods and non-employee services transaction</a></td>
<td class="text">to be paid quarterly $12,500 in cash and $15,000 in common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NonemployeeServicesTransactionCost', window );">Nonemployee services transaction cost</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction', window );">Share-based goods and non-employee services transaction</a></td>
<td class="text">to be paid quarterly $12,500 in cash and $22,500 in common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockBasedCompensationSharesIssuable', window );">Stock issuable under plan (in shares)</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharesAvailableForIssuanceShareBasedCompensation', window );">Shares available for issuance</a></td>
<td class="nump">2,724,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member] | Executives Employees Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Common stock outstanding</a></td>
<td class="nump">2,436,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan', window );">Shares issued under plan</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="nump">445,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockBasedCompensationSharesIssuable', window );">Stock issuable under plan (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharesAvailableForIssuanceShareBasedCompensation', window );">Shares available for issuance</a></td>
<td class="nump">822,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock awards (in shares)</a></td>
<td class="nump">21,100<span></span>
</td>
<td class="nump">97,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember', window );">Stock Option Plans 2015 and 2021 Combined [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Per share weighted average fair value of stock options granted</a></td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 1.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_TaxBenefitFromStockBasedCompensation', window );">Tax benefit from stock-based compensation</a></td>
<td class="nump">$ 256,315<span></span>
</td>
<td class="nump">$ 231,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember', window );">Stock Option Plans 2015 and 2021 Combined [Member] | Time Based Shares Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockBasedCompensationStockOptions', window );">Stock-based compensation expense</a></td>
<td class="nump">1,940,720<span></span>
</td>
<td class="nump">2,083,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CashReceivedFromOptionExercise', window );">Cash received from option exercise</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">406,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value options granted</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1', window );">Number of options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,031,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 3,145,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average period</a></td>
<td class="text">46 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 4,819,658<span></span>
</td>
<td class="nump">$ 2,703,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember', window );">Stock Option Plans 2015 and 2021 Combined [Member] | Performance Based Shares Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 176,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_TaxBenefitFromRestrictedStockCompensation', window );">Tax benefit from restricted stock compensation</a></td>
<td class="nump">$ 1,137<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CashReceivedFromOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents cash received from option exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CashReceivedFromOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NonemployeeServicesTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents nonemployee services transaction cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NonemployeeServicesTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award grants in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_SharesAvailableForIssuanceShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents shares available for issuance share based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_SharesAvailableForIssuanceShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents shares issued under plan in total shares employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockBasedCompensationSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock based compensation shares issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockBasedCompensationSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockBasedCompensationStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock based compensation stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockBasedCompensationStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period shares stock options exercised1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_TaxBenefitFromRestrictedStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents tax benefit from restricted stock compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_TaxBenefitFromRestrictedStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_TaxBenefitFromStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents tax benefit from stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_TaxBenefitFromStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of transactions in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting method used for valuing the transaction, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=krmd_ExecutivesEmployeesConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=krmd_ExecutivesEmployeesConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_PerformanceBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_PerformanceBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295542923968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of components of lease expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 448,630<span></span>
</td>
<td class="nump">$ 514,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">130,483<span></span>
</td>
<td class="nump">131,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">579,113<span></span>
</td>
<td class="nump">645,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_FinanceLeaseCost1Abstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">110,566<span></span>
</td>
<td class="nump">50,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">25,343<span></span>
</td>
<td class="nump">5,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 135,909<span></span>
</td>
<td class="nump">$ 56,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents finance lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseCost1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents finance lease cost1 abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseCost1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541654656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of cash flow information related to leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 464,104<span></span>
</td>
<td class="nump">$ 247,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 125,259<span></span>
</td>
<td class="nump">$ 57,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541886416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of balance sheet information related to leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AssetsAndLiabilitiesOperatingLesseeAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,514,055<span></span>
</td>
<td class="nump">$ 3,786,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability &#8211; current</a></td>
<td class="nump">368,313<span></span>
</td>
<td class="nump">345,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">3,336,300<span></span>
</td>
<td class="nump">3,653,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">3,704,613<span></span>
</td>
<td class="nump">3,999,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AssetsAndLiabilitiesLesseeFinanceAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Property and equipment, at cost</a></td>
<td class="nump">577,929<span></span>
</td>
<td class="nump">544,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation', window );">Accumulated depreciation</a></td>
<td class="num">(161,461)<span></span>
</td>
<td class="num">(50,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property and equipment, net</a></td>
<td class="nump">416,468<span></span>
</td>
<td class="nump">493,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability &#8211; current</a></td>
<td class="nump">109,540<span></span>
</td>
<td class="nump">98,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liability, net of current portion</a></td>
<td class="nump">316,623<span></span>
</td>
<td class="nump">394,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 426,163<span></span>
</td>
<td class="nump">$ 492,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leases term</a></td>
<td class="text">6 years 10 months 25 days<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance leases term</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating leases discount rate</a></td>
<td class="nump">5.76%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance leases discount rate</a></td>
<td class="nump">6.19%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AssetsAndLiabilitiesLesseeFinanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents assets and liabilities lessee finance abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AssetsAndLiabilitiesLesseeFinanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AssetsAndLiabilitiesOperatingLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents assets and liabilities operating lessee abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AssetsAndLiabilitiesOperatingLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295543029264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of maturities of lease liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024 - Operating Leases</a></td>
<td class="nump">$ 512,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024 - Finance Leases</a></td>
<td class="nump">131,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025 - Operating Leases</a></td>
<td class="nump">512,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025 - Finance Leases</a></td>
<td class="nump">131,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026 - Operating Leases</a></td>
<td class="nump">512,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026 - Finance Leases</a></td>
<td class="nump">131,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027 - Operating Leases</a></td>
<td class="nump">512,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027 - Finance Leases</a></td>
<td class="nump">74,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028 - Operating Leases</a></td>
<td class="nump">512,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2028 - Finance Leases</a></td>
<td class="nump">6,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter - Operating Leases</a></td>
<td class="nump">1,832,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter - Finance Leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal', window );">Total undiscounted lease payments - Operating Leases</a></td>
<td class="nump">4,392,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal', window );">Total undiscounted lease payments - Finance Leases</a></td>
<td class="nump">474,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseImputedInterest', window );">Less: imputed interest - Operating Leases</a></td>
<td class="num">(688,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinancingLeaseImputedInterest', window );">Less: imputed interest - Finance Leases</a></td>
<td class="num">(48,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities - Operating Leases</a></td>
<td class="nump">3,704,613<span></span>
</td>
<td class="nump">$ 3,999,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities - Finance Leases</a></td>
<td class="nump">$ 426,163<span></span>
</td>
<td class="nump">$ 492,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeFinancingLeaseImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee financing lease imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeFinancingLeaseImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee financing lease lease liability payments due total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee operating lease imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee operating lease liability payments due total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295538337680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseOneMember', window );">Lease One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseRemainingTerm', window );">Operating lease remaining term</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinanceLeaseRemainingTerm', window );">Finance lease remaining term</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseTwoMember', window );">Lease Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseRemainingTerm', window );">Operating lease remaining term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinanceLeaseRemainingTerm', window );">Finance lease remaining term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseThreeMember', window );">Lease Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinanceLeaseRemainingTerm', window );">Finance lease remaining term</a></td>
<td class="text">4 years 9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeFinanceLeaseRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeFinanceLeaseRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=krmd_LeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=krmd_LeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=krmd_LeaseThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=krmd_LeaseThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295539873264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of provision for income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current, net of refund</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">2,035,297<span></span>
</td>
<td class="nump">2,014,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_WriteoffOfDeferredTaxAsset', window );">Write-off of deferred tax asset</a></td>
<td class="num">(6,002,777)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit/(expense)</a></td>
<td class="num">$ (3,967,480)<span></span>
</td>
<td class="nump">$ 2,014,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_WriteoffOfDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents writeoff of deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_WriteoffOfDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295547954432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of reconciliation of income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before taxes</a></td>
<td class="num">$ (9,773,582)<span></span>
</td>
<td class="num">$ (10,675,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income taxes computed at the federal statutory rate</a></td>
<td class="nump">2,052,452<span></span>
</td>
<td class="nump">2,241,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income and franchise tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Permanent differences and other</a></td>
<td class="num">(17,155)<span></span>
</td>
<td class="num">(227,766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_WriteoffOfDeferredTaxAsset', window );">Write-off of deferred tax asset</a></td>
<td class="num">(6,002,777)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit/(expense)</a></td>
<td class="num">$ (3,967,480)<span></span>
</td>
<td class="nump">$ 2,014,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_WriteoffOfDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents writeoff of deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_WriteoffOfDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295541805904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of components of deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred compensation cost</a></td>
<td class="nump">$ 1,047,608<span></span>
</td>
<td class="nump">$ 557,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DepreciationDepletionAndAmortization1', window );">Depreciation and amortization</a></td>
<td class="num">(913,671)<span></span>
</td>
<td class="num">(624,184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_RdCredit', window );">R&amp;D credit</a></td>
<td class="nump">142,030<span></span>
</td>
<td class="nump">142,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_Nol', window );">NOL</a></td>
<td class="nump">3,566,630<span></span>
</td>
<td class="nump">2,956,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AllowanceForDoubtfulOtherReceivables1Current', window );">Allowance for bad debts and other</a></td>
<td class="nump">2,160,180<span></span>
</td>
<td class="nump">935,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AllowanceForNonRealizationOfDeferredTaxAsset', window );">Allowance for non-realization of deferred tax asset</a></td>
<td class="num">(6,002,777)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred income tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,967,480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AllowanceForDoubtfulOtherReceivables1Current">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents allowance for doubtful other receivables1 current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AllowanceForDoubtfulOtherReceivables1Current</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AllowanceForNonRealizationOfDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents allowance for non realization of deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AllowanceForNonRealizationOfDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DepreciationDepletionAndAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents depreciation depletion and amortization1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DepreciationDepletionAndAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_Nol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents nol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_Nol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_RdCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents rd credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_RdCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295655085168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Account eceivable from customers</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=krmd_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=krmd_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295540251168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFITS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DescriptionOfMatchingContribution', window );">Description of matching contribution</a></td>
<td class="text">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#8217;s contribution, not to exceed 3% of employee&#8217;s compensation plus 50% of employee&#8217;s pay
contributed between 3% and 5% of employee&#8217;s compensation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Matching expense</a></td>
<td class="nump">$ 227,447<span></span>
</td>
<td class="nump">$ 214,931<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DescriptionOfMatchingContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents description of matching contribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DescriptionOfMatchingContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295538650000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT OBLIGATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Description of the frequency of periodic payments</a></td>
<td class="text">Monthly payments are due on the first of each month beginning August 1, 2023 through
June 1, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krmd_AONPremiumFinanceLLCMember', window );">AON Premium Finance LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Balance of AON note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314,344<span></span>
</td>
<td class="nump">$ 433,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krmd_AONPremiumFinanceLLCMember', window );">AON Premium Finance LLC [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">$ 570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krmd_AONPremiumFinanceLLCMember', window );">AON Premium Finance LLC [Member] | Promissory Note [Member] | Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NotePayableTerms', window );">Note payable terms</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NotePayableTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents note payable terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NotePayableTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krmd_AONPremiumFinanceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krmd_AONPremiumFinanceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=krmd_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=krmd_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140295535978704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENT (Details Narrative) - Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 08, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Description of subsequent event</a></td>
<td class="text">Borrowings under the term loan will bear interest at
the greater of Prime minus 0.50% or 6.50% and will be interest-only through December 31, 2025, followed by 24 equal monthly payments of
principal plus interest.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Loan provided, as lender</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Inteest rate on borrowings</a></td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Loan provided, as lender</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in security owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=krmd_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=krmd_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MV](ZVX_6+9.1"/,;'X&;K_8:M4-I<ZMKO=>A]5VA&1)K0/NPA?9A/VC741K
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M.<MA"'HA##GI@=F( 3*L!CX9J]'U0"*[[,X(9YRW$7;M."SQL&\;-B* #*N
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M26C5&/#GMV7)OMTT+_KT[YK-_P502P,$%     @ 1H)M6 )2P[7W!P  (2(
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M/;E9])1NURI)(78-[-$2JUA?]@$#5D%\682-3Q"--F2F?>42!DLWFF6@8+.
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M)^/@W"J:X047"+M-_XX:V8ZF);VU1?\!<*,A W?E6S$AMN +2@T'1T.AV7"
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M"#5>":\#6>-:J=(Z[)LQN^<U817YPQ.@4+P^:#=B(SR1,PV_;J*XTF:4U &
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M+W=O<FMS:&5E=',O<VAE970Y+GAM;)5548_;-@Q^SZ\@W*'8 .-LRW;BI$F
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M4 ]["#];V.A-JZ6PK<8.696ER/$DP2\0^4G$_&B<]'(Z]B=).OH#Z1[N5%6
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M0J(2WZ,Y@.=B(>YR3O<C%B=_.( @J/C Q3MT1R8R^%8R9;C*MW 0A&Z"FZ*
M&=-+J^N#H!*=UE#AZ 76G!X$\8\BA8]K3Y!(EVL42E.^@8TM#.A [)XKK',P
M1PGAGN4E)R&?.I/5,])FI1+%PB&-;#E34,4/)D2^ND/D)BE:/G970]B@3Z)J
MO&&,/Z,AA$GJ1N@V(5)$<0!3+*M0Y<%NP&K+^5SF6*GQ=C",U%V5:_$7U]9
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MN''2W!^CK#"(!K7H,4%\>3UU[$\:UO:8?H3LZL(F@^YT-')L[-<>,NO61?Y
M8]ZE=T>8'@>AWUD+77\8N=%H %-IL&CI[\'5::F%>@3XBRL)L9^Z*3H4.?IF
M-_JLC(<9!<=;E>"\,=/4?/G>$!OL/">.@\ZXD!T'VA>$MM\KL,2+HGI)HE-H
M (.O1)9*5J'8C2VG85N^Z&(5FT^#]>4;]N Y-]39TK$F.&""O0QV1J6]HO6N
M=K"SX1R$7C \/!AY\:CC\$-,E+73/W/@<YM)]BB;JGSC 1'V"(F;!BG$^.<.
M@Y&;)D-J1GR,(DQU$ZZLG-CW[2U3DU+IDAH2%!Q;A4[[Q1:80^T(__'&#%5&
MVBFP';RO>$H;EJI"]=B+6,\>'.M7VC%R&>H0BVZ?A_A+T6T"W2<=3MU),ML/
M84>1B[G >64P.KPNU0S[3H[IM$IINDJ>J,AN7T$]DK'5%)LP^SZ+;-Y7+% >
M9SFG*) ;LR3?13I9<.W]6$UWFII>%G03\KGNV*);%IKVMBGK9L-S[,A6U2O@
M]\N[,ZT.=-\9_VYU^:UA]DEI>5X(GJVTQ:51/67&>+B'\'-UP5LPV^K2GY'6
M\C<>ZPK1+1+?8^UM,1<,L 7$"A=1T 91G7)OQK?3FP^74WS[LV^"</[E_.;J
M]F_V@:W//+XU.?5;T[_=5T:)W]9N/^Z\W]B%H/63)';C45JEOU?<).B<1A,F
MW=D_[1\CO^$)>Y;!KB1O<P[71_=(TQ@&(S<*T45\S.S!:-^7BW[G6Q/FQX7]
MHJ8Q4Y6%J3X[M:OM1[OSZEO5(WGUQ>\C4PN!Z3SG<SSJ>X.D!ZKZBE9-C%S;
M+U=WTABYLL,E9QE71(#[<RE-,Z$+VD^99_\'4$L#!!0    ( $:";5BY%UF0
M. <  &43   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*58:V_CMA+]
MKE]!N$6Q"VAMO2UEDP#91]$"W;N+).WBXN)^H"7:$BJ)*D7%F_[Z>X:4'3_3
M#>X76Z(X9X9GY@PI7:ZE^K,OA=#L6U.W_=6DU+J[F,WZO!0-[Z>R$RV>+*5J
MN,:M6LWZ3@E>&*.FG@6>E\P:7K63ZTLS]D5=7\I!UU4KOBC6#TW#U>,[4<OU
MU<2?; 9NJU6I:6!V?=GQE;@3^O?NB\+=;(M25(UH^TJV3(GEU>3&OW@7T7PS
MX8]*K/N=:T8K64CY)]W\6EQ-/ I(U"+7A,#Q]R#>B[HF((3QUX@YV;HDP]WK
M#?K/9NU8RX+WXKVLOU:%+J\FZ8058LF'6M_*]2]B7$],>+FL>_/+UG:NC\GY
MT&O9C,:(H*E:^\^_C3SL&*3>&8-@- A,W-:1B?(#U_SZ4LDU4S0;:'1AEFJL
M$5S54E+NM,+3"G;Z^K>/-W<?[RYG&E@T,LM'NW?6+CACYP?LDVQUV;./;2&*
M?8 9@MA&$FPB>1<\B_A!Y%,6^BX+O"!\!B_<KBPT>.&YE0DDJV?_N5GT6B'Y
M_SVU2 L1G88@05ST'<_%U005WPOU(";7/_W@)][;9P*,M@%&SZ$_0_VS=J>C
M^M?G^X\L9C_]D 9^\)99;/95L)(_"+:L6M[F@O&V8-"SXKIJ5ZRV#$'93 Z*
MY5)U$H\$D\ME-<[.A=*0MK,[))MNT$(Q\==0=1"HGK+/L-=K>0QNW"M![6$[
MRF#<]/#"TFF"H,-IQ$(63><QN]& ;TV^6(6(.Y*NR]:"B0=>#Q3<NA2ZA'<.
M22O%VY6@$%@%0&6,X:IW^.B*%K<NJ[PD#*[@NQ1XU/="L%>ZY&3H[@+UX_1.
MR8>J$&S 0*5+8Z=(XDQ+&R.TREE7/O95SG$)2&W<85"H2H+II:/1P%Z#GD-:
M*!*>YW)HM2AL!EKC8L%KDRFCZ-'U[>??+7S/%H) E,CEJJW^AFG5FIP'WML#
M'S;8-W+Y9NB%8\W-3/^MR:*=5%=\4=65KA#3=Z%N#!YMJ0$L'Y0";[O8_V3K
M.BVX0OY'6X:ZHT1/-R _C_7Z0K9.KN"+HJ)$P!39MF1=AA!&=\X+^-B+[$5L
MG+$T@>QPX1QR<<BB^(8-></*3HRTQ3%J=2;OU#1HNR)9/$ M8,MY$M^4?:7"
M0O?HL#M212_W&(<B&@KC;VZV3D1';&_KD,1F6H_)1R\Z3FVC?F1+)1N0!1>B
MUYM(X:;&X\*!&X)9GB9BNNU69LL&L!%:LZ"5V+G$9BO;-_:.^I!LC62-[.K:
M3G,V'82DC$B.E3]E-T51T=)@A P8\[T60.P<]"KL>(W=\3";<$Q;*B0BTD]Y
M())&M9V1V=-HQQ^MNY=F<B<T&^H#5_!0BP-@9[^$R7)L3;BS;8[&Y**N5C;3
M<(*V2Y583'?[#D78 'M0HP"KIN.5,IT7)%/ &@UG!704JGB@<9D#J)^R^W(O
M5Z!RKY#!(LF;DECCB-A?L#N</(NA%D85YPU[Y]^"J_$ XN#X()H%^,$1PJ$C
M!)TC N=0/;E$8?[(HBAUD]##5>Q';I!%SEV)@G]C*-V9Z8>>&Z4A_GTWRCSG
M7FI>[T/%\\SU_1!7212[\S1R]I5.TRZ<FP,][7;G#<D_,M_WW#A)"-5STRQV
M?MUH"5;'I13$;AB%#+]9.(:V//)-L&'L9EY&L(D;I"F[&[JN-K4.DYSW)5N"
M>J3>GO+M@=N(ED0X=N$U<G0V3=^'\3T9>T]0*"Y;9^A# R4?55D/Q5,=C\5H
M"G!;&#O<7.QD?AM<;QO4T2$%]9!$KN]%N JBN1M[FR2>,M]OE40O\A#$AMZY
M&R A>_3N[5'_!\4OP-FCENWQ_,2*/1\?">1T888NZ<2+8W,]3Q,WCN(CV[/;
M(0N3U TADA 22</HO.7A=K@Y&L!K&"9NZ'FX2N(0A,_'DI=GL"IA(Y][D9L8
M@89NEF6NE_E;B8XDG#LC</VD\KF;!2;'4>1&2>K<H+TU@V6^$-@.\\JFXY6?
MH%DD/GO-7ED9L]=G/=!J47Y^0IATE8'J>>A\YSF#^5Z&5'@L []A?,[L/*MP
MG$!Y888NF)YN(OM\1D'B^DEH0@W :_I,L7TU[\3@YP8;%U[QV>WV1< 0S^[1
M;@]KH6?)-&/9=.X<G +#Z1PO"<DQZH>J-V=#=HMD',/%TWD"0\\[!$RF?H8'
M0<P^<3THN\)3S<0>0,_HLGG>UK0\ZG@4T1Y5AU)D!T6);AAA>PJ,[,P&%,YI
M,#XUF)P:G&\'YVAOV.0PEF['D,?4=^[IB,27]#[G0YJ!&\?SS6OD6 X#@N\W
MI^^#HTN$O2<@.Q;!1Y(FSF\X&EW0^6#0IEV/&]BK)$U=G(-)%=A\8Q3=Z[WM
M]+QL-R5WZIU[MO/IHQ%J93[P],Q$:[^";$>WWY!N[*>3I^GV ]0GKE9X=40X
M2YAZ>!V=V&ZXN=&R,Q]2%E)KV9C+4O!"*)J YTLI]>:&'&R_K%W_#U!+ P04
M    " !&@FU8%=9!P:4$  "^"@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6R]5M]OVS80?O=?0:A=D0)J+,GZ8:>) 2=.L )M$L3INF'8 RV=;*(2
MZ9%4G>ROWQTE*T[1>-@>]N"(HGC????='7.G6Z6_FC6 90]U)<V9M[9V<S(<
MFGP--3?':@,2OY1*U]SBJUX-S48#+YQ170VC($B'-1?2FYZZO5L]/56-K82$
M6\U,4]=</YY#I;9G7NCM-N[$:FUI8S@]W? 5+,!^WMQJ?!OV*(6H01JA)--0
MGGFS\.0\IO/NP"\"MF9OS2B2I5)?Z>5#<>8%1 @JR"TA<'Q\@PNH*@)"&G]V
MF%[OD@SWUSOT*Q<[QK+D!BY4]444=GWFC3U60,F;RMZI[<_0Q9,07JXJX_ZR
M;7MV-/)8WABKZLX8&=1"MD_^T.FP9S .7C"(.H/(\6X=.99S;OGT5*LMTW0:
MT6CA0G762$Y(2LK":OPJT,Y.KR[GEW>SCVQV/6>+^]G])?MP?7'SZ9+=SWZ]
M7)P.+?J@D\.\PSMO\:(7\,*(?5+2K@V[E 44SP&&2*YG&.T8GD<'$>>0'[-1
MZ+,HB$8'\$9]Q".'-WH![X/,50WLGC^PN3!YI4RC@?T^6QJKL4;^^%',+6+\
M8T3JFQ.SX3F<>=@8!O0W\*9O7H5I\/X W[CG&Q]"_P\9.HQW?8,0*7OS:AR%
MT7MV&)YU:EE4"Q[P)C# <H4M:2P43)7,KH&5JL+>%G)UPA9X:11-!?1IH]4W
MX9H7[PXF>B P@]^ Z[9 V--RL+#<PM[!D\%%HS5(ZS.)UQ-"8L<VLF"O64"_
MP144H'GUS&0.):!1P2(_&"5^-,EH%<;X&^_P^N"[Y^"+%A;>J;(D)\4.@8+F
MQJ#KH]0/@LC/LHR][8WVI%F"A%+8X5&GT5ND=S3R)VGFQ^. T6M/@MVC9!I0
MQ5Q4@KN[";WNZ\/,6FTE;K7R"LGQ+,9I2""\$:UA7!8#7JN&UFBX:2@?RT?&
M-YOJ$5/A+'?Z$*O<=A%I$AD=1N%/+C&/E #J+<*D1<0$XILNK>9Y4@\3?R&Q
M'Y4QJ!%ZVP6(\DQ0SI&?C",GSU$8^&F6^-@T[.V>M+ 7'K>M'EU4I$9CE7YL
M0W(2)Y$?)Y%;1W'H9^/X>551B*5&.=?"M*G[OA1N >]Z2452B!(+ 60.3FZF
MT+E&HID?)@F2/HJBS,_2%/G^[_5CQ$J*4N0<>9(^2KJJV/?^E)>6A&F[B&,.
M7DKN"TA/$-A=.=1+E($NY/V7I[XC$(RAK8]<&8OD0S^(,S\-QKA.DLR?C$(T
MP,LR[^J(],5RUE;\U6X<3<(1%D1(.J=1[(?C&'6^>\/KS?LYR]&1L"R,J<F#
MW7-P??.184FEJ9_B;N1/$ER-D\&,8L6D@ROX)2\PMJ7=SVI$A8=. C;!2X.N
MBN<V4LEW./-4.WK_(LWS?TC(Z[X$7[.GE-\TFGT^7ASWU4Y<S7<7)':C;;0T
M^*3YB]&HQJS"?N<X*CBF V)/74/'J=4-M7B 6UHUJ[7K]^,?_9<:[LT4->B5
MFYRH&?'*:<>+?K<?SF;M3/)TO)WL/G&]$LBR@A)-@^,L\9ANIZ7VQ:J-FU"6
MRN*\XY9K'#!!TP'\7BIE=R_DH!]9IW\#4$L#!!0    ( $:";5B):CO@)P,
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M"$EWQ,.IE']G23?I'-8/'$0)NT5'S3 SE-2P-I0WT26W!C*^<"13*#"3J5#
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MY7O65%GJ@'Y8T"<'M7,@>ZZ474W<!NU';/0;4$L#!!0    ( $:";5CAQ6F
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M0:$51$4MXBS(2 SH\!4?3P0D@)+S 4G-L[QB(>%/BP@KM/<45RO^VY@"L!V
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M*"XK#1,*X*%%]49('M3HR#\:G:G1T!\<';)%;Y:;S45"22XS*$$3 $*^-!^
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MU;S+FHZ1E7L++:6!EY5K;N$I*Y2= -_74II]QSKH'L>S_P!02P,$%     @
M1H)M6-I!QT"/!   M L  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
MS59M;^HV%/[.K["X746EW)*8O$ +2+10K5+;6Q6VNVG:!Y.<@'43F]FFM/OU
M.TY"2B>@W;=]@-B.SW/>GG-R^ANI?N@E@"$O>2;TH+DT9G71;NMX"3G3YW(%
M M^D4N7,X%8MVGJE@"6%4)ZUJ>N&[9QQT1SVB[-'->S+M<FX@$=%]#K/F7J]
M@DQN!DVON3UXXHNEL0?M87_%%C %\\OJ4>&N7:,D/ >AN11$03IHCKR+J]#>
M+R[\RF&C=];$>C*7\H?=W":#IFL-@@QB8Q$8/I[A&K+, J$9?U68S5JE%=Q=
M;]%O"M_1ESG3<"VS[SPQRT&SVR0)I&R=F2>Y^1DJ?P*+%\M,%_]D4][UPR:)
MU]K(O!)&"W(NRB=[J>*P(]!U#PC02H 6=I>*"BO'S+!A7\D-4?8VHME%X6HA
MC<9Q89,R-0K?<I0SPYO)>/(TNB.CAS&9SD:S";E]N/YV/R&ST6^3*6G-V#P#
M?=9O&U1F1=IQ!7Q5 M,#P!XE]U*8I283D4#R'J"-5M:FTJVI5_0HXACB<]+Q
M'$)=VCF"UZE=[Q1XG0-XMR*6.9 9>R%CKN-,ZK4"\L=HKHU"LORYS^<2T=^/
M: OH0J]8#(,F5H@&]0S-X>D7+W0OC]CKU_;ZQ]"'4RS(9)T!D2E9*?G,B\+
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M<,37%17U>R(>-_P &>^DUIA7U+9U$%/:0PITG*!+BY2V/-<)H\#!NB9G.W2
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M]89P(=;8(Y<U5?&"\"=2Z_[Q&W2M/XOR4!)8+@U.F@;'A-Y-)HDM@"!+35V
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MD@7QY8JHVN)Z@'J_8$R^W6@'Z5E[]W]02P,$%     @ 1H)M6-2OWCV^ @
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M*=#OEYRK7<=LT=V)G/P%4$L#!!0    ( $:";5C-5>\@CP,  -T.   9
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;+5776_;-A3]*X16#"V01J*H+WNV
M@#59L0 -9C1M]S#L@9&O;*&2J)*4W>[7CY04V;)9M0:4%YND[CT\]_"2O%SL
M&?\LM@ 2?2WR4BRMK935W+9%LH6"BFM60:F^I(P75*HNW]BBXD#7C5.1VZ[C
M!'9!L]**%\W8BL<+5LL\*V'%D:B+@O)O;R!G^Z6%K:>!]]EF*_6 '2\JNH$'
MD!^K%5<]NT=99P64(F,EXI NK=_Q_ 9[VJ&Q^)3!7ARUD0[ED;'/NG.W7EJ.
M9@0Y)%)#4/6W@QO(<XVD>'SI0*U^3NUXW'Y"?]L$KX)YI )N6/YWMI;;I159
M: TIK7/YGNW_A"X@7^,E+!?-+]JWMB&Q4%(+R8K.63$HLK+]IU\[(8X<5*!F
M![=S<'_6@70.I FT9=:$=4LEC1><[1'7U@I--QIM&F\535;J97R07'W-E)^,
M5UQE!)??$"W7"+[46:762**$J8424B"6(KD%E+)<+7A6;A"5<_3R%B3-<O$*
MO48?'V[1RQ>O%K94;#2FG70SOVEG=K\S\RTDUXC@*^0Z+C&XW_R\NSMTMY4&
MO1!N+X3;X)$?"'&%5CE5"F@]_NCU^.>=,D=W$@KQKRG4%MLS8^NM.!<536!I
MJ;TF@._ BG_]!0?.;Z; )P(;R$!Z&<@8>OR!29JCRI@5IL!;-+]!TT?&+@Y\
M/YH19V'OCF,RV 41)F'4VPWH>CU=;Y3N.Q!BKLZ"I"[JG$I8JRVL5$DRVAX2
MBCXM&)?9?\V *8)V@N"(V6LW=+$;DI,0C(8SSW.(.0:_C\$?C<&\!:]0"4;%
M_3,:)")AX(<G=$UV43 +?3/;H&<;C+)]6_,RDS6'ANY?:9HE<+Q1[J%X!&[<
M)*/ EVZ2B< &&H2]!N$SGA7AE#),!#:0(>IEB"8]*Z*SC,0>=G'@G62NR<X/
M0N\[F3OKZ<Y^<%:HZW[+\C6Z*Q3I'6B>8C1C1P$O7:J)P :Q8^=PSSO/F+,=
M^$1*3(4VE.*HY,&3YFT'-TC(F4\"__2&,!BZ'B:1ZY@S%Q^*$SQZZ<?WM*Q3
M5?+67-=@AW73W#\PENO1L40>A[]X_9ZC0L&'$@63YTSET0+H8BDF0AM*<2A_
M\'C]<W$J>V=U&,$S@O%9*I\;NA%V(GQ:[-A';P_]\+NG?).5 N60*D_G.E00
MO'U+M1W)JN8Y\LBD>MPTS:UZ?P+7!NI[RIA\ZN@73O^BC?\'4$L#!!0    (
M $:";5A3Z[PJK@,  .8.   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;,57;8_B-A#^*U9:57M2=Q,GA(4M1%K@3CVIJZ*EU_MPN@\F&<#:)$YM \N_
MK^UD0T)-CJN0[@OQR\SC9\:>86:T9_Q%;  D>LW27(R=C93%@^N*> ,9$7>L
M@%SMK!C/B%13OG9%P8$D1BE+7=_S^FY&:.Y$([,VY]&(;65*<YAS)+991OAA
M BG;CQWLO"T\T_5&Z@4W&A5D#0N0GXHY5S.W1DEH!KF@+$<<5F/G$3],<:@5
MC,3?%/:B,4;:E"5C+WKR,1D[GF8$*<120Q#UV<$4TE0C*1[_5*!.?:96;([?
MT#\8XY4Q2R)@RM+/-)&;L3-P4 (KLDWE,]O_#I5!AF#,4F%^T;Z2]1P4;X5D
M6:6L&&0T+[_DM7)$0P'WSRCXE8)_JM [HQ!4"H$QM&1FS)H12:(19WO$M;1"
MTP/C&Z.MK*&YOL:%Y&J7*CT9+=2[2+8I(+9"4MV/\4F"U+GQ"V*%=K5 -S.0
MA*;B';I%"[/SI]E!\Y3DR/=PB+X\0;8$_E5)_*5A)@9FL2$<1"4MFD*?%C-T
M\_.[D2N5$9J*&U>$)R5A_PQA[*,GELN-0._S!)(V@*NLKUW@O[E@XG<BSB"^
M0P'^51GB!Q9"T\O5_0XZ07TC@<$+SMV(]MEMZ;\IRU2\"F*<_<@YR=>@8DBB
MY0$UY>;D8)8?]X0GZ,L?"A)]E)")KS8'E^?W[.?KO/$@"A+#V%&)00#?@1/]
M\A/N>[_9G',EL):K>K6K>EWHT8SN: )Y@@X4TL1F:JD_,/HZH^TB;^3NFOR[
M)%JDPII4V$GJL\D<D-R2'7"5"=&.I>H"4RH/-H;A-QEV2;08]FN&_4Z&[U\+
ME435LTDJ_PD;L1(C["#6)=$B=E\3N[^,F 2>H1N:HP,0+JQ9HAL)>Z6J[<7^
M'\V6.8/:G$$GU!/-:;;-ZK1G,Z,3X7MC\4I@+6.'M;'#'YRVAM=TU97 6J["
MWO%/U[OLH7?GA@IEV(RPNQ /3^+0*M8/_:$]&G&C-L"=-)^I>+E=<0#$B00K
M0VPYV@O"4X96,3S 9QCZ1X9^=XB1UV^&6#?$]SZ<:Z&U#3X6!_A'5P?XJN7!
MM=#:[CH6"+B[0K@TT'JV",+!Z3.VB=W?AV=>\;%BP-TEPP5Q%MH"J!?^AZ%=
MSO-/*+J-CB$#OC:-E$ QV^:RK)SKU;I9>S0MRLGZ1#=QIA,YPI0=X!/A:ZJ*
M_A16"E+Y25'C95-53B0K3%^R9%)U.6:X48TH<"V@]E>,R;>)/J!N;:-_ 5!+
M P04    " !&@FU8[9F+USD$   ?#P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6RM5VV/XC80_BM66E5[4I?$SAML 6E?[MJ3NKK5T>M].-T'0P:(
M-HFI;6#WW]=VLB$0)W!5OX#MS#QYYLG8XQGO&7\6:P")7O*L$!-G+>7FQG7%
M8@TY%0.V@4(]63*>4ZFF?.6*#0>:&*<\<XGG16Y.T\*9CLW:$Y^.V59F:0%/
M'(EMGE/^>@<9VT\<[+PM?$Y7:ZD7W.EX0U<P _EE\\35S*U1DC2'0J2L0!R6
M$^<6W]SC6#L8B[]3V(O&&.E0YHP]Z\G'9.)XFA%DL) :@JJ_'=Q#EFDDQ>.?
M"M2IWZD=F^,W] \F>!7,G JX9]G7-)'KB3-T4 )+NLWD9[;_ ZJ 0HVW8)DP
MOVA?V7H.6FR%9'GEK!CD:5'^TY=*B(8#CCH<2.5 3AV"#@>_<O!-H"4S$]8#
ME70ZYFR/N+96:'I@M#'>*IJTT)]Q)KEZFBH_.9VIO$BV&2"V1$)2N15Z)-67
M,NHD:I$MGA';:-$%NGH 2=-,O$/7:&:>?#)/T%-&"T0\'*)OCY#/@7]7%G]I
MF#L#,UM3#J*R%DVC+[,'=/7SN[$K53B:E+NHJ-^5U$D'=4S0(ROD6J#W10+)
M,8"K=*C%(&]BW)%>Q =8#)"/?U6!$-]"Z/YR=])#QZ^_C6_P_*YOHS6[+O6[
M9[G:N8(:L6\YI\4*U&Z2:/Z*FG9/]-4LW^XI3]"W/Q4D^B@A%]]M I?O#^SO
MUR?(C=C0!4P<=40(X#MPIK_\A"/O-YLX_Q/8D51!+570AS[]M)4J>XLD+5:(
M*E%@E1:%GERE!1(F]ZP95J)&!E6?>+NI[_FAYWEC=]>,S6(7Q21LV!W1#FO:
MX7^B;:-:(L5-"H.1?\+39A00.\FH)AGUDOQ=)9M4J75&RJ@E4>![;27;9B-R
M9';$,:XYQI=PM/&*6Y*0012=L+(:=>@VK#D->SF]?P&^2,5YY7IA[!L'V3;@
ML"4M]GRLLM0>QZB.8W19'#;NO:X_P'W4^@!X$,9VXM@[%#>OE[JJ]$M(+TC>
M"J>I'?&&<7B:O1:[D$2=$N-&&<:7,;6RPRUUPD$0GG)K6Y%!['<P(P=FY$?.
M*"A'Y_0D[0.3A$="5:0MAB<G\#'O0_'$O07'SMO*U;<<FJT3PFHUZE+W4+?P
MF<)578B@W&1TKJYBY[1M%R,<A+9D;1O&?MQ9M/"A:N$S9:M-VDJT78V"9C6J
M6-JL.H4]%"W<7[6^F@N\VOET!UPU)&A)4XYV--N:N^[;A795%;=DRW6BR#6@
M#?"4V?=A9#FEAL%I0#:KT:@CH$.%P_TESERWK\M+^:)Y&X07/;9_@1(R;%(9
M!5Y,6JG2-E3GG^^/3H]@M]%JY,!7I@,3BM"VD.5%NUZMN[Q;T]N<K-_I[L^T
M, >8LG5\I%Q=@P3*8*D@O4&L6/&R&RLGDFU,0S-G4K5'9KA6'2QP;:">+QF3
M;Q/]@KHGGOX+4$L#!!0    ( $:";5AI94^<"P,  ,L'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;+55;6_3,!#^*Z> $$BL>>DKHXVT;D-,8E"M
MP#Y,?'"3:QO-B8/MMJO$C^=LIUG'V@@^\"7QR]WCYYX[GX<;(>_5$E'#0\X+
M-?*66I>GOJ^2)>9,M42)!>W,A<R9IJE<^*J4R%+KE',_"H*>G[.L\.*A79O(
M>"A6FF<%3B2H59XSN1TC%YN1%WJ[A9MLL=1FP8^')5O@%/6W<B)IYM<H:99C
MH3)1@,3YR#L+3\<#8V\-OF>X47MC,)',A+@WDZMTY 6&$'),M$%@]%OC.7)N
M@(C&SPK3JX\TCOOC'?H'&SO%,F,*SP6_S5*]''D##U*<LQ77-V+S$:MXN@8O
M$5S9+VPJV\"#9*6TR"MG8I!GA?NSATJ'/8=V=,0AJAPBR]L=9%E>,,WBH10;
MD,::T,S AFJ]B5Q6F*1,M:3=C/QT/*4LIRN.(.:0%2[)1JT2I::49L4"M !1
MFD4%E%6E69&:Y=<72!9<O8$3F&J1W,,7:P43S@J(@K +=]>8SU#^((NOE$D8
MDWPI3)=,HJJLU;[1Y0/*)%,($YDE&-9;0U]3J(:PGU1AC5U8T9&PP@BN1:&7
M"BZ+%-.G #YI5 L5[80:1XV(%YBTH!V^I<BB-KP$'Y2+P_T:3FC7J6C;$]K'
M4F& 3IQ&YR*G:Z=<+LZD9,4"Z2IHF&UAWV["MG;Y;,-D"G>?"!*N-.;JH&;N
M_,[A\\WU/U4E2W#DT?U6*-?HQ:]>A+W@?4-TG3JZ3A-Z_'EE4OFD@GX=U,Y1
M=6 ]"V8:RSIN1]U>U V&_OH BV[-HMO(XM;>4A*.K5%2TZ&^DE=EGE"]2&H2
M*\:!9W,\Q*H9? !;9%)!&W)7>^$[2-FVJ39Z->_>O_'&W54IS54A*1\K\A!Q
MA][?E[/5ZQW6LE]SZO]-1BLF;,:Q,:/]9QD-.]U!_UA&!S6+P7]59O!,F4ZK
M$_W!R=]KL#G*A7U&%)7,JM"NU]:K]4MUYAKTH[E[YJZ97&34]CC.R35H]:FF
MI'LZW$2+TK;KF=#4_.UP2:\M2F- ^W,A]&YB#JC?[_@W4$L#!!0    ( $:"
M;5A?\H'_E ,  .H,   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;*U7
M76_;-A3]*X16#"W06A]V'">U!<3.NA5H4*-9NX>B#[1T;1&12(^D[6:_?I>D
M+$NI(MMH\Q"3U+V'YQQ2Y-5X)^2#R@ T^5[D7$V\3.OUM>^K)(."JIY8 \<G
M2R$+JK$K5[Y:2Z"I32IR/PJ"H5]0QKUX;,?F,AZ+C<X9A[DD:E,45#Y.(1>[
MB1=Z^X%/;)5I,^#'XS5=P3WHS^NYQ)Y?H:2L *Z8X$3"<N+=A->SL&\2;,07
M!CM5:Q,C92'$@^F\3R=>8!A!#HDV$!1_MC"#/#=(R./?$M2KYC2)]?8>_9T5
MCV(65,%,Y/^P5&<3;^21%)9TD^M/8O<7E((N#%XB<F7_DUT9&W@DV2@MBC(9
M&12,NU_ZO32BEA .GTF(RH3H:<+@F81^F6"=\QTS*^N6:AJ/I=@1::(1S32L
M-S8;U3!NEO%>2WS*,$_'?V= EB+'U61\131=Y% N*?L/%-'XV#K--,,N;ALB
M-I)L^!:4AI2L0=JMQ!-,TR)Y(&+MEF='9>H2#(;>0;X%4@BN,T6 IYA["PD4
M"Y"D'[XF41#U7Q/*4].*>N3E+6C*<O6*O"'SVB137+*4W&=4(IV/=BY%OMY9
MH&\8^X+X1-FG8U^C/T:EGY1>3)T7T3->A!&Y<P3_, 2; #X:6[D;[=V=1IV(
M*+%7R6LA-#L]/>J@TZ\6NV_Q^L_@6=O>. MGHL"C0%&[6C=24KX"?#TU63R2
M>MR</MKA&[.@Y.L'A"3O-13J6YO!;OY!^_SF2+I6:YK Q,,S1X'<@A?__ELX
M#-ZVF?.+P!I6#2JK!EWH\>?]#J?H"*P8Y^;]>,EXN;M>M:GOA&PG3-J$_SQ.
M0_-%I?GB?,UM.CMASM#Y\S@-G<-*Y[!3YY^XV8W,(ZOI0(86Q-R&VQCO1OP;
M^]NZB!_##A$->I<5O<M3Z+51<HF7M;G"WF#TA) +NCA.:%01&G42^N)VQ1&[
M1AT^.&)=$0UB5Q6QJQ.(M9&YZO# D>F*:) )@\-5&G32P;IB"0P9^8FYJ_+C
MGI6 7:9UAC2)UN[\\$RBK>3"HR9VAC3)10=RT<FG$!8*)QR[)>#1-[5[XO//
MF_!P[X:==U6+IE8=_5->[^ZISE#AUZK& N3*%M.*)&+#M2MQJM&J8+^Q9>J3
M\:DIY&TU>H!Q7P%W5.(UHD@.2X0,>I>X4Z0KK%U'B[6M31="8Z5KFQE^C( T
M ?A\*83>=\P$U>=-_#]02P,$%     @ 1H)M6&:@3_R] P  )PT  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&ULK5=MC]HX$/XK5JXZM5)+WB# 'D1:
MV.M=I:Z*=N]Z'ZI^,,D UB8V9QOHWJ^_L9,- 4+8K98/Q'9F'C_S>&Q/1CLA
M']0*0),?><;5V%EIO;YR796L(*>J(]; \<U"R)QJ[,JEJ]82:&J=\LP-/"]R
M<\JX$X_LV$S&(['1&>,PDT1M\IS*QPED8C=V?.=IX(XM5]H,N/%H39=P#_KO
M]4QBSZU04I8#5TQP(F$Q=J[]JZD?&@=K\97!3M7:Q(0R%^+!=#ZE8\<SC""#
M1!L(BH\M3"'+#!+R^+<$=:HYC6.]_83^T0:/P<RI@JG(_F&I7HV=@4-26-!-
MIN_$[D\H ^H9O$1DROZ376GK.239*"WRTAD9Y(P73_JC%*+FX$=G'(+2(3AV
MZ)YQ"$L'JYQ;,+-AW5!-XY$4.R*--:*9AM7&>F,TC)MEO-<2WS+TT_%?*R +
MD>%J,KXDFLXS*)>4_0>*:'QME6::81?3AHB-)!N^!:4AQ8546K+$-)%J\D#H
MCLJT,#2^>@?9%D@NN%XI CQ%PQM(()^#)*'_G@1>$+XGE*>F%73(VQO0E&7J
M'?E [O;@]Q;\N@#_=FO]OZ-),?YE;5-BEE%N8/RZQ1OB$K6B2'3D:A3,A.TF
MI3B30IS@C#A^0&X+YK\;YH< +BI=R1T\R3T)6A$Q]DX5=P.AZ?/=@Q8Z8;7Z
MH<4+S^#=&V$^3' ;I&0J<CP;%+527DM)^1)POVHR?R1UNQE]M,-V,<BWSPA)
M/FG(U?<F@8OYN\WSFS/J2JUI F,'#R$%<@M._.LO?N3]UB3.*X$=2-6MI.JV
MH<=?-EIIS%.S32B* DO&N>F\9;Q,L'=- A2HD44U9^HV'O8\_(W<;3VT4S/?
M\P[L#ECW*M:]GV+=Q+1 ZM<HA!VO>\2ST<AO)AE5)*-6DG]@KIE-?D')Z$2B
M7K<[C(X(MD[5G".D)3WZ50S]Y\30Q+O?(%DT.*+=BOYRVH.*]J"5]M?B&+^@
M_.!,<A[%<&K6.Y_!PXKA\!D,FU@-&W0-_2-.%XP.*/G>_M+T6DEA!;$ AKS<
MA/($:Y)&@NT@SUK4(HA7 #H,M%8=^*\1:"O(2P+]":"+)[P?[*,-7G):0M&Z
ML#E*S(,3WFLXF)KL6O:'O[_#_=9[KYEU(]/P9#,$G7[_F.>IU<$]4+!T:R5G
M#G)I*W%%$K'ANBB'JM&JVK^V->[1^,1\!=A2=@]3?$+<4HFWE2(9+!#2Z_3Q
M[I%%55YTM%C;PG8N-);)MKG"+QF0Q@#?+X303QTS0?5M%/\/4$L#!!0    (
M $:";5C"[NXZC <  $LM   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM
M;,5:76_;-A3]*X17#!W0Q"(IRW:7!$B<# NV-D&3K@_%'FB)MH5*HDO23C+L
MQX^B9%%?IFM/1OK0V#)Y>._5O8>''V=/C'\3"THE>(ZC1)SW%E(NW_?[PE_0
MF(A3MJ2)^F7&>$RD^LKG?;'DE 2Z4QSUD>-X_9B$2>_B3#^[YQ=G;"6C,*'W
M'(A5'!/^<D4C]G3>@[W-@T_A?"'3!_V+LR69TP<J/R_ON?K6+U"",*:)"%D"
M.)V=]R[A^XD[2#OH%G^%]$F4/H/4E2ECW](OM\%YSTDMHA'U90I!U)\UG= H
M2I&4'=]ST%XQ9MJQ_'F#_IMV7CDS)8).6/0E#.3BO#?J@8#.R"J2G]C3[S1W
M2!OHLTCH_\%3WM;I 7\E)(OSSLJ".$RRO^0Y#T2I@^=MZ8#R#JC6 ;I;.N"\
M ]:.9I9IMZZ))!=GG#T!GK96:.D''1O=6WD3)NEK?)!<_1JJ?O+BX?%N\L?)
MU>7#S368W'VXO_GX</EX>_<1O+VFDH21 !\)YR2-]2_@!'Q^N 9OW_QRUI=J
M[!2A[^?C7&7CH"WC0 0^L$0N!+A) AI4 ?K*Z,)RM+'\"ED1KZE_"C!\!Y"#
M<(M!DQ_OCBSFX"*06..Y6_ ^42%YZ$L:@ ?)_&_@\HGP0("O'V@\I?SOMI!9
M$=,"?B^6Q*?G/56A@O(U[5W\_!/TG%_;W.T(K.*\6SCO:G2\+8L6A-.3*U5.
M 9BP6'&,(+I*+U7N)'.JZEZ"Z0LHM[LG+_JQCA/X^J>"!+>2QJ(U5&Z7H>H(
MK!*J01&J@35//B><^FR>A/^H&/CE6/E,R#;7,[R!QDM9>7T!G:'G>>Y9?UWV
MRCKN@5YYA5>>U:M'\@RF-*&S4((99[%B^*(<A"Z'LJMM7GH-+X=CC+R:C\U6
MT($N'!?-*M8/"^N'5NL_JNC?Q,N(O5 *KD/U@B3C@"0!N&)I<EX&ZU"H)[9:
MMHZP;X)V!%8)QJ@(QNB5:WG49:@Z JN$:ER$:KPK;^@F;5+LT*<"2!4E07QK
M26>P7CF-H:/^U;+=.OJ!OD''* /'ZEWV@J?Z!<\94W-96A$)2TZL3K=J _M(
MDBGR $L2!N#[BG!)>?0"WD#T;N X(%1A)&*A!W\#!^^<_!F+8Q5A32ZG;8EA
M'_/0Z)5T%;3ZE#$'FQ5\(L!D04*E/!,KC]AA]ZV.KM"J04 F".B5N20WH*MP
M=816#9>1D-"N(0_FDQRW0BAN"Z'8QS_4/Z,2H559=<HH]I%^G%&0>;:348ZA
M&Z$1CM"N'+-EQ=U29\)]I'@$.7!@)Y..-&'N_S$4)C02$WJO3296D;MWN#I"
MJX;+:%IH%[59NH1"K,@THF"EEMT<+-.T>:N27:1!$NT+^6&#3#S':6.38\A4
M:'0JM&J[+!\4A:Q)&&D79TJB:W\3G[8Z-FHXAH;(18.&8\<0E="H2FB7E3L*
M'?P+;IZIOTKW9$2Q;E'R@B5B%4F22/NN@WWTO;/\&"(5&9&*G%<F!=21CLPW
MI8ZA2I%1I<BN2B>E.0ZPE10J78(PF;<Z#IOEXF*O62[V,0_UR8A,9%5E&QY(
M*U^]7,-SK3ZAAD^C09/96IJY;J5=U5:C\)!=X;65-H+6<K4C[IU_QU" R"A
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M%ZP$JI[,&"^P5":?VZ+D@*<FJ,AMSW$BN\"$6FG?[-WQM,^6,B<4[C@2RZ+
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M4QAP[:">SQB36T,GJ.>Z]#]02P,$%     @ 1H)M6':'IR&H @  L 8  !D
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M7LH+:9^HJFV3P$/I2BI.&V=-0 FKW_BI68@MAZBSQR%J'"++74]D*2=8X=%
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M<NV@WB\9D[N)7J#Z_@C^ %!+ P04    " !&@FU83E("0/0"  "+!P  &0
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M/\$F'BLP$JFR_V19V-;1.)HK+;(-&!5DC!=?NMKD80=PZ>T!!!M \ ;@U_<
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MKR5(8X#[4R'T=F(<E.]OYQ=02P,$%     @ 1H)M6!B0P^NO P  VA$  !D
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MH>MN7D^L*GT'G2E+_=@/<_H"0NT.T/Y<*;N=N*;<?%,E/P%02P,$%     @
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MX)_7JW>;79Z/X5Q<S@1='[;8#W\/^/0O4$L#!!0    ( $:";5B.83CZO0$
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M!=$6 K4%V18"MP7A%@*Y!>D6 KL%\18"O17U5@*]%?56 KWUX6>;0&]%O95
M;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T.]C4!O0[V-0&]#O8U
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M;%!+ 0(4 Q0    ( $:";5CDUNCS[P   "L"   1              "  :\
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M2P$"% ,4    " !&@FU8AW^7770#   C"@  &               @(%<%P
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 1H)M6#S7GF^+
M!0  ;14  !@              ("!!AL  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( $:";5B,:CR-\ 4  '<F   8              "
M@<<@  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !&@FU8
M E+#M?<'   A(@  &               @('M)@  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ 1H)M6**D8T$G&P  *D8  !@
M     ("!&B\  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M $:";5@4*QSQN (  ,$%   8              " @7=*  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " !&@FU8:TJGA @#  " !@  &
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M970Q,RYX;6Q02P$"% ,4    " !&@FU8-[>C^<L$  """@  &0
M    @($O:   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M $:";5@;JA(9!@,  - &   9              " @3%M  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ 1H)M6.'%:8#- @  VP4  !D
M             ("!;G   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " !&@FU8=5;+M1 $  "2"   &0              @(%R<P  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( $:";5C0A+F6'AP
M )--   9              " @;EW  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ 1H)M6)7H(I+%!   X@P  !D              ("!
M#I0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !&@FU8
M7Y"BDK("  "^!0  &0              @($*F0  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( $:";5CE'JT$ 0,  ($&   9
M      " @?.;  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ 1H)M6!#]K;_;!0  MQ(  !D              ("!*Y\  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !&@FU86E*KMUX%   H#P
M&0              @($]I0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( $:";5C:0<= CP0  +0+   9              " @=*J  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 1H)M6'SV,2G6
M @  L0D  !D              ("!F*\  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " !&@FU8I4.JJ.0"  "+!P  &0
M@(&EL@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( $:"
M;5@XF]8=EP,  ,,.   9              " @<"U  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ 1H)M6&O,(^K, @  ^0<  !D
M         ("!CKD  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " !&@FU8?1O"[;D%  !W'P  &0              @(&1O   >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $:";5C4K]X]O@(  )T'
M   9              " @8'"  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ 1H)M6,U5[R"/ P  W0X  !D              ("!=L4
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !&@FU84^N\
M*JX#  #F#@  &0              @($\R0  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( $:";5CMF8O7.00  !\/   9
M  " @2'-  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M1H)M6&EE3YP+ P  RP<  !D              ("!D=$  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " !&@FU87_*!_Y0#  #J#   &0
M            @('3U   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( $:";5AFH$_\O0,  "<-   9              " @9[8  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 1H)M6,+N[CJ,!P
M2RT  !D              ("!DMP  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " !&@FU88&"LVC,#  #C"0  &0              @(%5
MY   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( $:";5AV
MAZ<AJ (  + &   9              " @;_G  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ 1H)M6! (W"(;!   M@\  !D
M     ("!GNH  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M" !&@FU8SH&9,]$#  !8$P  &0              @('P[@  >&PO=V]R:W-H
M965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $:";5A<]V&EQP(  *0*   9
M              " @?CR  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L!
M A0#%     @ 1H)M6,OT9(KP @  ?PD  !D              ("!]O4  'AL
M+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !&@FU833ILLU #
M  "?"0  &0              @($=^0  >&PO=V]R:W-H965T<R]S:&5E=#0T
M+GAM;%!+ 0(4 Q0    ( $:";5A^HM#['@,  &@)   9              "
M@:3\  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ 1H)M
M6%_E?W[- @  BP@  !D              ("!^?\  'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " !&@FU83E("0/0"  "+!P  &0
M        @('] @$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( $:";5@8D,/KKP,  -H1   9              " @2@& 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 1H)M6(2DY:LJ P  7PD
M !D              ("!#@H! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " !&@FU8YB67"Q\#  !($0  #0              @ %O#0$
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $:";5B7BKL<P    !,"   +
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4!08     .0 Y (8/  !K&@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>99</ContextCount>
  <ElementCount>314</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FederalAndStateIncomeTaxes</Role>
      <ShortName>FEDERAL AND STATE INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - MAJOR CUSTOMERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/MajorCustomers</Role>
      <ShortName>MAJOR CUSTOMERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - EMPLOYEE BENEFITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/EmployeeBenefits</Role>
      <ShortName>EMPLOYEE BENEFITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - DEBT OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/DebtObligations</Role>
      <ShortName>DEBT OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/SubsequentEvent</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/Inventory</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/PropertyAndEquipment</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/Stock-basedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FederalAndStateIncomeTaxesTables</Role>
      <ShortName>FEDERAL AND STATE INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/FederalAndStateIncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails</Role>
      <ShortName>The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails</Role>
      <ShortName>The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Schedule of net income per common share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails</Role>
      <ShortName>Schedule of net income per common share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details</Role>
      <ShortName>The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Inventory consists of: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/InventoryConsistsOfDetails</Role>
      <ShortName>Inventory consists of: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Property and equipment consists of the following at: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails</Role>
      <ShortName>Property and equipment consists of the following at: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of time based stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails</Role>
      <ShortName>Schedule of time based stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of status of time based stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails</Role>
      <ShortName>Schedule of status of time based stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Schedule of information pertaining to options outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails</Role>
      <ShortName>Schedule of information pertaining to options outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details</Role>
      <ShortName>The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details</Role>
      <ShortName>The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of components of lease expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails</Role>
      <ShortName>Schedule of components of lease expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of cash flow information related to leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>Schedule of cash flow information related to leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of balance sheet information related to leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails</Role>
      <ShortName>Schedule of balance sheet information related to leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Schedule of maturities of lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Schedule of maturities of lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/LeasesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of provision for income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Schedule of provision for income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Schedule of reconciliation of income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails</Role>
      <ShortName>Schedule of reconciliation of income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of components of deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of components of deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - MAJOR CUSTOMERS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/MajorCustomersDetailsNarrative</Role>
      <ShortName>MAJOR CUSTOMERS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/MajorCustomers</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/EmployeeBenefitsDetailsNarrative</Role>
      <ShortName>EMPLOYEE BENEFITS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/EmployeeBenefits</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - DEBT OBLIGATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/DebtObligationsDetailsNarrative</Role>
      <ShortName>DEBT OBLIGATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/DebtObligations</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SUBSEQUENT EVENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/SubsequentEventDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/SubsequentEvent</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form_10-k.htm">form_10-k.htm</File>
    <File>krmd-20231231.xsd</File>
    <File>krmd-20231231_cal.xml</File>
    <File>krmd-20231231_def.xml</File>
    <File>krmd-20231231_lab.xml</File>
    <File>krmd-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="489">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form_10-k.htm": {
   "nsprefix": "krmd",
   "nsuri": "http://korumedical.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "form_10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "krmd-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "krmd-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "krmd-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "krmd-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "krmd-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 255,
   "keyCustom": 59,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 15,
   "memberCustom": 20,
   "hidden": {
    "total": 92,
    "http://fasb.org/us-gaap/2023": 60,
    "http://korumedical.com/20231231": 27,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 99,
   "entityCount": 1,
   "segmentCount": 35,
   "elementCount": 464,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 489,
    "http://xbrl.sec.gov/dei/2023": 36
   },
   "report": {
    "R1": {
     "role": "http://korumedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://korumedical.com/role/BalanceSheets",
     "longName": "00000002 - Statement - BALANCE SHEETS",
     "shortName": "BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://korumedical.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - BALANCE SHEETS (Parenthetical)",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://korumedical.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - STATEMENTS OF OPERATIONS",
     "shortName": "STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://korumedical.com/role/StatementsOfStockholdersEquity",
     "longName": "00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://korumedical.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - STATEMENTS OF CASH FLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies",
     "longName": "00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://korumedical.com/role/Inventory",
     "longName": "00000008 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://korumedical.com/role/PropertyAndEquipment",
     "longName": "00000009 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://korumedical.com/role/Stock-basedCompensation",
     "longName": "00000010 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://korumedical.com/role/Leases",
     "longName": "00000011 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://korumedical.com/role/FederalAndStateIncomeTaxes",
     "longName": "00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES",
     "shortName": "FEDERAL AND STATE INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://korumedical.com/role/MajorCustomers",
     "longName": "00000013 - Disclosure - MAJOR CUSTOMERS",
     "shortName": "MAJOR CUSTOMERS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://korumedical.com/role/CommitmentsAndContingencies",
     "longName": "00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://korumedical.com/role/EmployeeBenefits",
     "longName": "00000015 - Disclosure - EMPLOYEE BENEFITS",
     "shortName": "EMPLOYEE BENEFITS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://korumedical.com/role/DebtObligations",
     "longName": "00000016 - Disclosure - DEBT OBLIGATIONS",
     "shortName": "DEBT OBLIGATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://korumedical.com/role/SubsequentEvent",
     "longName": "00000017 - Disclosure - SUBSEQUENT EVENT",
     "shortName": "SUBSEQUENT EVENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000019 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://korumedical.com/role/InventoryTables",
     "longName": "00000020 - Disclosure - INVENTORY (Tables)",
     "shortName": "INVENTORY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://korumedical.com/role/PropertyAndEquipmentTables",
     "longName": "00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://korumedical.com/role/Stock-basedCompensationTables",
     "longName": "00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://korumedical.com/role/LeasesTables",
     "longName": "00000023 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://korumedical.com/role/FederalAndStateIncomeTaxesTables",
     "longName": "00000024 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)",
     "shortName": "FEDERAL AND STATE INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails",
     "longName": "00000025 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)",
     "shortName": "The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails",
     "longName": "00000026 - Disclosure - The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive: (Details)",
     "shortName": "The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "krmd:StockOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfSecuritiesTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "krmd:StockOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfSecuritiesTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
     "longName": "00000027 - Disclosure - Schedule of net income per common share (Details)",
     "shortName": "Schedule of net income per common share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details",
     "longName": "00000028 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022: (Details)",
     "shortName": "The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_country_US",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfNetRevenuesByGeography",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000029 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://korumedical.com/role/InventoryConsistsOfDetails",
     "longName": "00000030 - Disclosure - Inventory consists of: (Details)",
     "shortName": "Inventory consists of: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:InventoryWorkInProcessAndRawMaterials",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:InventoryWorkInProcessAndRawMaterials",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails",
     "longName": "00000031 - Disclosure - Property and equipment consists of the following at: (Details)",
     "shortName": "Property and equipment consists of the following at: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
     "longName": "00000032 - Disclosure - Schedule of time based stock options (Details)",
     "shortName": "Schedule of time based stock options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
     "longName": "00000033 - Disclosure - Schedule of status of time based stock options (Details)",
     "shortName": "Schedule of status of time based stock options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
     "longName": "00000034 - Disclosure - Schedule of information pertaining to options outstanding (Details)",
     "shortName": "Schedule of information pertaining to options outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details",
     "longName": "00000035 - Disclosure - The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022. (Details)",
     "shortName": "The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember",
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember",
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details",
     "longName": "00000036 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022. (Details)",
     "shortName": "The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member",
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member",
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_RestrictedStockAwardsMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_RestrictedStockAwardsMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails",
     "longName": "00000038 - Disclosure - Schedule of components of lease expenses (Details)",
     "shortName": "Schedule of components of lease expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails",
     "longName": "00000039 - Disclosure - Schedule of cash flow information related to leases (Details)",
     "shortName": "Schedule of cash flow information related to leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails",
     "longName": "00000040 - Disclosure - Schedule of balance sheet information related to leases (Details)",
     "shortName": "Schedule of balance sheet information related to leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentOther",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
     "longName": "00000041 - Disclosure - Schedule of maturities of lease liabilities (Details)",
     "shortName": "Schedule of maturities of lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://korumedical.com/role/LeasesDetailsNarrative",
     "longName": "00000042 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
     "longName": "00000043 - Disclosure - Schedule of provision for income taxes (Details)",
     "shortName": "Schedule of provision for income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails",
     "longName": "00000044 - Disclosure - Schedule of reconciliation of income taxes (Details)",
     "shortName": "Schedule of reconciliation of income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails",
     "longName": "00000045 - Disclosure - Schedule of components of deferred tax assets (Details)",
     "shortName": "Schedule of components of deferred tax assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredCompensationPlanAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredCompensationPlanAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://korumedical.com/role/MajorCustomersDetailsNarrative",
     "longName": "00000046 - Disclosure - MAJOR CUSTOMERS (Details Narrative)",
     "shortName": "MAJOR CUSTOMERS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://korumedical.com/role/EmployeeBenefitsDetailsNarrative",
     "longName": "00000047 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)",
     "shortName": "EMPLOYEE BENEFITS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "krmd:DescriptionOfMatchingContribution",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "krmd:DescriptionOfMatchingContribution",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://korumedical.com/role/DebtObligationsDetailsNarrative",
     "longName": "00000048 - Disclosure - DEBT OBLIGATIONS (Details Narrative)",
     "shortName": "DEBT OBLIGATIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2023-07-262023-07-28",
      "name": "us-gaap:DebtInstrumentFrequencyOfPeriodicPayment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-262023-07-28",
      "name": "us-gaap:DebtInstrumentFrequencyOfPeriodicPayment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://korumedical.com/role/SubsequentEventDetailsNarrative",
     "longName": "00000049 - Disclosure - SUBSEQUENT EVENT (Details Narrative)",
     "shortName": "SUBSEQUENT EVENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-03-062024-03-08_us-gaap_SubsequentEventMember",
      "name": "us-gaap:SubsequentEventDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-03-062024-03-08_us-gaap_SubsequentEventMember",
      "name": "us-gaap:SubsequentEventDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "krmd_AONPremiumFinanceLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "AONPremiumFinanceLLCMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AON Premium Finance LLC [Member]",
        "documentation": "The element represents a o n premium finance l l c member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Account eceivable from customers",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r551"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable less allowance for doubtful accounts of $24,777 and $21,459 for December 31, 2023, and December 31, 2022, respectively",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r129",
      "r408"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r425",
      "r596",
      "r597",
      "r598",
      "r644",
      "r666"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense related to stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense related to restricted stock awards",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r85"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r321"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, allowance for credit loss, current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r198",
      "r202"
     ]
    },
    "krmd_AllowanceForDoubtfulOtherReceivables1Current": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "AllowanceForDoubtfulOtherReceivables1Current",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for bad debts and other",
        "documentation": "The element represents allowance for doubtful other receivables1 current."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_AllowanceForNonRealizationOfDeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "AllowanceForNonRealizationOfDeferredTaxAsset",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Allowance for non-realization of deferred tax asset",
        "documentation": "The element represents allowance for non realization of deferred tax asset.",
        "label": "Allowance for Non Realization of Deferred Tax Asset"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_AmortizationOfIntangibleAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "AmortizationOfIntangibleAssets1",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense of intangible assets",
        "documentation": "The element represents amortization of intangible assets1."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "krmd_AntiDilutedSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "AntiDilutedSecurities",
     "presentation": [
      "http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "The element represents anti diluted securities."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_AntiDilutiveRestrictedStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "AntiDilutiveRestrictedStock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive restricted stock"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_AntiDilutiveStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "AntiDilutiveStockOptions",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r132",
      "r153",
      "r179",
      "r186",
      "r190",
      "r199",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r345",
      "r347",
      "r358",
      "r402",
      "r460",
      "r551",
      "r562",
      "r607",
      "r608",
      "r652"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_AssetsAndLiabilitiesLesseeFinanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "AssetsAndLiabilitiesLesseeFinanceAbstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Leases",
        "documentation": "The element represents assets and liabilities lessee finance abstract."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_AssetsAndLiabilitiesOperatingLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "AssetsAndLiabilitiesOperatingLesseeAbstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases",
        "documentation": "The element represents assets and liabilities operating lessee abstract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT ASSETS",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r138",
      "r153",
      "r199",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r345",
      "r347",
      "r358",
      "r551",
      "r607",
      "r608",
      "r652"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r576",
      "r577"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r576",
      "r577"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r576",
      "r577"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "krmd_BorrowingsFromIndebtedness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "BorrowingsFromIndebtedness",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings from indebtedness",
        "documentation": "The element represents borrowings from indebtedness."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r127",
      "r529"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH AND CASH EQUIVALENTS",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF YEAR",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r72",
      "r151"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r72"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FDIC cash insurance limit",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Non-Cash Operating, Investing and Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_CashPaidDuringPeriodsForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "CashPaidDuringPeriodsForAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the years for:",
        "documentation": "The element represents cash paid during periods for abstract."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_CashReceivedFromOptionExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "CashReceivedFromOptionExercise",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash received from option exercise",
        "documentation": "The element represents cash received from option exercise."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Refer to Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r50",
      "r403",
      "r446"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r212",
      "r213",
      "r515",
      "r606"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r557",
      "r558",
      "r559",
      "r560",
      "r596",
      "r597",
      "r644",
      "r664",
      "r666"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par or stated value per share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r447"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r56",
      "r447",
      "r466",
      "r666",
      "r667"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.01 par value, 75,000,000 shares authorized, 49,089,864 and 48,861,891 shares issued; 45,669,362 and 45,441,389 shares outstanding at December 31, 2023, and December 31, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r404",
      "r551"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_CompensationeExpenseRelatedToRestrictedStockAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "CompensationeExpenseRelatedToRestrictedStockAwards",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense related to restricted stock awards (in shares)",
        "documentation": "The element represents compensatione expense related to restricted stock awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r29",
      "r47",
      "r48",
      "r195",
      "r514"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r29",
      "r47",
      "r48",
      "r195",
      "r420",
      "r514"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r29",
      "r47",
      "r48",
      "r195",
      "r514",
      "r585"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/MajorCustomers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MAJOR CUSTOMERS",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r29",
      "r47",
      "r48",
      "r195"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r29",
      "r30",
      "r47",
      "r92",
      "r514"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r29",
      "r47",
      "r48",
      "r195",
      "r514"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r396"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative",
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative",
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r595",
      "r640"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current, net of refund",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r595",
      "r640"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r195"
     ]
    },
    "krmd_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer One [Member]",
        "documentation": "The element represents customer one member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/DebtObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT OBLIGATIONS",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r152",
      "r227",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r243",
      "r250",
      "r251",
      "r252"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53",
      "r54",
      "r94",
      "r95",
      "r155",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r370",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r593"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of the frequency of periodic payments",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r51"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r155",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r370",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r593"
     ]
    },
    "us-gaap_DeferredCompensationPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation cost",
        "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r639",
      "r640"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income tax assets, net allowance for non-realization of deferred tax assets of $6,002,777 and zero for December 31, 2023 and December 31, 2022, respectively",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_DeferredPurchasedPowerCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredPurchasedPowerCosts",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for non-realization of deferred tax asset",
        "documentation": "Costs of power used for operations in prior periods that were expected to be recovered from customers in future periods."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_DeferredRentReceivablesNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRentReceivablesNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Rent Receivables, Net, Noncurrent",
        "documentation": "Amount of excess of rental income recognized over rental payment required by lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r650"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income tax assets, net",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EmployeeBenefitsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Matching expense",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_DepreciationAndAmortizationPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "DepreciationAndAmortizationPropertyAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization, property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r182"
     ]
    },
    "krmd_DepreciationDepletionAndAmortization1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "DepreciationDepletionAndAmortization1",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "documentation": "The element represents depreciation depletion and amortization1.",
        "label": "Depreciation Depletion and Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_DescriptionOfMatchingContribution": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "DescriptionOfMatchingContribution",
     "presentation": [
      "http://korumedical.com/role/EmployeeBenefitsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of matching contribution",
        "documentation": "The element represents description of matching contribution."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive effect of outstanding stock options and unvested restricted stock",
        "documentation": "The element represents dilutive effect of outstanding stock options and unvested restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r279",
      "r310",
      "r311",
      "r313",
      "r548"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r576",
      "r577"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r576",
      "r577",
      "r579"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE",
        "verboseLabel": "Net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r169",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r356",
      "r357",
      "r399",
      "r411",
      "r534"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r356",
      "r357",
      "r399",
      "r411",
      "r534"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER COMMON SHARE",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r329",
      "r341"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued payroll and related taxes",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "krmd_EquipmentAndToolingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "EquipmentAndToolingMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment and Tooling [Member]",
        "documentation": "The element represents equipment and tooling member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r122",
      "r142",
      "r143",
      "r144",
      "r156",
      "r157",
      "r158",
      "r160",
      "r166",
      "r168",
      "r178",
      "r200",
      "r201",
      "r253",
      "r314",
      "r315",
      "r316",
      "r337",
      "r338",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r386",
      "r415",
      "r416",
      "r417",
      "r425",
      "r486"
     ]
    },
    "krmd_ExecutivesEmployeesConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ExecutivesEmployeesConsultantsMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executives Employees Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ExercisePrice1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ExercisePrice1Member",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price1 [Member]",
        "documentation": "The element represents exercise price1 member."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal income tax:"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total finance lease cost",
        "documentation": "The element represents finance lease cost."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_FinanceLeaseCost1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "FinanceLeaseCost1Abstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease cost:",
        "documentation": "The element represents finance lease cost1 abstract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r380",
      "r550"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing cash flows from finance leases",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r383"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total finance lease liabilities",
        "verboseLabel": "Total lease liabilities - Finance Leases",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r384"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liability \u2013 current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liability, net current portion",
        "verboseLabel": "Finance lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance lease liability",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r383"
     ]
    },
    "krmd_FinanceLeaseROUAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "FinanceLeaseROUAsset",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance lease ROU asset",
        "documentation": "The element represents finance lease rou asset.",
        "label": "Finance Lease ROU Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right-of-use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r380",
      "r550"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-lived intangible assets, accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r210"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The estimated amortization expense for the succeeding years for the intangible assets is approximately:",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r397",
      "r398"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net of accumulated amortization of $390,341 and $325,872 at December 31, 2023 and December 31, 2022, respectively",
        "verboseLabel": "Total amortization expense",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r397"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on foreign currency exchange",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r483"
     ]
    },
    "krmd_FurnitureAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "FurnitureAndOfficeEquipmentMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Office Equipment [Member]",
        "documentation": "The element represents furniture and office equipment member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of other assets."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on disposal of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross Profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r153",
      "r179",
      "r185",
      "r189",
      "r191",
      "r199",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r358",
      "r536",
      "r607"
     ]
    },
    "krmd_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IMPAIRMENT OF LONG-LIVED ASSETS",
        "documentation": "The element represents impairment or disposal of long lived assets policy text bloc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE TAXES",
        "label": "Loss before taxes",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r185",
      "r189",
      "r191",
      "r412",
      "r536"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FEDERAL AND STATE INCOME TAXES",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r323",
      "r330",
      "r331",
      "r335",
      "r339",
      "r342",
      "r343",
      "r344",
      "r424"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income (tax)/benefit",
        "label": "Income tax benefit",
        "negatedTerseLabel": "Income tax benefit/(expense)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r119",
      "r167",
      "r168",
      "r183",
      "r328",
      "r340",
      "r413"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r324",
      "r325",
      "r331",
      "r332",
      "r334",
      "r336",
      "r422"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes computed at the federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences and other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income and franchise tax",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Decrease)/Increase in accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Increase)/Decrease in accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Decrease)/Increase in accrued expenses",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Decrease)/Increase in accrued payroll and related taxes",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease/(Increase) in inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in other liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease/(Increase) in other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r393",
      "r394",
      "r395",
      "r397",
      "r532"
     ]
    },
    "us-gaap_InterestIncomeSecuritiesUSTreasury": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeSecuritiesUSTreasury",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment securities treasury bill",
        "documentation": "Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r149",
      "r150"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORY",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryGross",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r530",
      "r551"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INVENTORY",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r126",
      "r135",
      "r203",
      "r204",
      "r205",
      "r392",
      "r533"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: reserve for obsolete inventory",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r590"
     ]
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials and work-in-process",
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_InvestmentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentInterestRate",
     "presentation": [
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inteest rate on borrowings",
        "documentation": "Rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491",
      "r495",
      "r496",
      "r498",
      "r499",
      "r508",
      "r509",
      "r555",
      "r602",
      "r603"
     ]
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan provided, as lender",
        "documentation": "Fair value of investment in security owned."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r438",
      "r450",
      "r451",
      "r489",
      "r492",
      "r493",
      "r494",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r555",
      "r562",
      "r665"
     ]
    },
    "krmd_IssuanceOfCommonStockCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "IssuanceOfCommonStockCompensation",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock as compensation",
        "documentation": "The element represents issuance of common stock compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r550"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of lease expenses",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "krmd_LeaseOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "LeaseOneMember",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease One [Member]",
        "documentation": "The element represents lease one member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_LeaseThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "LeaseThreeMember",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Three [Member]",
        "documentation": "The element represents lease three member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_LeaseTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "LeaseTwoMember",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Two [Member]",
        "documentation": "The element represents lease two member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance leases discount rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "krmd_LesseeFinanceLeaseRemainingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "LesseeFinanceLeaseRemainingTerm",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease remaining term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance leases term",
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "krmd_LesseeFinancingLeaseImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "LesseeFinancingLeaseImputedInterest",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest - Finance Leases",
        "documentation": "The element represents lessee financing lease imputed interest.",
        "label": "Lessee Financing Lease Imputed interest"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total undiscounted lease payments - Finance Leases",
        "documentation": "The element represents lessee financing lease lease liability payments due total."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LEASES",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "krmd_LesseeOperatingLeaseImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "LesseeOperatingLeaseImputedInterest",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest - Operating Leases",
        "documentation": "The element represents lessee operating lease imputed interest.",
        "label": "Lessee Operating Lease Imputed interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of maturities of lease liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueTotal",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total undiscounted lease payments - Operating Leases",
        "documentation": "The element represents lessee operating lease liability payments due total."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "krmd_LesseeOperatingLeaseRemainingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "LesseeOperatingLeaseRemainingTerm",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease remaining term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r153",
      "r199",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r346",
      "r347",
      "r348",
      "r358",
      "r445",
      "r535",
      "r562",
      "r607",
      "r652",
      "r653"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r96",
      "r406",
      "r551",
      "r594",
      "r604",
      "r645"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r125",
      "r153",
      "r199",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r346",
      "r347",
      "r348",
      "r358",
      "r551",
      "r607",
      "r652",
      "r653"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r545",
      "r610",
      "r662",
      "r663"
     ]
    },
    "krmd_ManufacturingEquipmentAndToolingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ManufacturingEquipmentAndToolingMember",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing Equipment and Tooling [Member]",
        "documentation": "The element represents manufacturing equipment and tooling member."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r275",
      "r391",
      "r414",
      "r435",
      "r436",
      "r490",
      "r495",
      "r499",
      "r500",
      "r508",
      "r525",
      "r526",
      "r537",
      "r543",
      "r547",
      "r552",
      "r609",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r275",
      "r391",
      "r414",
      "r435",
      "r436",
      "r490",
      "r495",
      "r499",
      "r500",
      "r508",
      "r525",
      "r526",
      "r537",
      "r543",
      "r547",
      "r552",
      "r609",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "auth_ref": [
      "r195",
      "r545",
      "r610",
      "r662",
      "r663"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r120"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfCashFlows",
      "http://korumedical.com/role/StatementsOfOperations",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "Net loss",
        "verboseLabel": "Net Loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r74",
      "r97",
      "r123",
      "r139",
      "r140",
      "r144",
      "r153",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r172",
      "r179",
      "r185",
      "r189",
      "r191",
      "r199",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r357",
      "r358",
      "r410",
      "r468",
      "r484",
      "r485",
      "r536",
      "r561",
      "r607"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_Nol": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "Nol",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL",
        "documentation": "The element represents nol."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_NonEmployeeDirectorAndBoardAdvisorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "NonEmployeeDirectorAndBoardAdvisorMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Employee Director and Board Advisor [Member]",
        "documentation": "The element represents non employee director and board advisor member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r669",
      "r670",
      "r671"
     ]
    },
    "krmd_NonemployeeServicesTransactionCost": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "NonemployeeServicesTransactionCost",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonemployee services transaction cost",
        "documentation": "The element represents nonemployee services transaction cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL OTHER INCOME",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Operating Income"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_NotePayableTerms": {
     "xbrltype": "percentItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "NotePayableTerms",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable terms",
        "documentation": "The element represents note payable terms."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r95",
      "r661"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Operating Loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r185",
      "r189",
      "r191",
      "r536"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r550"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of cash flow information related to leases",
        "documentation": "Tabular disclosure of components of income from operating lease."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r385"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating lease liabilities",
        "verboseLabel": "Total lease liabilities - Operating Leases",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability \u2013 current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r383"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of balance sheet information related to leases",
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r103",
      "r104",
      "r106",
      "r107"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r91"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r551"
     ]
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance of AON note",
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r444"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r455"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "krmd_PatentsAndTrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "PatentsAndTrademarksMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents and Trademarks [Member]",
        "documentation": "The element represents patents and trademarks member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_PaymentsOnIndebtedness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "PaymentsOnIndebtedness",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on indebtedness",
        "documentation": "The element represents payments on indebtedness.",
        "label": "Payments on Indebtedness"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r641",
      "r642",
      "r643"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/EmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EMPLOYEE BENEFITS",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r546"
     ]
    },
    "krmd_PerformanceBasedSharesOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "PerformanceBasedSharesOptionsMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Based Shares Options [Member]",
        "documentation": "The element represents performance based shares options member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r206",
      "r207",
      "r531"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of equity",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "krmd_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]",
        "documentation": "The element represents promissory note member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r114",
      "r117",
      "r118"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r128",
      "r409"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r401",
      "r409",
      "r551"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentOther",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, at cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Property, Plant and Equipment, Other, Accumulated Depreciation",
        "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentOtherNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentOtherNet",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Other, Net",
        "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r114",
      "r117",
      "r407"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment consists of the following at:",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives of property and equipment",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r263",
      "r275",
      "r305",
      "r306",
      "r307",
      "r390",
      "r391",
      "r414",
      "r435",
      "r436",
      "r490",
      "r495",
      "r499",
      "r500",
      "r508",
      "r525",
      "r526",
      "r537",
      "r543",
      "r547",
      "r552",
      "r555",
      "r605",
      "r609",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r263",
      "r275",
      "r305",
      "r306",
      "r307",
      "r390",
      "r391",
      "r414",
      "r435",
      "r436",
      "r490",
      "r495",
      "r499",
      "r500",
      "r508",
      "r525",
      "r526",
      "r537",
      "r543",
      "r547",
      "r552",
      "r555",
      "r605",
      "r609",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "krmd_RdCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "RdCredit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D credit",
        "documentation": "The element represents rd credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r322",
      "r660"
     ]
    },
    "krmd_RestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "RestrictedStockAwardsMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards [Member]",
        "documentation": "The element represents restricted stock awards member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_RestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "RestrictedStockUnits",
     "presentation": [
      "http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock",
        "documentation": "The element represents restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r85",
      "r405",
      "r418",
      "r419",
      "r423",
      "r448",
      "r551"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r156",
      "r157",
      "r158",
      "r160",
      "r166",
      "r168",
      "r200",
      "r201",
      "r314",
      "r315",
      "r316",
      "r337",
      "r338",
      "r349",
      "r351",
      "r352",
      "r354",
      "r355",
      "r415",
      "r417",
      "r425",
      "r666"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUE RECOGNITION",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r527"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET REVENUES",
        "verboseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r153",
      "r180",
      "r181",
      "r184",
      "r187",
      "r188",
      "r192",
      "r193",
      "r195",
      "r199",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r358",
      "r400",
      "r607"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_RouLandlordCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "RouLandlordCredit",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ROU landlord credit",
        "documentation": "The element represents rou landlord credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r584"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of provision for income taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of net income per common share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of income taxes",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory consists of:",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r63",
      "r64"
     ]
    },
    "krmd_ScheduleOfNetRevenuesByGeography": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ScheduleOfNetRevenuesByGeography",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes net revenues by geography for the years ended December 31, 2023 and 2022:",
        "documentation": "The element represents schedule of net revenues by geography."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "krmd_ScheduleOfSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ScheduleOfSecuritiesTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following securities were not included in the computation of diluted shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive:",
        "documentation": "The element represents schedule of securities text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of information pertaining to options outstanding",
        "documentation": "The element represents schedule of share based compensation stock options activity amended table text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of status of time based stock options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r40"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of time based stock options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Short-Term Debt [Table]",
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2023, and 2022.",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details"
     ],
     "auth_ref": [
      "r193",
      "r194",
      "r429",
      "r431",
      "r433",
      "r492",
      "r497",
      "r503",
      "r511",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r528",
      "r544",
      "r555",
      "r610",
      "r662"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividends",
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average volatility",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value options granted",
        "documentation": "The element represents share based compensation arrangement by share based payment award grants in period weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/canceled (in shares)",
        "documentation": "The element represents share based compensation arrangement by share based payment award options forfeitures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited/canceled",
        "documentation": "The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options forfeitures in Period Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "documentation": "The element represents share based compensation arrangement by share based payment award options grants.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "documentation": "The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period Gross Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of options granted during the period",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning (in shares)",
        "periodEndLabel": "Outstanding at ending (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning (in shares)",
        "periodEndLabel": "Outstanding at ending (in shares)",
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding number unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Number Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning",
        "periodEndLabel": "Outstanding at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning",
        "periodEndLabel": "Outstanding at ending",
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Weighted Average Exercise Price Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at beginning",
        "periodEndLabel": "Unvested at ending",
        "documentation": "The element represents share based compensation arrangement by share based payment award options unvested weighted average exercise price.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Unvested Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested (in shares)",
        "documentation": "The element represents share based compensation arrangement by share based payment award options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total fair value of shares vested",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested (in shares)",
        "documentation": "The element represents share based compensation arrangement by share based payment award options vested in period gross.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Vested in Period Gross"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementByUnvestedAwardOptions",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at beginning (in shares)",
        "periodEndLabel": "Unvested at ending (in shares)",
        "documentation": "The element represents share based compensation arrangement by unvested award options.",
        "label": "Share Based Compensation Arrangement by Unvested Award Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/canceled",
        "documentation": "The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited/canceled",
        "documentation": "The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award Options forfeitures in Period Weighted Average Exercise Price Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted",
        "documentation": "The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award Options Grants in Period Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted",
        "documentation": "The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award Options Grants in Period Weighted Average Exercise Price Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested",
        "documentation": "The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award Options Vested in Period Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformanceStockOptionAwardsForTwelveMonthsEndedDecember312023And2022.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested",
        "documentation": "The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r283",
      "r302",
      "r303",
      "r304",
      "r305",
      "r308",
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes the activities for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022.",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number outstanding",
        "verboseLabel": "Common stock outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransaction",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based goods and non-employee services transaction",
        "documentation": "Description of transactions in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting method used for valuing the transaction, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average period",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share weighted average fair value of stock options granted",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "krmd_SharesAvailableForIssuanceShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "SharesAvailableForIssuanceShareBasedCompensation",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for issuance",
        "documentation": "The element represents shares available for issuance share based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under plan",
        "documentation": "The element represents shares issued under plan in total shares employee stock ownership plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r550"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r20",
      "r122",
      "r142",
      "r143",
      "r144",
      "r156",
      "r157",
      "r158",
      "r160",
      "r166",
      "r168",
      "r178",
      "r200",
      "r201",
      "r253",
      "r314",
      "r315",
      "r316",
      "r337",
      "r338",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r386",
      "r415",
      "r416",
      "r417",
      "r425",
      "r486"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r429",
      "r431",
      "r433",
      "r492",
      "r497",
      "r503",
      "r511",
      "r513",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r528",
      "r544",
      "r555",
      "r610",
      "r662"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details",
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r178",
      "r396",
      "r421",
      "r426",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r447",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r486",
      "r556"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details",
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r178",
      "r396",
      "r421",
      "r426",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r447",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r486",
      "r556"
     ]
    },
    "krmd_StockBasedCompensationSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "StockBasedCompensationSharesIssuable",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issuable under plan (in shares)",
        "documentation": "The element represents stock based compensation shares issuable."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockBasedCompensationStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "StockBasedCompensationStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "The element represents stock based compensation stock options.",
        "label": "Stock Based Compensation Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock awards (in shares)",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r85"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation paid in shares (in shares)",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r55",
      "r56",
      "r85"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance upon options exercised (in shares)",
        "verboseLabel": "Exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r55",
      "r56",
      "r85",
      "r289"
     ]
    },
    "krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options exercised",
        "documentation": "The element represents stock issued during period shares stock options exercised1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation paid in shares",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r55",
      "r56",
      "r85"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance upon options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r20",
      "r85"
     ]
    },
    "krmd_StockOptionPlan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "StockOptionPlan2015Member",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2015 [Member]",
        "documentation": "The element represents stock option plan2015 member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockOptionPlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "StockOptionPlan2021Member",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312023And2022.Details",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2021 [Member]",
        "documentation": "The element represents stock option plan2021 member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockOptionPlans2015And2021CombinedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "StockOptionPlans2015And2021CombinedMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plans 2015 and 2021 Combined [Member]",
        "documentation": "The element represents stock option plans2015 and2021 combined member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "StockOptions",
     "presentation": [
      "http://korumedical.com/role/FollowingSecuritiesWereNotIncludedInComputationOfDilutedSharesOutstandingForYearsEndedDecember312023And2022BecauseEffectWouldBeAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options",
        "documentation": "The element represents stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r60",
      "r78",
      "r449",
      "r466",
      "r487",
      "r488",
      "r551",
      "r562",
      "r594",
      "r604",
      "r645",
      "r666"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventDescription",
     "presentation": [
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of subsequent event",
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r388"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r388"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r388"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r388"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r388"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://korumedical.com/role/SubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENT",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r389"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Information"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_TaxBenefitFromRestrictedStockCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "TaxBenefitFromRestrictedStockCompensation",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit from restricted stock compensation",
        "documentation": "The element represents tax benefit from restricted stock compensation."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_TaxBenefitFromStockBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "TaxBenefitFromStockBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit from stock-based compensation",
        "documentation": "The element represents tax benefit from stock based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_TermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "TermLoanFacilityMember",
     "presentation": [
      "http://korumedical.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan Facility [Member]",
        "documentation": "The element represents term loan facility member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_TimeBasedSharesOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "TimeBasedSharesOptionsMember",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time Based Shares Options [Member]",
        "documentation": "The element represents time based shares options member."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r601",
      "r651"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_TreasuryStockPreferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockPreferredShares",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock, shares",
        "documentation": "Number of previously issued preferred shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, 3,420,502 shares at December 31, 2023 and December 31, 2022, at cost",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r38",
      "r39"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312023And2022Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "USE OF ESTIMATES IN THE FINANCIAL STATEMENTS",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r112",
      "r113",
      "r115",
      "r116"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "label": "Diluted weighted average shares outstanding",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r175"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "label": "Basic weighted average shares outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r175"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Outstanding Shares:"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_WriteoffOfDeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20231231",
     "localname": "WriteoffOfDeferredTaxAsset",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Write-off of deferred tax asset",
        "documentation": "The element represents writeoff of deferred tax asset."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//840/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479341/842-30-25-11"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001161697-24-000139-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001161697-24-000139-xbrl.zip
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M5OL]I(6HH^\I$4!Y0A.P:4SS-14PZ.G0-_H#(!6D+$/3&4Q(XZU@DN&1"$_
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M+>A&B)9N9ZQI/R#9RL+F$.6<TZAB.8='5NVAVE/0.:])"CXM<E%!GL 'S]_
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M#'#<_JILCM/@KP,12ROP?]%&LYWF1?XXI[[YZ@GO\0Y'^769E8.^NU<JZT2
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M85@]@;,/V,'F_7;0;/S9.&CL/'P;TP["3(D7-DUCD)9G+7]KL0[@#BM_?4_
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MPB.8?A\VU'X2HJU&^>V1W^DK0'-,J?8C/GG'GAWE?N!? @NO?TE L_9S%>0
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MX.I?!EE8C]/T"V8+V_1E?6J2/8#X,U!!HA,D)(%\=;,UO1BNU'9<JV'/N&!
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MP:FG [X"W.".A_<Z&G?S%:9T_CO5"; ,T#5W.B/#D<XJXY$< #FU;:,$L\P
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M@:/,D%PS^3'F?9?(&->2L_RJ/T4OGFPK,&;:)GKI>)/)2T51E^-^JB@C6*R
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M54$14M8ISGY\17(WN3\]1^] +U&*O&NJLUN;5%$H VAQ;),)BL;\$\YVJ\8
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M_B"FYF3,&V*)J"+C3\,TC +^P+9 $+]3<B# :T#V-8"$6DXT8,;P*+A Y)3
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M2<U8A'_A^-"9V%PMMSU?\26LUK15<MH)&L.K"!-J\GI+3?P;[O8XVEO%]H\
MG80ZN8[K04Z@6W58>!F]0X0<Q@RL,\?)G\B22EXY*/+1HJ\V*!,.H@6*7C-R
M1=['9M<]D&*!11O7+)\D/!9S&I^N^H:>1NH<I\OM9FI8LH"FC;,M4X =)2[6
MBECC",(PX_6/[0K0=N#D&^$M0C54&HRX_OMJERD*7*H:Q0-/"YEX/UEJYXQ
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MQ:275#8^/<2&-C"?\6 =:$9UA;<O5^>,PJ]8N*1N_D7J.9H;GBF9,F>DB&2
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M3DA0, )<H @71^57^S,*)T,8_F;/SA@%B%<9+EM]?/;5(P18$E?Z%"BK-XW
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MQQ:1]R\DGU*R[+@5WT;/-]\&.QB('-WDL1<;5H1[!K=TT_TV 'XH#H*#L@G
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M]BVNAV4R9K'YL7I?LW1JOYWR^'H:3N NR@Z#H?F_.*?CRW^[EGW,"@VJVIM
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MO6UR< #?@;OJY<;W8V2M"EX]#(>Z1OS08S^2S-R)9,ZX4KF2J^3+N6NN :?
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MI$F;%;TY$N"\;> 8M(6-GG\A1KU3&,0O_-R7,V!T!H! .(!\-!;X2*?T!2?
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M7H)(.IU)\V)F9]\^[<\3.6,QKG'.51VI4.W>6G17,S:F.BZ^E,SV2_TMOF-
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MY;QFJGGFZL VA@'W!H'W"A))F)"B+ET]65#6M^-CM[BRH#2.6#22Y!HTD1)
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M&RHPU;LF:FC"EQ)V!)[ZV\:.[//8OT.'2ET#/3Q1 *(TM3[$-A7UE:L;?7G
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M*;XUO4O'=QUB[T_(TN+).3 6'\]^$*":K<D;A<!*H,%P%/'NB;7D,G>;5-!
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MN).*VHE%Y%2L=14/V_1P0%\.)_!^+%]NW8TG/MK&#R&I(<@@HN@**3XE!8V
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M =Z" 837QX95R5-EV38J=7RU@6VXKYJ%36@XJP![=)RN)];B1(N2?:3@_*1
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M_.C>50?/%4)G["1^45%;6W.-W%)R%L_+CR.ZQ;-;DQ_2I/;R\SDOWXCA1G[
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MXFP#WO"L^H:B$: BRQKU'2P[Q#"1::*3(*[U*5ZW.T&&M5L&+L5!/2(8*@3
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MKC6SEK O!WMJ.F5?FY*@#5G%U6^D]<PL'Y;!%L%-=HY= KV!QE!3<&F2VW:
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M&7/M;YN(7^A#JM3'Z1_#T"#A WO=T-M2F(--BW?)&D,O\1*'EH1IB5\7Y)G
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MV .>20_4># %B]R#3#Z=BU;\AQH<NTTV>0#Z^]J+];*B?G'/+_4*NT[81U0
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M;-AS07>S%JAXV^/')>3[J\%+EZ8GS8&\B9 30;R_B@U.X]DZVUHWDB9QC[V
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MDA.C8 )N2/+>B;,]M,,O@)*0TG&? BDC*D!YZ>F5;7OLTEAAKUV7JC0C>_/
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MD(H,B$G).J[/<%P%=^.'"#B41],11597( S<3^7N.]6 G#?U9X^D$,$6QOH
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M?N-CU26L"E!V#CO$!0D'O;QY-NT7E[324L4%6,]7DH<IF)N!0$\#=6@]8B4
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M,Z9L!IVX@]$E7[;+[$'95](FEVH[]51F3$5YG<C*CC+5Z:J24R/L+^T3IF8
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MX5OBL\ LFA.I?HFIBJSB$/[=M\1IC6M0=2(VNB\TCMW1A"6D7TJ#C-?6I]@
M-)[$>9LE-6\41W=/O28B)Z**5&L\"Z1L'[TSK?*[7.KP*ZM%D6J-9XA>8S6]
M61?.)[K2XI64EU:AR+?&TTBU[:4WV?DKZ>+P<[B*X75MH&[-BDU#XTFI4UE7
MIQ938I1P[\#;EA4+ZVCISG-K+]: EZ1G_Q9@B@"K$W!8J"J?51#5=/E1PN'Q
M#>FJYM$J2<VA/KXXO :I>5%-5RK?0&J9>;0BM43M\*JGM_FCPCI:>P>#C9 C
MMFR-& OXJ7/Q[L#J&V$41#7U1Q(.\V]L4#-/\XL'?4*I>#5R",9ST IR?@\5
M[D[A$C(!37V* C%5FIV+CMBI33T%*LH*:[IK09$&N0E.Z<Q+.$A?NS>?/I2]
M[X*7+2ZJZ58#1?O+U-<JE*:!SB@&U7;\YJU]Q?F%"C%-MQ:H!Q<ELVA%)-?W
MZ"60<T@"*;:A\T<OB<Q^D"HY0Q3SO>#'0U?;#1QQ -3>0%:(YI:/S/4:V9(-
MV.?&T78>TX[=\UM#Z\Y::'GL16=CR@95;S!F<QF$SL:4>6*]KON:6'Y 4?JZ
M+'[7#F> [J?K!7[T\!HD/#]:W &=9L3%=EJCS F"O_#W46-FNX1!Q?#'I+=\
MF)O92[6,WF1H+![N[WOS+^)@Q.AN,KH=#7J3I=$;#*8/D^5H<F?,IN/18&0N
MFCT>D;PIM5BAOQXK-)K\8DZ6TWG#IS;BP\+IM_45(_QPC' VYZ9>?A%FYB=,
M9OP(1].'3&!,VEF5[@I/(^Z^.T8L3L9T^KV%.30&T_N9.5F(EM(L9I'_%+?C
M;O<8XM@$= TWQ5OD1!</B4,XJ9V?Q2"OCT'>FD/H8^.P?_&S.]!:P9ZFL>S]
MJVGP]]:_"1T$S ?,M 3PS3'@^][?IW-C\  -X-Z<-XR0SY[@\#0@?Z>X.&WX
MB+Q29]9]?PP7;'D_6H8'HKB-!U/AJ<Q)\VXJ7G*-3LV5(/[^&+%Y/QM/OYBF
MT3<GYNUHV3#*(8S&IRL7/UKE=R]V?S@&.33[2V/:'X_NHDL7FW55P8JAWP)^
M0]13F5/MYN+8XJ&_ %\*U!OF+XV[TS?$96E\[N;"V0GBL_%=_,R&+_A\@U66
MV>UG&9OD NA);!(^L6&+),F+1+_K7+A-4I@SH2S*962 <\&W.*,Y$_J2U$:F
M0"XPER4X9U(AS'1DB'.1.<QWSH2O//&18<Z%9WGZ<R9=3!A&;_FNJ/0!NFC?
MXRVAB\#F"SO@FKX@BS+XY'A1<L1ZNQTE+Z(6=S_D=YR[)2;(Q?OE!ADH1F!8
M*0@&"C$8:T(-'XJQ!(FQYU"2+W "R+ $(@,SPTIC^FA\%\%JNF$0UQ4++@MD
M!U2,I#\CBB;$#P?K?+3-.V7@BR=.UT/L!J"Y.*/*IH'/0!6N(MA9V-ODSX<!
M/]JN$+WI\HE&:'7PX[J/;"M@T7C_,PE<IX]Z$$,Z#J\2/R$I$;F<AA.QCM$;
M+($/PW[XWB,^F#G4 'X19K</>AAD;3BA)@83JACDH$M"5$B;,*D1ZV3<=/]L
M<+7^;$!I_MNUL0I5$S)(Z&<\<P7A"RB44O%LO"[L#7("?D8Q.?<]XZ>BQ/(F
M5UAJ['QR%E7'[>8A85JHT8"@PZT*=896/'NK%0XG3%#P[XB_ASJ^8[J_OT/D
MD5J[S;ZZ:4J-D<OHLBW/YQ ,EF 0]J$1"F.U-QYC'&K-*FE59VLK;\CZ(H 3
MBX8W^!9;L)G\+WJVD3S\7*D@#&P99ORV#UF[N<EGA7$%T&?"&J [G8WEHASQ
MH$G2HWJ^5*E\YAA5*YHMBBM.:RB:_*&_6'X+3G")M^&-"B+7G.Y$*Y<JFL\P
M4RX0PC\R1,)J,%ZA0<(:SZ\83^<"]AH%<PEI6D$FJM5+U9$'_C-<N8!0QM]+
MPP, B71-I2)2M7,Y;5IM?'@$CVW1,PR?)%JGLX26@]UA[0,"W#2@#V*%"3E@
M'*$%?\O(H3'TGBWJ\)++9^0^H7OB^1M)1+R4&K$P*Y:$1.X!K 2NB(,DH$80
M(>:VCB%G6IEA"=1)X/0%=F,KP%?G99>Z4G18-Q,,G92;BD2Y-C<TP1I1\XUP
M4C*KH)2QW.03X-+YA7.G(0>'R-4B7GCOF)B B&_:EK:/7#J;=H!V4B7_R^65
MQL/:%CQ^?)E:RO-'!Z*6))QQD6J:2SLSFD+=QAHJSSA]&E;//;Y0O@6ETR^(
M>IWB[_/+?RG%5V'],&!#8B"GE?+W?"@B'%'4I%-'6Z0JY_+2M,K;I-9#JW8/
M%9]+S0QS<@?T/I=^QM.%[;D;L0F#0:UB2BV90)32(DTR=W&%(I9$4PH^K_/\
M#6^.8,1B0X.(IKE4%92FDS13:9A@MJED.F#$!\9!Q7!65*IF+N$K#QI.5#%7
M,I[>/).FV15RM8Z62Y>.5LS/W^..%Z+5],AE++F%Z?-K<K18K:9(+C\Y7KQN
MP0=F%[35],AG'T<+W.5Z1+O4^'\\?X5/_@-02P,$%     @ 1X)M6)WPX)[3
M(0  7D," !4   !K<FUD+3(P,C,Q,C,Q7V1E9BYX;6SM75ESVSJ6?I^J^0\<
M3]543]5U'#O;36YGNK30:77+DEN2<SM/+IJ";'8HP@V2LGU__0!<)%(D%E(@
M"<K,@V-+6+ZS  <X.#CX\U^>U[:V <BUH//UY/S-VQ,-."9<6L[]UY.;^6EO
M/AB-3C37,YRE84,'?#UQX,E?_N\__T/#__[\7Z>GVJ4%[.47;0C-TY&S@K]I
M$V,-OFC?@ .0X4'TF_;=L'WR";RT;("T 5P_VL #^(NPXR_:AS<7YW?:Z:E
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MO6=A&U%8)H9.;P]C7?N<KX?8EZA\%5$01;KOE+8TU^KQ&A35USL^Z7=%2%\
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M8]"N_ 6Z??#<JP34"LUM_UG\9XN*>X&@L65&#E+N$_3T*LUX 7C<YLI&77^
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M1,GC1S+YS*) 9I5,R!4AU  K-H@2(*B@A"7D"ZL%427IF 2W&:8DQ*0AV"5
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M[>?EAW^/;UBZ=IK<JW[RQW!.2RGM-HF[%G([G[M4% R/]/C$_)4L$=ON?29
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MV,W>H7+=7;M?/OD.*Z_*HW?9]F>_[$XKM54X/50*H^=:^LOJNYU<&.Z[L '
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MC.P%5SXIE3&T-88?*U9C<Q5Z]>YFYUT;/4PS+O=7=Q;A#3"J#OYZZ'HGX$#
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MS#RX98QI#JP2=DHN+> 6K:22< BE@R=0J4L?2!/>:5K@_#9XTSBGMHA+OLC
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MP/=\I%2@@Z8[4W,2/E,D,5%:1JU@9R+,":9 Q%L* C.S)T:M2AI9G0ZMDW:
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M 7F\0>2!#FJ?"'Z)'[.[G3*P!15T00>,;)6J"@/^Z_X>>7K_38I\0VGM[ 2
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M]F3L%Q)9G^I:(@8^'_:\"NF)HP, [_/FE W1Q06G!,LM3U'BLPO;TGKTWWZ
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M$EMF+X4(>*U8G^_>^P%=:MVP6!V#U6^KQJ#7N)JC:6N8[%ABB!/4RI8=M52
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M*S4'URXJ7'N=6ZH#/9H9LJ-6W\@/F?V&_>?>C1#]R?\'4$L! A0#%     @
M1X)M6"LF?!&8 @  ,0H   L              ( !     &5X7S(S+3$N:'1M
M4$L! A0#%     @ 1X)M6-G=CI^7!@  HQH   L              ( !P0(
M &5X7S,Q+3$N:'1M4$L! A0#%     @ 1X)M6''>P7*.!@  HQH   L
M         ( !@0D  &5X7S,Q+3(N:'1M4$L! A0#%     @ 1X)M6#+7^.N%
M P  =@H   L              ( !.!   &5X7S,R+3$N:'1M4$L! A0#%
M  @ 1X)M6"Q0I=Z! P  A H   L              ( !YA,  &5X7S,R+3(N
M:'1M4$L! A0#%     @ 1X)M6+MF361IO@$ W@T,  T              ( !
MD!<  &9O<FU?,3 M:RYH=&U02P$"% ,4    " !'@FU8CD2B=.01  !CO0
M$0              @ $DU@$ :W)M9"TR,#(S,3(S,2YX<V102P$"% ,4
M" !'@FU8)N.LL]$2  "3R   %0              @ $WZ $ :W)M9"TR,#(S
M,3(S,5]C86PN>&UL4$L! A0#%     @ 1X)M6)WPX)[3(0  7D," !4
M         ( !._L! &MR;60M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M $>";5CRS%[K[V(  !S-!0 5              "  4$= @!K<FUD+3(P,C,Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    " !'@FU8Z?)R(4!   "#4 0 %0
M        @ %C@ ( :W)M9"TR,#(S,3(S,5]P<F4N>&UL4$L%!@     +  L
*HP(  -;  @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>form_10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krmd="http://korumedical.com/20231231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krmd-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember_custom_EquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember_custom_EquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ManufacturingEquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutivesEmployeesConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutivesEmployeesConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutivesEmployeesConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceBasedSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LeaseOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LeaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LeaseThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">krmd:LeaseThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="From2023-07-262023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="From2023-07-262023-07-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AONPremiumFinanceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AONPremiumFinanceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-08_us-gaap_SubsequentEventMember_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_TermLoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">krmd:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="From2024-03-062024-03-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-06</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="N">
        <measure>krmd:Number</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="ixv-6876">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="ixv-6877">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="ixv-6878">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="ixv-6879">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="ixv-6880">0000704440</dei:EntityCentralIndexKey>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0088"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredRentReceivablesNetNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="xdx2ixbrl0091"
      unitRef="USD">0</us-gaap:DeferredRentReceivablesNetNoncurrent>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredPurchasedPowerCosts
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:FinanceLeaseROUAsset
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="xdx2ixbrl0466"
      unitRef="N">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember"
      id="xdx2ixbrl0480">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember"
      id="xdx2ixbrl0482">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="xdx2ixbrl0506"
      unitRef="USD">3967480</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="xdx2ixbrl0508"
      unitRef="USD">-2014018</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MinimumMember_custom_FurnitureAndOfficeEquipmentMember"
      id="xdx2ixbrl0516">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MaximumMember_custom_FurnitureAndOfficeEquipmentMember"
      id="xdx2ixbrl0517">P10Y0M0D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MinimumMember_custom_EquipmentAndToolingMember"
      id="xdx2ixbrl0518">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MaximumMember_custom_EquipmentAndToolingMember"
      id="xdx2ixbrl0519">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <krmd:AntiDilutiveStockOptions
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="xdx2ixbrl0531"
      unitRef="Shares">0</krmd:AntiDilutiveStockOptions>
    <krmd:StockOptions
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0541"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0560"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0561"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0707">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0709">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0737"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0739"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:CashReceivedFromOptionExercise
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="xdx2ixbrl0781"
      unitRef="USD">0</krmd:CashReceivedFromOptionExercise>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      id="xdx2ixbrl0797">P8Y3M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0807">P46M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions
      contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember"
      id="xdx2ixbrl0816"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember"
      id="xdx2ixbrl0818"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions
      contextRef="AsOf2021-12-31_custom_PerformanceBasedSharesOptionsMember"
      id="xdx2ixbrl0820"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_PerformanceBasedSharesOptionsMember"
      id="xdx2ixbrl0822"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions
      contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember"
      id="xdx2ixbrl0852"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_PerformanceBasedSharesOptionsMember"
      id="xdx2ixbrl0854"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember"
      id="xdx2ixbrl0858">P36M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <krmd:TaxBenefitFromRestrictedStockCompensation
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember"
      decimals="0"
      id="xdx2ixbrl0862"
      unitRef="USD">0</krmd:TaxBenefitFromRestrictedStockCompensation>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0878"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0880"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0890"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0892"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0894"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0896"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:LesseeOperatingLeaseRemainingTerm
      contextRef="From2023-01-012023-12-31_custom_LeaseOneMember"
      id="xdx2ixbrl0914">P8Y7M6D</krmd:LesseeOperatingLeaseRemainingTerm>
    <krmd:LesseeOperatingLeaseRemainingTerm
      contextRef="From2023-01-012023-12-31_custom_LeaseTwoMember"
      id="xdx2ixbrl0916">P5Y</krmd:LesseeOperatingLeaseRemainingTerm>
    <krmd:LesseeFinanceLeaseRemainingTerm
      contextRef="From2023-01-012023-12-31_custom_LeaseOneMember"
      id="xdx2ixbrl0918">P3Y4M24D</krmd:LesseeFinanceLeaseRemainingTerm>
    <krmd:LesseeFinanceLeaseRemainingTerm
      contextRef="From2023-01-012023-12-31_custom_LeaseTwoMember"
      id="xdx2ixbrl0920">P3Y</krmd:LesseeFinanceLeaseRemainingTerm>
    <krmd:LesseeFinanceLeaseRemainingTerm
      contextRef="From2023-01-012023-12-31_custom_LeaseThreeMember"
      id="xdx2ixbrl0922">P4Y9M0D</krmd:LesseeFinanceLeaseRemainingTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2023-12-31" id="xdx2ixbrl0997">P6Y10M25D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2022-12-31" id="xdx2ixbrl0998">P9Y8M12D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2023-12-31" id="xdx2ixbrl1000">P3Y8M12D</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2022-12-31" id="xdx2ixbrl1001">P4Y7M6D</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1033"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1063"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1064"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:WriteoffOfDeferredTaxAsset
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1067"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1082"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:WriteoffOfDeferredTaxAsset
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1088"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:AllowanceForNonRealizationOfDeferredTaxAsset
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1114"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="ixv-7757">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="ixv-7758">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="ixv-7759">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="ixv-7760">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="ixv-7761">0-12305</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="ixv-7762">KORU MEDICAL SYSTEMS, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="ixv-7763">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="ixv-7764">13-3044880</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="ixv-7765">100 Corporate Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="ixv-7766">Mahwah</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="ixv-7767">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="ixv-7768">07430</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="ixv-7769">845</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="ixv-7770">469-2042</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-12-31" id="ixv-7771">common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-12-31" id="ixv-7772">KRMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-12-31" id="ixv-7773">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="ixv-7774">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="ixv-7775">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="ixv-7776">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="ixv-7777">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="ixv-7778">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="ixv-7779">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="ixv-7780">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="ixv-7781">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="ixv-7782">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="ixv-7783"
      unitRef="USD">111191841</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-03-13"
      decimals="INF"
      id="ixv-7784"
      unitRef="Shares">45710500</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-03-13"
      decimals="INF"
      id="ixv-7785"
      unitRef="Shares">3420502</us-gaap:TreasuryStockCommonShares>
    <dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="ixv-7786">256</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="ixv-7787">McGrail Merkel Quinn &amp; Associates, P.C.</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="ixv-7788">Scranton, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7789"
      unitRef="USD">11482240</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7790"
      unitRef="USD">17408257</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7791"
      unitRef="USD">24777</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7792"
      unitRef="USD">21459</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7793"
      unitRef="USD">4045211</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7794"
      unitRef="USD">3558884</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7795"
      unitRef="USD">3481301</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7796"
      unitRef="USD">6404867</us-gaap:InventoryNet>
    <us-gaap:OtherReceivables
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7797"
      unitRef="USD">28889</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7798"
      unitRef="USD">972396</us-gaap:OtherReceivables>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7799"
      unitRef="USD">1218288</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7800"
      unitRef="USD">1457232</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7801"
      unitRef="USD">20255929</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7802"
      unitRef="USD">29801636</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7803"
      unitRef="USD">3837657</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7804"
      unitRef="USD">3886975</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7805"
      unitRef="USD">390341</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7806"
      unitRef="USD">325872</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7807"
      unitRef="USD">754361</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7808"
      unitRef="USD">787182</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7809"
      unitRef="USD">3514055</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7810"
      unitRef="USD">3786545</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredRentReceivablesNetNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7811"
      unitRef="USD">6002777</us-gaap:DeferredRentReceivablesNetNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7812"
      unitRef="USD">3967480</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7813"
      unitRef="USD">98970</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7814"
      unitRef="USD">102625</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7815"
      unitRef="USD">28460972</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7816"
      unitRef="USD">42332443</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7817"
      unitRef="USD">975193</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7818"
      unitRef="USD">2391799</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7819"
      unitRef="USD">1711427</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7820"
      unitRef="USD">2889941</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7821"
      unitRef="USD">314344</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7822"
      unitRef="USD">433295</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7823"
      unitRef="USD">512520</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7824"
      unitRef="USD">257337</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7825"
      unitRef="USD">462941</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7826"
      unitRef="USD">542399</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7827"
      unitRef="USD">109540</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7828"
      unitRef="USD">98335</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7829"
      unitRef="USD">368313</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7830"
      unitRef="USD">345834</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7831"
      unitRef="USD">4454278</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7832"
      unitRef="USD">6958940</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7833"
      unitRef="USD">316623</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7834"
      unitRef="USD">394283</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7835"
      unitRef="USD">3336300</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7836"
      unitRef="USD">3653257</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7837"
      unitRef="USD">8107201</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7838"
      unitRef="USD">11006480</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-7839"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-7840"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-7841"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-7842"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-7843"
      unitRef="Shares">49089864</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-7844"
      unitRef="Shares">48861891</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-7845"
      unitRef="Shares">45669362</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-7846"
      unitRef="Shares">45441389</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7847"
      unitRef="USD">490899</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7848"
      unitRef="USD">488619</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7849"
      unitRef="USD">47018707</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7850"
      unitRef="USD">44252117</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockPreferredShares
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-7851"
      unitRef="Shares">3420502</us-gaap:TreasuryStockPreferredShares>
    <us-gaap:TreasuryStockPreferredShares
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-7852"
      unitRef="Shares">3420502</us-gaap:TreasuryStockPreferredShares>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7853"
      unitRef="USD">3843562</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7854"
      unitRef="USD">3843562</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7855"
      unitRef="USD">-23312273</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7856"
      unitRef="USD">-9571211</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7857"
      unitRef="USD">20353771</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7858"
      unitRef="USD">31325963</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7859"
      unitRef="USD">28460972</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7860"
      unitRef="USD">42332443</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7861"
      unitRef="USD">28517666</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7862"
      unitRef="USD">27896037</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7863"
      unitRef="USD">11809384</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7864"
      unitRef="USD">12527051</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7865"
      unitRef="USD">16708282</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7866"
      unitRef="USD">15368986</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7867"
      unitRef="USD">20365617</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7868"
      unitRef="USD">20606507</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7869"
      unitRef="USD">5742254</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7870"
      unitRef="USD">4956215</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7871"
      unitRef="USD">870390</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7872"
      unitRef="USD">587137</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7873"
      unitRef="USD">26978261</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7874"
      unitRef="USD">26149859</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7875"
      unitRef="USD">-10269979</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7876"
      unitRef="USD">-10780873</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7877"
      unitRef="USD">-5124</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7878"
      unitRef="USD">-39874</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7879"
      unitRef="USD">-59807</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7880"
      unitRef="USD">561328</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7881"
      unitRef="USD">145587</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7882"
      unitRef="USD">496397</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7883"
      unitRef="USD">105713</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7884"
      unitRef="USD">-9773582</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7885"
      unitRef="USD">-10675160</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7886"
      unitRef="USD">3967480</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7887"
      unitRef="USD">-2014018</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7888"
      unitRef="USD">-13741062</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7889"
      unitRef="USD">-8661142</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-7890"
      unitRef="USDPShares">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-7891"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-7892"
      unitRef="USDPShares">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-7893"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-7894"
      unitRef="Shares">45601346</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-7895"
      unitRef="Shares">45002074</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-7896"
      unitRef="Shares">45601346</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-7897"
      unitRef="Shares">45002074</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-7898"
      unitRef="Shares">48044162</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-7899"
      unitRef="USD">480441</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-7900"
      unitRef="USD">40774245</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-7901"
      unitRef="USD">-910069</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="ixv-7902"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="ixv-7903"
      unitRef="USD">36501055</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-7904"
      unitRef="Shares">206570</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-7905"
      unitRef="USD">2066</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-7906"
      unitRef="USD">511016</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7907"
      unitRef="USD">513082</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-7908"
      unitRef="USD">2083396</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7909"
      unitRef="USD">2083396</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <krmd:CompensationeExpenseRelatedToRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-7910"
      unitRef="Shares">50000</krmd:CompensationeExpenseRelatedToRestrictedStockAwards>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-7911"
      unitRef="USD">500</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-7912"
      unitRef="USD">482449</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7913"
      unitRef="USD">482949</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-7914"
      unitRef="Shares">561159</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-7915"
      unitRef="USD">5612</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-7916"
      unitRef="USD">401011</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7917"
      unitRef="USD">406623</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-7918"
      unitRef="USD">-8661142</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7919"
      unitRef="USD">-8661142</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-7920"
      unitRef="Shares">48861891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-7921"
      unitRef="USD">488619</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-7922"
      unitRef="USD">44252117</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-7923"
      unitRef="USD">-9571211</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="ixv-7924"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7925"
      unitRef="USD">31325963</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-7926"
      unitRef="Shares">127973</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-7927"
      unitRef="USD">1280</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-7928"
      unitRef="USD">445069</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7929"
      unitRef="USD">446349</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-7930"
      unitRef="USD">1940720</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7931"
      unitRef="USD">1940720</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <krmd:CompensationeExpenseRelatedToRestrictedStockAwards
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-7932"
      unitRef="Shares">100000</krmd:CompensationeExpenseRelatedToRestrictedStockAwards>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-7933"
      unitRef="USD">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-7934"
      unitRef="USD">380801</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7935"
      unitRef="USD">381801</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-7936"
      unitRef="USD">-13741062</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7937"
      unitRef="USD">-13741062</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-7938"
      unitRef="Shares">49089864</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-7939"
      unitRef="USD">490899</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="ixv-7940"
      unitRef="USD">47018707</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="ixv-7941"
      unitRef="USD">-23312273</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="ixv-7942"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7943"
      unitRef="USD">20353771</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7944"
      unitRef="USD">-13741062</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7945"
      unitRef="USD">-8661142</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7946"
      unitRef="USD">2768870</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7947"
      unitRef="USD">3079427</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7948"
      unitRef="USD">870390</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7949"
      unitRef="USD">587137</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7950"
      unitRef="USD">-59807</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7951"
      unitRef="USD">-2035297</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7952"
      unitRef="USD">-2026226</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredPurchasedPowerCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7953"
      unitRef="USD">6002777</us-gaap:DeferredPurchasedPowerCosts>
    <krmd:RouLandlordCredit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7954"
      unitRef="USD">-21988</krmd:RouLandlordCredit>
    <krmd:RouLandlordCredit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7955"
      unitRef="USD">212546</krmd:RouLandlordCredit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7956"
      unitRef="USD">486327</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7957"
      unitRef="USD">-34002</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7958"
      unitRef="USD">-2923566</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7959"
      unitRef="USD">298529</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7960"
      unitRef="USD">-943507</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7961"
      unitRef="USD">254176</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7962"
      unitRef="USD">-242599</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7963"
      unitRef="USD">-28776</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7964"
      unitRef="USD">-1416606</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7965"
      unitRef="USD">1164266</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7966"
      unitRef="USD">-79458</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7967"
      unitRef="USD">381796</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7968"
      unitRef="USD">255183</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7969"
      unitRef="USD">167337</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7970"
      unitRef="USD">-1178514</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7971"
      unitRef="USD">180237</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7972"
      unitRef="USD">-4892553</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7973"
      unitRef="USD">-5404549</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7974"
      unitRef="USD">782949</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7975"
      unitRef="USD">2761056</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7976"
      unitRef="USD">31648</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7977"
      unitRef="USD">40512</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7978"
      unitRef="USD">-814597</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7979"
      unitRef="USD">-2801568</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7980"
      unitRef="USD">406623</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <krmd:BorrowingsFromIndebtedness
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7981"
      unitRef="USD">565172</krmd:BorrowingsFromIndebtedness>
    <krmd:BorrowingsFromIndebtedness
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7982"
      unitRef="USD">783799</krmd:BorrowingsFromIndebtedness>
    <krmd:PaymentsOnIndebtedness
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7983"
      unitRef="USD">684123</krmd:PaymentsOnIndebtedness>
    <krmd:PaymentsOnIndebtedness
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7984"
      unitRef="USD">859087</krmd:PaymentsOnIndebtedness>
    <krmd:FinanceLeaseROUAsset
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7985"
      unitRef="USD">33461</krmd:FinanceLeaseROUAsset>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7986"
      unitRef="USD">66455</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7987"
      unitRef="USD">51850</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7988"
      unitRef="USD">-218867</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7989"
      unitRef="USD">279485</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7990"
      unitRef="USD">-5926017</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7991"
      unitRef="USD">-7926632</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7992"
      unitRef="USD">17408257</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="ixv-7993"
      unitRef="USD">25334889</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-7994"
      unitRef="USD">11482240</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-7995"
      unitRef="USD">17408257</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7996"
      unitRef="USD">50832</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-7997"
      unitRef="USD">28490</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7998"
      unitRef="USD">3160</us-gaap:IncomeTaxesPaidNet>
    <krmd:IssuanceOfCommonStockCompensation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-7999"
      unitRef="USD">446349</krmd:IssuanceOfCommonStockCompensation>
    <krmd:IssuanceOfCommonStockCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8000"
      unitRef="USD">513082</krmd:IssuanceOfCommonStockCompensation>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4119">&lt;p id="xdx_80C_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zLKDHnybvnVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 1 &#x2014; &lt;span id="xdx_820_zs762yR0Y2dk"&gt;NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--NatureOfOperations_zRRRz9m674vk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86F_zrYF4NWrhPF6"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;KORU MEDICAL SYSTEMS, INC. (the &#x201c;Company,&#x201d; &#x201c;KORU Medical,&#x201d;
&#x201c;KORU,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) develops, manufactures and commercializes innovative and
patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United
States Food and Drug Administration (the &#x201c;FDA&#x201d;) quality and regulatory system and international standards for quality system
management. &#160;The Company operates as &lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxH_uN_c20230101__20231231_zZ9xrjClTPk7" title="Number of segments::XDX::1"&gt;one&lt;/span&gt; segment.&lt;/p&gt;

&lt;p id="xdx_853_zMIe7tIiDdu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbn4X8lTGPme" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_869_z3Y0F1FhUOdb"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We prepare our financial statements and accompanying notes in accordance
with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). &#160;Certain prior year amounts have
been reclassified to conform to the current year presentation in our Financial Statements.&lt;/p&gt;

&lt;p id="xdx_853_zrCUXeIPMf9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z2QYCi9sxaV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86B_zTqFTpDCew02"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For purposes of the statements of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company has historically held
cash balances in excess of $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zAWPnCTIiF41" title="FDIC cash insurance limit"&gt;250,000&lt;/span&gt; at its primary commercial bank, which exceeds FDIC insurance limits. To reduce the risk of uninsured
deposits, the Company entered an insured cash sweep program with KeyBank during the second quarter of 2023 to automatically invest its
uninsured bank cash balances over $250,000 into FDIC insured banks so there is no more than $250,000 maintained at any one bank. Further,
as of December 31, 2023 the Company had invested $&lt;span id="xdx_90C_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20230101__20231231_zv5GLwAzoGZ" title="Investment securities treasury bill"&gt;10.2 million&lt;/span&gt; in a US Treasury bill that matures every 90 days.&lt;/p&gt;

&lt;p id="xdx_853_zDD9WrxjHK89" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zLy0eLjaRDX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_860_z0sXNcja7QFh"&gt;INVENTORY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.&lt;/p&gt;

&lt;p id="xdx_853_zfJIwzfaU0W5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zITQ163r6qLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_zqyfSbinHex6"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from &lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_z6RzZC0sqY6k" title="Estimated useful lives::XDX::P6Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0480"&gt;6&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zfnkxoE5vxd9" title="Estimated useful lives::XDX::P20Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0482"&gt;20&lt;/span&gt;&lt;/span&gt; years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2023 and 2022 was $&lt;span id="xdx_903_ecustom--AmortizationOfIntangibleAssets1_c20230101__20231231_zXukqMc8c7Hg" title="Amortization expense of intangible assets"&gt;64,469&lt;/span&gt; and
$&lt;span id="xdx_90C_ecustom--AmortizationOfIntangibleAssets1_c20220101__20221231_zgUYqRRQcSW3"&gt;62,143&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zksHIEC1OdYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_zOrGNsW3BTte"&gt;The estimated amortization expense for the succeeding years for the intangible
assets is approximately:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20231231_zDrzIiBttqZ5" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zpLNLu9FFqQ6" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 68%"&gt;2024&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 4%"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 24%; text-align: right"&gt;65,869&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zz7zWibfl9Cg" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;65,729&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zh5sEDXZveSa" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;64,674&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zmJwnFnhwN54" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;64,242&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zKXXXIq6HIb7" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;64,242&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zLHLDXaIUDv9" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;429,605&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zYPWgwFKa1jj" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total amortization expense&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;754,361&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_znSzBPf6D04d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_853_z3yWxcUzGDOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zShXOqtPrub8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;INCOME TAXES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For interim income tax reporting, the Company estimates its annual effective
tax rate and applies it to fiscal year-to-date pretax loss, excluding unusual or infrequently occurring discrete items. Tax jurisdictions
with losses for which tax benefits cannot be realized are excluded. The Company reported an income tax expense of $&lt;span id="xdx_90A_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20230101__20231231_zXmOncdOr4Rl" title="Income tax benefit::XDX::3967480"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0506"&gt;4.0&lt;/span&gt;&lt;/span&gt; million and income
tax benefit of $&lt;span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20220101__20221231_zoh7fVjM73E2" title="Income tax benefit::XDX::-2014018"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0508"&gt;2.0&lt;/span&gt;&lt;/span&gt; million for the years ended December 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We evaluate our deferred tax assets to determine if they are more likely
than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income Taxes.&#160; After considering
our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all available evidence,&#160; we
have recorded a valuation allowance of $&lt;span id="xdx_905_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dm_c20231231_zq2OWt9v3MCf" title="Valuation allowance"&gt;6.0 million&lt;/span&gt; against our net deferred tax assets during the year ended December 31, 2023.&#160;
As we continue to assess the realizability of our deferred tax assets, reported pretax income and new evidence may result in a partial
or full reduction of the valuation allowance in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Recurring items cause our effective tax rate to differ from the U.S. federal
statutory rate of &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zpGbrAiKG3qc" title="Statutory rate"&gt;21&lt;/span&gt;%, including U.S. federal R&amp;amp;D credits, U.S. state tax rates, and stock-based compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Beginning in 2022, certain research and development costs are required
to be capitalized and amortized over a five-year period under the Tax Cuts and Jobs Act enacted in December 2017. This change will impact
the expected U.S. federal and state income tax expense and cash taxes to be paid for our fiscal 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company files income tax returns in the U.S. federal jurisdiction and
in various state jurisdictions. Income tax returns for years prior to fiscal 2019 are no longer subject to examination by tax authorities.&lt;/p&gt;

&lt;p id="xdx_853_zG2DqhxrMm5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgArdpYLNeI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zmoMv5cFWNEa"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zR7gwH0bQ3Oe" title="Estimated useful lives of property and equipment::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0516"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zl14xJrx2uqc" title="::XDX::P10Y0M0D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0517"&gt;10&lt;/span&gt;&lt;/span&gt; years for furniture
and office equipment, &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zBTCv7TEdGFd" title="::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0518"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zPML4eKFwqsd" title="::XDX::P12Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0519"&gt;12&lt;/span&gt;&lt;/span&gt; years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2023
and 2022 was $&lt;span id="xdx_90F_ecustom--DepreciationAndAmortizationPropertyAndEquipment_c20230101__20231231_ziA6P2npF5v" title="Depreciation and amortization, property and equipment"&gt;805,921&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--DepreciationAndAmortizationPropertyAndEquipment_c20220101__20221231_zNRekgHPDcna" title="Depreciation and amortization, property and equipment"&gt;524,994&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p id="xdx_853_zHfZIY2IkFT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zQ2zPvVkCaM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_861_zwjIzp2ufOF2"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock options outside
of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing
model. &#160;All options are charged against income at their fair value. &#160;The entire compensation expense of the award is recognized
over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Shares of stock granted for director fees under the non-employee director
compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company issues restricted stock awards under its omnibus equity incentive
plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at the fair market value of
the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization thresholds
were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of other restricted stock awards
were estimated on the date of grant at the current stock price. We recognize restricted stock expense using the straight-line attribution
method over the requisite service period and account for forfeitures as they occur.&lt;/p&gt;

&lt;p id="xdx_853_zL0dqwu47sgb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_z1hUayy5s3X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_868_zaZI5CgC3olc"&gt;NET LOSS PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Basic net loss per common share is calculated by dividing net loss by the
weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net
loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company&#x2019;s potentially
dilutive common shares are those that result from diluted common stock options and unvested restricted stock awards. The calculation of
diluted loss per share excluded stock options of &lt;span id="xdx_90C_ecustom--AntiDilutiveStockOptions_pid_uShares_c20230101__20231231_zziGeBajGgUk" title="Anti-dilutive stock options"&gt;12,335&lt;/span&gt; and &lt;span id="xdx_904_ecustom--AntiDilutiveStockOptions_pid_dxL_uShares_c20220101__20221231_z5tD5FVp81p4" title="Anti-dilutive stock options::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0531"&gt;zero&lt;/span&gt;&lt;/span&gt; in weighted-average shares for each of the years ended
December 31, 2023 and 2022, respectively, as their effect was anti-dilutive as a result of the net loss incurred for those periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The calculation of diluted loss per share excluded performance-based restricted
stock and time-based restricted stock of &lt;span id="xdx_904_ecustom--AntiDilutiveRestrictedStock_pid_uShares_c20230101__20231231_z8W4A0kYm7m6" title="Anti-dilutive restricted stock"&gt;904,496&lt;/span&gt; and &lt;span id="xdx_905_ecustom--AntiDilutiveRestrictedStock_pid_uShares_c20220101__20221231_zYsUlyhb8ALh" title="Anti-dilutive restricted stock"&gt;950,000&lt;/span&gt; in weighted-average shares for each of the years ended December
31, 2023 and 2022, respectively, as their effect was anti-dilutive as a result of the net loss incurred for those periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfSecuritiesTextBlock_zCAYv9Hd6LWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BF_zEUvOauTXLBj"&gt;The following securities were not included in the computation of diluted
shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 39%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20230101__20231231_zvTejDmQtR0c" style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20220101__20221231_z5ouRlWwl5gg" style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 3%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StockOptions_pid_uShares_ztWXeR7pq7rd" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Stock options&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;12,335&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--RestrictedStockUnits_pid_uShares_zB7X80sRCGLl" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Restricted stock&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;904,496&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;950,000&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_uShares_zcuV9Hh5wmM3" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;916,831&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;950,000&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zDqCtW4WYiEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNaXvfvueqkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zcL7Io9SHgCd" style="display: none; visibility: hidden"&gt;Schedule of net income per common share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_ztU38QDRs1il" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_z5NhXHxgA985" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 69%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_zGYjl5DfEOx4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(13,741,062&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(8,661,142&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zbX0ho5sfmT8" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo1PThvKWyg8" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,601,346&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,002,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zqRV9gTQ3b8f" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Dilutive effect of outstanding stock options and unvested restricted stock&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0560"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0561"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziVtziaxQivj" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,601,346&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,020,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zLKU6CbTJXmg" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zvEIXmwPQtFk" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.30&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zgo7lA10NY5a" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.30&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zUiOb4deb5ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Therefore, diluted weighted average number of shares outstanding and diluted
net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the years ended December
31, 2023 and 2022. See &#x201c;NOTE 4 &#x2014; STOCK-BASED COMPENSATION&#x201d; for further detail.&lt;/p&gt;

&lt;p id="xdx_853_znY2BDTAcEPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zNFNFYuQAZI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86F_zjJSsksRpBe5"&gt;USE OF ESTIMATES IN THE FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.&lt;/p&gt;

&lt;p id="xdx_853_znUV9ope84m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zOtO34xIQuE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_861_zzayRpQjOfy5"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting
Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#x201c;Product Revenue&#x201d;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#x201c;PIDD&#x201d;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#x201c;CIDP&#x201d;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#x201c;NRE&#x201d;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers and are included
in Product Revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#x2019;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#x2019;s revenue recognition criteria described above. As of December 31, 2023, the Company has recognized
a contract asset of zero which is included in other accounts receivable in the accompanying balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfNetRevenuesByGeography_zgOk39Kpl3P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B4_zzLqgxExCEz2"&gt;The following table summarizes net revenues by geography for the years
ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 39%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 3%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Net Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Domestic&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zlJvfdkf0eva" style="text-align: right" title="Net Revenue"&gt;23,676,039&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zxd3On1nZsl7" style="text-align: right" title="Net Revenue"&gt;23,586,254&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;International&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z9WJMe07cdac" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,841,627&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zWLgskHZsh1h" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,309,783&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20230101__20231231_zjh9E8vQnmA2" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;28,517,666&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20220101__20221231_zuQ3cmZ8ak6a" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;27,896,037&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zJHH3WsFODQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_853_zRYrPM1r0gkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zutAeD5nwoZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_zVguakYwV0S9"&gt;LEASES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#x201c;NOTE 5 &lt;b&gt;&#x2014; &lt;/b&gt;LEASES&#x201d; for further detail.&lt;/p&gt;

&lt;p id="xdx_853_znNPxFFGSCwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBQ7gh9jSITg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86E_zCzypJsogS6i"&gt;ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i&gt;Financial Instruments
&#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company adopted this standard on January 1, 2023, and it did not have a
significant impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.&lt;/p&gt;

&lt;p id="xdx_853_zdycsE4UWRe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zfpebkPQILed" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86E_zqY8Tw8pNwb9"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 7in"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2023.&lt;/p&gt;

&lt;p id="xdx_853_zS0TbtpWyY9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc_zNaHnezOrga1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;IMPAIRMENT OF LONG-LIVED ASSETS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2023.&lt;/p&gt;

&lt;p id="xdx_853_znYMkSVW9tHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NatureOfOperations contextRef="From2023-01-01to2023-12-31" id="ixv-4124">&lt;p id="xdx_843_eus-gaap--NatureOfOperations_zRRRz9m674vk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86F_zrYF4NWrhPF6"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;KORU MEDICAL SYSTEMS, INC. (the &#x201c;Company,&#x201d; &#x201c;KORU Medical,&#x201d;
&#x201c;KORU,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) develops, manufactures and commercializes innovative and
patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United
States Food and Drug Administration (the &#x201c;FDA&#x201d;) quality and regulatory system and international standards for quality system
management. &#160;The Company operates as &lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxH_uN_c20230101__20231231_zZ9xrjClTPk7" title="Number of segments::XDX::1"&gt;one&lt;/span&gt; segment.&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4131">&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbn4X8lTGPme" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_869_z3Y0F1FhUOdb"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We prepare our financial statements and accompanying notes in accordance
with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). &#160;Certain prior year amounts have
been reclassified to conform to the current year presentation in our Financial Statements.&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4137">&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z2QYCi9sxaV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86B_zTqFTpDCew02"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For purposes of the statements of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company has historically held
cash balances in excess of $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zAWPnCTIiF41" title="FDIC cash insurance limit"&gt;250,000&lt;/span&gt; at its primary commercial bank, which exceeds FDIC insurance limits. To reduce the risk of uninsured
deposits, the Company entered an insured cash sweep program with KeyBank during the second quarter of 2023 to automatically invest its
uninsured bank cash balances over $250,000 into FDIC insured banks so there is no more than $250,000 maintained at any one bank. Further,
as of December 31, 2023 the Company had invested $&lt;span id="xdx_90C_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20230101__20231231_zv5GLwAzoGZ" title="Investment securities treasury bill"&gt;10.2 million&lt;/span&gt; in a US Treasury bill that matures every 90 days.&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8001"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:InterestIncomeSecuritiesUSTreasury
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8002"
      unitRef="USD">10200000</us-gaap:InterestIncomeSecuritiesUSTreasury>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4145">&lt;p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zLy0eLjaRDX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_860_z0sXNcja7QFh"&gt;INVENTORY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-12-31" id="ixv-4153">&lt;p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zITQ163r6qLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_zqyfSbinHex6"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from &lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_z6RzZC0sqY6k" title="Estimated useful lives::XDX::P6Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0480"&gt;6&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zfnkxoE5vxd9" title="Estimated useful lives::XDX::P20Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0482"&gt;20&lt;/span&gt;&lt;/span&gt; years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2023 and 2022 was $&lt;span id="xdx_903_ecustom--AmortizationOfIntangibleAssets1_c20230101__20231231_zXukqMc8c7Hg" title="Amortization expense of intangible assets"&gt;64,469&lt;/span&gt; and
$&lt;span id="xdx_90C_ecustom--AmortizationOfIntangibleAssets1_c20220101__20221231_zgUYqRRQcSW3"&gt;62,143&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zksHIEC1OdYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_zOrGNsW3BTte"&gt;The estimated amortization expense for the succeeding years for the intangible
assets is approximately:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20231231_zDrzIiBttqZ5" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zpLNLu9FFqQ6" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 68%"&gt;2024&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 4%"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 24%; text-align: right"&gt;65,869&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zz7zWibfl9Cg" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;65,729&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zh5sEDXZveSa" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;64,674&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zmJwnFnhwN54" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;64,242&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zKXXXIq6HIb7" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;64,242&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zLHLDXaIUDv9" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;429,605&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zYPWgwFKa1jj" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total amortization expense&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;754,361&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_znSzBPf6D04d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <krmd:AmortizationOfIntangibleAssets1
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8003"
      unitRef="USD">64469</krmd:AmortizationOfIntangibleAssets1>
    <krmd:AmortizationOfIntangibleAssets1
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8004"
      unitRef="USD">62143</krmd:AmortizationOfIntangibleAssets1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4165">&lt;p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zksHIEC1OdYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_zOrGNsW3BTte"&gt;The estimated amortization expense for the succeeding years for the intangible
assets is approximately:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20231231_zDrzIiBttqZ5" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zpLNLu9FFqQ6" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 68%"&gt;2024&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 4%"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 24%; text-align: right"&gt;65,869&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zz7zWibfl9Cg" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;65,729&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zh5sEDXZveSa" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;64,674&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zmJwnFnhwN54" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;64,242&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zKXXXIq6HIb7" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;64,242&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zLHLDXaIUDv9" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;429,605&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zYPWgwFKa1jj" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total amortization expense&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;754,361&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8005"
      unitRef="USD">65869</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8006"
      unitRef="USD">65729</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8007"
      unitRef="USD">64674</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8008"
      unitRef="USD">64242</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8009"
      unitRef="USD">64242</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8010"
      unitRef="USD">429605</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8011"
      unitRef="USD">754361</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4222">&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zShXOqtPrub8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;INCOME TAXES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For interim income tax reporting, the Company estimates its annual effective
tax rate and applies it to fiscal year-to-date pretax loss, excluding unusual or infrequently occurring discrete items. Tax jurisdictions
with losses for which tax benefits cannot be realized are excluded. The Company reported an income tax expense of $&lt;span id="xdx_90A_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20230101__20231231_zXmOncdOr4Rl" title="Income tax benefit::XDX::3967480"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0506"&gt;4.0&lt;/span&gt;&lt;/span&gt; million and income
tax benefit of $&lt;span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_dxL_c20220101__20221231_zoh7fVjM73E2" title="Income tax benefit::XDX::-2014018"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0508"&gt;2.0&lt;/span&gt;&lt;/span&gt; million for the years ended December 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We evaluate our deferred tax assets to determine if they are more likely
than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income Taxes.&#160; After considering
our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all available evidence,&#160; we
have recorded a valuation allowance of $&lt;span id="xdx_905_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dm_c20231231_zq2OWt9v3MCf" title="Valuation allowance"&gt;6.0 million&lt;/span&gt; against our net deferred tax assets during the year ended December 31, 2023.&#160;
As we continue to assess the realizability of our deferred tax assets, reported pretax income and new evidence may result in a partial
or full reduction of the valuation allowance in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Recurring items cause our effective tax rate to differ from the U.S. federal
statutory rate of &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zpGbrAiKG3qc" title="Statutory rate"&gt;21&lt;/span&gt;%, including U.S. federal R&amp;amp;D credits, U.S. state tax rates, and stock-based compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Beginning in 2022, certain research and development costs are required
to be capitalized and amortized over a five-year period under the Tax Cuts and Jobs Act enacted in December 2017. This change will impact
the expected U.S. federal and state income tax expense and cash taxes to be paid for our fiscal 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company files income tax returns in the U.S. federal jurisdiction and
in various state jurisdictions. Income tax returns for years prior to fiscal 2019 are no longer subject to examination by tax authorities.&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8012"
      unitRef="USD">6000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-8013"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4241">&lt;p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgArdpYLNeI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zmoMv5cFWNEa"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from &lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zR7gwH0bQ3Oe" title="Estimated useful lives of property and equipment::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0516"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zl14xJrx2uqc" title="::XDX::P10Y0M0D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0517"&gt;10&lt;/span&gt;&lt;/span&gt; years for furniture
and office equipment, &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zBTCv7TEdGFd" title="::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0518"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zPML4eKFwqsd" title="::XDX::P12Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0519"&gt;12&lt;/span&gt;&lt;/span&gt; years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2023
and 2022 was $&lt;span id="xdx_90F_ecustom--DepreciationAndAmortizationPropertyAndEquipment_c20230101__20231231_ziA6P2npF5v" title="Depreciation and amortization, property and equipment"&gt;805,921&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--DepreciationAndAmortizationPropertyAndEquipment_c20220101__20221231_zNRekgHPDcna" title="Depreciation and amortization, property and equipment"&gt;524,994&lt;/span&gt;, respectively.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <krmd:DepreciationAndAmortizationPropertyAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8014"
      unitRef="USD">805921</krmd:DepreciationAndAmortizationPropertyAndEquipment>
    <krmd:DepreciationAndAmortizationPropertyAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8015"
      unitRef="USD">524994</krmd:DepreciationAndAmortizationPropertyAndEquipment>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-12-31" id="ixv-4257">&lt;p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zQ2zPvVkCaM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_861_zwjIzp2ufOF2"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock options outside
of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing
model. &#160;All options are charged against income at their fair value. &#160;The entire compensation expense of the award is recognized
over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Shares of stock granted for director fees under the non-employee director
compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company issues restricted stock awards under its omnibus equity incentive
plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at the fair market value of
the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization thresholds
were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of other restricted stock awards
were estimated on the date of grant at the current stock price. We recognize restricted stock expense using the straight-line attribution
method over the requisite service period and account for forfeitures as they occur.&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4267">&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_z1hUayy5s3X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_868_zaZI5CgC3olc"&gt;NET LOSS PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Basic net loss per common share is calculated by dividing net loss by the
weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net
loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company&#x2019;s potentially
dilutive common shares are those that result from diluted common stock options and unvested restricted stock awards. The calculation of
diluted loss per share excluded stock options of &lt;span id="xdx_90C_ecustom--AntiDilutiveStockOptions_pid_uShares_c20230101__20231231_zziGeBajGgUk" title="Anti-dilutive stock options"&gt;12,335&lt;/span&gt; and &lt;span id="xdx_904_ecustom--AntiDilutiveStockOptions_pid_dxL_uShares_c20220101__20221231_z5tD5FVp81p4" title="Anti-dilutive stock options::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0531"&gt;zero&lt;/span&gt;&lt;/span&gt; in weighted-average shares for each of the years ended
December 31, 2023 and 2022, respectively, as their effect was anti-dilutive as a result of the net loss incurred for those periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The calculation of diluted loss per share excluded performance-based restricted
stock and time-based restricted stock of &lt;span id="xdx_904_ecustom--AntiDilutiveRestrictedStock_pid_uShares_c20230101__20231231_z8W4A0kYm7m6" title="Anti-dilutive restricted stock"&gt;904,496&lt;/span&gt; and &lt;span id="xdx_905_ecustom--AntiDilutiveRestrictedStock_pid_uShares_c20220101__20221231_zYsUlyhb8ALh" title="Anti-dilutive restricted stock"&gt;950,000&lt;/span&gt; in weighted-average shares for each of the years ended December
31, 2023 and 2022, respectively, as their effect was anti-dilutive as a result of the net loss incurred for those periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfSecuritiesTextBlock_zCAYv9Hd6LWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BF_zEUvOauTXLBj"&gt;The following securities were not included in the computation of diluted
shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 39%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20230101__20231231_zvTejDmQtR0c" style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20220101__20221231_z5ouRlWwl5gg" style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 3%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StockOptions_pid_uShares_ztWXeR7pq7rd" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Stock options&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;12,335&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--RestrictedStockUnits_pid_uShares_zB7X80sRCGLl" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Restricted stock&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;904,496&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;950,000&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_uShares_zcuV9Hh5wmM3" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;916,831&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;950,000&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zDqCtW4WYiEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNaXvfvueqkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zcL7Io9SHgCd" style="display: none; visibility: hidden"&gt;Schedule of net income per common share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_ztU38QDRs1il" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_z5NhXHxgA985" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 69%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_zGYjl5DfEOx4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(13,741,062&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(8,661,142&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zbX0ho5sfmT8" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo1PThvKWyg8" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,601,346&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,002,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zqRV9gTQ3b8f" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Dilutive effect of outstanding stock options and unvested restricted stock&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0560"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0561"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziVtziaxQivj" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,601,346&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,020,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zLKU6CbTJXmg" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zvEIXmwPQtFk" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.30&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zgo7lA10NY5a" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.30&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zUiOb4deb5ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Therefore, diluted weighted average number of shares outstanding and diluted
net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the years ended December
31, 2023 and 2022. See &#x201c;NOTE 4 &#x2014; STOCK-BASED COMPENSATION&#x201d; for further detail.&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <krmd:AntiDilutiveStockOptions
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-8016"
      unitRef="Shares">12335</krmd:AntiDilutiveStockOptions>
    <krmd:AntiDilutiveRestrictedStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-8017"
      unitRef="Shares">904496</krmd:AntiDilutiveRestrictedStock>
    <krmd:AntiDilutiveRestrictedStock
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-8018"
      unitRef="Shares">950000</krmd:AntiDilutiveRestrictedStock>
    <krmd:ScheduleOfSecuritiesTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4289">&lt;p id="xdx_89C_ecustom--ScheduleOfSecuritiesTextBlock_zCAYv9Hd6LWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BF_zEUvOauTXLBj"&gt;The following securities were not included in the computation of diluted
shares outstanding for the years ended December 31, 2023, and 2022 because the effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 39%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20230101__20231231_zvTejDmQtR0c" style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20220101__20221231_z5ouRlWwl5gg" style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 3%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--StockOptions_pid_uShares_ztWXeR7pq7rd" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Stock options&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;12,335&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--RestrictedStockUnits_pid_uShares_zB7X80sRCGLl" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Restricted stock&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;904,496&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;950,000&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AntiDilutedSecurities_pid_uShares_zcuV9Hh5wmM3" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;916,831&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;950,000&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</krmd:ScheduleOfSecuritiesTextBlock>
    <krmd:StockOptions
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-8019"
      unitRef="Shares">12335</krmd:StockOptions>
    <krmd:RestrictedStockUnits
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-8020"
      unitRef="Shares">904496</krmd:RestrictedStockUnits>
    <krmd:RestrictedStockUnits
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-8021"
      unitRef="Shares">950000</krmd:RestrictedStockUnits>
    <krmd:AntiDilutedSecurities
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-8022"
      unitRef="Shares">916831</krmd:AntiDilutedSecurities>
    <krmd:AntiDilutedSecurities
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-8023"
      unitRef="Shares">950000</krmd:AntiDilutedSecurities>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4347">&lt;p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNaXvfvueqkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zcL7Io9SHgCd" style="display: none; visibility: hidden"&gt;Schedule of net income per common share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_ztU38QDRs1il" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_z5NhXHxgA985" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 69%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_zGYjl5DfEOx4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(13,741,062&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(8,661,142&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zbX0ho5sfmT8" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo1PThvKWyg8" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,601,346&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,002,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DilutiveEffectOfOutstandingStockOptionsAndUnvestedRestrictedStock_pid_uShares_zqRV9gTQ3b8f" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Dilutive effect of outstanding stock options and unvested restricted stock&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0560"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0561"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziVtziaxQivj" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,601,346&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,020,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zLKU6CbTJXmg" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zvEIXmwPQtFk" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.30&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zgo7lA10NY5a" style="vertical-align: bottom; background-color: #E7E6E6"&gt;
    &lt;td style="padding-left: 0.2in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.30&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8024"
      unitRef="USD">-13741062</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8025"
      unitRef="USD">-8661142</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8026"
      unitRef="Shares">45601346</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8027"
      unitRef="Shares">45002074</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8028"
      unitRef="Shares">45601346</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-8029"
      unitRef="Shares">45020074</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-8030"
      unitRef="USDPShares">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-8031"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-8032"
      unitRef="USDPShares">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-8033"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="ixv-4477">&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zNFNFYuQAZI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86F_zjJSsksRpBe5"&gt;USE OF ESTIMATES IN THE FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4483">&lt;p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zOtO34xIQuE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_861_zzayRpQjOfy5"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting
Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#x201c;Product Revenue&#x201d;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#x201c;PIDD&#x201d;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#x201c;CIDP&#x201d;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#x201c;NRE&#x201d;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers and are included
in Product Revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#x2019;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#x2019;s revenue recognition criteria described above. As of December 31, 2023, the Company has recognized
a contract asset of zero which is included in other accounts receivable in the accompanying balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfNetRevenuesByGeography_zgOk39Kpl3P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B4_zzLqgxExCEz2"&gt;The following table summarizes net revenues by geography for the years
ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 39%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 3%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Net Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Domestic&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zlJvfdkf0eva" style="text-align: right" title="Net Revenue"&gt;23,676,039&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zxd3On1nZsl7" style="text-align: right" title="Net Revenue"&gt;23,586,254&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;International&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z9WJMe07cdac" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,841,627&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zWLgskHZsh1h" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,309,783&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20230101__20231231_zjh9E8vQnmA2" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;28,517,666&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20220101__20221231_zuQ3cmZ8ak6a" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;27,896,037&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zJHH3WsFODQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <krmd:ScheduleOfNetRevenuesByGeography contextRef="From2023-01-01to2023-12-31" id="ixv-4513">&lt;p id="xdx_898_ecustom--ScheduleOfNetRevenuesByGeography_zgOk39Kpl3P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B4_zzLqgxExCEz2"&gt;The following table summarizes net revenues by geography for the years
ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 39%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 3%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Net Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Domestic&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zlJvfdkf0eva" style="text-align: right" title="Net Revenue"&gt;23,676,039&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zxd3On1nZsl7" style="text-align: right" title="Net Revenue"&gt;23,586,254&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;International&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z9WJMe07cdac" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,841,627&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zWLgskHZsh1h" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,309,783&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20230101__20231231_zjh9E8vQnmA2" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;28,517,666&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--Revenues_c20220101__20221231_zuQ3cmZ8ak6a" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;27,896,037&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</krmd:ScheduleOfNetRevenuesByGeography>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_country_US"
      decimals="0"
      id="ixv-8034"
      unitRef="USD">23676039</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_country_US"
      decimals="0"
      id="ixv-8035"
      unitRef="USD">23586254</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_us-gaap_NonUsMember"
      decimals="0"
      id="ixv-8036"
      unitRef="USD">4841627</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_us-gaap_NonUsMember"
      decimals="0"
      id="ixv-8037"
      unitRef="USD">4309783</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8038"
      unitRef="USD">28517666</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8039"
      unitRef="USD">27896037</us-gaap:Revenues>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4581">&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zutAeD5nwoZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_zVguakYwV0S9"&gt;LEASES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#x201c;NOTE 5 &lt;b&gt;&#x2014; &lt;/b&gt;LEASES&#x201d; for further detail.&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4597">&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBQ7gh9jSITg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86E_zCzypJsogS6i"&gt;ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i&gt;Financial Instruments
&#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company adopted this standard on January 1, 2023, and it did not have a
significant impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4606">&lt;p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zfpebkPQILed" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86E_zqY8Tw8pNwb9"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 7in"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2023.&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <krmd:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc contextRef="From2023-01-01to2023-12-31" id="ixv-4631">&lt;p id="xdx_842_ecustom--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc_zNaHnezOrga1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;IMPAIRMENT OF LONG-LIVED ASSETS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2023.&lt;/p&gt;

</krmd:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBloc>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4644">&lt;p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zAZN0q0lV7g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 2 &#x2014; &lt;span id="xdx_829_zMF3gAEHYfw"&gt;INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zX61zdvEhwd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_z3jmSyQGRb25"&gt;Inventory consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Raw materials and work-in-process&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20231231_ziUbnwr5bKH9" style="text-align: right" title="Raw materials and work-in-process"&gt;1,869,356&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20221231_z18xyOI1Xrli" style="text-align: right" title="Raw materials and work-in-process"&gt;3,853,034&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Finished goods&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20231231_zLAfc6m67f0c" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;1,862,525&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20221231_zURHm1TjbASa" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;2,611,951&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--InventoryGross_iI_c20231231_zWyuTK3Nl3Yl" style="text-align: right" title="Inventory, Gross"&gt;3,731,881&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryGross_iI_c20221231_zEljUY9NZ9Il" style="text-align: right" title="Inventory, Gross"&gt;6,464,985&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Less: reserve for obsolete inventory&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryValuationReserves_iNI_di_c20231231_zThgvIKcoY1j" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory"&gt;(250,580&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--InventoryValuationReserves_iNI_di_c20221231_zm7BmshG5f29" style="border-bottom: black 1pt solid; text-align: right"&gt;(60,118&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Inventory, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--InventoryNet_iI_c20231231_zI0bFlNRqbFb" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory"&gt;3,481,301&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--InventoryNet_iI_c20221231_zHXuNssReZHh" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory"&gt;6,404,867&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zUuKdZTb19Wc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4649">&lt;p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zX61zdvEhwd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_z3jmSyQGRb25"&gt;Inventory consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Raw materials and work-in-process&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20231231_ziUbnwr5bKH9" style="text-align: right" title="Raw materials and work-in-process"&gt;1,869,356&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20221231_z18xyOI1Xrli" style="text-align: right" title="Raw materials and work-in-process"&gt;3,853,034&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Finished goods&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20231231_zLAfc6m67f0c" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;1,862,525&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20221231_zURHm1TjbASa" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;2,611,951&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--InventoryGross_iI_c20231231_zWyuTK3Nl3Yl" style="text-align: right" title="Inventory, Gross"&gt;3,731,881&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryGross_iI_c20221231_zEljUY9NZ9Il" style="text-align: right" title="Inventory, Gross"&gt;6,464,985&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Less: reserve for obsolete inventory&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryValuationReserves_iNI_di_c20231231_zThgvIKcoY1j" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory"&gt;(250,580&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--InventoryValuationReserves_iNI_di_c20221231_zm7BmshG5f29" style="border-bottom: black 1pt solid; text-align: right"&gt;(60,118&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Inventory, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--InventoryNet_iI_c20231231_zI0bFlNRqbFb" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory"&gt;3,481,301&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--InventoryNet_iI_c20221231_zHXuNssReZHh" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory"&gt;6,404,867&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8040"
      unitRef="USD">1869356</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8041"
      unitRef="USD">3853034</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8042"
      unitRef="USD">1862525</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8043"
      unitRef="USD">2611951</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8044"
      unitRef="USD">3731881</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8045"
      unitRef="USD">6464985</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8046"
      unitRef="USD">250580</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8047"
      unitRef="USD">60118</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8048"
      unitRef="USD">3481301</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8049"
      unitRef="USD">6404867</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4719">&lt;p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z6ZnPVaegca" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 3 &#x2014; &lt;span id="xdx_825_zm2p7COcH577"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWkScz5mmSN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_zqsL5fj7Yt7d"&gt;Property and equipment consists of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zjYZmReSfphf" style="text-align: right"&gt;1,412,164&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z7IveEZuNol4" style="text-align: right"&gt;1,456,745&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6rdrelA7794" style="text-align: right"&gt;1,953,653&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWLszAyseh2g" style="text-align: right"&gt;2,413,820&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Manufacturing equipment and tooling&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zGAhw6PPKAhj" style="border-bottom: black 1pt solid; text-align: right"&gt;3,193,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zQjvAVCRM5Y3" style="border-bottom: black 1pt solid; text-align: right"&gt;2,810,813&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total property and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zCiLDQVZ8Pe5" style="text-align: right" title="Total property and equipment"&gt;6,558,930&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_ziqRGyjJPcvj" style="text-align: right" title="Total property and equipment"&gt;6,681,378&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Less: accumulated depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zSoBNiLqIM11" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,721,273&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_znwnqS9d6snk" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,794,403&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_z6QzVcp39uX4" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;3,837,657&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zarNcWLbaTlg" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;3,886,975&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zhRm7KyvCy03" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4724">&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWkScz5mmSN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_zqsL5fj7Yt7d"&gt;Property and equipment consists of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 55%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zjYZmReSfphf" style="text-align: right"&gt;1,412,164&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_z7IveEZuNol4" style="text-align: right"&gt;1,456,745&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6rdrelA7794" style="text-align: right"&gt;1,953,653&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWLszAyseh2g" style="text-align: right"&gt;2,413,820&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Manufacturing equipment and tooling&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zGAhw6PPKAhj" style="border-bottom: black 1pt solid; text-align: right"&gt;3,193,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zQjvAVCRM5Y3" style="border-bottom: black 1pt solid; text-align: right"&gt;2,810,813&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total property and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zCiLDQVZ8Pe5" style="text-align: right" title="Total property and equipment"&gt;6,558,930&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_ziqRGyjJPcvj" style="text-align: right" title="Total property and equipment"&gt;6,681,378&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Less: accumulated depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_zSoBNiLqIM11" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,721,273&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_znwnqS9d6snk" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,794,403&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_z6QzVcp39uX4" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;3,837,657&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zarNcWLbaTlg" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;3,886,975&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember"
      decimals="0"
      id="ixv-8050"
      unitRef="USD">1412164</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_FurnitureAndOfficeEquipmentMember"
      decimals="0"
      id="ixv-8051"
      unitRef="USD">1456745</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="ixv-8052"
      unitRef="USD">1953653</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="ixv-8053"
      unitRef="USD">2413820</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember"
      decimals="0"
      id="ixv-8054"
      unitRef="USD">3193113</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_ManufacturingEquipmentAndToolingMember"
      decimals="0"
      id="ixv-8055"
      unitRef="USD">2810813</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8056"
      unitRef="USD">6558930</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8057"
      unitRef="USD">6681378</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8058"
      unitRef="USD">2721273</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8059"
      unitRef="USD">2794403</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8060"
      unitRef="USD">3837657</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8061"
      unitRef="USD">3886975</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4803">&lt;p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z1NaC8021y5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 4 &#x2014; &lt;span id="xdx_823_zZTNnGoCxnUa"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has three equity incentive plans: the 2015 Stock Option Plan,
as amended (the &#x201c;2015 Plan&#x201d;), the 2021 Omnibus Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), and the Non-Employee Director
Compensation Plan. The Company has also issued restricted stock and stock options as employment inducement awards to its Chief Executive
Officer and Chief Commercial Officer, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The 2015 plan provides for the grant of up to &lt;span id="xdx_904_ecustom--StockBasedCompensationSharesIssuable_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zT0QROv0DeC4" title="Stock issuable under plan (in shares)"&gt;6,000,000&lt;/span&gt; incentive stock
options and nonqualified stock options. As of December 31, 2023, there were options to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutivesEmployeesConsultantsMember_zUB55jKbf5gf" title="Common stock outstanding"&gt;2,436,250&lt;/span&gt; shares of the Company&#x2019;s
common stock outstanding to certain executives, key employees and consultants under the 2015 Plan, of which &lt;span id="xdx_906_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutivesEmployeesConsultantsMember_z0WHvqJLij82" title="Shares issued under plan"&gt;85,000&lt;/span&gt; were issued during
the year ended December 31, 2023 and &lt;span id="xdx_900_ecustom--SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutivesEmployeesConsultantsMember_zo7SftfeuDc" title="Shares issued under plan"&gt;445,000&lt;/span&gt; were issued during the year ended December 31, 2022. Additional options may be issued under
the 2015 Plan as outstanding options are forfeited. As of December 31, 2023, there were &lt;span id="xdx_908_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zwSJfCutYt32" title="Shares available for issuance"&gt;2,724,250&lt;/span&gt; shares reserved for outstanding awards
and available for issuance under the 2015 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The 2021 Plan provides for the grant of up to &lt;span id="xdx_900_ecustom--StockBasedCompensationSharesIssuable_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBlr2lwki6B1" title="Stock issuable under plan (in shares)"&gt;1,000,000&lt;/span&gt; incentive stock
options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units and/or stock appreciation rights to
employees, consultants and directors. During the years ended December 31, 2023 and 2022, there were awards with respect to &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zHwCbWgbCZHj" title="Issuance of common stock awards (in shares)"&gt;21,100&lt;/span&gt; and
&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMobm31jjFc4" title="Issuance of common stock awards (in shares)"&gt;97,100&lt;/span&gt; shares of common stock, respectively, issued under the 2021 Plan. Additional awards may be issued under the 2021 Plan as outstanding
awards are forfeited. As of December 31, 2023, there were &lt;span id="xdx_90D_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLsYA3sXInul" title="Shares available for issuance"&gt;822,142&lt;/span&gt; shares reserved for outstanding awards and available for issuance under
the 2021 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Each non-employee director of the Company (other than the Chairman of the
Board) is eligible to receive $&lt;span id="xdx_907_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zzU90Xag2hN5" title="Nonemployee services transaction cost"&gt;110,000&lt;/span&gt; annually, &lt;span id="xdx_90E_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zBJCRRoZx3Sd" title="Share-based goods and non-employee services transaction"&gt;to be paid quarterly $12,500 in cash and $15,000 in common stock.&lt;/span&gt; &#160;The Chairman
of the Board is eligible to receive $&lt;span id="xdx_905_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20230101__20231231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zbtLZW3tBcua" title="Nonemployee services transaction cost"&gt;140,000&lt;/span&gt; annually, &lt;span id="xdx_909_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20230101__20231231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zrsn21IWhGT5" title="Share-based goods and non-employee services transaction"&gt;to be paid quarterly $12,500 in cash and $22,500 in common stock.&lt;/span&gt; From May 18,
2021 to May 6, 2022, non-employee director compensation was paid pursuant to the 2021 Plan. Since May 6, 2022, non-employee director compensation
has been paid pursuant to the Non-Employee Director Compensation Plan. All payments were and are pro-rated for partial service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The per share weighted average fair value of stock options granted during
the year ended December 31, 2023 and December 31, 2022 was $&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zMtzRLd4mVTb" title="Per share weighted average fair value of stock options granted"&gt;1.84&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zkRmBYMMMtg3" title="Per share weighted average fair value of stock options granted"&gt;1.98&lt;/span&gt;, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
year ended December 31, 2023 and December 31, 2022. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued. We have recognized tax benefits associated with
stock-based compensation of $&lt;span id="xdx_903_ecustom--TaxBenefitFromStockBasedCompensation_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zPdNFe7dVFp8" title="Tax benefit from stock-based compensation"&gt;256,315&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--TaxBenefitFromStockBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zIRnF23Rv2z2" title="Tax benefit from stock-based compensation"&gt;231,341&lt;/span&gt; for the year ended December 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Time Based Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zNNM5iwpmL2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the activities for our stock options with
time based vesting for the years ended December 31, 2023, and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;span id="xdx_8B2_ziuflerqMOHi" style="display: none; visibility: hidden"&gt;Schedule of time based stock options&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 44%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zimUbs6WZcF6" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5YA1TzdK49c" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z2vcbNA95U5k" title="Expected volatility"&gt;51.9&lt;/span&gt;% - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zwZ6FEgiJBCk" title="Expected volatility"&gt;61.3&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zig3jesCAfTj" title="Expected volatility"&gt;65.29&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zNyFUhbYt9oh" title="Expected volatility"&gt;77.5&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zp3fRJqsu2x2" title="Weighted-average volatility"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zPgzCrXzqFOd" title="Weighted-average volatility"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zr6v1ZKIKVx5" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxYlkrjitIT" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z1jOmn5MPA17" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJPw7MTmiVhe" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0709"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z94OrWsBFtQ1" title="Risk-free rate"&gt;3.50&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_z2myhkGzx1s7" title="Risk-free rate"&gt;4.53&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zrlTY08nfwRf" title="Risk-free rate"&gt;1.81&lt;/span&gt;% - &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zaZdGXGs6nf2" title="Risk-free rate"&gt;4.02&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A7_zMZeEPBfEfkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3skaw4hoX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the time-based stock options:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;span id="xdx_8BD_zoOm84bn8TLe" style="display: none; visibility: hidden"&gt;Schedule of status of time based stock options&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 54%"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoLlsLS6XsAh" style="width: 9%; text-align: right" title="Outstanding at beginning (in shares)"&gt;3,035,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zPSMutrubaIb" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3.93&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zXasPHkR3FDg" style="width: 9%; text-align: right" title="Outstanding at beginning (in shares)"&gt;3,672,500&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zkzXZZM8cv0c" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3.42&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zjte071jhx2" style="text-align: right" title="Granted (in shares)"&gt;430,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z8sNdtWX97a5" style="text-align: right" title="Granted"&gt;2.66&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLIog2GcPmef" style="text-align: right" title="Granted (in shares)"&gt;920,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zsSlCgKCXM5j" style="text-align: right" title="Granted"&gt;2.62&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zHXx0yI8QvGd" style="text-align: right" title="Exercised (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoUfFM3QUx5d" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoW0l8NJRtB2" style="text-align: right" title="Exercised (in shares)"&gt;1,031,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z8g7ILueyDl7" style="text-align: right" title="Exercised"&gt;1.57&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zD9OhpaXZyH1" style="text-align: right" title="Forfeited (in shares)"&gt;208,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zOFlnx4XYOI3" style="text-align: right" title="Forfeited"&gt;5.45&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDhc90Lf6hag" style="text-align: right" title="Forfeited (in shares)"&gt;526,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdMkB7B1eYnf" style="text-align: right" title="Forfeited"&gt;2.73&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zkGQr6YVYqE9" style="text-align: right" title="Outstanding at ending (in shares)"&gt;3,256,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJQIAoa2Qxzd" style="text-align: right" title="Outstanding at ending"&gt;3.66&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDQ6iHbmxkTl" style="text-align: right" title="Outstanding at ending (in shares)"&gt;3,035,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMEXyyRdawhc" style="text-align: right" title="Outstanding at ending"&gt;3.93&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Options exercisable at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zWOHeaN7VNRe" style="text-align: right" title="Options exercisable (in shares)"&gt;1,458,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQGgYc11tSgi" style="text-align: right" title="Options exercisable"&gt;4.42&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5jwCQQwe2Xg" style="text-align: right" title="Options exercisable (in shares)"&gt;737,500&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zD00fFY3ETEd" style="text-align: right" title="Options exercisable"&gt;4.93&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.1in; text-indent: -0.1in"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZfHcarGtsB7" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.84&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJHZIM1njtld" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.99&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zh2JESU6bYW6" style="text-align: right" title="Stock-based compensation expense"&gt;1,940,720&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJErI9jW98fl" style="text-align: right" title="Stock-based compensation expense"&gt;2,083,397&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zugjYjiqXz27" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total stock-based compensation expense was $&lt;span id="xdx_901_ecustom--StockBasedCompensationStockOptions_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zmqwQXtA5Ez9" title="Stock-based compensation expense"&gt;1,940,720&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--StockBasedCompensationStockOptions_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zsAFaeFyrCs4" title="Stock-based compensation expense"&gt;2,083,397&lt;/span&gt; for
the years ended December 31, 2023, and 2022, respectively. Net cash received from option exercises for the years ended December 31, 2023,
and 2022 was &lt;span id="xdx_909_ecustom--CashReceivedFromOptionExercise_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMzzHm6IFemc" title="Cash received from option exercise::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0781"&gt;zero&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--CashReceivedFromOptionExercise_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zk5E17xjVo1f" title="Cash received from option exercise"&gt;406,623&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The weighted-average grant-date fair value of options granted during the
years ended December 31, 2023, and 2022 was $&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_iI_dm_c20231231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zydFj7nRr8T" title="Weighted-average grant-date fair value options granted"&gt;0.8 million&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_iI_dm_c20221231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_z2AIsRS2c9R1" title="Weighted-average grant-date fair value options granted"&gt;1.8 million&lt;/span&gt;, respectively. &#160;There were &lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_do_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zJ6iy1rgrUy9" title="Number of options exercised"&gt;no&lt;/span&gt; options exercised during
the year ended December 31,2023 and &lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zMwVooYBO5B1" title="Number of options exercised"&gt;1,031,250&lt;/span&gt; options exercised during the year ended December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_za2BNGCvvJj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents information pertaining to time- based stock
options outstanding at December 31, 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;span id="xdx_8B9_zJbw7ma0vV06" style="display: none; visibility: hidden"&gt;Schedule of information pertaining to options outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 29%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$2.18-$9.49&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zX5ktyylRsTc" style="text-align: right" title="Number outstanding"&gt;3,256,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zW5jUzrzHVGe" title="Weighted average remaining contractual life::XDX::P8Y3M19D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0797"&gt;8.3&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zj1nuAG2OW51" style="text-align: right" title="Weighted average exercise price"&gt;3.66&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z8blGC4c8V35" style="text-align: right" title="Number exercisable"&gt;1,458,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zqcISb4booHa" style="text-align: right" title="Weighted average exercise price"&gt;4.42&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zxB7BceAd42b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2023, there was $&lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zKWtJMB4iuPb" title="Total unrecognized compensation cost"&gt;3,145,616&lt;/span&gt; of total unrecognized compensation
cost related to non-vested time- based stock options granted under the Company&#x2019;s plans. &#160;That cost is expected to be recognized
over a weighted-average period of&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zqjj9fintAD" title="Weighted-average period::XDX::P46M"&gt; &lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;46&lt;/span&gt;&lt;/span&gt; months. &#160;The total fair value of shares vested as of December 31, 2023, and December 31, 2022,
was $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAFzJB4auBdf" title="Total fair value of shares vested"&gt;4,819,658&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zqA49jZqYHN4" title="Total fair value of shares vested"&gt;2,703,002&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Performance Based Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zhPAnldze47a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Pursuant to an employment agreement entered into on November 6, 2023, with
the Company&#x2019;s Chief Commercial Officer, and as an inducement to his employment, the Company issued a non-qualified option to purchase
200,000 shares of common stock that vest upon achievement of sales growth milestones.&#160;&lt;span id="xdx_8BA_zEyadYIGzkfl"&gt;The following table summarizes the activities
for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Twelve Months Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 46%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z45l6opaHkll" style="width: 10%; text-align: right" title="Unvested at beginning (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zVkxT1f68a5f" style="width: 12%; text-align: right" title="Unvested at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0818"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4NIoIoBzZ79" style="width: 10%; text-align: right" title="Unvested at beginning (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zy16y6lOlPo5" style="width: 12%; text-align: right" title="Unvested at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0822"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zzlB3j8bjNae" style="text-align: right" title="Granted (in shares)"&gt;200,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zt0o7PVVYzDl" style="text-align: right" title="Granted"&gt;1.48&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXRSLbJaIxN2" style="text-align: right" title="Granted (in shares)"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4M0NLYOVe3i" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4ipmvUnHem" style="text-align: right" title="Vested (in shares)"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zxDr35xjmIXc" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zFBn1TpWV5D5" style="text-align: right" title="Vested (in shares)"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zyVAZ3aERA02" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zxpEVIJUV7Oa" style="text-align: right" title="Forfeited/canceled (in shares)"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zkIABLM6hxxi" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zfwDAGdsgE73" style="text-align: right" title="Forfeited/canceled (in shares)"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z736TyxeOos3" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zlwqeSmQQTEc" style="text-align: right" title="Unvested at ending (in shares)"&gt;200,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zwFHpgH3Ya5a" style="text-align: right" title="Unvested at ending"&gt;1.48&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zum9GSPaaM4j" style="text-align: right" title="Unvested at ending (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zKSPREQa99M3" style="text-align: right" title="Unvested at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zLOFqNNWsLv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2023, there was $&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zvYjw3LvAWG2" title="Unrecognized compensation cost"&gt;176,345&lt;/span&gt; of unrecognized compensation
cost related to unvested employee performance options. This amount is expected to be recognized over a weighted-average period of&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zJJj6XPZO0r1" title="Weighted-average period::XDX::P36M"&gt; &lt;span style="-sec-ix-hidden: xdx2ixbrl0858"&gt;36&lt;/span&gt;&lt;/span&gt; months.
We have recognized tax benefits associated with restricted stock award compensation of $&lt;span id="xdx_908_ecustom--TaxBenefitFromRestrictedStockCompensation_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXXCK7rQ3YG3" title="Tax benefit from restricted stock award compensation"&gt;1,137&lt;/span&gt; and &lt;span id="xdx_90E_ecustom--TaxBenefitFromRestrictedStockCompensation_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z28UFQnymdH6" title="Tax benefit from restricted stock compensation::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0862"&gt;zero&lt;/span&gt;&lt;/span&gt; for the twelve months ended December
31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;RESTRICTED STOCK AWARDS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zfunpkl4nUhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B6_zyDtnkQEFQkc"&gt;The following table summarizes the activities for our unvested restricted
stock awards for the twelve months ended December 31, 2023, and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Twelve Months Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 46%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhJVfbeXIxP8" style="width: 10%; text-align: right" title="Outstanding at beginning (in shares)"&gt;950,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBPjvkLNa7yj" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;3.04&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z07BwXSgZmz6" style="width: 10%; text-align: right" title="Outstanding at beginning (in shares)"&gt;1,000,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zgeVGhrvxVX7" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;3.01&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3LAi9s9XCTe" style="text-align: right" title="Granted (in shares)"&gt;54,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zGzrTMrGQcXk" style="text-align: right" title="Granted"&gt;3.68&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zbQfXLgHb5W1" style="text-align: right" title="Granted (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zllcecbW3drk" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXK55JfgMdHi" style="text-align: right" title="Vested (in shares)"&gt;100,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zvmqSZ98yUEd" style="text-align: right" title="Vested"&gt;3.31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zl6HFN0Tc3rl" style="text-align: right" title="Vested (in shares)"&gt;50,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zlFjXfmwisW4" style="text-align: right" title="Vested"&gt;3.31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zpKU0AmugtS5" style="text-align: right" title="Forfeited/canceled (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0890"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zTdUZszxmIkc" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0892"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z7wMYrP3Yz3c" style="text-align: right" title="Forfeited/canceled (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJEyiezOocf6" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z143DXigTUDe" style="text-align: right" title="Outstanding at ending (in shares)"&gt;904,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLfz9jPJh54f" style="text-align: right" title="Outstanding at ending"&gt;2.77&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zq79WcillT5d" style="text-align: right" title="Outstanding at ending (in shares)"&gt;950,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zimyf8K4Ts39" style="text-align: right" title="Outstanding at ending"&gt;3.04&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zjoX3RCTXjc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2023, there was $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zAFg7ENbg7Od" title="Unrecognized compensation cost"&gt;1,076,664&lt;/span&gt; of unrecognized compensation
cost related to unvested employee restricted shares. This amount is expected to be recognized over a weighted-average period of 21 months.
We have recognized tax benefits associated with restricted stock award compensation of $&lt;span id="xdx_90F_ecustom--TaxBenefitFromRestrictedStockCompensation_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zN1uwWnsezSg" title="Tax benefit from restricted stock compensation"&gt;79,326&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--TaxBenefitFromRestrictedStockCompensation_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zCLpMEWruJI4" title="Tax benefit from restricted stock compensation"&gt;101,419&lt;/span&gt; for the twelve months ended
December 31, 2023 and 2022, respectively.&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <krmd:StockBasedCompensationSharesIssuable
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      id="ixv-8062"
      unitRef="Shares">6000000</krmd:StockBasedCompensationSharesIssuable>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember"
      decimals="INF"
      id="ixv-8063"
      unitRef="Shares">2436250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember"
      decimals="INF"
      id="ixv-8064"
      unitRef="Shares">85000</krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan>
    <krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_ExecutivesEmployeesConsultantsMember"
      decimals="INF"
      id="ixv-8065"
      unitRef="Shares">445000</krmd:SharesIssuedUnderPlanInTotalSharesEmployeeStockOwnershipPlan>
    <krmd:SharesAvailableForIssuanceShareBasedCompensation
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      id="ixv-8066"
      unitRef="Shares">2724250</krmd:SharesAvailableForIssuanceShareBasedCompensation>
    <krmd:StockBasedCompensationSharesIssuable
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8067"
      unitRef="Shares">1000000</krmd:StockBasedCompensationSharesIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8068"
      unitRef="Shares">21100</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8069"
      unitRef="Shares">97100</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <krmd:SharesAvailableForIssuanceShareBasedCompensation
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8070"
      unitRef="Shares">822142</krmd:SharesAvailableForIssuanceShareBasedCompensation>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2023-01-012023-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember"
      decimals="INF"
      id="ixv-8071"
      unitRef="Shares">110000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction
      contextRef="From2023-01-012023-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember"
      id="ixv-8072">to be paid quarterly $12,500 in cash and $15,000 in common stock.</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2023-01-012023-12-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="ixv-8073"
      unitRef="Shares">140000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction
      contextRef="From2023-01-012023-12-31_srt_BoardOfDirectorsChairmanMember"
      id="ixv-8074">to be paid quarterly $12,500 in cash and $22,500 in common stock.</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="INF"
      id="ixv-8075"
      unitRef="USDPShares">1.84</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="INF"
      id="ixv-8076"
      unitRef="USDPShares">1.98</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <krmd:TaxBenefitFromStockBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="0"
      id="ixv-8077"
      unitRef="USD">256315</krmd:TaxBenefitFromStockBasedCompensation>
    <krmd:TaxBenefitFromStockBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="0"
      id="ixv-8078"
      unitRef="USD">231341</krmd:TaxBenefitFromStockBasedCompensation>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4847">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zNNM5iwpmL2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the activities for our stock options with
time based vesting for the years ended December 31, 2023, and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;span id="xdx_8B2_ziuflerqMOHi" style="display: none; visibility: hidden"&gt;Schedule of time based stock options&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 44%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zimUbs6WZcF6" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5YA1TzdK49c" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z2vcbNA95U5k" title="Expected volatility"&gt;51.9&lt;/span&gt;% - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zwZ6FEgiJBCk" title="Expected volatility"&gt;61.3&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zig3jesCAfTj" title="Expected volatility"&gt;65.29&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zNyFUhbYt9oh" title="Expected volatility"&gt;77.5&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zp3fRJqsu2x2" title="Weighted-average volatility"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zPgzCrXzqFOd" title="Weighted-average volatility"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zr6v1ZKIKVx5" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zxYlkrjitIT" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z1jOmn5MPA17" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJPw7MTmiVhe" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0709"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z94OrWsBFtQ1" title="Risk-free rate"&gt;3.50&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_z2myhkGzx1s7" title="Risk-free rate"&gt;4.53&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zrlTY08nfwRf" title="Risk-free rate"&gt;1.81&lt;/span&gt;% - &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zaZdGXGs6nf2" title="Risk-free rate"&gt;4.02&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8079"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8080"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="ixv-8081"
      unitRef="Pure">0.519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="ixv-8082"
      unitRef="Pure">0.613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="ixv-8083"
      unitRef="Pure">0.6529</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="ixv-8084"
      unitRef="Pure">0.775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8085"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8086"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="ixv-8087"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="ixv-8088"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="ixv-8089"
      unitRef="Pure">0.0350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="ixv-8090"
      unitRef="Pure">0.0453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="ixv-8091"
      unitRef="Pure">0.0181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="ixv-8092"
      unitRef="Pure">0.0402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-4949">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3skaw4hoX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the time-based stock options:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;span id="xdx_8BD_zoOm84bn8TLe" style="display: none; visibility: hidden"&gt;Schedule of status of time based stock options&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 54%"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoLlsLS6XsAh" style="width: 9%; text-align: right" title="Outstanding at beginning (in shares)"&gt;3,035,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zPSMutrubaIb" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3.93&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zXasPHkR3FDg" style="width: 9%; text-align: right" title="Outstanding at beginning (in shares)"&gt;3,672,500&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zkzXZZM8cv0c" style="width: 9%; text-align: right" title="Outstanding at beginning"&gt;3.42&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zjte071jhx2" style="text-align: right" title="Granted (in shares)"&gt;430,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z8sNdtWX97a5" style="text-align: right" title="Granted"&gt;2.66&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLIog2GcPmef" style="text-align: right" title="Granted (in shares)"&gt;920,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zsSlCgKCXM5j" style="text-align: right" title="Granted"&gt;2.62&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zHXx0yI8QvGd" style="text-align: right" title="Exercised (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoUfFM3QUx5d" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoW0l8NJRtB2" style="text-align: right" title="Exercised (in shares)"&gt;1,031,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z8g7ILueyDl7" style="text-align: right" title="Exercised"&gt;1.57&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zD9OhpaXZyH1" style="text-align: right" title="Forfeited (in shares)"&gt;208,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zOFlnx4XYOI3" style="text-align: right" title="Forfeited"&gt;5.45&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDhc90Lf6hag" style="text-align: right" title="Forfeited (in shares)"&gt;526,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdMkB7B1eYnf" style="text-align: right" title="Forfeited"&gt;2.73&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zkGQr6YVYqE9" style="text-align: right" title="Outstanding at ending (in shares)"&gt;3,256,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJQIAoa2Qxzd" style="text-align: right" title="Outstanding at ending"&gt;3.66&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zDQ6iHbmxkTl" style="text-align: right" title="Outstanding at ending (in shares)"&gt;3,035,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zMEXyyRdawhc" style="text-align: right" title="Outstanding at ending"&gt;3.93&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Options exercisable at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zWOHeaN7VNRe" style="text-align: right" title="Options exercisable (in shares)"&gt;1,458,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zQGgYc11tSgi" style="text-align: right" title="Options exercisable"&gt;4.42&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z5jwCQQwe2Xg" style="text-align: right" title="Options exercisable (in shares)"&gt;737,500&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zD00fFY3ETEd" style="text-align: right" title="Options exercisable"&gt;4.93&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.1in; text-indent: -0.1in"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zZfHcarGtsB7" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.84&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJHZIM1njtld" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.99&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zh2JESU6bYW6" style="text-align: right" title="Stock-based compensation expense"&gt;1,940,720&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJErI9jW98fl" style="text-align: right" title="Stock-based compensation expense"&gt;2,083,397&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8093"
      unitRef="Shares">3035000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8094"
      unitRef="USDPShares">3.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8095"
      unitRef="Shares">3672500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8096"
      unitRef="USDPShares">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8097"
      unitRef="Shares">430000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8098"
      unitRef="USDPShares">2.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8099"
      unitRef="Shares">920000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8100"
      unitRef="USDPShares">2.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8101"
      unitRef="Shares">1031250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8102"
      unitRef="USDPShares">1.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8103"
      unitRef="Shares">208750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8104"
      unitRef="USDPShares">5.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8105"
      unitRef="Shares">526250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8106"
      unitRef="USDPShares">2.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8107"
      unitRef="Shares">3256250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8108"
      unitRef="USDPShares">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8109"
      unitRef="Shares">3035000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8110"
      unitRef="USDPShares">3.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8111"
      unitRef="Shares">1458750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8112"
      unitRef="USDPShares">4.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8113"
      unitRef="Shares">737500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8114"
      unitRef="USDPShares">4.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8115"
      unitRef="USDPShares">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8116"
      unitRef="USDPShares">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="ixv-8117"
      unitRef="USD">1940720</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="ixv-8118"
      unitRef="USD">2083397</us-gaap:AllocatedShareBasedCompensationExpense>
    <krmd:StockBasedCompensationStockOptions
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="ixv-8119"
      unitRef="USD">1940720</krmd:StockBasedCompensationStockOptions>
    <krmd:StockBasedCompensationStockOptions
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="ixv-8120"
      unitRef="USD">2083397</krmd:StockBasedCompensationStockOptions>
    <krmd:CashReceivedFromOptionExercise
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      id="ixv-8121"
      unitRef="USD">406623</krmd:CashReceivedFromOptionExercise>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="0"
      id="ixv-8122"
      unitRef="USD">800000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="0"
      id="ixv-8123"
      unitRef="USD">1800000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue>
    <krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8124"
      unitRef="Shares">0</krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8125"
      unitRef="Shares">1031250</krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-5121">&lt;p id="xdx_895_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_za2BNGCvvJj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents information pertaining to time- based stock
options outstanding at December 31, 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;span id="xdx_8B9_zJbw7ma0vV06" style="display: none; visibility: hidden"&gt;Schedule of information pertaining to options outstanding&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 29%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$2.18-$9.49&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zX5ktyylRsTc" style="text-align: right" title="Number outstanding"&gt;3,256,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zW5jUzrzHVGe" title="Weighted average remaining contractual life::XDX::P8Y3M19D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0797"&gt;8.3&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zj1nuAG2OW51" style="text-align: right" title="Weighted average exercise price"&gt;3.66&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z8blGC4c8V35" style="text-align: right" title="Number exercisable"&gt;1,458,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20231231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zqcISb4booHa" style="text-align: right" title="Weighted average exercise price"&gt;4.42&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="ixv-8126"
      unitRef="Shares">3256250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="ixv-8127"
      unitRef="USDPShares">3.66</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="ixv-8128"
      unitRef="Shares">1458750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2023-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="ixv-8129"
      unitRef="USDPShares">4.42</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="0"
      id="ixv-8130"
      unitRef="USD">3145616</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2023-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="0"
      id="ixv-8131"
      unitRef="USD">4819658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2022-12-31_custom_TimeBasedSharesOptionsMember_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="0"
      id="ixv-8132"
      unitRef="USD">2703002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-5209">&lt;p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zhPAnldze47a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Pursuant to an employment agreement entered into on November 6, 2023, with
the Company&#x2019;s Chief Commercial Officer, and as an inducement to his employment, the Company issued a non-qualified option to purchase
200,000 shares of common stock that vest upon achievement of sales growth milestones.&#160;&lt;span id="xdx_8BA_zEyadYIGzkfl"&gt;The following table summarizes the activities
for our unvested performance stock option awards for the twelve months ended December 31, 2023, and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Twelve Months Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 46%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z45l6opaHkll" style="width: 10%; text-align: right" title="Unvested at beginning (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zVkxT1f68a5f" style="width: 12%; text-align: right" title="Unvested at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0818"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4NIoIoBzZ79" style="width: 10%; text-align: right" title="Unvested at beginning (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zy16y6lOlPo5" style="width: 12%; text-align: right" title="Unvested at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0822"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zzlB3j8bjNae" style="text-align: right" title="Granted (in shares)"&gt;200,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zt0o7PVVYzDl" style="text-align: right" title="Granted"&gt;1.48&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zXRSLbJaIxN2" style="text-align: right" title="Granted (in shares)"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4M0NLYOVe3i" style="text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z4ipmvUnHem" style="text-align: right" title="Vested (in shares)"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zxDr35xjmIXc" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zFBn1TpWV5D5" style="text-align: right" title="Vested (in shares)"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zyVAZ3aERA02" style="text-align: right" title="Vested"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zxpEVIJUV7Oa" style="text-align: right" title="Forfeited/canceled (in shares)"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zkIABLM6hxxi" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zfwDAGdsgE73" style="text-align: right" title="Forfeited/canceled (in shares)"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_z736TyxeOos3" style="text-align: right" title="Forfeited/canceled"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zlwqeSmQQTEc" style="text-align: right" title="Unvested at ending (in shares)"&gt;200,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zwFHpgH3Ya5a" style="text-align: right" title="Unvested at ending"&gt;1.48&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zum9GSPaaM4j" style="text-align: right" title="Unvested at ending (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceBasedSharesOptionsMember_zKSPREQa99M3" style="text-align: right" title="Unvested at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8133"
      unitRef="Shares">200000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8134"
      unitRef="USDPShares">1.48</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants
      contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8135"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1
      contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8136"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8137"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8138"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested
      contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8139"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1
      contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8140"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8141"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1
      contextRef="From2023-01-012023-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8142"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures
      contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8143"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1
      contextRef="From2022-01-012022-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8144"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions
      contextRef="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8145"
      unitRef="Shares">200000</krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_PerformanceBasedSharesOptionsMember"
      decimals="INF"
      id="ixv-8146"
      unitRef="USDPShares">1.48</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember"
      decimals="0"
      id="ixv-8147"
      unitRef="USD">176345</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <krmd:TaxBenefitFromRestrictedStockCompensation
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember_custom_PerformanceBasedSharesOptionsMember"
      decimals="0"
      id="ixv-8148"
      unitRef="USD">1137</krmd:TaxBenefitFromRestrictedStockCompensation>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-5344">&lt;p id="xdx_898_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zfunpkl4nUhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B6_zyDtnkQEFQkc"&gt;The following table summarizes the activities for our unvested restricted
stock awards for the twelve months ended December 31, 2023, and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Twelve Months Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 46%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhJVfbeXIxP8" style="width: 10%; text-align: right" title="Outstanding at beginning (in shares)"&gt;950,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBPjvkLNa7yj" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;3.04&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z07BwXSgZmz6" style="width: 10%; text-align: right" title="Outstanding at beginning (in shares)"&gt;1,000,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zgeVGhrvxVX7" style="width: 12%; text-align: right" title="Outstanding at beginning"&gt;3.01&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3LAi9s9XCTe" style="text-align: right" title="Granted (in shares)"&gt;54,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zGzrTMrGQcXk" style="text-align: right" title="Granted"&gt;3.68&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zbQfXLgHb5W1" style="text-align: right" title="Granted (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zllcecbW3drk" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXK55JfgMdHi" style="text-align: right" title="Vested (in shares)"&gt;100,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zvmqSZ98yUEd" style="text-align: right" title="Vested"&gt;3.31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zl6HFN0Tc3rl" style="text-align: right" title="Vested (in shares)"&gt;50,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zlFjXfmwisW4" style="text-align: right" title="Vested"&gt;3.31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zpKU0AmugtS5" style="text-align: right" title="Forfeited/canceled (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0890"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zTdUZszxmIkc" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0892"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z7wMYrP3Yz3c" style="text-align: right" title="Forfeited/canceled (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJEyiezOocf6" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z143DXigTUDe" style="text-align: right" title="Outstanding at ending (in shares)"&gt;904,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zLfz9jPJh54f" style="text-align: right" title="Outstanding at ending"&gt;2.77&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zq79WcillT5d" style="text-align: right" title="Outstanding at ending (in shares)"&gt;950,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zimyf8K4Ts39" style="text-align: right" title="Outstanding at ending"&gt;3.04&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8149"
      unitRef="Shares">950000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8150"
      unitRef="USDPShares">3.04</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8151"
      unitRef="Shares">1000000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8152"
      unitRef="USDPShares">3.01</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8153"
      unitRef="Shares">54496</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8154"
      unitRef="USDPShares">3.68</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8155"
      unitRef="Shares">100000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8156"
      unitRef="USDPShares">3.31</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8157"
      unitRef="Shares">50000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8158"
      unitRef="USDPShares">3.31</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8159"
      unitRef="Shares">904496</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8160"
      unitRef="USDPShares">2.77</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8161"
      unitRef="Shares">950000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      id="ixv-8162"
      unitRef="USDPShares">3.04</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="ixv-8163"
      unitRef="USD">1076664</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <krmd:TaxBenefitFromRestrictedStockCompensation
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="ixv-8164"
      unitRef="USD">79326</krmd:TaxBenefitFromRestrictedStockCompensation>
    <krmd:TaxBenefitFromRestrictedStockCompensation
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="ixv-8165"
      unitRef="USD">101419</krmd:TaxBenefitFromRestrictedStockCompensation>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-5480">&lt;p id="xdx_801_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zGBiJgAYhFWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 5 &#x2014; &lt;span id="xdx_821_ztigHibf5dbb"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;Our two operating leases have remaining lease terms of &lt;span id="xdx_900_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zxwLY8V60Ktd" title="Operating lease remaining term::XDX::P8Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0914"&gt;8.6&lt;/span&gt;&lt;/span&gt; years and &lt;span id="xdx_906_ecustom--LesseeOperatingLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_z3rmYnhRglh6" title="Operating lease remaining term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;5&lt;/span&gt;&lt;/span&gt; years, respectively. Our three
finance leases have remaining lease terms of &lt;span id="xdx_90C_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_zGoMWa0ih2Nj" title="Finance lease remaining term::XDX::P3Y4M24D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;3.4&lt;/span&gt;&lt;/span&gt; years, &lt;span id="xdx_90D_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zNLYlSx7evQ" title="Finance lease remaining term::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0920"&gt;3&lt;/span&gt;&lt;/span&gt; years, and &lt;span id="xdx_906_ecustom--LesseeFinanceLeaseRemainingTerm_dxL_c20230101__20231231__us-gaap--LeaseContractualTermAxis__custom--LeaseThreeMember_zWmdu9M5xyWh" title="Finance lease remaining term::XDX::P4Y9M0D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;4.75&lt;/span&gt;&lt;/span&gt; years, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At contract inception, we evaluate whether an arrangement is or contains
a lease for which we are the lessee (that is, arrangements which provide us with the right to control a physical asset for a period of
time). &#160;Operating leases are accounted for on the balance sheets with ROU assets being recognized in &#x201c;Operating lease right-of-use
assets&#x201d; and lease liabilities recognized in &#x201c;Operating lease liability &#x2013; current&#x201d; and &#x201c;Operating lease liability,
net of current portion.&#x201d; Finance leases are accounted for on the balance sheets recognized in &#x201c;Property and equipment, net&#x201d;
and lease liabilities recognized in &#x201c;Finance lease liability &#x2013; current&#x201d; and &#x201c;Finance lease liability, net of current
portion.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Operating lease expenses are recognized on a straight-line basis over the
lease term. &#160;With respect to finance leases, amortization of the ROU asset is presented separately from interest expense related
to the finance lease liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We have elected to combine lease and non-lease components for all lease
contracts where we are the lessee. &#160;Additionally, for arrangements with lease terms of 12 months or less, we do not recognize ROU
assets and lease liabilities and lease payments are recognized on a straight-line basis over the lease term with variable lease payments
recognized in the period in which the obligation is incurred. &#160;ROU assets are measured for impairment when a triggering event occurs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_znhwFvHPWxwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The components of lease expense were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BE_zDfk5fgcQbcj" style="display: none; visibility: hidden"&gt;Schedule of components of lease expenses&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 57%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20230101__20231231_zKiB6cGbWRp4" style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20220101__20221231_zjAAY9T4ZDc9" style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zaS1RlIt9pb9" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;448,630&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;514,294&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zIdwXxVc5UYa" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Short-term lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;130,483&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;131,490&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCost_zdOriZH6Oifk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;579,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;645,784&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zkMAAx5sE1fi" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Finance lease cost:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zMeYf5mxIzA9" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Amortization of right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;110,566&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;50,895&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zdq5GiOb9S3a" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;25,343&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5,393&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zE4V3Y4Eq1ec" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;135,909&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;56,288&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z5LFep38Wfsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zselWVrMP4bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental cash flow information related to leases was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_zZ1w5yy5QMH1" style="display: none; visibility: hidden"&gt;Schedule of cash flow information related to leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 72%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20230101__20231231_zzRbf8rXOXUa" style="width: 11%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20220101__20221231_zhS65FBULqld" style="width: 11%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.45pt; text-indent: -9.45pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zdZi16PauUj1" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Operating cash flows from operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;464,104&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;247,504&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zUeDqJG34f1" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Financing cash flows from finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;125,259&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,243&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zZC3ZIqdAXid" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_897_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z2E5mzBdPO79" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_zc7YbtpSNOu6" style="display: none; visibility: hidden"&gt;Schedule of balance sheet information related to leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zB62PhKNaONd" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zKOJjTjXRV29" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zl9jr5wwyhvf" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 59%; padding-left: 9.1pt; text-indent: -9.1pt"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zgg4N1jXmim4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,514,055&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,786,545&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_zOkwuHUya5Nd" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease liability &#x2013; current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;368,313&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;345,834&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zNNxsHNUxT1g" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease liability, net of current portion&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,336,300&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,653,257&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_zr1ggNoOPBwl" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Total operating lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,704,613&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,999,091&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_z1yayVn0aEU5" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_zZ7rpgB4edL4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Property and equipment, at cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;577,929&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;544,468&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_zgo6WFpvwXi3" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Accumulated depreciation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(161,461&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(50,895&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zHdscoHEbKW4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;416,468&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;493,573&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zkwmxWl3bXMj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance lease liability &#x2013; current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;109,540&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;98,335&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zTfOwEsNtFF6" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance lease liability, net of current portion&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;316,623&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;394,283&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zSEELGZNZst8" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Total finance lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;426,163&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;492,618&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 58%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_zZf4F5Q30GP4" title="Operating leases term::XDX::P6Y10M25D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0997"&gt;6.9&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20221231_zcYRctEfugE8" title="::XDX::P9Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0998"&gt;9.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_zeaQD2VStw4d" title="Finance leases  term::XDX::P3Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;3.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20221231_zsvcgphj12G8" title="::XDX::P4Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;4.6 &lt;/span&gt;&lt;/span&gt;Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zT9ehFPKl5pf" title="Operating leases discount rate"&gt;5.76&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zGaketmYUWu3"&gt;4.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zFhp9PN6K93e" title="Finance leases discount rate"&gt;6.19&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20221231_z2Q80shkk67j"&gt;4.25&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zLVASEBRsQil" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z17mlvILdsol" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Maturities of lease liabilities are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;span id="xdx_8B7_zUFFKPAqsp18" style="display: none; visibility: hidden"&gt;Schedule of maturities of lease liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 57%"&gt;2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zQcC8joE0WEi" style="width: 18%; text-align: right" title="2024 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zJd3hfl0udD" style="width: 18%; text-align: right" title="2024 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zXUdyqsuMf2c" style="vertical-align: bottom; text-align: right" title="2025 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zVmq6vyxjuW4" style="vertical-align: bottom; text-align: right" title="2025 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zRyIIkYxIrb" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zwmZ6ay8nu6i" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zvkcp4xvrMuj" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zo0pWx6vMXck" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases"&gt;74,194&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20231231_zPLHgDfCcVjl" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20231231_zyvqrNESrjI6" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases"&gt;6,181&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20231231_zxlaI2rrxQ8e" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases"&gt;1,832,557&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20231231_zzgiBFk0TZE9" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total undiscounted lease payments&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20231231_zpU0MdldqvZ6" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases"&gt;4,392,832&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20231231_zJwCtKSR541j" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases"&gt;474,686&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 18.8pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20231231_zKdtxCiyRnU" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases"&gt;(688,220&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20231231_zzQ0Zerpow2b" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases"&gt;(48,523&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total lease liabilities&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20231231_zwvCLHDBLtte" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases"&gt;3,704,613&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--FinanceLeaseLiability_iI_c20231231_zkxSLnpFa6A" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases"&gt;426,163&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_znRQ2nVEkIP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-5503">&lt;p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_znhwFvHPWxwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The components of lease expense were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BE_zDfk5fgcQbcj" style="display: none; visibility: hidden"&gt;Schedule of components of lease expenses&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 57%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20230101__20231231_zKiB6cGbWRp4" style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20220101__20221231_zjAAY9T4ZDc9" style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zaS1RlIt9pb9" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;448,630&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;514,294&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zIdwXxVc5UYa" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Short-term lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;130,483&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;131,490&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCost_zdOriZH6Oifk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;579,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;645,784&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zkMAAx5sE1fi" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Finance lease cost:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zMeYf5mxIzA9" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Amortization of right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;110,566&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;50,895&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zdq5GiOb9S3a" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;25,343&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5,393&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zE4V3Y4Eq1ec" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;135,909&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;56,288&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8166"
      unitRef="USD">448630</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8167"
      unitRef="USD">514294</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8168"
      unitRef="USD">130483</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8169"
      unitRef="USD">131490</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8170"
      unitRef="USD">579113</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8171"
      unitRef="USD">645784</us-gaap:LeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8172"
      unitRef="USD">110566</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8173"
      unitRef="USD">50895</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8174"
      unitRef="USD">25343</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8175"
      unitRef="USD">5393</us-gaap:FinanceLeaseInterestExpense>
    <krmd:FinanceLeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8176"
      unitRef="USD">135909</krmd:FinanceLeaseCost>
    <krmd:FinanceLeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8177"
      unitRef="USD">56288</krmd:FinanceLeaseCost>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-5620">&lt;p id="xdx_89A_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zselWVrMP4bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental cash flow information related to leases was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_zZ1w5yy5QMH1" style="display: none; visibility: hidden"&gt;Schedule of cash flow information related to leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 72%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20230101__20231231_zzRbf8rXOXUa" style="width: 11%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20220101__20221231_zhS65FBULqld" style="width: 11%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.45pt; text-indent: -9.45pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zdZi16PauUj1" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Operating cash flows from operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;464,104&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;247,504&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zUeDqJG34f1" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Financing cash flows from finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;125,259&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,243&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8178"
      unitRef="USD">464104</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8179"
      unitRef="USD">247504</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8180"
      unitRef="USD">125259</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8181"
      unitRef="USD">57243</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-5701">&lt;p id="xdx_897_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z2E5mzBdPO79" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_zc7YbtpSNOu6" style="display: none; visibility: hidden"&gt;Schedule of balance sheet information related to leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zB62PhKNaONd" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zKOJjTjXRV29" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zl9jr5wwyhvf" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 59%; padding-left: 9.1pt; text-indent: -9.1pt"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zgg4N1jXmim4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,514,055&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,786,545&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_zOkwuHUya5Nd" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease liability &#x2013; current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;368,313&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;345,834&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zNNxsHNUxT1g" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease liability, net of current portion&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,336,300&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,653,257&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_zr1ggNoOPBwl" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Total operating lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,704,613&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,999,091&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_z1yayVn0aEU5" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_zZ7rpgB4edL4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Property and equipment, at cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;577,929&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;544,468&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_zgo6WFpvwXi3" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Accumulated depreciation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(161,461&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(50,895&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zHdscoHEbKW4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;416,468&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;493,573&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_zkwmxWl3bXMj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance lease liability &#x2013; current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;109,540&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;98,335&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zTfOwEsNtFF6" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance lease liability, net of current portion&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;316,623&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;394,283&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zSEELGZNZst8" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Total finance lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;426,163&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;492,618&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 58%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_zZf4F5Q30GP4" title="Operating leases term::XDX::P6Y10M25D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0997"&gt;6.9&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20221231_zcYRctEfugE8" title="::XDX::P9Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0998"&gt;9.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_zeaQD2VStw4d" title="Finance leases  term::XDX::P3Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;3.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20221231_zsvcgphj12G8" title="::XDX::P4Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;4.6 &lt;/span&gt;&lt;/span&gt;Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zT9ehFPKl5pf" title="Operating leases discount rate"&gt;5.76&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zGaketmYUWu3"&gt;4.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zFhp9PN6K93e" title="Finance leases discount rate"&gt;6.19&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20221231_z2Q80shkk67j"&gt;4.25&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8182"
      unitRef="USD">3514055</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8183"
      unitRef="USD">3786545</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8184"
      unitRef="USD">368313</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8185"
      unitRef="USD">345834</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8186"
      unitRef="USD">3336300</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8187"
      unitRef="USD">3653257</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8188"
      unitRef="USD">3704613</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8189"
      unitRef="USD">3999091</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8190"
      unitRef="USD">577929</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8191"
      unitRef="USD">544468</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8192"
      unitRef="USD">161461</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8193"
      unitRef="USD">50895</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8194"
      unitRef="USD">416468</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8195"
      unitRef="USD">493573</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8196"
      unitRef="USD">109540</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8197"
      unitRef="USD">98335</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8198"
      unitRef="USD">316623</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8199"
      unitRef="USD">394283</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8200"
      unitRef="USD">426163</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8201"
      unitRef="USD">492618</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-8202"
      unitRef="Pure">0.0576</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-8203"
      unitRef="Pure">0.0400</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-8204"
      unitRef="Pure">0.0619</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-8205"
      unitRef="Pure">0.0425</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-5945">&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z17mlvILdsol" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Maturities of lease liabilities are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;span id="xdx_8B7_zUFFKPAqsp18" style="display: none; visibility: hidden"&gt;Schedule of maturities of lease liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 57%"&gt;2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zQcC8joE0WEi" style="width: 18%; text-align: right" title="2024 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zJd3hfl0udD" style="width: 18%; text-align: right" title="2024 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zXUdyqsuMf2c" style="vertical-align: bottom; text-align: right" title="2025 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zVmq6vyxjuW4" style="vertical-align: bottom; text-align: right" title="2025 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zRyIIkYxIrb" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zwmZ6ay8nu6i" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zvkcp4xvrMuj" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zo0pWx6vMXck" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases"&gt;74,194&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20231231_zPLHgDfCcVjl" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases"&gt;512,055&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20231231_zyvqrNESrjI6" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases"&gt;6,181&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20231231_zxlaI2rrxQ8e" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases"&gt;1,832,557&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20231231_zzgiBFk0TZE9" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total undiscounted lease payments&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20231231_zpU0MdldqvZ6" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases"&gt;4,392,832&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20231231_zJwCtKSR541j" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases"&gt;474,686&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 18.8pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20231231_zKdtxCiyRnU" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases"&gt;(688,220&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20231231_zzQ0Zerpow2b" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases"&gt;(48,523&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total lease liabilities&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20231231_zwvCLHDBLtte" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases"&gt;3,704,613&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--FinanceLeaseLiability_iI_c20231231_zkxSLnpFa6A" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases"&gt;426,163&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8206"
      unitRef="USD">512055</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8207"
      unitRef="USD">131437</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8208"
      unitRef="USD">512055</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8209"
      unitRef="USD">131437</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8210"
      unitRef="USD">512055</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8211"
      unitRef="USD">131437</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8212"
      unitRef="USD">512055</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8213"
      unitRef="USD">74194</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8214"
      unitRef="USD">512055</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8215"
      unitRef="USD">6181</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8216"
      unitRef="USD">1832557</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8217"
      unitRef="USD">4392832</krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal>
    <krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8218"
      unitRef="USD">474686</krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal>
    <krmd:LesseeOperatingLeaseImputedInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8219"
      unitRef="USD">688220</krmd:LesseeOperatingLeaseImputedInterest>
    <krmd:LesseeFinancingLeaseImputedInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8220"
      unitRef="USD">48523</krmd:LesseeFinancingLeaseImputedInterest>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8221"
      unitRef="USD">3704613</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8222"
      unitRef="USD">426163</us-gaap:FinanceLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-6051">&lt;p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zkUXaGaEBiL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 6 &#x2014; &lt;span id="xdx_821_zRi2M8gtiuVk"&gt;FEDERAL AND STATE INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJTmOBimS5r" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Income tax expense consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B2_zxRW4mZ3lUN2" style="display: none; visibility: hidden"&gt;Schedule of provision for income taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zHctlo41dmwi" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_zlzqc0OUWIsk" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z2yKTLcu8wf7" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;State income tax:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_z51hzqwRstWb" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 51%; padding-left: 21.8pt"&gt;Current, net of refund&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;$&lt;/td&gt;
    &lt;td style="width: 19%; text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;$&lt;/td&gt;
    &lt;td style="width: 19%; text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z46egG0kC9ga" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Federal income tax:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zSX11M5F9p13" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Deferred&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,035,297&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,014,018&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_zu7w9rb70Pl9" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1064"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WriteoffOfDeferredTaxAsset_zK8xrqvwSSDk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Write-off of deferred tax asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(6,002,777&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1067"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Income tax benefit/(expense)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20230101__20231231_ztAptpNmii0a" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;(3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zgxeqZGjwYSk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;2,014,018&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zYsVoTGoj5ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zNPI1xPbzeml" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The reconciliation of income taxes shown in the financial statements and
amounts computed by applying the Federal expected tax rate of 21% for year 2023 and 2022 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B8_zg34NCCUtSid" style="display: none; visibility: hidden"&gt;Schedule of reconciliation of income taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zO2ZcN6jHd09" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zbJYaSwTn3Z1" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_zYAwaTqqPUS6" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 60%"&gt;Loss before taxes&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 16%; text-align: right"&gt;(9,773,582&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 4%"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 16%; text-align: right"&gt;(10,675,160&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 1%"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zbSzbna7zBt7" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Income taxes computed at the federal statutory rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,052,452&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,241,784&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_z2ktpkq5KsR8" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;State income and franchise tax&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1081"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1082"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zSRYt6WqZjI5" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Permanent differences and other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(17,155&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(227,766&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WriteoffOfDeferredTaxAsset_zvWKIs9VFZeb" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Write-off of deferred tax asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(6,002,777&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1088"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Income tax benefit/(expense)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20230101__20231231_ztoiOvHdE2D8" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;(3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zWeBKg45pzwj" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;2,014,018&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zhXaeMsAZSTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKFGMN3Kcpyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The significant components of deferred income tax assets, net are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;span id="xdx_8BC_z4sTd2qvGpIb" style="display: none; visibility: hidden"&gt;Schedule of components of deferred tax assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231_zR7qybW8bxCl" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_zcdy3sOF9V5b" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredCompensationPlanAssets_iI_zrqwDl1ZBlZi" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 60%"&gt;Deferred compensation cost&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;1,047,608&lt;/td&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;557,931&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DepreciationDepletionAndAmortization1_iI_zVkK6CbK4oBf" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(913,671&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(624,184&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--RdCredit_z3DOhi3YsAmc" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;R&amp;amp;D credit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--Nol_zHaKxqsnpMX4" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;NOL&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,566,630&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,956,685&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AllowanceForDoubtfulOtherReceivables1Current_zsM4g8zG4Dq2" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Allowance for bad debts and other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,160,180&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;935,018&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AllowanceForNonRealizationOfDeferredTaxAsset_iI_zxkfYdFg8anb" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Allowance for non-realization of deferred tax asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(6,002,777&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_zRu5Hm81Eft8" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Deferred income tax assets, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zvFWfXmIMEMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Our U.S. federal and state income tax returns remain open to examination
for the tax years 2020 through 2022.&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-6056">&lt;p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJTmOBimS5r" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Income tax expense consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B2_zxRW4mZ3lUN2" style="display: none; visibility: hidden"&gt;Schedule of provision for income taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zHctlo41dmwi" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_zlzqc0OUWIsk" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z2yKTLcu8wf7" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;State income tax:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_z51hzqwRstWb" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 51%; padding-left: 21.8pt"&gt;Current, net of refund&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;$&lt;/td&gt;
    &lt;td style="width: 19%; text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;$&lt;/td&gt;
    &lt;td style="width: 19%; text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z46egG0kC9ga" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Federal income tax:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zSX11M5F9p13" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Deferred&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,035,297&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,014,018&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_zu7w9rb70Pl9" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1064"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WriteoffOfDeferredTaxAsset_zK8xrqvwSSDk" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Write-off of deferred tax asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(6,002,777&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1067"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Income tax benefit/(expense)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20230101__20231231_ztAptpNmii0a" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;(3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zgxeqZGjwYSk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;2,014,018&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8223"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8224"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8225"
      unitRef="USD">2035297</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8226"
      unitRef="USD">2014018</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <krmd:WriteoffOfDeferredTaxAsset
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8227"
      unitRef="USD">-6002777</krmd:WriteoffOfDeferredTaxAsset>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8228"
      unitRef="USD">3967480</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8229"
      unitRef="USD">-2014018</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-6146">&lt;p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zNPI1xPbzeml" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The reconciliation of income taxes shown in the financial statements and
amounts computed by applying the Federal expected tax rate of 21% for year 2023 and 2022 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B8_zg34NCCUtSid" style="display: none; visibility: hidden"&gt;Schedule of reconciliation of income taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zO2ZcN6jHd09" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zbJYaSwTn3Z1" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_zYAwaTqqPUS6" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 60%"&gt;Loss before taxes&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 16%; text-align: right"&gt;(9,773,582&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 4%"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 16%; text-align: right"&gt;(10,675,160&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 1%"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zbSzbna7zBt7" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Income taxes computed at the federal statutory rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,052,452&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,241,784&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_z2ktpkq5KsR8" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;State income and franchise tax&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1081"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1082"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zSRYt6WqZjI5" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Permanent differences and other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(17,155&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(227,766&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WriteoffOfDeferredTaxAsset_zvWKIs9VFZeb" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Write-off of deferred tax asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(6,002,777&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1088"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Income tax benefit/(expense)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20230101__20231231_ztoiOvHdE2D8" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;(3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zWeBKg45pzwj" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;2,014,018&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8230"
      unitRef="USD">-9773582</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8231"
      unitRef="USD">-10675160</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8232"
      unitRef="USD">2052452</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8233"
      unitRef="USD">2241784</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8234"
      unitRef="USD">-17155</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8235"
      unitRef="USD">-227766</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <krmd:WriteoffOfDeferredTaxAsset
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8236"
      unitRef="USD">-6002777</krmd:WriteoffOfDeferredTaxAsset>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8237"
      unitRef="USD">3967480</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8238"
      unitRef="USD">-2014018</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-6236">&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKFGMN3Kcpyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The significant components of deferred income tax assets, net are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;span id="xdx_8BC_z4sTd2qvGpIb" style="display: none; visibility: hidden"&gt;Schedule of components of deferred tax assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231_zR7qybW8bxCl" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_zcdy3sOF9V5b" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredCompensationPlanAssets_iI_zrqwDl1ZBlZi" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 60%"&gt;Deferred compensation cost&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;1,047,608&lt;/td&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;557,931&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DepreciationDepletionAndAmortization1_iI_zVkK6CbK4oBf" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(913,671&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(624,184&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--RdCredit_z3DOhi3YsAmc" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;R&amp;amp;D credit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--Nol_zHaKxqsnpMX4" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;NOL&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,566,630&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,956,685&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AllowanceForDoubtfulOtherReceivables1Current_zsM4g8zG4Dq2" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Allowance for bad debts and other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,160,180&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;935,018&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AllowanceForNonRealizationOfDeferredTaxAsset_iI_zxkfYdFg8anb" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Allowance for non-realization of deferred tax asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(6,002,777&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_zRu5Hm81Eft8" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Deferred income tax assets, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8239"
      unitRef="USD">1047608</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8240"
      unitRef="USD">557931</us-gaap:DeferredCompensationPlanAssets>
    <krmd:DepreciationDepletionAndAmortization1
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8241"
      unitRef="USD">-913671</krmd:DepreciationDepletionAndAmortization1>
    <krmd:DepreciationDepletionAndAmortization1
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8242"
      unitRef="USD">-624184</krmd:DepreciationDepletionAndAmortization1>
    <krmd:RdCredit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8243"
      unitRef="USD">142030</krmd:RdCredit>
    <krmd:RdCredit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8244"
      unitRef="USD">142030</krmd:RdCredit>
    <krmd:Nol
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8245"
      unitRef="USD">3566630</krmd:Nol>
    <krmd:Nol
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8246"
      unitRef="USD">2956685</krmd:Nol>
    <krmd:AllowanceForDoubtfulOtherReceivables1Current
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8247"
      unitRef="USD">2160180</krmd:AllowanceForDoubtfulOtherReceivables1Current>
    <krmd:AllowanceForDoubtfulOtherReceivables1Current
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8248"
      unitRef="USD">935018</krmd:AllowanceForDoubtfulOtherReceivables1Current>
    <krmd:AllowanceForNonRealizationOfDeferredTaxAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8249"
      unitRef="USD">-6002777</krmd:AllowanceForNonRealizationOfDeferredTaxAsset>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8250"
      unitRef="USD">3967480</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-6327">&lt;p id="xdx_80A_eus-gaap--ConcentrationRiskDisclosureTextBlock_zbdQMjwffKEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 7 &#x2014; &lt;span id="xdx_82F_zgajdSoN0Jb"&gt;MAJOR CUSTOMERS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For the years ended December 31, 2023 and December 31, 2022, approximately
&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zue1I2mINIcb" title="Concentration risk, percentage"&gt;66&lt;/span&gt;% and &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zWqBZLOe73Kj" title="Concentration risk, percentage"&gt;64&lt;/span&gt;%, respectively, of the Company&#x2019;s net product revenues were derived from three major customers that are distributors.
&#160;As of December 31, 2023 and December 31, 2022, accounts receivable due from the three major customers was $&lt;span id="xdx_906_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20231231_zXl35KrkL7e9" title="Account eceivable from customers"&gt;2.6 million&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20221231_zpRC4ulyR6r6" title="Account eceivable from customers"&gt;2.2
million&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The largest customer in both years is a domestic medical products and supplies
distributor. &#160;Although a number of larger infusion customers have elected to consolidate their purchases through one or more distributors
in recent years, we continue to maintain strong direct relationships with them. &#160;We do not believe that their continued purchase
of FREEDOM System products and related supplies is contingent upon the distributor.&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      decimals="INF"
      id="ixv-8251"
      unitRef="Pure">0.66</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      decimals="INF"
      id="ixv-8252"
      unitRef="Pure">0.64</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-8253"
      unitRef="USD">2600000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-8254"
      unitRef="USD">2200000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-6347">&lt;p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zblDifXjcZ2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 8 &#x2014; &lt;span id="xdx_82C_zzipdBmphPsa"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;LEGAL PROCEEDINGS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;OTHER&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#x201c;Command&#x201d;), pursuant to which Command has agreed to manufacture and supply
the Company&#x2019;s subassemblies, needle sets and tubing products pursuant to the Company&#x2019;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#x201c;Effective
Date&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-6366">&lt;p id="xdx_803_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zNb2Zq5vbV14" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 9 &#x2014; &lt;span id="xdx_821_zO312PiFznTd"&gt;EMPLOYEE BENEFITS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We provide a safe harbor 401(k) plan for our employees that allows for
employee elective contributions, Company matching contributions and discretionary profit-sharing contributions. &#160;Employee elective
contributions are funded through voluntary payroll deductions. &#160;&lt;span id="xdx_900_ecustom--DescriptionOfMatchingContribution_c20230101__20231231_zrf827PcORCk" title="Description of matching contribution"&gt;The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#x2019;s contribution, not to exceed 3% of employee&#x2019;s compensation plus 50% of employee&#x2019;s pay
contributed between 3% and 5% of employee&#x2019;s compensation.&lt;/span&gt; &#160;Company matching expense for the years ended December 31, 2023 and
December 31, 2022 was $&lt;span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zxurb7Sk0cua" title="Matching expense"&gt;227,447&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zJcu9TGniUsg" title="Matching expense"&gt;214,931&lt;/span&gt;, respectively. &#160;The Company has not provided for a discretionary profit-sharing contribution.&lt;/p&gt;

</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <krmd:DescriptionOfMatchingContribution contextRef="From2023-01-01to2023-12-31" id="ixv-8255">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#x2019;s contribution, not to exceed 3% of employee&#x2019;s compensation plus 50% of employee&#x2019;s pay
contributed between 3% and 5% of employee&#x2019;s compensation.</krmd:DescriptionOfMatchingContribution>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="ixv-8256"
      unitRef="USD">227447</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="ixv-8257"
      unitRef="USD">214931</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-6376">&lt;p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_zugbuc7j3H03" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 10 &#x2014; &lt;span id="xdx_829_zgKwPlf1lqGe"&gt;DEBT OBLIGATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On July 28, 2023, the Company entered into a commercial insurance premium
finance and security agreement with AON Premium Finance, LLC in the aggregate principal amount of $&lt;span id="xdx_906_eus-gaap--NotesPayable_iI_dm_c20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z1pMWEqXixPi" title="Notes payable"&gt;0.57 million&lt;/span&gt; bearing an annual percentage
rate of &lt;span id="xdx_90B_ecustom--NotePayableTerms_pid_dp_uPure_c20230726__20230728__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zHqHEfQG4iq2" title="Note payable terms"&gt;9.5&lt;/span&gt;%, to finance its insurance premiums. &lt;span id="xdx_90C_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_c20230726__20230728_zsJcE1SMlza8" title="Description of the frequency of periodic payments"&gt;Monthly payments are due on the first of each month beginning August 1, 2023 through
June 1, 2024.&lt;/span&gt; The balance of AON note was $&lt;span id="xdx_903_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember_zwelvbDfXZ6k" title="Balance of AON note"&gt;314,344&lt;/span&gt; as of December 31, 2023 and $&lt;span id="xdx_90A_eus-gaap--OtherLongTermDebtNoncurrent_iI_c20221231__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember_zxU9rAK8pzra" title="Balance of AON note"&gt;433,295&lt;/span&gt; as of December 31, 2022, respectively.&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="ixv-8258"
      unitRef="USD">570000</us-gaap:NotesPayable>
    <krmd:NotePayableTerms
      contextRef="From2023-07-262023-07-28_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember"
      decimals="INF"
      id="ixv-8259"
      unitRef="Pure">0.095</krmd:NotePayableTerms>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="From2023-07-262023-07-28" id="ixv-8260">Monthly payments are due on the first of each month beginning August 1, 2023 through
June 1, 2024.</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="AsOf2023-12-31_custom_AONPremiumFinanceLLCMember"
      decimals="0"
      id="ixv-8261"
      unitRef="USD">314344</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="AsOf2022-12-31_custom_AONPremiumFinanceLLCMember"
      decimals="0"
      id="ixv-8262"
      unitRef="USD">433295</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-6388">&lt;p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zezBPiQjjKuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 11 &#x2014; &lt;span id="xdx_829_zY5BsxqjBb3i"&gt;SUBSEQUENT EVENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On March 8, 2024, the Company entered into a loan and security agreement
with HSBC Ventures USA Inc., as lender, providing for a $&lt;span id="xdx_904_eus-gaap--InvestmentOwnedAtFairValue_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zur2qbkjrTVj" title="Loan provided, as lender"&gt;5,000,000&lt;/span&gt; revolving credit facility and a $&lt;span id="xdx_903_eus-gaap--InvestmentOwnedAtFairValue_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zyuGQCjxXys5"&gt;5,000,000&lt;/span&gt; term loan facility. Borrowings
are secured by a first-priority lien on substantially all of the assets of the Company, subject to customary exceptions. The revolving
credit facility matures on December 31, 2025 and the term loan matures on December 1, 2028. Our former revolving credit facility with
Key Bank expired during the quarter ended September 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Borrowings under the revolving credit facility will bear interest at the
greater of Prime or &lt;span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_uPure_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zCTBf0SQorwb" title="Inteest rate on borrowings"&gt;6.50&lt;/span&gt;%, payable in arrears on a monthly basis and at maturity. &lt;span id="xdx_90F_eus-gaap--SubsequentEventDescription_c20240306__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLquczIIIEW7" title="Description of subsequent event"&gt;Borrowings under the term loan will bear interest at
the greater of Prime minus 0.50% or 6.50% and will be interest-only through December 31, 2025, followed by 24 equal monthly payments of
principal plus interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The loan and security agreement contains customary affirmative covenants
a financial maintenance covenant that requires the Company to maintain a minimum Adjusted Quick Ratio (defined as the ratio of the Company&#x2019;s
(i) unrestricted and unencumbered cash and cash equivalents maintained with the lender and its affiliates, plus eligible accounts receivable,
to (ii) current liabilities) of not less than 1.50 to 1.00 tested on the last day of each month.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;There are no outstanding borrowings under the facility as of March 13,
2024.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2024-03-08_us-gaap_SubsequentEventMember_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      id="ixv-8263"
      unitRef="USD">5000000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_TermLoanFacilityMember"
      decimals="0"
      id="ixv-8264"
      unitRef="USD">5000000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentInterestRate
      contextRef="AsOf2024-03-08_us-gaap_SubsequentEventMember_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      id="ixv-8265"
      unitRef="Pure">0.0650</us-gaap:InvestmentInterestRate>
    <us-gaap:SubsequentEventDescription
      contextRef="From2024-03-062024-03-08_us-gaap_SubsequentEventMember"
      id="ixv-8266">Borrowings under the term loan will bear interest at
the greater of Prime minus 0.50% or 6.50% and will be interest-only through December 31, 2025, followed by 24 equal monthly payments of
principal plus interest.</us-gaap:SubsequentEventDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
